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  I 
Abstract 
 
The plant family Elaeocarpaceae has been the source of a plethora of structurally 
related alkaloids isolated over the last 50 years. This Thesis describes our synthetic 
approaches to (−)-grandisine B I, a bioactive indolizidine alkaloid isolated from 
Elaocarpus grandis in 2005. An overview of alkaloids isolated from the family 
Elaeocarpaceae is provided and preliminary studies into the synthesis of grandisine B I 




Novel routes to bicyclic lactams II and isoquinuclidinone frameworks III have been 
developed using aqueous ammonia in a one-pot amination/cyclisation sequence 
(Chapters 3 and 4). The scope of the developed methodology was initially demonstrated 
with a concise synthesis of the alkaloid (−)-mearsine V. A biomimetic synthesis of (±)-
grandisine B I, using the alkaloid grandisine D IV as a synthetic precursor, is then 




The development of a formic acid mediated alkyne/acetal cyclisation for the synthesis 
of heterocyclic scaffolds is also reported. The scope and limitations of the methodology 
are discussed and applications of the methodology in the synthesis of (−)-grandisine B I 
and structurally related Elaeocarpus alkaloids are described (Chapter 6). 
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Chapter 1.  Introduction 
 
1.1  Alkaloids of Elaeocarpus sp. 
   
1.1.1  E. polydactylus 
 
The plant family elaeocarpaceae has been the source of a plethora of structurally 
related alkaloids isolated over the last 50 years.1 Initial studies by Lamberton and co-
workers on extracts from the species E. polydactylus revealed two members of a 
previously undescribed class of indolizidine alkaloids; elaeocarpine 1 and a stereo-
isomer isoelaeocarpine 2.2  
 
 
Figure 1.1  Alkaloids isolated from Elaeocarpus polydactylus.2, 3 
 
Unequivocal evidence for the structure of elaeocarpine 1 was provided by single crystal 
X-ray diffraction analysis of the hydrobromide salt, with NMR spectroscopic analysis 
showing the isomeric alkaloid 2 to possess cis-stereochemistry at the C-7 and C-8 ring 
junction (J = 2.1 Hz). Interconversion of the two species in methanolic potassium 
hydroxide at room temperature was reported to give, at equilibrium, a 1:1 mixture of the 
two diastereoisomers.2 
 
Further studies on extracts from the same species revealed a third alkaloid, 
isoelaeocarpicine 3.3 Whilst the previously isolated alkaloids were found to be racemic, 
isoelaeocarpicine 3 was optically active, isolated as (+)-3. Lamberton reported that 
heating isoeleaocarpicine 3 in methanolic sodium hydroxide resulted in the rapid 
formation of elaeocarpine (+)-1 and racemic isoelaeocarpine 2. 
 
 
  2 
1.1.2  E. dolichostylis 
 
Extracts from E. dolichostylis (New Guinea) revealed two additional structurally related 
indolizidine alkaloids, identified as (+)-elaeocarpiline 4 and (−)-isoelaeocarpiline 5 in 
which the C-15, C-16 bond is saturated.4,5 
 
 
Figure 1.2  Structures of (+)-elaeocarpiline 4 and (−)-isoelaeocarpiline 5.4, 
 
The relative stereochemistry of isoelaeocarpiline 5 at C-16 was determined by sodium 
borohydride reduction studies. On reduction, the carbonyl group of isoelaeocarpiline 5 
was unaffected, however, the C-13, C-14 double bond was reduced quantitatively,5 an 
observation Lamberton explained by steric factors. Attack at the carbonyl group is 
blocked by the C-1 and C-9 hydrogens and also by the C-16 methyl group on the 
opposite face. Whilst this method proved viable for determining the stereochemistry of 
isoelaeocarpiline 5, the relative configuration of elaeocarpiline 4 could not be 
determined. 
  
Subsequent studies determined the absolute configuration of (−)-isoelaeocarpiline 5 via 
oxidative degradation with KMnO4 to yield the known compound (S)-methylsuccinic 
acid 6, the absolute configuration of which corresponds to the C-16 stereocentre.6   
 
Dehydrogenation of elaeocarpiline 4 and isoelaeocarpiline 5 with Pd/C gave the known 
alkaloids elaeocarpine 1 and isoelaeocarpine 2 in optically active form, in contrast to 
those isolated from E. polydactylus which were racemic. Gradual racemisation of (+)-
elaeocarpine 1 in dilute methanolic sodium hydroxide at 50 ºC was reported to occur 




  3 
1.1.3  E. sphaericus 
 
 
Figure 1.3  Alkaloids isolated from Elaeocarpus sphaericus.6, 7 
 
Studies by Lamberton on extracts from E. sphaericus (Gaertn) K. Schum., revealed 5 
further isomeric alkaloids containing the same tetracyclic core, all but one differing only 
in the relative configurations of the 4 stereocentres.6, 7 The absolute configurations of 
the alkaloids were determined by dehydrogenation studies to yield the known 
compounds elaeocarpine 1 and isoelaeocarpine 2. Sodium borohydride reduction studies 
and optical rotatory dispersion studies provided further evidence for the assigned 
stereochemistry. The isolation of all potential diastereoisomers suggests that the 
biosynthetic pathway giving rise to such compounds is non-selective or that 
isomerisation/epimerisation readily occurs upon isolation from the plant material. 
  
The ongoing interest in the family Elaeocarpacae continues to reveal novel indolizidine 
alkaloids.  Recent studies by Gan et al. described the isolation and structural elucidation 
of (±)-oxoisoelaeocarpine 12 and (±)-elaeocarpine N-oxide 13 from Elaeocarpus 
sphaericus.8 In parallel with previous work by Lamberton, both alkaloids showed no 
optical rotation suggesting the compounds were isolated as racemates. 
 
 
Figure 1.4  Structures of the alkaloids (±)-oxoisoelaeocarpine 12 and (±)-elaeocarpine N-oxide 13.8 
 
  4 
1.1.4  E. grandis 
 
In 2005, Carroll and co-workers reported the isolation and characterisation of two novel 
indolizidine alkaloids from the leaves of the Australian rainforest species Elaeocarpus 
grandis.9 As part of an ongoing high throughput screening drug discovery program, 
extracts from the leaves of E. grandis were found to display an affinity for the human δ-
opioid recptors.  Isolation of the bioactive components revealed the known alkaloid (−)-
isoelaeocarpiline 5 along with the novel indolizidine alkaloids grandisine A 14 and 
grandisine B 15. 
 
 
Figure 1.5  Structures of grandisine A 14 and grandisine B 15 isolated from E. grandis.9 
 
A subsequent paper by Carroll and co-workers disclosed the isolation of 5 further 
biologically active indolizidine alkaloids from E. grandis, assigned the trivial names 
grandisine C 16, D 17, E 18, F 19 and G 20, all of which displayed an affinity for the 
human δ-opioid receptor.10 
 
 
Figure 1.6  Grandisines C-G 16-20 isolated from E. grandis by Carroll et al.10 
 
The relative stereochemistry of all the compounds was established through 
comprehensive 2D NMR studies, apart from two stereocentres in grandisine E 18, 
which remain to be assigned. 
  5 
1.1.5  E. habbemensis 
 
Extracts from the previously uninvestigated species E. habbemensis of Papua New 
Guinea, yielded two novel optically active alkaloids trivially named habbemines A 21 
and B 22.11 
 
 
Figure 1.7  Habbemines A 21 and B 22 isolated from E. habbemensis.11 
 
Isolated as an inseparable mixture, the structure and relative stereochemistry of the 
habbemines 21 and 22 was established through a combination of HRMS and extensive 
2D NMR studies. The closely related compounds were proposed to be diastereoisomers, 
potentially arising as a result of epimerisation of the C-5 stereocentre. In analogy with 
the pyrrolidine alkaloids peripentadenine and hygrine,12 epimerisation is believed to 
occur via the elimination/addition pathway shown in Scheme 1.1. 
 
 
Scheme 1.1  Racemisation of 2-pyrrolidine moiety in habbemines A 21 and B 22. 
 
Whilst not containing the indolizidine nucleus observed in other Elaeocarpus alkaloids 
isolated to date, it is conceivable the habbemines represent an early intermediate in the 




  6 
1.1.6  E. fuscoides 
 
Studies by Carroll and co-workers on extracts from the Papua New Guinea species E. 
fuscoides yielded the novel alkaloid elaeocarpenine 24, along with three previously 
isolated alkaloids.13 The analytical data for elaeocarpenine 24 were consistent with a 
structure closely resembling the previously isolated grandisine D 17, differing only in 
the 3-methylphenol moiety.  Interestingly, only when Carroll et al. avoided the 
previously used acid/base extraction protocols, instead using a strongly acidic ion 
exchange method, was the base sensitive alkaloid 24 isolated. 
 
 
Figure 1.8  Elaeocarpenine 24 isolated from E. fuscoides by Carroll et al.13 
 
Carroll reported that on treatment of elaeocarpenine 24 with aqueous ammonia in 
methanol conversion to the known alkaloids elaeocarpine 1 and isoelaeocarpine 2 was 
observed,13 highlighting potential problems associated with the use of ammonia in 
acid/base extraction procedures. 
 
1.2  Alkaloids of Peripentadenia mearsii 
 
The Australian rainforest species Peripentadenia mearsii of the family Elaeocarpaceae, 
has been the source of a range of structurally diverse alkaloids exhibiting similar 
structures to those isolated from Elaeocarpus sp. 
 
Initial studies by Lamberton et al. in 1983 revealed the unstable alkaloid 
peripentadenine 25.12  The molecular formula was assigned as C22H34N2O3 by HRMS, 
with NMR spectroscopic data suggesting the structure to be pyrrolidine 25.  Conclusive 
evidence was provided by synthesis of the proposed structure. The compound was 
isolated as a racemate possibly due to the presence of the β-amino ketone functionality, 
a motif known to racemise under basic conditions.  
  7 
 
Figure 1.9  Structure of peripentadenine 25 and 2-hydroxy-6-methylacetophenone 26.12 
 
On hydolysis under mild basic conditions, 2-hydroxy-6-methylacetophenone 26 was 
isolated along with a complex mixture of basic compounds.  The isolation of phenol 26 
from E. polydactylus had previously been reported by Lamberton et al.3 
 
Mearsine 27, a minor alkaloid of the North Queensland species P. mearsii, was isolated 
by Robertson et al. in 1984.14 The molecular formula was established by MS and 
combustion analysis of the crystalline picrate salt, with conclusive evidence obtained 
from single crystal X-ray diffraction data.15 To date, mearsine 27 is the only other 
alkaloid known to possess the isoquinuclidinone core found in grandisine B 15. 
Synthetic routes to mearsine 27 will be discussed later. 
 
 
Figure 1.10  Structure of mearsine 27 isolated from P. mearsii.14 
 
Recently, studies by Carroll and co-workers reported the isolation and characterisation 
of four additional alkaloids from the leaves of P. mearsii.16 The peripentonines A 28 
and B 29, were found to differ from the previously isolated habbemines 21 and 22 only 
in the substituent on the pyrrolidine nitrogen.   
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Figure 1.11  Alkaloids isolated from P. mearsii by Carroll et al.16  
 
The third compound, peripentonine C 30, still possessed the pyrrolidine ring, however, 
signals corresponding to the cyclohexenone ring were absent, consistent with a structure 
such as 30. The fourth alkaloid, mearsamine 31, was found to contain a unique tricyclic 
skeleton and quaternary amine moiety. The structure was established through 2D NMR 
spectroscopy, although the relative stereochemistry at C-2 remains to be assigned. 
 
The similar structures exhibited by the elaeocarpus and peripentadenia alkaloids 
isolated to date, suggest a closely related biosynthetic pathway. The development of a 
general synthetic strategy could provide rapid access to a range of biologically active 
compounds. 
 
1.3  Biological Activity 
 
1.3.1  Opioid Receptor Agonists 
 
Agonists and antagonists of the opioid receptors are known to modulate pain and 
therefore represent an important class of pharmaceutical compound.17 The opioid 
receptors are a class of G-protein coupled receptors widely distributed in the brain and 
spinal cord which can be divided into three subclasses (μ, κ and δ). Of the three 
subclasses, agonists such as morphine 32 and fentanyl 33 act on the μ-opioid 
receptors.17, 18  
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Figure 1.12  Structures of the selective μ-opioid receptor agonists morphine 32 and fentanyl 33. 
 
Although agonists of the μ-receptors are highly effective analgesics, activation of the 
receptors is often accompanied by major side effects, including: dependence, respiratory 
depression, muscle rigidity and euphoria. As a result, there is currently interest in 
compounds which display analgesic properties without such side effects. Recently, 
animal studies have shown that selective agonists of the δ-opioid receptors exhibit 
antinociceptive activity without the side effects and therefore represent a potential new 
class of analgesics.18, 19  
 
 
Figure 1.13  Structures of the selective δ-opioid receptor agonists SNC80 34 and KNT-127 35.20, 21 
 
Non-peptidic δ-opioid selective agonists, such as SNC80 34 and KNT-127 35 have also 
demonstrated antidepressant-like activity in animal studies.21 The wide ranging effects 
displayed by selective δ-opioid agonists could prove to be of both significant scientific 
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1.3.2  Biological Activity 
 
To date, 13 indolizidine alkaloids have been found to inhibit the binding of [125I]-
deltorphin II to HEK cell membranes expressing recombinant human δ-opioid receptors, 
with binding affinities in the micromolar range (1.6-86.4 μM).8, 10, 11, 13, 16 
 
A feature common to δ-opioid agonists is a basic nitrogen atom and as such, piperidines 
bearing aromatic substituents are often encountered.22 The orientation of the 
heterocyclic rings coupled to the indolizidine core has been found to play a role in 
determining activity, with more active compounds showing an orthogonal relationship 
between the piperidine ring and the coupled heterocycle. Conversely, in less active 
compounds, the piperidine ring is in the same plane as the attached heterocycle. 
 
Comparison of the habbemines and peripentonines also provides insight into the 
biological activity. Replacing the propyl alcohol N-substituent with a propylhexamide 
group has been shown to halve the binding affinity, whilst replacing the cyclohexenone 
group with a carboxylic acid or phenolic group was found to significantly increase the 
binding affinity. Interestingly, mearsamine 31 showed no affinity for the δ-opioid 
selective agonists, suggesting that steric crowding of the pyrrolidine nitrogen or 
quaternisation of the amine is not tolerated.16 
 
1.3.3  SAR Studies 
 
A recent publication by Tamura, detailed the synthesis of elaeocarpenine 24, and a 
range of structural analogues.  Whilst, the compounds were shown to display weak 
binding affinities for the δ-opioid receptor, all were found to be non-selective, 
displaying increased affinity for both the μ and κ receptor subtypes.23 
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Figure 1.14  Elaeocarpenine analogues prepared by Tamura and co-workers.23 
 
Structure activity relationship studies showed that replacing the piperidine ring with a 
pyrrolidine 36 or stemona alkaloid skeleton 39 altered the affinity for the three receptor 
subtypes, potentially providing a method for modulating receptor selectivity. The 
stereochemistry of the indolizidine core was also reported to play a critical role in 
receptor binding, with 9R-23 found to be more active than the 9S-23 enantiomer 
although a decreased selectivity for receptor subtypes was observed.23 
 
1.4 Grandisine B (15) – Structure Elucidation 
 
 
Figure 1.15  Grandisine B 15.9 
 
Grandisine B 15 was assigned the molecular formula C16H22N2O by high resolution 
mass spectrometry, with 2D NMR spectroscopy (COSY/HMBC) revealing a unique 
combination of unsaturated indolizidine and isoquinuclidinone moieties within the 
molecule. Correlations between H-7 and C-10 revealed the two cores were linked by a 
Csp2-Csp2 bond. The relative stereochemistry of the isoquinuclidinone core unit was 
established through coupling constant analysis. The large (12 Hz) coupling constant 
between H-15b and H-16 suggested the protons were in an eclipsed conformation. A W-
coupling between H-13b and H-15b was also evident in the COSY spectrum. The data 
were consistent with a structure in which the methyl substituent was on the same face as 
the ketone.9 
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Although the stereochemistry of the isoquinuclidinone core unit was determined, the 
stereochemistry of the indolizidine core unit relative to the isoquinuclidinone core could 
not be established using NMR techniques.9 
 
1.5  Elaeocarpus Alkaloid Biosynthesis 
 
In early studies on the family Elaeocarpaceae, Johns et al. proposed that the 
Elaeocarpus alkaloids are biosynthesised from a polyketomethylene chain derived from 
6 acetate units 40 and L-ornithine 41, Scheme 1.2.5 
 
 
Scheme 1.2  Johns‟ proposed biosysnthesis of Elaeocarpus alkaloids.5 
 
On the basis of Johns‟ biosynthetic proposal,5 Carroll et al. later hypothesised that the 
grandisine alkaloids could be derived from a common precursor 42, Scheme 1.3.9 
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Scheme 1.3  Carroll's proposed biosynthesis of the elaeocarpus alkaloids 5, 14, 15 and 17.9 
 
Carroll proposed that the presence of a common intermediate in the biosynthetic 
pathway would suggest that the stereochemistry of the grandisine alkaloids would be 
the same as that of the known compound isoelaeocarpiline 5,6 a proposal that was later 
confirmed by Danishefsky and Tamura.24,25 
 
Alternatively, Onaka proposed that the Elaeocarpus alkaloids are derived from the 
common intermediate 48,26 which could be obtained via the enzymatic oxidation of 
spermidine 47, Scheme 1.4. Gribble proposed that the alkaloid peripentadenine 25 
isolated from P. mearsii could also be derived from spermidine 47,27 providing 
evidence to support Onaka‟s biosynthetic proposal. 
 
 
Scheme 1.4  Onaka's proposed biosynthetic intermediate 48.26 
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The recent isolation of compounds such as habbemines A 21 and B 22 have raised 
further questions about the biosynthetic origins of the grandisine alkaloids. In particular, 
Carroll proposed that the habbemines could also represent an early intermediate in the 
biosynthesis of grandisine D 17 via the sequence shown in Scheme 1.5.11 However, 
whilst grandisine D 17 was isolated as a single enantiomer, the habbemines were 
isolated as a diastereomeric mixture and as such this pathway should also give rise to 
the diastereoisomer of grandisine D 50.  Further studies are therefore required to 
determine the biosynthetic origins of the grandisine alkaloids. 
 
 
Scheme 1.5  Proposed biosynthesis of grandisine D 17 from habbemine A 21.11 
 
1.5.1  Biosynthesis of Mearsine (27) 
 
Robertson postulated that mearsine 27, isolated from P. mearsii is also biosynthesised 
from acetate units via the intermediate diketone 51, a partial structure also common to 
certain Elaeocarpus/Peripentadenia alkaloids, Scheme 1.6.14  The final steps in the 
biosynthesis are also consistent with those proposed for grandisine B 15. 
 
 
Scheme 1.6  Robertson‟s proposed biosynthesis of mearsine 27.14 
 
With respect to the amination/cyclisation sequence, which is analogous to that proposed 
by Carroll for the synthesis of grandisine B 15, it is thought that an initial amination of 
the enone occurs to give the intermediate amine 52. An intramolecular 
cyclisation/dehydration sequence then occurs to furnish the isoquinuclidinone 27. 
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Alternatively, it is conceivable that the initial step in the sequence is imine formation on 
the exocyclic ketone, to give an intermediate such as 53, which can adopt a 
conformation allowing intramolecular conjugate addition of the imine into the enone. 
 
1.6  Indolizidine Alkaloids 
 
The indolizidine alkaloids represent an abundant and diverse family of natural products 
which have been isolated from myriad of sources including amphibians, fungi and 
trees.28  The compounds have been shown to possess interesting biological activities 
such as phytotoxicity, antibacterial and fungicidal properties. Representative examples 
include lepadiformine 54, isolated from sea squirt of the families Clavelina and 
Polycitoridae.29  Other members include the Lycopodium alkaloid serratinine 55,30 and 
the pumiliotoxins 56 isolated from the poison dart frog family Dendrobatidae.31 
 
 
Figure 1.16  A selection of indolizidine alkaloids. 
 
As a result of the varied structures exhibited by the indolizidine alkaloids, they have 
received sustained interest from the synthetic community. Accordingly, a brief overview 
of selected methodologies applied to the synthesis of the indolizidine alkaloids most 
closely resembling the unsaturated nucleus in grandisine B 15, is included. A more 
comprehensive review on the synthesis of indolzidine alkaloids was recently reported 
by Michael.32 
 
1.6.1  Elaeokanine A (57) 
 
The indolizidine alkaloid elaeokanine A 57 was isolated along with elaeokanines B 58 
and C 59 from the New Guinea rainforest species Elaeocarpus kainesis by Lamberton 
and co-workers.33 The compound has been the subject of numerous racemic syntheses, 
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Figure 1.17  Indolizidine alkaloids isolated from Elaeocarpus kaniensis.33 
 
Comins et al. utilised 1-acyl-5-(trialkylsilyl)-1,2-dihydropyridines in the synthesis of 
rac-57, Scheme 1.7.34  The presence of the silyl group promoted the regioselective 
addition of a Grignard reagent at the least sterically hindered C-6 position to afford the 
alkylated dihydropyridine 60.  Installation of the side chain was achieved through 
regioselective Friedel–Crafts acylation at the C-3 position, to give ketone 61 in 66% 
yield.  Protodesilylation in the presence of HBr/AcOH and subsequent reduction with 
triethylsilane furnished tetrahydropyridine 63, which was readily converted into (±)-
elaeokanine A 57 on treatment with NaI/TMSCl.  
 
 
Scheme 1.7  Comins' total synthesis of (±)-elaeokanine A 57.34 
 
A more practical synthesis of rac-57 was reported by Taber and co-workers via a tin(IV) 
chloride mediated N-acyliminium ion cyclisation, Scheme 1.8.35 Treatment of 
intermediate 65 with DBU gave the α,β-unsaturated ester 66 which was readily 
converted into (±)-elaeokanine A 57, in four steps. 
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A similar N-acyliminium ion approach was recently reported by Aggarwal for the 
synthesis of pyrrolizidine alkaloids, which was used to prepare the necine base (+)-
heliotridine 69.36 On subjecting intermediate 67 to non-classical Morita-Baylis-Hillman 
conditions, pyrrolizidine 68 was isolated in 65% yield as a 3:1 mixture of 
diastereoisomers, Scheme 1.9. Subsequent treatment with lithium aluminium hydride 
gave (+)-heliotridine 69 in 38% yield. 
 
 
Scheme 1.9  Concluding steps in Aggarwal's synthesis of (+)-heliotridine 69.36 
 
Gribble et al. proposed a general strategy for the synthesis of Elaeocarpus alkaloids,27 
based on a common intermediate 48 identified in Onaka‟s biosynthetic hypothesis.26 
Synthesis of intermediate 48 via treatment of the bis-acetal amine 70 with 1.4 M 
aqueous hydrochloric acid and subsequent buffering of the reaction mixture in the 
presence of 3-oxohexanoate ester gave indolizidine 71, Scheme 1.10. Conversion to 
elaeokanine A 57 was achieved in good yield on heating ester 71 at reflux in 8 M HCl. 
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Scheme 1.10  Gribble's synthesis of (±)-57.27 
  
In 2006, Dieter et al. reported an asymmetric synthesis of (+)-57 in which the 
stereocentre was installed via the asymmetric deprotonation of N-Boc pyrrolidine 72,37 
followed by in situ trapping with (E)-4-bromo-1-iodo-1-trimethylsilyl-1-butene.  
Subsequent one-pot olefin isomerisation and intramolecular alkylation furnished vinyl 
bromide 74. Halogen-lithium exchange and trapping of the resulting organolithium 




Scheme 1.11  Dieter's synthesis of (+)-57 via the asymmetric deprotonation of Boc-pyrrolidine 72.37 
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1.6.2  Elaeokanine B (58) 
 
A total synthesis of elaeokanine B 58 was reported by Hua et al. who determined the 
absolute configuration of 57 and 58 through single crystal X-ray diffraction analysis of 
the intermediate sulfoxide 80b.38  Sulfinyl ketimine 77 was obtained in excellent yield 
on treatment of lithiated ketimine 75 with (−)-(S)-1-menthyl-p-toluenesulfinate 76. 
Deprotonation of sulfoxide 77 with LDA, followed by addition of 1,3-diiodopropane 
furnished the β-enamino sulfoxide 78 in 61% yield.  Transfer of chirality from the 
sulfoxide to the indolizidine on reduction of enamine 77 with sodium borohydride gave 
a 4:4:1:1 ratio of diastereomeric sulfoxides 79 which were readily separable by 
chromatography. Treatment of sulfoxides 79a or 79b with LDA, then butyraldehyde 
gave a 2:1 ratio of alcohols 80a and 80b, which readily underwent dehydrosulfinylation 
in toluene at reflux to give (−)-elaeokanine B 58 in excellent yield, Scheme 1.12. 
 
 
Scheme 1.12  Hua's total synthesis of elaeokaine B 58 via α-sulfinyl ketimine 77.38 
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1.6.3  Indolizidine 209D (83) 
 
Rovis recently reported a novel synthesis of indolizidine frameworks via a rhodium-
catalysed [2+2+2]-cycloaddition between alkenyl isocyanates and terminal alkynes.39 
The use of phosphoramidite ligand 84 yielded indolizidine frameworks in good yield 
and excellent enantioselectivity, Scheme 1.13.  The methodology was applied to a 




Scheme 1.13  Rovis' Rh-catalysed synthesis of indolizidine architectures.39 
 
1.7  Isoquinuclidinones 
 
Whilst the saturated isoquinuclidine nucleus is incorporated into alkaloids from the 
species Daphniphyllum,40 such as methyl homosecodaphniphyllate 85 and Iboga 
alkaloids such as ibogaine 86,41 it is only mearsine 27,14 isolated from P. mearsii which 
shares the same structure and relative stereochemistry as the isoquinuclidinone core unit 
in grandisine B 15. A brief overview of literature detailing the synthesis of 
isoquinuclidinones is provided. 
 
 
Figure 1.18  A selection of isoquinuclidine/isoquinuclidinone alkaloids. 
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In 1989, Pinder et al. reported the total synthesis of (+)-mearsine 27, using a 
Mannich/conjugate addition sequence to rapidly assemble the isoquinuclidinone core 88, 
Scheme 1.14.42 Subsequent debenzylation and chlorination/elimination furnished (+)-
mearsine 27 in 30% overall yield. 
 
 
Scheme 1.14  Pinder's synthesis of (+)-27 via an intramolecular conjugate addtion.42 
 
An alternative synthesis of isoquinuclidinones reported by Bonjoch et al. utilised a 
trimethylaluminium-promoted lactamisation of the substituted cyclohexane derivative 
91,43 readily available in two steps from Danishefsky's diene and methyl acrylate. 




Scheme 1.15  Synthesis of isoquinuclidinone 93 via a trimethylaluminium-promoted epimerisation-
lactamisation sequence.43 
 
An early synthesis of simple isoquinuclidinone structures was reported by Rassat, using 
a double conjugate addition of ammonia to construct the bicyclic framework.44 The bis-
enone 94 was found to react with aqueous ammonia at ambient temperature to yield the 
corresponding isoquinuclidinone 95 in good yield, Scheme 1.16.  
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Scheme 1.16  Rassat's synthesis of isoquinuclidinones 95 via a double conjugate addition of ammonia.44 
 
1.7.1.  Diels-Alder Approaches to Isoquinuclidinones 
 
The Diels-Alder reaction is also well precedented for the synthesis of isoquinuclidinone 
frameworks.  McClure et al. reported the Diels-Alder reaction of tosyl cyanide with the 
cyclohexadiene derivative 96 to give the bicyclic silyl enol ether 97,45 which upon 




Scheme 1.17  Synthesis of isoquinuclidinone 98 via a nitrile Diels-Alder reaction.45 
 
Methoxy-dihydropyridine derivatives have also been used as dienes in Diels-Alder 
reactions. Sundberg et al. reported the reaction of 1-carbobenzyloxy-4-methoxy-1,2-
dihydropyridine 100 with the electron-deficient dienophile 99, Scheme 1.18.46 
Hydrolysis of enol ether 101 provided access to the corresponding isoquinuclidinone. 
 
 
Scheme 1.18  1,2-Dihydropyridine Diels-Alder reaction.46 
 
The strategy was successfully applied to the synthesis of the racemic iboga alkaloid 
analogues 102 and 103.46 
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Figure 1.19  Iboga alkaloids synthesised via a dihydropyridine Diels-Alder reaction.46 
 
Alternative approaches to isoquinuclidinone frameworks include the aza-Diels-Alder 
reaction. In 1998, Perumal and co-workers reported the unexpected synthesis of aryl-
substituted isoquinuclidinones 106 while attempting to prepare phenanthridone 
derivatives 107, Scheme 1.19.47 In the presence of indium(III) chloride, 2-
cyclohexenone 104, was found to react with aryl substituted imines 105 to give 
isoquinuclidinones 106 in moderate yield. 
 
 
Scheme 1.19  Indium(III) chloride mediated synthesis of isoquinuclidinones 106.47 
 
Mechanistically, the reaction is believed to proceed via the Mannich product 108 which 
then undergoes an intramolecular cyclisation to form the bicyclic core 106, Scheme 1.20. 
 
 
Scheme 1.20  Mechanism proposed for Perumal's synthesis of isoquinuclidinones. 
 
A similar approach to isoquinuclidinones was reported by Peirmatti et al., using an aza-
Diels-Alder reaction in aqueous media.48  Reaction of cyclohexenone 104 with a range 
of preformed imines in the presence of α-zirconium hydrogen phosphate (α-ZrP) (20 
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mol%) and catalytic sodium dodecyl sulfate (40 mol%) furnished isoquinuclidinone 
frameworks 110 in good yield, although diastereoselectivities were generally poor.  
Recycling of the α-ZrP was also found to be possible, with no appreciable loss of yield 
after three cycles, Scheme 1.21. 
 
 
Scheme 1.21  Piermatti's aza-Diels-Alder approach to isoquinuclidinones 110.48 
 
1.7.3. Asymmetric Syntheses of Isoquinuclidinones 
 
A number of methods have recently emerged for the asymmetric synthesis of 
isoquinuclidinone frameworks. Rueping et al. utilised the co-operative effect between 
two Brønsted acids to simultaneously activate cyclohexenones and imines to prepare 
isoquinuclidinones in reasonable yields and enantioselectivity, Scheme 1.22.49 
Mechanistically the reaction can be described as a Mannich/aza-Michael sequence. 
 
 
Scheme 1.22  Rueping‟s Brønsted acid catalysed synthesis of isoquinuclidinones.49  
 
Córdova and co-workers reported an organocatalytic enantioselective aza-Diels-Alder 
reaction between an imine generated in situ and a cyclohexenone derived diene, to give 
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Scheme 1.23  Proline catalysed enantioselective aza-Diels-Alder reaction.50 
 
Danishefsky et al. recently utilised the methodology in studies towards xestocyclamine 
A 117, a protein kinase inhibitor isolated from marine sponges of the genus 
Xestospongia.51 On subjecting intermediate 115 to the conditions reported by Cordova, 
the substituted isoquinuclidinone 116 was isolated in 68% yield, Scheme 1.24. 
 
 
Scheme 1.24  Application of Cordova's proline catalysed aza-Diels-Alder reaction in studies towards the 
synthesis of xestocyclamine A 117.51  
 
Carter and Yang also reported an organocatalytic approach to isoquinuclidinones using 
proline-derived catalysts.52 The reaction of cyclohexenone 104 and aryl imine 109 in the 
presence of sulfonamide catalyst 118, gave the isoquinuclidinone 110 in moderate yield 
but also excellent enantioselectivity, Scheme 1.25. 
 
 
Scheme 1.25  Carter's organocatalytic aza-Diels-Alder approach to isoquinuclidinones 110.52 
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Whilst yields for the transformation were generally modest, the reaction proceeded with 
a high degree of enantioselectivity, for a range of substrates. Interestingly, when 
aliphatic imines such as the cyclohexyl derivative 119 were used in the reaction, 
bicyclo[2.2.2]octane 120 products were obtained, Scheme 1.26.52 
 
 
Scheme 1.26  Alternative reaction pathway for aliphatic imines reported by Carter.52 
 
Carter's proposed mechanistic explanation for the observed transformation, shown in 
Scheme 1.27, involved an initial conjugate addition of enamine 121 into the activated 
enone 122.  Enamine isomerisation and intramolecular Mannich reaction gave the 





Scheme 1.27  Carter's proposed mechanism for bicyclo[2.2.2]octane formation.52 
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1.8  Previous Syntheses of Grandisine Alkaloids 
 
1.8.1  Grandisine A (14) 
 
As a result of unique structural features and intriguing biological activity, the grandisine 
alkaloids have attracted considerable interest since they were isolated in 2005/06. In 
2007, Danishefsky and Maloney reported the first total synthesis of a grandisine 
alkaloid, (+)-grandisine A 14.24,53 The approach centred on a Lewis acid catalysed diene 
aldehyde cyclisation to construct the tetrahydropyranone core 127. In the presence of 
boron trifluoride etherate and acetaldehyde, diene 126 underwent a selective 
cycloaddition reaction to afford the bicyclic pyranone 127, via transition state 128, 
Scheme 1.28. 
 
Scheme 1.28  Construction of the tetrahydropyranone core unit of grandisine A 14.24  
 
After resolution of rac-127 by chiral HPLC, alkylation of the lithium enolate of 127 
with aldehyde 129, and subsequent oxidation/deprotection gave the functionalised 
enantiopure tricyclic core 131.  Homologation of the vinyl chain was achieved via 
ozonolysis and Wittig condensation to give the α,β-unsaturated ester 132.  In the 
concluding steps of the synthesis, simultaneous reduction of the unsaturated ester and 
cleavage of the CBz group gave, after heating, the tetracyclic intermediate 133.  
Conversion into the corresponding thiolactam and reduction with Raney® nickel 
furnished grandisine A 14 in 92% yield, Scheme 1.29. 
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Scheme 1.29  Concluding steps in Danishefsky's synthesis of grandisine A 14.24 
 
1.8.2  Grandisine D (17) 
 
In 2009, during the research described in this thesis, Tamura and co-workers reported 
the first total synthesis of grandisine D 17.25 Tamura's approach utilised Aggarwal‟s 
Brønsted acid mediated Morita-Baylis-Hillman (MBH) ring closure to construct the 
indolizidine ring.36 Imide 134, prepared from (S)-malic acid using Lee's method,54 was 
subjected to regioselective reduction with NaBH4, furnishing aminal 135 in 94% yield.  
Installation of the unsaturated aldehyde via cross metathesis gave the MBH precursor 
136 in 84% yield, Scheme 1.30. 
 
Scheme 1.30  Initial steps in Tamura's synthesis of grandisine D 17.25 
 
Treatment of aldehyde 136 with trifluoromethanesulfonic acid and dimethyl sulfide in 
acetonitrile, afforded the cyclised product 137 as a 96:4 mixture of diastereoisomers, 
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Scheme 1.31.  Significant nOe effects observed on conversion to acetal 138a and 138b 
confirmed the major product to be the desired trans-isomer. 
 
 
Scheme 1.31  Stereochemical outcome of the N-acyliminium MBH reaction.25 
 
Deacetylation and subsequent Barton-McCombie deoxygenation gave the indolizidine 
139 in 66% yield over three steps.  Aldehyde 140, obtained on acidic hydrolysis of the 
acetal protecting group was coupled to (S)-5-methylcyclohexenone 87 using boron-aldol 
methodology, to furnish alcohol 141 in quantitative yield as a single diastereoisomer, 
Scheme 1.32. 
 
Scheme 1.32  Tamura's synthesis of the grandisine D carbon skeleton 141.25 
 
Oxidation of alcohol 141 with Dess-Martin periodinane and protection of the enone 
moiety afforded thiophenyl adduct 142, which was converted into grandisine D 17, in 
51% yield over 3 steps, Scheme 1.33. 
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1.8.3  Grandisine B (15) and F (19) 
 
More recently, Tamura and co-workers also reported the conversion of grandisine D 17 
into grandisines B 15 and F 19.55 On treatment of grandisine D 17 with aqueous 
ammonia, the compound was found to undergo a 1,4-addition of ammonia and  
intramolecular cyclisation to construct the isoquinuclidinone core unit, Scheme 1.34. 
 
 
Scheme 1.34  Conversion of grandisine D 17 into grandisine B 15.55 
 
Alternatively, treatment of amide 143 with aqueous ammonia yielded amine 144, which 
was readily converted into grandisine F 19 in 50% over four steps, Scheme 1.35. 
 
 
Scheme 1.35  Conversion of diketone 143 into grandisine F 19.55 
 
1.9   Aims and Objectives: Retrosynthetic Analysis 
 
Following on from worked carried out by Geyelin,56 our initial aim was to complete the 
total synthesis of grandisine B 15. Despite grandisine B 15 exhibiting one of the highest 
IC50 values of the Elaeocarpus alkaloids isolated to date, the unique structure, 
exemplified by a previously unknown combination of isoquinuclidinone and 
indolizidine cores made the total synthesis of grandisine B 15 an interesting synthetic 
challenge. It should be noted that at the time this project commenced, there were no 
published syntheses of grandisines B 15 or D 17. 
 
On the basis that grandisine B 15 is composed of two distinct N-heterocyclic 
frameworks, namely, the indolizidine and isoquinuclidinone cores, a convergent 
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strategy involving a carbon-carbon bond formation as outlined retrosynthetically in 
Scheme 1.36 was initially proposed. 
 
 
Scheme 1.36  Retrosynthetic analysis of grandisine B 15. 
 
When work began on the project the relative stereochemistry of grandisine B 15 was 
unknown; the strategy would therefore provide access to both diastereoisomers of 
grandisine B 15 by switching the stereochemistry of the coupling partners. From a 
biological screening point of view, the route is also attractive, as analogue formation 
could be achieved by preparing libraries of indolizidine and isoquinuclidinone 
frameworks. 
 
Initially, we planned to prepare a racemic model of the indolizidine core unit using the 
synthesis reported by Overman et al.57  Through lithium-halogen exchange, vinyl 
bromide 74 would provide access to a range of potential organometallic coupling 
partners, for use in cross-coupling studies. 
 
 
Scheme 1.37  Retrosynthetic analysis of indolizidine coupling partners. 
 
Alternatively, vinyllithium 147 could be trapped with an isoquinuclidinone-derived 
electrophile such as an imidoyl chloride 148, imidoyl triflate 149 or nitrone 150 (Figure 
1.20). 
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Figure 1.20  Electrophilic isoquinuclidinone coupling partners. 
 
Direct addition of an organometallic reagent 146 to lactam derivatives of the 
isoquinuclidinone core unit 152 as outlined in Scheme 1.38 could also be investigated 
as a potential method for coupling the two core units. 
 
 
Scheme 1.38  Synthesis of the grandisine B core unit 151 via addition of an organometallic reagent to 
bicyclic lactam 152. 
 
It was envisaged that a simple model isoquinuclidinone core unit 154 would be prepared 
via the thermal cyclisation of 4-aminocyclohexane carboxylic acid 153 (Scheme 1.39),58 
providing an ideal substrate for initially investigating the formation of coupling partners. 
The synthesis of a functionalised isoquinuclidinone core unit constitutes an important 
challenge of the project. 
 
 
Scheme 1.39  Synthesis of a model isoquinuclidinone core 154.58 
 
The first objective of the project was to investigate routes towards an unfunctionalised 
model of grandisine B 155 via the proposed coupling strategy, Scheme 1.40. 
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Scheme 1.40  Retrosynthesis of the grandisine B model 155. 
 
With an established route in hand, the synthesis of a functionalised isoquinuclidinone 
core unit would be required in order to investigate the viability of the developed route.  
If successful, an asymmetric synthesis of grandisine B 15 was to be undertaken, with 
the intention of also developing routes to other grandisine alkaloids. 
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Chapter 2.  A Potential Cross-Coupling Approach to 
Grandisine B (15) 
  
2.1  Synthesis of 8-Bromo-1,2,3,5,6,8a-hexahydroindolizidine (74) 
 
Initial studies towards the synthesis of grandisine B 15 commenced with the preparation 
of a racemic indolizidine core unit for use in cross-coupling investigations. The 
requirement for a racemic indolizidine core providing a suitable handle for further 
functionalisation, led us to prepare bromo-indolizidine 74, an intermediate reported 
previously by Overman et al. in their synthesis of the Elaeocarpus alkaloids (±)-
elaeokanine A 57 and B 58, Scheme 2.1.57 
 
 
Scheme 2.1  Selected steps in Overman's synthesis of elaeokanines A 57 and B 58.57 
 
Although not as concise as other reported syntheses of indolizidine frameworks,35,37 
compound 74 provided an ideal substrate with which to investigate halogen/lithium 
exchange and the subsequent synthesis of organometallic reagents for use in cross-
coupling studies. 
 
Following the reported procedure,57 synthesis of vinyl bromide 74, commenced with 
THP protection of 3-butyn-1-ol to afford the protected alcohol 158 in near-quantitative 
yield, Scheme 2.2.  Deprotonation of alkyne 158 with n-butyllithium and trapping with 
chlorotrimethylsilane at −78 ºC gave alkyne 159 in 95% yield. Using Zweifel's 
hydroalumination protocol,59 followed by treatment with bromine in pyridine, the 
desired ((E)-1-bromo-alkenyl)silane 160 was obtained in a disappointing 55% yield 
(Lit.57 83%). Cleavage of the THP protecting group using catalytic pyridinium p-
toluenesulfonate (PPTS) proceeded readily, giving alcohol 161 in quantitative yield. 
Mitsunobu coupling of alcohol 161 with succinimide, gave imide 162 in 85% yield; 
however, in our hands the reaction was not amenable to scale-up due to difficulties with 
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the isolation and purification of imide 162.  Reduction of imide 162 using sodium 
borohydride gave the hydroxylactam 163 in 93% yield.  Cyclisation of hydroxylactam 
163 proceeded cleanly in trifluoroacetic acid at reflux to furnish indolizidine 164 in 
83% yield, with no evidence of the corresponding protodesilylation product.  Finally, 
reduction of lactam 164 with lithium aluminium hydride gave bromo-indolizidine 74 in 




Scheme 2.2  Overman's synthesis of vinyl bromide 74.57 
 
2.1.1 Proposed Mechanism for the N-Acyliminium Ion Cyclisation 
 
Although no conclusive evidence for the mechanism of the N-acyliminium cyclisation 
was reported, Overman et al. proposed two viable pathways,57 Scheme 2.3.  Mechanism 
A involved direct cyclisation onto iminium ion 165 to give the intermediate β-silyl 
cation 166, which yields vinyl bromide 164 on loss of the trimethylsilyl group. 
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Scheme 2.3  Mechanisms proposed for the N-acyliminium ion cyclisation.57 
 
Alternatively, iminium ion 165, may undergo a cationic aza-Cope rearrangement to give 
an allylsilane iminium ion 167 which cyclises to furnish the vinyl bromide 164.  
Additional studies by Overman et al. suggested that the vinylsilane 165 and allylsilane 
167 intermediates equilibrate more rapidly than cyclisation occurs.  It was therefore 
proposed that bromide 164 results from cyclisation of the more nucleophilic allylsilane, 
in accordance with mechanism B. 
 
2.1.2 Challenges of Overman’s Route 
 
Whilst the yields for the indolizidine synthesis sequence were generally good, in our 
hands, the Mitsunobu coupling did not prove amenable to scale-up as a result of 
difficulties encountered with the purification of imide 162. Alternative routes to imide 
162, were therefore investigated. We proposed that conversion of alcohol 161 into the 
corresponding mesylate 168 or bromo 169 derivatives and displacement with sodium 




Scheme 2.4  Alternative routes to imide 162. 
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Treament of alcohol 161 with methanesulfonyl chloride and triethylamine in DCM, 
furnished mesylate 168 in 94% yield after 1 h at room temperature, Scheme 2.5. 
Furthermore, the material was found to be homogeneous by 1H NMR spectroscopic 
analysis and could be used in subsequent chemistry without purification. 
 
 
Scheme 2.5  Synthesis of mesylate 168. 
 
With mesylate in hand, we were in a position to investigate the displacement with 
succinimide-derived nucleophiles. Thus, mesylate 168 was added to a preformed 
solution of sodium succinimide in THF. Disappointingly, after 24 h at reflux, TLC 
analysis of the reaction mixture showed only starting material to be present, Scheme 2.6.  




Scheme 2.6  Attempted synthesis of imide 162 from mesylate 168. 
 
With no success in the displacement of mesylate 168, alcohol 161 was converted into 
the bromo-derivative 169 under standard Appel conditions.60 Following the procedure 
of Marsden,61 addition of bromide 169 to a preformed solution of sodium succinimide 
in DMF resulted in clean conversion into imide 162. Disappointingly, after purification, 
imide 162 was isolated in only 46% yield, Scheme 2.7. 
 
 
Scheme 2.7  Attempted synthesis of imide 162 via bromide 162. 
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Although attempts to displace the mesylate in refluxing THF were unsuccessful, 
displacement of the bromo group in 169 proceeded cleanly in DMF at room temperature.  
Whilst the mesylate is a better leaving group, the difference in reactivity was attributed 
to the change in solvent, the polar aprotic solvent DMF favouring the SN2 displacement. 
 
Despite partial success with the modified route, due to the low yield for the 
displacement, we felt it would be counter-productive to spend further time optimising 
the sequence, and the Mitsunobu coupling reported by Overman was therefore used in 
subsequent reactions.57 
 
2.1.3  Halogen-Lithium Exchange 
 
With vinyl bromide 74 in hand we were in a position to investigate the synthesis of 
cross-coupling partners. In order to confirm that halogen-lithium exchange proceeded 
cleanly, the reaction was investigated via trapping with simple electrophiles. 
 
Following the procedure of Geyelin,56 treatment of vinyl bromide 74 with t-butyllithium 
in THF at −78 ºC and subsequent trapping with benzaldehyde, gave the alcohols 170 




Scheme 2.8  Halogen-lithium exchange reaction on vinyl bromide 74. 
 
The reaction was also repeated using DMF as electrophile to give the volatile 
indolizidine aldehyde 172, in 92% yield, Scheme 2.9. It was subsequently found that the 
lithiation could be successfully effected using s-butyllithium with no appreciable loss of 
yield. 
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Scheme 2.9  Synthesis of aldehyde 172 from vinyl bromide 74. 
 
Previous work in the Taylor group had shown that the corresponding vinyl stannane 173 
could be accessed via trapping with tributyltin chloride.56 We also envisaged that 
trapping with triisopropyl borate would provide access to the boronate/boronic acid 
derivative. At this point in time attention was turned to the synthesis of a model 
isoquinuclidinone core unit, for use in initial coupling studies. 
 
2.2  Synthesis of a Model Bicyclic Lactam (154) 
 
For the purposes of initial studies, an unfunctionalised bicyclic lactam 154 was required. 
Following the procedure reported by Werner,58 bicyclic lactam 154 was prepared in 
84% yield via a thermally induced cyclisation of commercially available cis-
aminocyclohexane carboxylic acid 153, Scheme 2.10. 
 
 
Scheme 2.10  Thermally induced cyclisation of 4-aminocyclohexene carboxylic acid 153.58 
 
Due to the high cost of cis-aminocyclohexane carboxylic acid, we felt it would be 
instructive to attempt the reaction using the cheaper cis/trans-mixture.  On subjecting 
the cis/trans-mixture to the thermal cyclisation conditions, bicyclic lactam 154 was 
isolated in 80% yield; the trans-isomer clearly epimerises when subjected to the high 
temperatures. Although lacking the ketone functionality present in the 
isoquinuclidinone core unit of grandisine B 15, we felt the bicyclic lactam 154 would 
provide an ideal model for initial coupling studies. 
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2.3  Synthesis of a Bicyclic Imidoyl Chloride/Triflate Cross-Coupling 
Partner 
 
As a continuation of early studies by Geyelin,56 attempts were made to prepare the 
novel imidoyl chloride 174 for use in cross-coupling studies. Treatment of lactam 154 
with phosphoryl(V) oxychloride at reflux resulted in complete consumption of the 
starting material, Scheme 2.11. However, the 1H NMR spectrum of the unpurified 
reaction mixture showed no evidence of the desired imidoyl chloride 174. Repeating the 
reaction using conditions reported by Olsson,62 in which lactam 154 was treated with 
PCl5 in toluene at reflux, was also unsuccessful. 
 
 
Scheme 2.11  Attempted synthesis of imidoyl chloride 174. 
 
Due to failed efforts to prepare imidoyl chloride 174, attention was turned to the 
synthesis of the corresponding imidoyl triflate 175, which we envisaged could also be 
used in cross-coupling studies. Treatment of lactam 154 with Tf2O and DIPEA in DCM 
at −78 ºC, failed to give any of the desired imidoyl triflate 175, Scheme 2.12. 
 
 
Scheme 2.12  Attempted synthesis of imidoyl triflate 175. 
 
Alternative conditions reported by Donohoe were also investigated.63  Disappointingly, 
treatment of lactam 154 with NaHMDS and Comins' reagent 176 in anhydrous THF 
was also unsuccessful. The unsuccessful attempts were attributed to the instability of 
both the imidoyl chloride 174 and imidoyl triflate 175 which we proposed rapidly 
hydrolysed/decomposed on isolation.  
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2.4  Nitrone Chemistry 
 
Whilst attention had initially focussed on a transition metal catalysed cross-coupling 
strategy, we proposed that direct addition of a metallated indolizidine core unit to an 
electrophilic isoquinuclidinone derivative could also prove a viable method for coupling 
of the two core units. A paper by Murahashi was brought to our attention, detailing the 
synthesis of imines from N,N-disubstituted hydroxylamines on treatment with TiCl3,
64 
providing a potential route to the model grandisine B skeleton 155, as outlined 
retrosynthetically in Scheme 2.13. 
 
 
Scheme 2.13  Retrosynthetic analysis of the grandisine B model 155. 
 
The required N,N-disubstituted hydroxylamine 177 could be obtained from nitrone 178 
via the addition of an organolithium or Grignard reagent.64 In order to investigate this 
strategy, the known nitrone 180 was initially prepared.  
 
 
Scheme 2.14  Synthesis of nitrone 180 using the procedure of Murahashi.65,66 
 
Initial attempts to prepare nitrone 180 using Murahashi's sodium tungstate-mediated 
oxidation proved unsuccessful.65  The reaction was found to be highly exothermic, 
giving only trace amounts of product after work-up (Lit.65 42% yield).  An alternative 
procedure also reported by Murahashi using catalytic selenium dioxide was found to be 
more reproducible,66 yielding nitrone 180 in ~90% yield after work-up, the material of 
sufficient purity to be used without purification. Disappointingly, attempts to further 
purify the product on silica or alumina were unsuccessful, resulting in complete 
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decomposition.  In the knowledge that nitrone 180 could be prepared, attempts were 
made to prepare the corresponding bicyclic nitrone 178. Although not commercially 
available, amine 181 was readily accessed from lactam 154. Reduction of lactam 154 
with lithium aluminium hydride in THF gave the volatile amine 181, which was 
immediately subjected to nitrone formation without purification, Scheme 2.15. 
 
 
Scheme 2.15  Attempted synthesis of nitrone 178. 
 
Addition of hydrogen peroxide to a solution of amine 181 in the presence of catalytic 
selenium dioxide in acetone resulted in complete consumption of the starting material. 
Unfortunately, 1H NMR spectroscopic analysis of the unpurified mixture showed no 
signals corresponding to the desired product 178. 
 
In order to confirm that the reduction of lactam 154 was proceeding, the unpurified 
amine 181 was treated with Boc2O, which gave after purification the Boc-protected 
amine 182 in 75% yield, Scheme 2.16. The result provided evidence to suggest that 
nitrone formation was the problematic step in the sequence. 
 
 
Scheme 2.16  Trapping of amine 181 with Boc2O. 
 
2.4.1 Addition of Organolithium Reagents to Cyclic Nitrones 
 
In parallel to the synthesis of bicyclic nitrone 178, attempts were made to couple the 
racemic indolizidine core unit 74 with model nitrone 180, to test the viability of this 
strategy. 
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Lithiation of vinyl bromide 74 with t-butyllithium in THF at −78 ºC followed by 
addition of nitrone 180 resulted in complete consumption of the starting material, 
evident by TLC analysis, Scheme 2.17.  
 
 
Scheme 2.17  Attempted coupling of indolizidine 74 with nitrone 180. 
 
Disappointingly, no evidence of the desired hydroxylamine 183 was observed upon 
inspection of the 1H NMR spectrum of the unpurifed reaction mixture, or peaks 
corresponding to an indolizidine species. It was therefore proposed that vinyllithium 
intermediate was protonated during work-up and lost as the volatile indolizidine 184. 
Further evidence for this was provided when lithiation of bromide 160 under identical 
conditions, gave only the protonated alkene 186, after work-up, Scheme 2.18. 
 
 
Scheme 2.18  Attempted coupling of vinyl bromide 160 with nitrone 180. 
 
Due to unsuccessful attempts to prepare the model bicyclic nitrone 178 and failed 
attempts to couple lithiated species with nitrone 180, further worker on this approach 
was suspended. 
 
2.5  Addition of Organolithium Reagents to N-Silylated Lactams 
 
An alternative route to cyclic imines was reported by Hua and co-workers via the 
addition of organolithium reagents to N-TMS lactams, Scheme 2.19.67 Following Hua's 
procedure, treatment of 2-pyrrolidinone 187 with trimethylsilyl chloride and 
triethylamine gave the known silylated lactam 188 in 73% yield. 
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Scheme 2.19  Hua's procedure for the synthesis of cyclic ketimine 189.67 
 
Disappointingly, attempts to utilise this procedure in the synthesis of silylated bicyclic 
lactam 190 gave only recovered starting material 154, Scheme 2.20. Similarly, only 
starting material was recovered when the reaction was repeated using the procedure of 
Menezes.68  Repeating the reaction in the presence of stronger bases such as n-
butyllithium and sodium hydride also failed to yield any of the silylated lactam 190. 
 
 
Scheme 2.20  Attempted synthesis of TMS-Lactam 190 using Hua's procedure.67 
 
The difficulties encountered were initially attributed to the instability of the TMS-
lactam 190, and a one-pot procedure was therefore attempted in order to negate the 
possibility that silyl lactam 190 was decomposing during work-up. Thus, attempts were 
made to trap the silylated species in situ with MeLi to give the corresponding cyclic 
imine 191.  Disappointingly, treatment of lactam 154 with n-butyllithium and 
trimethylsilyl chloride, followed by addition of methyllithium, gave after work-up only 
recovered lactam 154, Scheme 2.21. 
 
 
Scheme 2.21  Attempted in situ trapping on TMS-lactam 190. 
 
Using a similar procedure reported by Romo et al.;69 lactam 154 was treated with n-
butyllithium and TMSOTf in DME; subsequent addition of methyllithium gave only 
recovered starting material on work-up. These further experiments suggested that initial 
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formation of the TMS-lactam 190 was not occurring, as a result, an alternative coupling 
strategy was sought. 
 
2.6  Addition of Organometallic Reagent to Amides 
 
In the search for alternative strategies, a particularly relevant paper by Speckamp and 
co-workers reporting the synthesis of the alkaloid peduncularine 194,70 was brought to 
our attention. A key transformation in the paper was the addition of a Grignard reagent 
to the bicyclic lactam 192 and subsequent reduction of the iminium ion to give amine 
193, Scheme 2.22. 
 
Scheme 2.22  Addition of a Grignard reagent to bicyclic lactam 192.70 
 
Whilst not providing direct access to the required imine, there is literature precedent for 
the conversion of secondary amines into imines.42 In order to investigate this approach, 
benzyl lactam 195 was prepared in 97% yield from lactam 154 via deprotonation with 
sodium hydride and alkylation with benzyl bromide. 
 
 
Scheme 2.23  N-Benzylation of lactam 154. 
 
With benzyl lactam 195 in hand, the addition of simple Grignard and organolithium 
reagents was investigated. Treatment of 195 with propenyl magnesium bromide in THF 
at 0 ºC followed by sodium triacetoxyborohydride gave only recovered starting material 
after work-up, Scheme 2.24. 
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Scheme 2.24  Attempted coupling of Grignard reagents with benzyl lactam 195. 
 
Alternative reaction conditions using n-butyllithium as the nucleophile and lithium 
aluminium hydride as the reductant under a variety of conditions, also failed to give the 
substituted amine. 
 
Due to unsuccessful attempts to add organometallic reagents into the N-benzyl bicyclic 
lactam 195, the corresponding N-Boc derivative 197 was considered. Addition of 
organometallic reagents to Boc-amides has recently been utilised by Martin and 
Weinreb in two differing approaches to the immunosuppressant FR901483 198.71,72  In 
order to investigate this approach, the model Boc-protected lactam 197 was prepared via 
treatment of lactam 154 with n-butyllithium and Boc2O, to give after purification, the 
novel Boc-lactam 197 in 80% yield, Scheme 2.25. 
 
 
Scheme 2.25  Synthesis of Boc-lactam 197 from bicyclic lactam 154. 
 
Following the general procedure reported by Weinreb,72 addition of 
propenylmagnesium bromide to Boc-lactam 197 in THF resulted in complete 
consumption of starting material evident by TLC analysis, Scheme 2.26.  
 
 
Scheme 2.26  Attempted addition of propenyl magnesium bromide to Boc-lactam 197. 
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Pleasingly, upon inspection of the 1H NMR spectrum of the crude product, trace signals 
potentially corresponding to the expected product 199 were observed. Unfortunately, 
none of the desired product was recovered after attempted purification on silica. 
Subsequent attempts to repeat the reaction also failed to give the alkylated product 199. 
 
2.7  Grignard Addition to Thioimidates 
 
An alternative coupling approach reported by Speckamp involved the addition of 
Grignard reagents to thioiminium ions.70 Thus, thioiminium ion 201 was prepared from 
benzyl lactam 195 in two steps. Treatment of lactam 195 with Lawesson's reagent in 
toluene gave the novel thioamide 200 in 94% yield, which upon treatment with methyl 
iodide gave thioiminium ion 201 in 91% yield, Scheme 2.27. 
 
 
Scheme 2.27  Synthesis of thioiminium ion 201 using the procedure of Speckamp.70 
 
With thioiminium ion 201 in hand, we were in a position to investigate the addition of 
organometallic reagents.  Upon addition of n-butyllithium to iminium ion 201 in THF 
and subsequent reduction with lithium aluminium hydride consumption of the starting 
material was evident by TLC analysis, however, all attempts to isolate the polar 
products from the crude mixture were unsuccessful. Attempts to repeat the reaction 
using propenyl magnesium bromide also gave complex mixtures of products, with no 
evidence of the bicyclic amine 203 observed in the 1H NMR spectrum of the crude 
reaction mixture, Scheme 2.28. 
 
 
Scheme 2.28  Attempted addition of Grignard and organolithium reagents to thioiminium ion 201. 
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Despite the literature precedent for the addition of organometallic reagents to 
amides/thioiminium ions, it became quickly apparent during initial studies on the model 
system, that the strategy was not viable for the synthesis of grandisine B 15.  
 
2.8  A Liebeskind-Srogl Cross-Coupling Strategy  
 
Despite unsuccessful attempts to react organometallic reagents directly with 
thioiminium ions, we felt the thioamide derivatives could still be utilised as a potential 
coupling partner. 
 
Returning to the originally proposed cross-coupling strategy, we were keen to 
investigate metal-catalysed coupling reactions such as the Kumada coupling of Grignard 
reagents with thioimidates using nickel catalysts or the copper-mediated Liebeskind-
Srogl coupling. A recent publication by Kappe et al. reported the palladium-catalysed, 
copper-mediated coupling of thioamides with aryl boronic acids.73 The Liebeskind-
Srogl type reaction was reported to give imine products in moderate to excellent yield.  
In order to investigate this approach the required isoquinuclidinone coupling partner 
204 was prepared in 79% yield via treatment of lactam 154 with Lawesson's reagent in 
toluene, Scheme 2.29. 
 
 
Scheme 2.29  Synthesis of thiolactam 204 from bicyclic lactam 154. 
 
The publication by Kappe focused on the coupling of aromatic boronic acids,73 and we 
therefore initially examined the coupling reaction using commercially available phenyl 
boronic acid. Upon subjecting thiolactam to the reported microwave conditions we were 
pleased to observe the formation of bicyclic imine 205, evident from characteristic 
bridgehead signals at 4.3 ppm and 3.3 ppm apparent in the 1H NMR spectrum of the 
unpurified reaction mixture, Scheme 2.30. Although the bicyclic imine 205 was only 
isolated in 27% yield, we felt this could be optimised at a later stage. 
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Scheme 2.30  Liebeskind-Srogl type cross-coupling of thiolactam 204 with phenyl boronic acid. 
 
In order for the methodology to be applied to the synthesis of grandisine B 15, it would 
be necessary to couple a vinyl boronic acid coupling partner with a thioamide.  
However, initial attempts to couple thiolactam 204 with cis-propenyl boronic acid 206 
under microwave or sealed-tube conditions failed to give any of the desired imine 207, 
Scheme 2.31.  
 
 
Scheme 2.31  Attempted cross-coupling of thiolactam 204 with propenyl boronic acid 206. 
 
Despite the disappointing result with the vinyl boronic acid, we felt the route warranted 
further investigation. The synthesis of a functionalised isoquinuclidinone coupling 
partner 208 was therefore investigated in order to further study the Liebeskind-Srogl-
type cross-coupling. 
 
2.9  Summary 
 
A number of strategies for the coupling of model indolizidine and isoquinuclidinone 
core units have been investigated. A Liebeskind-Srogl-type approach has shown 
promising results on simple model systems; a functionalised isoquinuclidinone coupling 
partner 208 will therefore be prepared in order to test the viability of the strategy for the 
synthesis of grandisine B 15. The results of these studies are described in Chapter 3. 
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Chapter 3.  Synthesis of a Functionalised Bicyclic Lactam 
  
3.1  Introduction 
 
In the previous chapter, a potential route to grandisine B 15 was reported, via a 
Liebeskind-Srogl-type coupling of a thioamide derived from bicyclic lactam 154 with a 
boronic acid. A route to the functionalised bicyclic lactam 209 (Figure 3.1) was 
therefore required in order to further investigate the cross-coupling approach. 
 
 
Figure 3.1  Bicyclic lactam 154 and functionalised bicyclic lactam 209. 
 
3.2  A Nitrile Diels-Alder Approach 
 
A paper by McClure et al. reported the synthesis of isoquinuclidinone 98 via an aza-
Diels-Alder reaction between p-toluenesulfonyl cyanide and diene 96, Scheme 3.1.45 
 
 
Scheme 3.1  Attempted synthesis of bicyclic lactam 98 using the procedure of McClure.45 
 
Although only providing racemic material, we felt the brevity of the route justified the 
use of the sequence in the synthesis of a model isoquinuclidinone core unit. Whilst 
lacking the required methyl substituent, it was envisaged that the methodology could be 
extended to the synthesis of a methyl substituted isoquinuclidinone via the use of the 
silyl enol ether 210. Following the procedure of Shibasaki,74 diene 96 was prepared in 
88% yield from commercially available cyclohexenone via deprotonation with 
LiHMDS in THF at 0 ºC and subsequent trapping with chlorotrimethyl silane. 
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Subjecting diene 96 to the conditions reported by McClure gave, after work-up, a pale 
yellow solid, the analytical data for which showed a number of unidentified products. 
Attempts to isolate the bicyclic lactam 98 from the mixture were unsuccessful, yielding 
only trace amounts of the desired product 98 (Lit.45 77%).  Due to the relatively high 
cost of p-toluenesulfonyl cyanide and unsuccessful attempts to repeat the literature 
procedure, alternative routes to the functionalised isoquinuclidinone core unit were 
sought. 
 
3.3  Cordova Diels-Alder Chemistry 
 
A recent paper by Cordova et al. came to our attention detailing the enantioselective 
synthesis of isoquinuclidinones 212 using proline catalysis, Scheme 3.2.50 Although 
lacking the amide functionality required, it was envisaged that this could be 
subsequently installed by oxidation of isoquinuclidinone 212. 
 
 
Scheme 3.2  Cordova's enantioselective synthesis of isoquinuclidinones 212.50 
 
Following the reported procedure,50 isoquinuclidinone 213 was prepared in a moderate 
34% yield (Lit.50 82% after reduction to the corresponding alcohol), Scheme 3.3. In 
accordance with the literature, isoquinuclidinone 213 proved to be unstable in our hands, 
readily decomposing on silica resulting in low recovery of the product. Under acidic 
conditions, Cordova reported that isoquinuclidinone 213 undergoes a retro-aza-Michael 
reaction, although no evidence was found to support this; analysis of the material 
showed only decomposition products. 
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Scheme 3.3  Synthesis of isoquinuclidinone 213 using the procedure of Cordova.50 
 
In situ reduction of isoquinuclidinone 213 using NaBH4 and subsequent isolation of the 
diastereomeric alcohols 214 was also attempted. Addition of excess NaBH4 to the 
reaction mixture gave, after work-up, a brown oil which contained a number of 
components as evident by TLC analysis.  Attempts to purify the mixture were 
unsuccessful with none of the desired alcohol 214 isolated. Reduction of the unpurified 
isoquinuclidinone 213, obtained after an aqueous work-up, also failed to give alcohol 
214. 
 
Due to the low stability and poor yields encountered during the synthesis of 
isoquinuclidinone 213, the reportedly more stable isoquinuclidinone 114 was prepared 
in 67% yield (Lit.50 70%), Scheme 3.4.   
 
 
Scheme 3.4  Synthesis of isoquinuclidinone 114 using the procedure of Cordova.50 
 
Analysis of the unpurified reaction mixture by 1H NMR spectroscopy showed the 
reaction proceeded cleanly to give isoquinuclidinone 114, with unreacted 4,4-
dimethylcyclohexenone 113 the only impurity present. The problems previously 
encountered with stability were not found with isoquinuclidinone 114, which could be 
purified by silica gel chromatography.  
 
Whilst the reaction is described as an aza-Diels-Alder reaction, mechanistically, 
Cordova proposed a stepwise process involving an initial Mannich reaction to yield 
amine 218, Scheme 3.5. The secondary amine subsequently adds into the activated 
enone to furnish the isoquinuclidinone 213. 
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Scheme 3.5  Proposed mechanism of Cordova's aza-Diels-Alder reaction.50 
 
3.3.1  PMP Deprotection 
 
Before investigating potential coupling strategies, the removal of the PMP group and 
installation of the amide function had to be addressed. Initially, we chose to investigate 
the removal of the PMP group. Although removal of the PMP group from primary 
amines is widely precedented in the literature, the removal of PMP groups from 
secondary amines has received less attention.  Initially, isoquinuclidinone 213 was 
subjected to standard deprotection conditions using excess ceric ammonium nitrate in 
aqueous acetonitrile.75 After 1 h at 0 ºC, TLC analysis showed complete consumption of 
the starting material, with the formation of two products, one baseline species and the 
other more lipophilic than the starting material, Scheme 3.6.  The more lipophilic 
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Scheme 3.6  Attempted cleavage of the PMP group using CAN. 
Inspection of the 1H NMR spectrum of the unpurified material showed no evidence of 
the expected bicyclic amine 220, although the presence of p-benzoquinone 221 was 
suggested by a singlet at ~6.8 ppm.  Due to the low stability of isoquinuclidinone 213, 
further investigations were carried out using the more stable isoquinuclidinone 114. 
 
Initially, isoquinuclidinone 114 was subjected to the standard conditions used 
previously, Scheme 3.8.  Analysis of the reaction mixture by 1H NMR spectroscopy, 
showed an absence of signals corresponding to the PMP group, but no signals 
corresponding to amine 222 were observed. The formation of p-benzoquinone 221 in 
both reactions was consistent with the removal of the PMP group, suggesting the 
products were decomposing under the reaction conditions. 
 
 
Scheme 3.8  Attempted cleavage of the PMP group with CAN. 
 
A one-pot deprotection/acetate protection procedure reported by Tomioka caught our 
attention as it would negate the need to isolate amine 222.76  Thus, following the 
reported procedure, a solution of isoquinuclidinone 114 in acetonitrile was treated with 
CAN, Scheme 3.9. After 5 min., the reaction was quenched with aqueous sodium 
hydroxide and excess acetic anhydride was added. 
 
 
Scheme 3.9  Attempted deprotection/acetate protection strategy.76 
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Disappointingly, analysis of the 1H NMR spectrum of the crude reaction mixture, 
showed signals corresponding to a p-substituted aromatic group were still present, but, 
no signals corresponding to the methoxy group were observed.  The 1H NMR 
spectroscopic data were consistent with a product such as the acetate derivative 224, 
however, insufficient material was obtained to allow full characterisation. 
 
Due to the unsuccessful attempt to isolate acetate-protected isoquinuclidinone 223 an 
alternative deprotection/Boc-protection strategy reported by Buchwald was 
investigated.77  Treatment of isoquinuclidinone 114 with CAN in acetonitrile and 
subsequent protection with Boc2O in aqueous toluene, gave after purification, the novel 
Boc-protected isoquinuclidinone 225 in an unoptimised 39% yield, Scheme 3.10 
 
 
Scheme 3.10  Synthesis of isoquinuclidinone 225 via a deprotection/Boc-protection strategy.77 
 
3.4  Oxidation of Isoquinuclidinones 
 
In order to investigate the synthesis of grandisine B 15 via the proposed coupling 
strategy, a route to thioamide 208 was required, which we envisaged could be obtained 
from the corresponding bicyclic lactam.  A method for the oxidation of 




Scheme 3.11  Proposed oxidation of isoquinuclidinones 212 to give bicyclic lactams 226. 
 
With limited quantities of the Boc-protected compound 225 obtained after deprotection, 
oxidation of the PMP derivative 114 was initially considered. 
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Although ruthenium-based oxidations of secondary amines are precedented in the 
literature,78 to our knowledge, there are only limited reported oxidations of tertiary 
amines bearing aromatic substituents.79 Initial studies were undertaken using conditions 
reported by Arakawa.80 Disappointingly, treatment of isoquinuclidinone 114 with 
catalytic ruthenium(IV) oxide hydrate and aqueous sodium periodate resulted in 




Scheme 3.12  Attempted ruthenium-mediated oxidation of isoquinuclidinone 227.80 
 
A particularly relevant paper by Benn et al., reported the oxidation of the alkaloid 
lycoctonine using potassium permanganate in aqueous solvent systems to yield the 
corresponding tertiary amide.81 Following the reported procedure, on addition of a slight 
excess of aqueous potassium permanganate to a solution of amine 114 in DCM, the 
appearance of a more polar species was observed by TLC analysis, Scheme 3.13. 
Pleasingly, 1H NMR spectroscopic analysis of the unpurified product, revealed signals 
corresponding to residual starting material 114 and the desired bicyclic lactam 227 
(evident from the loss of the C-3 proton signals at 3.47 ppm and a downfield shift of the 
C-4 bridgehead proton from 2.61 ppm to 3.37 ppm). 
 
 
Scheme 3.13  Oxidation of isoquinuclidinone 114 using the conditions reported by Benn.81 
 
A paper published by Suginome, reported the oxidation of tertiary amines with KMnO4 
in aqueous acetone.82 The reaction of amine 114 with KMnO4 was therefore repeated in 
both aqueous acetone and acetonitrile, to establish whether complete oxidation of amine 
114 could be achieved. After 5 h, TLC analysis of the reactions showed the presence of 
both starting material and product. Additional KMnO4 was added to both reactions until 
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complete consumption of the starting material was observed. In both instances, it was 
found that 5 equivalents of KMnO4 were required to achieve complete conversion into 
lactam 227.  Upon work-up of the reaction carried out in aqueous acetonitrile, lactam 
227 was obtained in 48% isolated yield. Analysis of the unpurified material by 1H NMR 
spectroscopy showed the product to be homogeneous, requiring no purification. When 
repeated on a larger scale, the reaction went to completion in 3 h using only 3 
equivalents of KMnO4, to give bicyclic lactam 227 in 47% yield, Scheme 3.14.  
 
 
Scheme 3.14  Oxidation of isoquinuclidinone 114 using KMnO4 in aqueous acetonitrile. 
 
Disappointingly, attempts to optimise the reaction and work-up conditions failed to give 
yields higher than 50%, with yields reproducibly between 45% and 50%. Concentration 
of the aqueous phase in vacuo and subsequent analysis of the residue failed to show any 
organic products, providing no explanation to account for the poor mass balance. 
 
Despite the moderate yield for the oxidation, the removal of the PMP group was briefly 
investigated on small-scale. Treatment of lactam 227 with ceric ammonium nitrate in 
aqueous acetonitrile, resulted in clean conversion to a single product 228, Scheme 3.15.  
Analysis of the unpurified material by 1H NMR spectroscopy showed the desired 
bicyclic lactam 228 contaminated with minor traces of p-benzoquinone 221.  
 
 
Scheme 3.15  Synthesis of bicyclic lactam 228 via PMP deprotection. 
With these pleasing results in hand, we were keen to explore the use of the sequence in 
the synthesis of the grandisine B isoquinuclidinone core unit 209. Disconnection via the 
aza-Diels-Alder strategy reveals the known cyclohexenone 87, bearing the methyl 
substituent found in grandisine B 15, Scheme 3.16. 
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Scheme 3.16  Retrosynthesis of functionalised bicyclic lactam 209. 
 
3.5  Synthesis of 5-Methylcyclohexenone (87) 
 
For initial investigations we chose to prepare racemic 5-methylcyclohexenone 87 using 
the procedure reported by Koo et al.;83 the low cost of the starting materials and brevity 
of the route appeared to be ideal. However, upon treatment of ethyl acetoacetate 230 
and crotonaldehyde 231 with potassium tert-butoxide in tert-butanol, following the 
reported procedure, a 1:1 mixture of enones 87 and 232 was obtained, Scheme 3.17. 
Disappointingly, attempts to separate the products chromatographically were 
unsuccessful, giving only trace amounts of the desired cyclohexenone 87. 
 
 
Scheme 3.17  Attempted synthesis of cyclohexenone 87 using Koo's procedure.83 
 
Mechanistically, the formation of enone 87 is reported to proceed via a base-catalysed 
Michael addition of ethyl acetoacetate into crotonaldehyde, Scheme 3.18. Cyclisation of 
the resulting intermediate 233 gives a bicyclic lactone 234, which collapses with 
concomitant loss of CO2 to yield enone 87. It was proposed that the presence of water 
may result in the protonation of intermediate 233 before cyclisation occurs, giving rise 
to the alternative enone 232 via an elimination pathway.83 
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Scheme 3.18  Koo's proposed mechanism for the formation of enone 87 and 232.83 
 
Repeating the reaction in tert-butanol, freshly distilled from sodium, also gave enone 87 
in a disappointing 15% yield (Lit.83 78%).  
 
An alternative synthesis reported by Fuchs et al. via reduction of ethoxy enone 237 
came to our attention, Scheme 3.19.84 Synthesis of ethoxy enone 237, was accomplished 
using the procedure of Pattenden et al.;85 treatment of commercially available 5-methyl-
1,3-cyclohexanedione 236 with p-TsOH in ethanol and benzene at reflux under Dean-
Stark conditions gave, after work-up, β-ethoxy enone 237 in 94% yield.  On subjecting 
enone 237 to the reductive transposition sequence reported by Fuchs et al.,84 methyl 
cyclohexenone 87 was isolated in 59% yield after distillation (Lit.84 84%). 
 
 
Scheme 3.19  Synthesis of cyclohexenone 87 using the procedure reported by Fuchs.84 
 
With cyclohexenone 87 in hand we were in a position to investigate the synthesis of 
isoquinuclidinone 229 using Cordova's "aza-Diels-Alder" methodology. Subjecting 
enone 87 to the (S)-proline-catalysed Diels-Alder conditions gave, after work-up, a 
brown oil, Scheme 3.20. Upon inspection of the 1H NMR spectrum of the unpurified 
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material, minor peaks corresponding to the diastereomeric isoquinuclidinones 229 and 
239 were apparent, but, attempts to isolate the compounds by flash column 
chromatography gave none of the desired product 229.   
 
 
Scheme 3.20  Aza-Diels-Alder reaction using cyclohexenone 87. 
 
On repeating the reaction at 50 ºC traces of the desired product were apparent in the 1H 
NMR spectrum of the crude material, but isolation attempts again proved unsuccessful. 
Due to the difficulties encountered with the preparation of the methyl-substituted 
isoquinuclidinone 229 and the known instability of previously prepared 
isoquinuclidinones 213, an alternative approach to a functionalised isoquinuclidinone 
core unit 209 was sought. 
 
3.6  An Alternative Strategy for the Synthesis of Isoquinuclidinones 
 
Owing to the difficulties encountered with the preparation of a functionalised bicyclic 
lactam using precedented procedures, an alternative route to the isoquinuclidinone core 
unit 209 was proposed, Scheme 3.21. We envisaged that disconnection of the amide 
bond would reveal the 4-amino cyclohexane carboxylate derivative 240; a structure 
resembling the intermediate 91 used by Bonjoch in the synthesis of 
isoquinuclidinones.43 
 
Scheme 3.21  Retrosynthesis of isoquinuclidinone 209. 
 
The required amine could be potentially installed via a Lewis acid-catalysed conjugate 
addition of benzyl carbamate to enone 232 following a number of reported procedures, 
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Scheme 3.22.86,87 Recent reports on the asymmetric addition of carbamates to 
unsaturated carbonyl compounds using chiral Lewis acid catalysts,88 could provide an 
enantioselective route to the isoquinuclidinone core. 
 
 
Scheme 3.22  Spencer's copper-catalysed conjugate addition of benzyl carbamate.86 
 
Alternatively, the conjugate addition of aqueous ammonia into unsaturated ketones was 
previously used by Rassat in the synthesis of isoquinuclidinones,44 and by Snider in the 
synthesis of the cyclindricine alkaloids.89  
 
A speculative strategy was proposed, using aqueous ammonia to install the required 
nitrogen functionality, Scheme 3.23. Previous research by Bonjoch had shown that 
structurally related compounds undergo lactamisation on heating to afford the 
corresponding bicyclic lactam as a mixture of diastereoisomers.43  
 
 
Scheme 3.23  Proposed synthesis of bicyclic lactams 209 and 242. 
 
Synthesis of the racemic β-ketoester 232 was accomplished using a modification of the 
procedure reported by Hamada.90 Treatment of ethyl acetoacetate and crotonaldehyde 
with freshly prepared sodium ethoxide gave the β-hydroxy ketone 235, which yielded 
the desired enone 232 on treatment with p-TsOH in toluene, Scheme 3.24.  Whilst the 
yield for the transformation was moderate, the low cost of the starting materials and 
brevity of the route allowed multi-gram quantities of enone 232 to be prepared. 
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Scheme 3.24  Synthesis of β-ketoester 232 using a modification of Hamada‟s procedure.90 
 
The relative stereochemistry was determined by 1H NMR spectroscopy; the large (11.7 
Hz) coupling constant between the adjacent protons was consistent with a trans-
equatorial relationship between the methyl substituent and ester group. 
 
3.6.1  Initial Studies 
 
Following the proposed synthesis, the addition of ammonia into the enone was 
investigated, Scheme 3.25, Table 3.1. 
 
 
Scheme 3.25  Attempted synthesis of β-amino ketone 240. 
 
Table 3.1  Conditions screened for the amination of enone 232.a 
Entry NH3 Source Co-solvent Time (h) Conversion
b
 
1 2.0 M in IPA - 24 <5% 
2 35% aq. DCM 24 100% 
3 35% aq. THF 24 100% 
4 35% aq. MeCN 6 100% 
5 35% aq. MeOH 2 100% 
6 35% aq. - 1 100% 
a All reactions were performed on a 0.1 mmol scale; entries 2-6 were carried out using 35% aq. NH3 (0.25 
mL) and solvent (0.5 mL). 
b Conversion estimated by 1H NMR spectroscopic analysis of the unpurified reaction mixture. 
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An initial amination attempt using ammonia in isopropanol resulted in the formation of 
a number of products as evident by TLC analysis, which were also seen in the 1H NMR 
spectrum of the unpurified material (entry 1).  Enone peaks at 6.1 and 7.0 ppm 
suggested significant amounts of starting material were still present; however, the 
identities of the other products could not be established. 
 
On treatment of enone 232 with 35% aqueous ammonia in a range of co-solvents, 
conversion of the starting material to a single, more polar species was evident by TLC 
analysis. Using THF or DCM as solvent, complete consumption of starting material was 
observed after 24 h at room temperature (entries 2 and 3), however, when water-
miscible solvents such as acetonitrile or methanol were used, reaction times were 
reduced to a few hours (entries 4 and 5). In the absence of a co-solvent, rapid 
consumption of the starting material was observed giving rise to a single product in 1 h. 
On inspection of the 1H NMR spectra for all the reaction, signals corresponding to the 
expected ethyl ester 240 were absent. Further analysis suggested the isolated product in 
all reactions was the novel bicyclic lactam 209, presumed to form as a result of in situ 
cyclisation of the intermediate amine 240, Scheme 3.26. 
 
 
Scheme 3.26  In situ cyclisation of amine 240. 
 
3.6.2  Structure Elucidation 
 
The isolated product was assigned the molecular formula C8H12NO2 based on HRMS 
and elemental analysis. Analysis of the material by 1H/13C NMR spectroscopy revealed 
characteristic bridgehead signals at δ 4.0 and 3.1 ppm and two quaternary signals in the 
13C NMR spectrum corresponding to the bridging ketone and lactam (205.1 ppm and 
171.8 ppm respectively). Although not conlusive, evidence for the stereochemistry of 
the methyl group was established via coupling constant analysis in analogy with that 
used to determine the relative stereochemistry of the isoquinuclidinone core unit in 
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grandisine B 15.9 The large coupling (10.8 Hz) between H-7a and H-8 suggested the 
protons were in an eclipsed conformation. An additional coupling (3-4 Hz) to H-7a was 




Figure 3.2  Evidence for the stereochemistry of bicyclic lactam 209. 
 
The 1H NMR spectroscopic data were conclusive with a bicyclic structure in which the 
methyl substituent was on the same face as the bridging ketone. 
 
3.6.3  Mechanism of the Amination/Cyclisation Sequence 
 
Mechanistically, the reaction is believed to proceed via an initial conjugate addition of 
ammonia to give the intermediate β-amino ketone 240 which cyclises in situ to yield a 
single diastereoisomer of the bicyclic lactam 209.  
 
 
Scheme 3.27  Proposed mechanism for the amination/cyclisation sequence. 
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We proposed that the formation of a single diastereoisomer could be rationalised by the 
reversible nature of the initial conjugate addition of ammonia. Under the reaction 
conditions, the conjugate addition of aqueous ammonia could give rise to two 
diastereomeric β-amino ketones 240 and 243, Scheme 3.27. The addition of ammonia 
syn to the methyl substituent gives rise to the cyclohexanone derivative 243 in which 
there is an anti relationship between the amine and ester. In order for the cyclisation to 
occur, the ester must initially epimerise to establish the syn-stereochemistry required for 
cyclisation. A slow cyclisation on the sterically hindered face of the cyclohexanone 244 
would yield isoquinuclidinone 242. Alternatively, addition of ammonia, anti to the 
methyl group would give rise to cyclohexanone 240 in which a syn-relationship 
between the amine and ester is already established. Rapid cyclisation on the less 
hindered face of the cyclohexane 240 proceeds to give lactam 209. 
 
Under the reaction conditions, it is also conceivable that β-keto ester 232 is in 
equilibrium with β-enamino ester 245, Scheme 3.28. The low conversion observed 
when ammonia in isopropanol was used in the reaction could possibly be attributed to 
the absence of water, which prevents hydrolysis of the β-enamino ester intermediate 245. 
 
 
Scheme 3.28  Possible equilibrium established under the reaction conditions. 
 
3.6.4  Scope of the Amination/Cyclisation Sequence 
 
Having established a viable process for the synthesis of isoquinuclidinones via a one-
pot amination/lactamisation sequence, the scope of the transformation was investigated. 
Following the procedure of Shing,91 the substrates 246 were prepared from the 
corresponding cyclohexenones 211 on treatment with LDA in THF/DMPU and 
subsequent trapping of the lithium enolate with ethyl cyanoformate, Scheme 3.29.  
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Scheme 3.29  Synthesis of β-ketoester substrates 246 from cyclohexenones 211.91 
 
The phenyl substituted derivative 246b was prepared in 61% yield using the procedure 
reported by Pietrusiewicz,92 Scheme 3.30. 
 
 
Scheme 3.30  Synthesis of substrate 246b using the procedure of Pietrusiewicz.92 
 
As seen in Table 3.2, the developed amination/cyclisation sequence was applicable to a 
range of substrates, Scheme 3.31.  
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Table 3.2  Scope of amination/cyclisation sequence for the synthesis of bicyclic lactams 248.a 




















a All reactions were performed on a 0.25 mmol scale using 35% aq. NH3 (1.0 mL) at rt. 
b Isolated yields. 
c Diastereomeric ratio ~4:1. 
 
The model substrate 246a used in initial studies cleanly cyclised to afford the methyl 
substituted lactam 248a in 93% yield and the corresponding phenyl substituted lactam 
248b was also prepared as a single diastereoisomer in good yield (entries 1 and 2). The 
process was also found to be applicable to disubstituted enones, the dimethyl substrate 
246c cyclised in good yield to afford the 7,7-substituted isoquinuclidinone 248c (entry 
3).  The carvone-derived substrate 246d was also found to cyclise, giving rise to a 
mixture of two diastereomeric lactams 248d, in excellent yield, however, the reaction 
time was extended, which was attributed to steric effects (entry 4). Attempts to separate 
the carvone-derived bicyclic lactams 248d by chromatography or fractional 
crystallisation proved to be unsuccessful and we were therefore unable to conclusively 
determine the structure by X-ray analysis. The relative stereochemistry was 
speculatively assigned from analysis of the 1H NMR spectroscopy coupling constants, 
Scheme 3.32. The C-6 proton in the major product showed couplings only to the methyl 
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substituent (C-12) and bridgehead proton (H-1), whereas the minor product showed an 
additional coupling (2.7 Hz), consistent with a W-coupling to H-7a. 
 
 
Scheme 3.32  Stereochemistry proposed for bicyclic lactams 248d. 
 
Finally, the cyclisation of the parent unsubstituted enone 246e was examined. On 
subjecting enone 246e to the optimised conditions, the formation of a number of 
products was observed by TLC analysis of the reaction mixture.  Although the crude 
mixture was more complex than previous examples, the known isoquinuclidinone 248e 
was isolated in 60% yield (entry 5). The NMR spectroscopic data for the unsubstituted 
isoquinuclidinone 248e were consistent with those reported,45 but, a significant 
difference in the melting point was noted; 207-209 ºC (Lit.45 143-144 ºC).  
 
3.6.5  Synthesis of Bridgehead Substituted Isoquinuclidinones 
 
The synthesis of isoquinuclidinones bearing substituents at the bridgedhead positions 
was also investigated. On subjecting the β-substituted enone 249 to the optimised 
reaction conditions, Scheme 3.33, no cyclisation to the corresponding isoquinuclidinone 
250 was observed even after extended reaction times. 
 
 
Scheme 3.33  Attempted cyclisation of bridgehead substituted enone 249. 
 
The result suggests that substitution at the β-position of the enone disfavours the initial 
1,4-addition of ammonia preventing cyclisation. However, the bridgehead substituted 
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isoquinuclidinone 95 was previously prepared by Rassat, suggesting that 1,4-addition of 
ammonia into β-substituted enones can occur under similar conditions.44 
 
Despite the unsuccessful attempts to prepare the C-1 substituted isoquinuclidinone 250, 
the synthesis of C-4 substituted isoquinuclidinones was investigated. Treatment of β-
keto ester 246a with sodium hydride in THF and subsequent trapping of the enolate 
with methyl iodide gave substrate 251 in 38% yield.  The stereochemistry of the product 
was assumed to be that depicted in Scheme 3.34, formed via approach of the 
electrophile on the opposite face to the methyl substituent. Attempts to confirm the 
stereochemistry of ester 251 by nOe studies proved inconclusive; the C-6 methyl group 
showed correlations to both the C-5 proton and C-5 methyl substituent. 
 
 
Scheme 3.34  Synthesis of substrate 251. 
 
On subjecting enone 251 to the optimised reaction conditions, isoquinuclidinone 252 
was successfully prepared in 83% yield, with a slight increase in reaction time, which 




Scheme 3.35  Synthesis of isoquinuclidinone 251 from enone 252. 
 
1H NMR spectroscopic analysis of the purified product provided evidence for the 
stereochemistry. A small coupling (3.4 Hz) between H-6a and H-7a was attributed to a 
W-coupling, however, in contrast to isoquinuclidinones isolated previously, the small 
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(4.6 Hz) coupling between H-7a and H-8 was consistent with an axial-equatorial 
coupling (Figure 3.3). The data were consistent with a structure in which the methyl 
substituent was on the opposite face to the bridging ketone. 
 
 
Figure 3.3  Stereochemistry of isoquinuclidinone 252. 
 
Conclusive evidence for the structure was obtained by single crystal X-ray diffraction 
analysis of the product, which confirmed the methyl group was on the opposite face to 
the bridging ketone (Figure 3.4). 
 
 
Figure 3.4  X-ray strucutre of compound 252 depicted using ORTEP-3 (CCDC 789903). 
 
The result confirms that cyclisation can occur on the hindered face of the 
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3.7  Synthesis of N-Substituted Bicyclic Lactams 
 
Having demonstrated the scope of the amination/cyclisation sequence using aqueous 
ammonia, alternative nitrogen sources were considered.  Initially, the reaction of enone 
246a with methylamine was investigated.  On treatment of enone 246a with excess 
aqueous methylamine, consumption of the starting material was observed, with the 
formation of a single product apparent by TLC analysis. However, on inspection of the 
1H NMR spectrum of the unpurified material, signals corresponding to two structurally 
related products were evident, with additional methyl signals also apparent.  The NMR 
spectroscopic and HRMS data were consistent with structures 253 and 254 




Scheme 3.36  Formation of N-methyl lactam 255 via hydrolysis of imine 253 and 254. 
 
Further evidence for the structures 253 and 254 was obtained on treatment of the imine 
with 10% aqueous HCl, which gave the expected isoquinuclidinone 255 in 53% yield. 
Gradual hydrolysis of imines 253 and 254 was also observed when a sample was left to 
stand in chloroform. 
 
In an attempt to negate the formation of imines 253 and 254, the reaction was repeated 
using stoichiometric amine. Pleasingly, on treatment of enone 246a with 1 equivalent of 
methylamine in water, the N-methyl isoquinuclidinone 255a was isolated in 62% yield, 
without the need for an additional hydrolysis step. Conclusive evidence for the structure 
of N-methyl lactam 255a was obtained by single crystal X-ray diffraction analysis, 
which confirmed the relative stereochemistry, Figure 3.5. 
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Figure 3.5  X-ray strucutre of compound 255a depicted using ORTEP-3 (CCDC 789904). 
 
Having demonstrated that primary amines could also be successfully employed in the 
cyclisation sequence, the use of other amines was investigated, Scheme 3.37, Table 3.3. 
 
 
Scheme 3.37  Synthesis of N-substituted bicyclic lactams 255. 
 
Table 3.3  Synthesis of N-substituted bicyclic lactams 255.a 
Entry Amine Time Yield
b
 
1 Methylamine 24 h 62% 
2 n-Propylamine 48 h 49% (49%)c 
3 Allylamine 48 h 43% 
4 Hexylamine 48 h 0% 
5 Benzylamine 48 h 0% 
6 Tryptamine 48 h 0% 
7 tert-Butylamine 48 h 0% 
a All reactions performed on 0.25 mmol scale using amine (0.25 mmol) in H2O (1 mL). 
b Isolated yields after purification by column chromatography. 
c Reaction complete in 18 h at 80 ºC. 
 
As seen in Table 3.3, propyl and allyllamine gave the corresponding N-substituted 
isoquinuclidinones in 255b and 255c in 49% and 43% yield respectively (entries 2 and 
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3). Disappointingly, lactam formation was not observed when hexylamine, benzylamine 
tryptamine or tert-butylamine were employed (entries 4-7), which gave complex 
mixtures of unidentified products. The unsuccessful cyclisations were attributed to 
steric effects, however, it is also conceivable that poor solubility of the reaction 
intermediates in the aqueous solvent system could prevent the cyclisation. 
 
3.8  Synthesis of a Thiolactam Cross-Coupling Partner 
 
Having established a viable procedure for the synthesis of a functionalised 
isoquinuclidinone core, conversion into the corresponding thiolactam was investigated 
in order to prepare a suitable cross-coupling partner for use in the Liebeskind-Srogl-type 
coupling. Pleasingly, on treatment with Lawesson's reagent in toluene at reflux, 
thiolactam 208 was isolated in an unoptimised 38% yield, the low yield partially 
attributed to purification on a small-scale, Scheme 3.38.  
 
 
Scheme 3.38  Conversion of bicyclic lactam 248a to the thiolactam 208. 
 
3.9  Summary 
 
A one-pot procedure for the synthesis of bicyclic lactams 248 from cyclohexenone 
derivatives 246, via an amination/cyclisation sequence has been successfully developed. 
The methodology was extended to enable the synthesis N-substituted bicyclic lactams 
255. A suitable partner 208 for use in cross-coupling studies has also been prepared via 
conversion of a functionalised bicyclic lactam into the corresponding thioamide.  A 
further extension of the amination/cyclisation sequence, with potential applications in 
the synthesis of grandisine B 15, is described in Chapter 4. 
 
The work described in this Chapter was the subject of a recent publication.93 
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Chapter 4.  An Amination/Cyclisation Approach to 
Isoquinuclidinones 
 
4.1  Initial Cyclisation Studies 
 
In the previous chapter the development of a one-pot synthesis of bicyclic lactams via 
an amination/lactamisation sequence was described. Although in a position to 
investigate the synthesis of grandisine B 15 via the proposed cross-coupling strategy, 
we were keen to further explore the utility of the amination/cyclisation sequence in the 
synthesis of other aza-bicyclic systems. We proposed that replacement of the ester 
functionality with a ketone would afford the corresponding imine on cyclisation, 
Scheme 4.1. Such a route would provide rapid access to isoquinuclidinone structures 
similar to that found in grandisine B 15. 
 
 
Scheme 4.1  Proposed synthesis of isoquinuclidinone 259 via an amination/cyclisation sequence. 
 
The proposed sequence would constitute a biomimetic synthesis of isoquinuclidinones, 
in accordance with the final step in Carroll's proposed synthesis of grandisine B 15 and 
Robertson‟s proposed synthesis of mearsine 27, Scheme 4.2.9,14 
  
 
Scheme 4.2  Selected steps in the synthesis of grandisine B 15 and mearsine 27.9,14 
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Retrosynthetically, it was envisaged that the 1,3-diketone substrates 257 could be 
readily prepared from cyclohexenone 104 via an aldol/oxidation sequence as shown in 
Scheme 4.3.  
 
Scheme 4.3  Retrosynthesis of 1,3-diketone substrates 257. 
 
4.1.2  A Phenyl-Substituted Model Substrate 
 
Initially we chose to prepare diketone 257a, which was accomplished in 2 steps from 
commercially available cyclohexenone 104. Deprotonation of cyclohexenone 104 with 
lithium diisopropylamide at −78 ºC and subsequent trapping with benzaldehyde, gave 
the aldol product 260a in 71% yield, Scheme 4.4. Oxidation of benzylic alcohol 260a 
under modified Swern conditions94 using trifluoroacetic anhydride furnished the 




Scheme 4.4  Synthesis of substrate 257a via aldol/oxidation sequence. 
 
With diketone 257a in hand, we were in a position to investigate the 
amination/cyclisation sequence. Using the conditions previously optimised for the 
amination/lactamisation sequence, treatment of diketone 257a with 35% aqueous 
ammonia, resulted in the rapid consumption of the starting material with the 
concomitant formation of a number of species apparent by TLC analysis, Scheme 4.5. 
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Scheme 4.5  Attempted cyclisation of 1,3-diketone 257a. 
 
Pleasingly, 1H NMR spectroscopic analysis of the unpurified material showed signals 
corresponding to the desired bicyclic imine 259a, along with a number of minor 
impurities. However, attempts to purify the material proved unsuccessful, with no 
product recovered after silica gel chromatography. It was proposed that the 
isoquinuclidinone product 259a was unstable, or susceptible to hydrolysis, in the 
presence of acid. In the initial reaction we were therefore unable to fully characterise 
isoquinuclidinone 259a and conclusively confirm the structure. Disappointingly, on 
scale-up, TLC analysis showed the formation of a number of species. Analysis of the 
unpurified material by 1H NMR spectroscopy revealed a complex mixture of 
compounds containing only minor amounts of the desired bicyclic imine 259a. 
 
Due to the difficulties encountered with purification, a screen of reaction conditions was 
undertaken to determine whether bicyclic imine 259a could be formed exclusively, 
without the need for purification. Whereas previously the reaction had been carried out 
neat, it was proposed that addition of aqueous ammonia to a solution of diketone 257a 
in a water miscible solvent would ensure the reaction mixture was homogeneous. 
Repeating the reaction in aqueous acetonitrile, however, failed to offer any 
improvement on the previously observed product distribution. A further screen of 
reaction conditions (temperature, concentration) also failed to improve the product 
distribution, with isoquinuclidinone 259a generally a minor product observed by 1H 
NMR spectroscopy. The addition of NH4Cl to buffer the aqueous ammonia, as reported 
by Snider and co-workers in their synthesis of cylindricine A, also proved 
unsuccessful.89 
 
Due to limited success in preparing the model isoquinuclidinone 259a using the 
amination/cyclisation sequence, the analogous cyclohexyl substituted diketone 257b 
was prepared, to determine whether this would cyclise on treatment with ammonia. 
  77 
4.1.2  A Cyclohexyl-Substituted Model Substrate 
 
Deprotonation of cyclohexenone 104 with LDA at −78 ºC and subsequent trapping with 
cyclohexane carboxaldehyde gave the aldol product 260b, Scheme 4.6. Oxidation with 
Dess-Martin periodinane,95 gave diketone 257b in 55% yield, which again was found to 
exist as a mixture of keto/enol tautomers. 
 
 
Scheme 4.6  Synthesis of cyclohexyl-substituted 1,3-diketone 257b. 
 
In parallel with the previous results, an initial small-scale reaction yielded 
isoquinuclidinone 259b as the predominant product on treatment with aqueous 
ammonia, Scheme 4.7. The product was sufficiently pure to allow full characterisation 




Scheme 4.7  Synthesis of isoquinuclidinone 259b via amination/cyclisation sequence. 
 
Bridgehead signals at 4.50 ppm and 3.34 ppm in the 1H NMR spectrum were consistent 
with the bicyclic structure. The 13C NMR spectrum showed two quaternary signals 
corresponding to the bridging ketone (209.6 ppm) and the cyclic imine (178.8 ppm). 
Disappointingly, repeating the reaction on a larger scale led to the formation of a 
number of products, evident in the 1H NMR spectrum of the unpurified product.  
Attempts to separate/characterise the products in order to provide further insights into 
the reaction proved unsuccessful. 
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Although at this stage results were mixed, we felt it would be instructive to apply the 
methodology to a model system representative of that found in grandisine B 15, in order 
to determine whether the route was viable for use in the proposed synthesis. Initial 
studies on model compounds 257a and 257b suggested that the exocyclic ketone 
substituent had little effect on the cyclisation, however, we proposed that the 
cyclohexenone methyl substituent may play a role in the cyclisation. In Chapter 3 it was 
noted that in the cyclisation of the unsubstituted bicyclic lactam 248e the unpurified 
reaction mixture was more complex than substituted examples. 
 
4.2  Synthesis of Substituted Isoquinuclidinones 
 
The methyl substituted diketone 262a was prepared using the two step aldol/oxidation 
sequence in 68% overall yield from 5-methylcyclohexenone 87, Scheme 4.8.  The 1H 
NMR spectroscopic data were consistent with the trans-stereochemistry depicted, 
evident from the large (10.7 Hz) coupling constant between protons H-5 and H-6.  
 
 
Scheme 4.8  Synthesis of methyl-substituted diketone 262a. 
 
On treatment of diketone 262a with 35% aqueous ammonia, the rapid consumption of 
starting material was observed, however, in contrast to previous reactions, TLC analysis 
showed the formation of only one product, Scheme 4.9. 
 
 
Scheme 4.9  Synthesis of isoquinuclidinone 263a via amination/cyclisation sequence. 
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Pleasingly, analysis of the 1H NMR spectrum of the unpurifed reaction mixture showed 
the predominant product was the desired bicyclic imine 263a, which was isolated in 
91% yield after purification by column chromatography. In subsequent studies it was 
found that methanol could be successfully employed as a co-solvent in the reaction, 
ensuring substrate solubility in the aqueous solvent system. 
 
4.2.1  Structure Elucidation 
 
The HRMS data were consistent with the expected product, supporting a molecular 
formula of C14H16NO. Analysis of the purified material by 
1H/13C NMR spectroscopy 
provided further evidence to suggest the product was the desired isoquinuclidinone 
263a. Characteristic bridgehead signals were observed at 4.8 ppm and 3.9 ppm in the 1H 
NMR spectrum and the 13C NMR spectrum showed signals at 208.3 ppm and 171.6 
ppm consistent with the bridging ketone and bicyclic imine respectively. 
 
Unfortunately, attempts to confirm the relative stereochemistry of the product by 
coupling constant analysis, in analogy with the previously prepared bicyclic lactams, 
was not possible. An additional coupling (~3 Hz) to proton H-6a was consistent with a 
W-coupling, but, the signals for the C-7 protons were obscured, and so the 
corresponding coupling constant could not be picked out. 
 
4.3  Scope of the Amination/Imination Sequence 
 
Having demonstrated the viability of the amination/imination sequence we were keen to 
explore the scope of the transformation. A range of substrates 262 was prepared using 
the lithium aldol reaction to yield the β-hydroxy ketones 261 which were readily 
oxidised with Dess-Martin periodinane or modified Swern conditions using TFAA, 
Scheme 4.10. 
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Scheme 4.10  Synthesis of 1,3-diketone substrates 262. 
 
Using the optimised reaction conditions, a range of substrates were found to cyclise in 
moderate to excellent yield, Scheme 4.11, Table 4.1. 
 
 
Scheme 4.11  Scope of the amination/cyclisation sequence. 
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Table 4.1  Scope of amination/imination sequence.a 




























8 ~ 50%d 
a All reaction were performed on 0.25 mmol scale using MeOH (1 mL), 35% aq. NH3 (0.5 mL) at 0 ºC to rt. 
b Isolated yields. 
c dr = 3.4:1. 
d An inseperable mixture of 263g and side-products (yield estimated by 1H NMR spectroscopy).  
 
The phenyl substituted diketone 262a used in initial studies gave isoquinuclidinone 
263a in 91% yield (entry 1). The reaction was also found to be applicable to aliphatic 
diketones. The cyclohexyl and hexyl substituted isoquinuclidinones were prepared in 
89% and 65% yield respectively (entries 2 and 3).  The bis-enone substrate 262d readily 
cyclised to give the isoquinuclidinone 263d in 80% yield, containing the α,β-
unsaturated imine found in grandisine B 15 (entry 4). Whilst it was previously assumed 
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that the unsaturated imine moiety would be unstable, no evidence of degradation was 
noted with isoquinuclidinone 263d.  The reaction was not just applicable to the 
synthesis of methyl substituted isoquinuclidinones, although on increasing the steric 
bulk of the cyclohexenone ring substitutents an increase in the reaction time was 
observed. Initially, the cyclisation of the trisubstituted carvone derived diketone 262e 
was investigated.  Although the cyclisation proceeded using the optimised conditions, 
the reaction took three days to go to completion. 1H NMR spectroscopic analysis of the 
purified product revealed a diastereomeric mixture (~3.4-1) corresponding to the two 
possible isomers at the C-6 stereocentre (entry 5). Attempts to determine the relative 
stereochemistry of the diastereoisomers by 1H NMR spectroscopy were unsuccessful 
and we were unable to obtain a crystalline derivative for X-ray analysis. The relative 
stereochemistry of the major isomer 262e remains to be assigned. 
  
The propyl substituted cyclohexenone cyclised in good yield to afford the 
corresponding isoquinuclidinone 263f (entry 6). However, in the case of the phenyl 
substituted diketone 262g, whilst cyclisation was observed, the product 263g was 
inseparable from a number of side-products formed during the reaction (entry 7). 
 
4.4  Bridgehead Substituted Isoquinuclidinones 
 
The synthesis of isoquinuclidinones with bridgehead substitution was also investigated. 
Alkylation of the 1,3-diketone 262b with methyl iodide in the presence of K2CO3 gave 
the substituted derivative 264 in 26% yield, Scheme 4.12. On subjecting diketone 264 to 
the optimised reaction conditions, the formation of a number of products was observed 
by TLC analysis. 
 
 
Scheme 4.12  Attempted synthesis of bridgehead substituted isoquinuclidinone 265. 
 
Disappointingly, 1H NMR spectroscopic analysis revealed a complex mixture of 
compounds in the unpurified material, but, no evidence of the bicyclic imine 265 was 
  83 
observed. In this instance, cyclisation on the sterically hindered face of the 
cyclohexenone ring was not possible, which we attributed the increased steric bulk of 
the cyclohexyl substituent on the ketone. 
 
4.5  Attempted Synthesis of Unsubstituted Isoquinuclidinones 
 
In the final part of this study we returned to investigate the cyclisation of unsubstituted 
cyclohexenone derivatives using the optimised reaction conditions.  In contrast to the 
initial investigations, on addition of aqueous ammonia to a solution of diketone 257a in 
methanol, rapid consumption of the starting material was observed with the formation 
of a single product apparent by TLC analysis, Scheme 4.13. 
 
 
Scheme 4.13  Unexpected ring opening of isoquinuclidinones to form methyl esters 266. 
 
Upon inspection of the 1H NMR spectrum of the unpurified product, signals 
corresponding to the expected isoquinuclidinone 259a were absent and the presence of a 
3 H singlet at 3.74 ppm was consistent with a methoxy group. The molecular formula 
was established as C14H18NO2 based on HRMS data, which was also consistent with the 
addition of a methoxy group. 1H/13C NMR spectroscopy revealed a number of 
differences with the previously isolated isoquinuclidinones.  The absence of bridgehead 
signals in the 1H NMR spectrum was noted, however, a multiplet at 3.98 ppm was 
consistent with a proton adjacent to a heteroatom.  In the 13C NMR spectrum, the signal 
corresponding to the bridging ketone was also absent; however, a quaternary carbon 
signal at 165.4 ppm suggested an ester or related functional group. An IR stretch at 
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1735 cm−1 was also consistent with the proposed ester. The spectroscopic data were 
consistent with the monocyclic imine 266a. 
 
4.5.1  Proposed Mechanism of Ring Opening 
 
Mechanistically, the formation of imine 266a is proposed to proceed via the expected 
isoquinuclidinone 259a, which underwent in situ methoxide induced ring opening to 
give the methyl ester 266a, Scheme 4.14. An analogous mechanism was proposed by 
Carroll and co-workers to account for the formation of grandisine G 20.10 
 
 
Scheme 4.14  Mechanism proposed for the formation of methyl ester 266a. 
 
It seems likely that the presence of the methyl susbtituent on previously prepared 
isoquinuclidinones increased the steric hindrance around the bridging ketone, 
preventing the attack of methoxide, however, more detailed studies would be required to 
prove this conclusively.  
 
4.5.2  Scope of the Ring Opening 
 
The in situ ring opening was found to be general for a range of unsubsituted enones 257, 
Scheme 4.15, Table 4.2. 
 
Scheme 4.15  Scope of methyl ester formation. 
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Table 4.2  Scope of methyl ester formation. 





















a Isolated yields. 
 
The phenyl substituted monocyclic imine 266a was prepared in 72% yield and the 
cyclohexyl derivative 266b was prepared in an excellent 89% yield (entries 1 and 2). 
The pentyl and cyclohexenyl derivative also underwent the cyclisation/ring-opening to 
yield the methyl esters 266c and 266d in 89% and 96% yield, respectively (entries 3 and 
4). In all instances, the crude material was found to be essentially homogeneous 
requiring no purification. 
 
Further evidence for the proposed structure was obtained on reduction of imine 266c 
with sodium borohydride in methanol, which gave the diastereomeric piperidine 
derivatives 267 and 268 in 93% yield, Scheme 4.16. These known compounds were 
previously isolated from the ladybird species Calvia 14-guttata,96 and recently used by 
Daloze as an intermediate in the synthesis of calvine 270.97 The reduction could 
potentially be used as a route into other 2,6-disubstituted piperidine derivatives, 
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Scheme 4.16  Reduction of imine 266c with sodium borohydride. 
 
4.6  Applications of β-Imino Esters (266) 
 
While the monocyclic imines 266 prepared were all novel, a structurally related 
piperidine was used by Corey et al. in the synthesis of analogues of the alkaloid 
histrionicotoxin 269.98 The partial structure is also common to a number of alkaloids, 
with representative examples including calvine 270 and sederine 271 (Figure 4.1).96,99 
 
 
Figure 4.1  Structures of histrionicotoxin 269, calvine 270 and sederine 271. 
 
More relevant to current research is the close resemblance of the monocyclic imines 266 
to grandisine G 20. The alkaloid, isolated by Carroll and co-workers,10 was proposed to 
arise via methoxide promoted ring opening of grandisine B 15, a transformation 
analogous to that observed for the unsubstituted isoquinuclidinones 259, Scheme 4.17. 
 
Scheme 4.17  Proposed formation of grandisine G 20 from grandisine B 15.10 
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It is interesting to note that grandisine G 20 possesses a methyl substituent, however in 
the current study, isoquinuclidinones bearing methyl substituents were found not to 
undergo the methanol promoted ring opening. The isolation of grandisine G 20 provides 
evidence to suggest that ring opening is possible when the methyl group is present, 
however, this may not occur via the mechanism proposed. Additional work would be 
required to determine whether the sequence could be used in the synthesis of grandisine 
G 20. 
 
4.7 The Total Synthesis of (−)-Mearsine (27) 
 
Mearsine 27, was isolated by Robertson et al. in 1984 from the leaves of the species 
Peripentadenia mearsii.14 To date, it remains the only alkaloid known to possess the 
same structure as the isoquinuclidinone core unit in grandisine B 15. The compound has 
been the subject of one total synthesis reported by Pinder and Crouse in 1989, but this 
was of the unnatural (+)-mearsine 27 (Figure 4.2). 
 
 
Figure 4.2  Structure of the Elaeocarpus alkaloid mearsine 27.14 
 
It was proposed that mearsine 27 is derived from diketone 51, a biosynthetic pathway 
unusual in the fact that the carbon skeleton is comprised entirely of acetate units.14 We 
envisaged that mearsine 27 would provide an ideal target to further test the utility of the 
amination/cyclisation methodology using the proposed biosynthetic intermediate 51 as a 
synthetic intermediate, Scheme 4.19. 
 
 
Scheme 4.19  Proposed synthesis of mearsine 27 from diketone 51. 
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Although the racemic synthesis of diketone 51 had previously been reported by 
Geirsson, Scheme 4.20,100 there was no precedent for its enantioselective synthesis.  
 
 
Scheme 4.20  Geirsson's synthesis of diketone 51.100 
 
We envisaged preparing diketone 51 from acetylacetone as depicted retrosynthetically 
in Scheme 4.21. 
 
 
Scheme 4.21  Retrosynthetic analysis of diketone 51. 
 
4.7.1  Synthesis of Aldehyde (274) 
 
It was proposed that an organocatalytic Michael addition of acetylacetone 273 to 
crotonaldehyde using the silyl prolinol catalyst 275 would afford the novel aldehyde 
274,101 which would undergo an acid catalysed aldol condensation to afford the desired 
enone 51. Thus, an initial reaction of acetylacetone 273 and crotonaldehyde in toluene 
mediated by Jørgensen‟s prolinol catalyst 275 (10 mol%) gave the desired aldehyde 274 
in 91% yield after purification.   
 
While no extensive optimisation studies were undertaken, it was subsequently found 
that the catalyst loading could be decreased to 1 mol% if the reaction was carried out 
neat, giving aldehyde 274 in essentially quantitative yield, which was of sufficient 
purity to use without purification, Scheme 4.22.  
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Scheme 4.22  Synthesis of aldehyde 274. 
 
Although at the time unprecedented, a paper by Rovis and Lathrop recently reported the 
synthesis of aldehyde 274 using the described sequence.102 Importantly, Rovis reported 
that a retro-Michael reaction was observed in the presence of catalyst 275, which was 
enhanced in the presence of silica, highlighting the need to avoid purification of 
aldehyde 274 on silica. 
 
Attempts to determine the enantiomeric excess of aldehyde 274 by chiral HPLC were 
unsuccessful, however, condensation of aldehyde 274 with enantiomerically pure α-
methyl benzylamine yielded an ~80:20 diastereomeric mixture of imines 276 observable 
in the 1H NMR spectrum of the unpurified product, Scheme 4.23. 
 
 
Scheme 4.23  Formation of the diastereomeric imines 276. 
 
Imine 276 could also potentially undergo a retro-Micheal reaction in the presence of α-
methyl benzylamine and as such, the actual enantiomeric ratio could be greater than the 
NMR spectroscopic data would suggest. 
 
In order to prepare material for chiral HPLC studies and to optimise the concluding 
steps in the sequence, we felt it would be instructive to also consider the synthesis of 
racemic aldehyde 274.  Attempts to use pyrrolidine or Et3N in place of organocatalyst 
275 gave only traces of the desired aldehyde, along with numerous unidentified 
products. A modification of the procedure reported by Ranu,103 using alumina to 
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catalyse the Michael addition of β-ketoesters to unsaturated aldehydes, also failed to 
yield aldehyde 274, Scheme 4.24. 
 
 
Scheme 4.24  Attempted synthesis of aldehyde 274 using the procedure of Ranu.103 
 
An alternative strategy for the racemic synthesis of aldehyde 274 was proposed, 
commencing from the known tert-butyl ester 277,104 readily prepared by treatment of 
tert-butyl acetoacetate with acetyl chloride in the presence of magnesium chloride. We 
envisaged that conjugate addition into crotonaldehyde would yield aldehyde 278, which 
would undergo an acid-catalysed decarboxylation on treatment with acid. 
Disappointingly, all attempts to promote the conjugate addition proved unsuccessful, 




Scheme 4.25  Attempted synthesis of aldehyde 274 from tert-butyl ester 277. 
 
At this point in time we felt it would be counter-productive to spend further time 
attempting the racemic synthesis of aldehyde 274; for the purpose of chiral HPLC 
studies a sample of racemic material was prepared using equimolar amounts of (R) and 
(S)-organocatalysts using the previously described procedure. 
 
4.7.2  Synthesis of the Mearsine Biosynthetic Precursor (51) 
 
With aldehyde 274 in hand, we were in a position to investigate the aldol condensation. 
On treatment of aldehyde 274 with p-TsOH in toluene at 80 ºC, following the procedure 
of Jørgensen,105 enone 51 was isolated in a disappointing 22% yield. It was thought that 
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carrying out the reaction at a lower concentration would favour the intramolecular ring 
closure. Pleasingly, treatment of aldehyde 274 with p-TsOH (10 mol%) in toluene (0.15 
M) at 50 ºC furnished enone 51 in a respectable 74% yield, Scheme 4.26. 
 
 
Scheme 4.26  Synthesis of diketone 51 via an acid-catalysed aldol condensation. 
 
Alternative procedures using Amberlyst H-15 acidic resin failed to offer any 
improvement over the initial yield.  A base induced ring closure using NaOH in ethanol 
also failed to yield the desired enone 51. 
 
The isolation of a minor impurity observed in the 1H NMR spectrum of the unpurified 
reaction mixture revealed a structurally intriguing side-product formed during the 
reaction.  The molecular formula was established as C9H14O3 through HRMS analysis, 
suggesting a rearrangement product of aldehyde 274. 1D and 2D NMR spectroscopic 
data were consistent with the loss of both ketones, however, a signal at 168.5 ppm in the 
13C NMR spectrum suggested the presence of an ester functionality (an IR stretch at 
1736 cm−1 was also observed). A quaternary carbon at 104.4 ppm was consistent with a 
carbon bonded to two heteroatoms. The spectroscopic data were consistent with a 
structure such as lactone 279 (Figure 4.3), however, the relative stereochemistry 
remains to be established. 
 
 
Figure 4.3  Structure proposed for side-product 279. 
 
Although no conclusive evidence for the mechanism of formation of lactone 279 has 
been obtained, it was proposed that enone 51 could undergo a retro-Claisen reaction in 
the presence of p-TsOH to give the unsaturated carboxylic acid derivative 282, Scheme 
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4.27. The enol tautomer 282 of the methyl ketone could add into the enone to form the 
pyran derivative 283. Under acidic conditions an intramolecular cyclisation would occur 
to give the lactone 279. A structurally similar compound 280 was previously prepared 
by Adams and Frenette, however, in this instance, the lactone was installed via Baeyer-
Villiger oxidation of the corresponding ketone.106 
 
 
Scheme 4.27  Proposed mechanism for the formation of side-product 279. 
 
4.7.3  Application of the Amination/Cyclisation Sequence to the Synthesis of 
(−)-Mearsine (27) 
 
With enone 51 in hand we were in a position to investigate the one-pot amination/ 
cyclisation sequence. On treatment of enone 51 with 35% aqueous ammonia, 
consumption of the starting material was observed with the concomitant formation of a 
more polar species apparent by TLC analysis, Scheme 4.28.  
 
 
Scheme 4.28  An amination/cyclisation approach to mearsine 27. 
 
On inspection of the 1H NMR spectrum of the unpurified product, we were pleased to 
observe signals corresponding to those reported for mearsine 27, although slight 
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discrepancies were noted. Whilst the 13C NMR spectroscopic data were consistent with 
those reported, the signals in the 1H NMR spectrum corresponding to the C-4 
bridgehead proton was shifted by ~0.15 ppm (3.13 ppm, Lit.42 3.27 ppm). The [α]D also 
differed significantly from that reported in the literature, the optical rotation for the 
synthetic material was found to be −252.6 (c 0.51, DCM), while the optical rotation for 
the natural product was reported to be −34.5 (c 0.495, DCM).42 These inconsistencies 
raised concerns about the structure of the isolated material. We initially proposed that 
conjugate addition of ammonia occurred anti to the methyl substituent, in order to 
minimise steric interactions, however, the epimeric compound 284 could potentially 
form if the addition of ammonia occurs syn to the methyl substituent. A sample of the 
synthetic material was therefore converted into the crystalline picrate salt for X-ray 
diffraction analysis, which provided conclusive evidence for the structure of the 
synthetic mearsine 27 (Figure 4.4). 
 
 
Figure 4.4  Crystal structure of mearsine 27 depicted using ORTEP-3 (picrate counter anion omitted for 
clarity) (CCDC 825975). 
 
Due to the inconsistency noted with the optical rotation value, the enantiomeric ratio 
was determined through chiral HPLC analysis (Phenomenex Lux Cellulose-2 column, 
95:5 iso-hexane/EtOH, flow rate 1.0 mL/min) which showed the enantiomeric ratio to 
be 90.5:9.5 (peak identity was confirmed using racemic material). Whilst the 
inconsistencies in the NMR spectroscopic data could possibly be attributed to 
solvent/concentration effects, no satisfactory explanation for the significant difference 
in the optical rotation has been found. 
 
                                                 
 We thank Dr. A. Hard (AZ Macclesfield) for assistance with chiral HPLC analysis. 
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4.7.4  A One-pot Aldol Condensation/Cyclisation Strategy 
 
A speculative one pot base-catalysed aldol condensation and subsequent 
amination/cyclisation was also considered for the synthesis of mearsine 27. It was 
proposed that aldehyde 274 would undergo a base-catalysed aldol condensation to yield 
the intermediate enone 51, which would cyclise in situ. On treatment of aldehyde 274 
with 35% aqueous ammonia, complete consumption of the starting material was 
observed, to give a single product apparent by TLC analysis, which had an Rf value 
similar to that observed for mearsine 27, Scheme 4.29. 
 
 
Scheme 4.29  Formation of novel bis-imine 285. 
 
1H NMR spectroscopic analysis of the unpurified reaction mixture showed peaks 
corresponding to a bicyclic species, including bridgehead signals at 6.24 ppm and 3.71 
ppm, however, these were not consistent with mearsine 27. The molecular formula was 
determined to be C9H14N2 through HRMS analysis. The absence of the bridging ketone 
was apparent in the 13C NMR spectrum, but an additional quaternary carbon was 
present at ~170 ppm, consistent with a second imine.  The structure of the isolated 
material was eventually established through a combination of 2D NMR spectroscopy 
techniques which showed the compound to be the novel bis-imine 285. The compound 
was proposed to form via the intermediate monocyclic imine/enamine 286. Subsequent 
cyclisation of the exo-cyclic enamine, yields the novel bis-imine 285, after 
tautomerisation, Scheme 4.30. 
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Scheme 4.30  Mechanism proposed for the formation of bis-imine 285. 
 
It was subsequently found that bis-imine 285 could also be prepared by treatment of 
acetylacetone and crotonaldehyde with aqueous ammonia.  Whilst the unpurified 
reaction mixture was more complex than that from the reaction using the preformed 
aldehyde 274, the bis-imine 285 was the predominant product evident in the 1H NMR 
spectrum. Disappointingly, attempts to isolate the product from the mixture were 
unsuccessful, which we attributed to the low stability of bis-imine 285. 
 
4.8  Summary 
 
An expedient synthesis of isoquinuclidinones has been developed using aqueous 
ammonia in a one-pot amination/imination sequence. Using the optimised methodology, 
we have completed the total synthesis of enantioenriched (−)-mearsine 27 in 3 steps 
(60% overall yield, 81% ee) from commercially available materials. Unsubstituted 
isoquinuclidinones have been shown to undergo in situ ring opening to afford 
monocyclic imines structurally similar to the alkaloid grandsine G 20. This 
transformation provides a potential synthetic route to grandisine G 20 which will be 
discussed in Chapter 5.  
 
The work described in this chapter was the subject of a recent publication.107 
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Chapter 5.  A Biomimetic Synthesis of (±)-Grandisine B (15) 
 
5.1  A Biomimetic Approach to Grandisine B (15) 
 
Having developed a viable route to isoquinuclidinone frameworks using aqueous 
ammonia in a one-pot amination/cyclisation sequence, we set out to apply the 
methodology to the synthesis grandisine B 15. The biomimetic strategy, based on 
Carroll's proposed biosynthesis,9 would use the 1,3-diketone grandisine D 17 as a 
synthetic intermediate, Scheme 5.1. 
 
 
Scheme 5.1  Proposed synthesis of grandisine B 15 via a biomimetic amination/cyclisation sequence.9 
 
As proposed retrosynthetically in Scheme 5.2, we envisaged preparing grandisine D 17, 




Scheme 5.2  Retrosynthetic analysis of grandisine D 17. 
 
Although we had previously shown that aldehyde 172 could be accessed from vinyl 
bromide 74 via halogen-lithium exchange and subsequent trapping with DMF, Scheme 
5.3, Overman's eight step synthesis of vinyl bromide 74 was unsuitable for bringing 
through large quantities of material.57 
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Scheme 5.3  Synthesis of indolizidine aldehyde 172 using Overman's route.57 
 
To begin our racemic synthesis of grandisine B 15, we chose to prepare allylic alcohol 
288, an intermediate previously reported by Taber et al. in their synthesis of the 
Elaeocarpus alkaloid (±)-elaeokanine A 57, Scheme 5.4.35 The brevity of the route (six 




Scheme 5.4  Concluding steps in Taber's synthesis of elaeokanine A 57.35 
 
5.2  Synthesis (1,2,3,5,6,8a-Hexahydroindolizin-8-yl)methanol (288) 
 
Following the reported procedure,35 the synthesis of alcohol 288 commenced with the 
conjugate addition of succinimide 289 to acrolein 290 in the presence of catalytic 
sodium ethoxide.  Olefination of aldehyde 291 with trimethylphosphonoacetate 292 and 
sodium hydride in THF gave the unsaturated ester 293 in 51% yield after distillation. In 
our hands, the reduction of imide 293 with sodium borohydride was capricious, 
generally requiring additional reductant to ensure complete consumption of the starting 
material. Attempts to optimise the reaction by changing the solvent, concentration and 
reaction temperature failed to offer a reproducible method for the reduction. Subsequent 
treatment of hydroxylactam 64a with catalytic HCl gave the methoxy-lactam 64b in 
25% yield over 2 steps, Scheme 5.5. 
 
The tin(IV) chloride promoted cyclisation of methoxy-lactam 64b proceeded in 1,2-
dichloroethane at 70 ºC to give the chloroester 65 isolated as a complex mixture of 
diastereoisomers. Dehydrochlorination with DBN in toluene furnished the indolizidine 
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ester 66 in 29% over 2 steps (Lit.35 27%). Reduction of both the amide and ester 
functionalities with excess DIBAL-H gave allylic alcohol 288 in a moderate 53% yield 
(Lit.35 44%), Scheme 5.5. Alternative conditions for the reduction using LiAlH4 offered 
no improvement over the published conditions. The low yield was partially attributed to 
losses during work-up and purification, due to the polarity of alcohol 288. 
 
 
Scheme 5.5 Taber's synthesis of alcohol 288.35 
 
Although the yields for the sequence were generally modest, the expedient nature of the 
route enabled allylic alcohol 288 to be prepared in gram-scale quantities. 
 
5.2.1  Challenges of Taber’s Synthesis 
 
A number of difficulties were encountered with Taber's route to alcohol 288. The 
conjugate addition of succinimide to acrolein generally proceeded cleanly, but the 
viscous nature of the unpurified aldehyde 291 made it difficult to remove residual 
ethanol. It was proposed that running the reaction in methanol using catalytic sodium 
methoxide would enable easier removal of the residual solvent. However, on repeating 
the reaction in methanol, 1H NMR spectroscopic analysis of the isolated material 
showed a number of impurities along with residual solvent.  
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The HWE olefination using trimethylphosphonoacetate and sodium hydride required 
large volumes of solvent to mobilise the thick slurries caused by sodium salts. Although 
distillation of the product was precedented, in our hands this generally led to poor yields 
and partial decomposition of the material. An alternative HWE procedure reported by 
Cordero came to our attention utilising potassium carbonate in aqueous ether to give 
unsaturated esters in near-quantitative yield.108 Addition of a solution of aldehyde 291 
in THF to an aqueous solution of potassium carbonate and trimethylphosphonoacetate 
gave after work-up the unsaturated ester 293 in 95% yield, Scheme 5.6; the unpurified 




Scheme 5.6  Olefination of aldehyde 291 using the procedure of Cordero.108 
 
Furthermore, subjecting imide 293 to the sodium borohydride reduction conditions, 
which had previously proved capricious, proceeded cleanly to give methoxy-lactam 64b 
in quantitative yield. The problems observed previously with the reduction were 
attributed to minor impurities present in the unsaturated ester 293.  Having optimised a 
number of steps in the reaction sequence, we were in a position to investigate the 
concluding steps in the racemic synthesis of grandisine B 15. 
 
5.3  Oxidation of Allylic Alcohol (288) 
 
Although the oxidation of allylic alcohol 288 is precedented in the literature using 
Swern conditions,35 in our hands, the yields for the reaction were inconsistent. 
Alternative reaction conditions were briefly investigated. Oxidation using manganese 
dioxide gave traces amounts of the desired aldehyde 172, but attempts to force the 
reaction to completion were unsuccessful. Oxidation of allylic alcohol 288 with Dess-
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Martin periodinane furnished aldehyde 172 in a disappointing 32% yield after 
purification. When repeated using sodium bicarbonate as a buffer, following the 
procedure of De Brabander and Liu,109 fewer impurities were observed in the 1H NMR 




Scheme 5.7  Oxidation of allylic alcohol 288 using Swern Conditions. 
 
It was subsequently found that more consistent yields could be obtained using Swern 
conditions if the reaction was quenched with saturated aqueous sodium bicarbonate. 
Using the optimised reaction conditions, aldehyde 172 was isolated in 66% yield, 
Scheme 5.7. Furthermore, 1H NMR spectroscopic analysis showed the material to be of 
sufficient purity to use without purification. The problems encountered with the 
oxidation were partially attributed to instability of aldehyde 172. 
 
5.4  Synthesis of the Grandisine B Carbon Skeleton 
 
With indolizidine aldehyde 172 in hand, we were in a position to investigate the aldol 
coupling with methylcyclohexenone 87. For the purposes of initial studies we chose to 
couple racemic methylcyclohexenone 87 with aldehyde 172. When work initially 
commenced on the project, the relative stereochemistry of grandisine B 15 was 
unknown, the route would therefore provide access to both possible diastereoisomers of 
grandisine B 15. 
 
Treatment of methylcyclohexenone 87 with LDA in THF at −78 ºC and subsequent 
trapping with aldehyde 172 furnished a diastereomeric mixture of hydroxy-ketones 287 
and 294, contaminated with minor amounts of unreacted aldehyde 172, Scheme 5.8. 
Initial attempts to separate the products from unreacted starting material were 
unsuccessful, with no product recovered after attempted purification on silica. 
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Scheme 5.8  Synthesis of hydroxy-ketones 287 and 294 via aldol coupling with cyclohexenone 87. 
 
Before further investigating the aldol reaction, we were keen to determine whether the 
developed cyclisation sequence would work. The diastereomeric mixture was therefore 
oxidised using DMP to give the diastereomeric diketones 17 and 295 in 88% unpurified 
yield, Scheme 5.9. 
 
 
Scheme 5.9  Oxidation of hydroxy-ketones 287 and 294 using Dess-Martin Periodinane. 
 
With diketones 17 and 295 in hand, we were in a position to investigate the cyclisation 
reaction using aqueous ammonia, a transformation also used by Tamura and co-workers 
in their synthesis of grandisine B 15.55 On treatment of the mixture of diketones 17 and 
295 with 35% aqueous ammonia, complete consumption of starting material was 
observed, with the formation of a number of products apparent by TLC analysis. HRMS 
analysis of the unpurified reaction mixture revealed a molecular ion peak consistent 
with grandisine B 15 but on inspection of the 1H NMR spectrum of the unpurified 
product, signals corresponding to grandisine B 15 were absent. More striking 
differences were apparent with the 13C NMR spectroscopic data, notably, the absence of 
peaks corresponding to the ketone and imine functionality. 
 
Whilst the identity of the isolated compound remained to be established, we were keen 
to continue efforts to prepare grandisine B 15.  Despite initial disappointment with the 
amination/cyclisation result, we felt that the synthesis of grandisine B 15 using the 
proposed sequence was still possible. The use of aqueous ammonia buffered with 
ammonium chloride had been shown by Korshevets to alter the selectivity of amination 
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reactions,110 an effect employed by Snider in the synthesis of the cyclindricines.89 
Repeating the amination/cyclisation sequence using aqueous ammonia buffered to pH 
~10 with ammonium chloride again resulted in complete consumption of starting 
material to give a single product apparent by TLC analysis. 
 
 
Scheme 5.10  Cyclisation of diketones 17 and 295 using buffered aqueous ammonia. 
 
Spectroscopic analysis of the isolated product revealed signals corresponding to 
grandisine B 15 and the diastereomeric product 296, arising from the coupling of the 
racemic cores, Scheme 5.10. Although the isolated yield was low, we felt the sequence 
provided a viable route to grandisine B 15 and as such, attempts were made to optimise 
the concluding steps in the synthesis. 
 
5.5 Optimisation of the Aldol Reaction 
 
Whilst the lithium aldol reaction had provided an intial route to the hydroxy-ketones 
287 and 294, the yields for the reaction were unreliable. Difficulties in forcing the 
reaction to completion led us to search for alternative conditions. A similar procedure 
reported by Kita using LHMDS,111 also failed to deliver the required hydroxy-ketones. 
A recent publication by Tamura and co-workers et al. utilised a diastereoselective 
boron-aldol coupling (on different substrates) in their total synthesis of grandisine D 
17.25 Following the reported procedure, treatment of methylcyclohexenone 87 with 
triethylamine and dibutylboron triflate followed by addition of indolizidine aldehyde 
172 gave only traces of the aldol products 287 and 294.  
 
Returning to the lithium aldol reaction, it was found that yields for the reaction were 
generally improved using freshly prepared aldehyde 172. Quenching the reaction with 
acetic acid was also found to give more consistent results. The reaction was also 
repeated in the presence of HMPA, however, this offered no improvement over previous 
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reactions, with hydroxy-ketones 287 and 294 obtained in 47% yield. Using the 
optimised procedure, formation of the lithium enolate of cyclohexenone 87 with LDA 
and trapping with aldehyde 172, gave hydroxy-ketones 287 and 294 in 64% yield (73% 
BRSM) as a mixture of diastereoisomers (~1:1.5), which were separable by column 
chromatography, Scheme 5.11. 
 
 
Scheme 5.11  Optimised formation of hydroxy-ketones 287 and 294. 
 
In an attempt to ensure complete consumption of aldehyde 172, an excess of 
cyclohexenone 87 had been used in the reaction. It was noted that the ratio of products 
obtained was not 50:50 as expected, but favoured the formation of one isomer 
preferentially. The result suggests a matched/mismatched reaction in which one isomer 
of methylcyclohexenone 87 reacts more favourably with aldehyde 172, to give an 
excess of the matched (kinetic) product. A similar observation was made by 
Danishefsky and co-workers in studies towards the epothilones, who reported long-
range stereochemical induction in aldol reactions,112 giving, in some instances, the 
matched product exclusively. 
 
Although the relative stereochemistry of grandisine B 15 has recently been confirmed 
by Tamura,55 we were unable to determine the relative stereochemistry of the hydroxy-
ketones 287 and 294, which were tentatively assigined as the anti-aldol products.  The 
initial cyclisation reaction suggested the minor product 287 corresponded to the 
grandisine stereochemical series; however, subsequent chemistry was carried out on 
both diastereoisomers in order to confirm which compound had the same relative 
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5.6   Synthesis of rac-Grandisine D (17) 
 
Previous work by Geyelin had shown that oxidation of a diastereomeric mixture of aldol 
products 287 and 294 to the corresponding diketones 17 and 295 could be achieved 
using modified Swern oxidation conditions.56 Initial attempts to repeat the reaction gave 
diketones 17 and 295 in 71% yield. The stereochemistry around the cyclohexenone ring 
was determined to be that depicted in Scheme 5.12, evident from the large (11.5 Hz) 
coupling constant between the protons adjacent to the methyl substitutent and exo-cyclic 
ketone. In contrast to 1,3-diketone substrates used in previous studies, only traces of the 
cis-isomer/enol tautomer were apparent in the 1H NMR spectrum. 
 
Alternative oxidation conditions were briefly investigated to determine whether the 
yield for the oxidation could be improved further. On treatment of alcohol 287 with 
MnO2, no reaction was observed by TLC analysis after 24 h, and furthermore, attempts 
to recover the polar starting material from the reaction mixture were unsuccessful. 
Conditions reported by Taber,35 using PCC buffered with NaOAc resulted in complete 
conversion to diketone 17 as determined by 1H NMR spectroscopy, but the product 
could not be recovered from the chromium residues. Dess-Martin periodinane oxidation 
of alcohol 287 proceeded cleanly to furnish diketone 17 in 67% isolated yield. 
Oxidations using DMP and the TFAA Swern conditions both gave similar yields, 
however, the modified Swern reaction conditions were generally cleaner and we 
therefore chose to use these conditions in subsequent chemistry. 
 
 
Scheme 5.12  Oxidation of hydroxy-ketone 287 using Swern conditions. 
 
Treatment of grandisine D 17 with TFA in DCM gave the grandisine D 17.TFA salt, the 
1H/13C NMR spectroscopic data for which were consistent with those reported by 
Tamura and Carroll,10, 55 Appendix I.  
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5.7  Synthesis of Grandisine B (15) via an Amination/Cyclisation Strategy 
 
On treatment of rac-grandisine D 17 with a pH 10 aqueous ammonia/ammonium 
chloride solution, using the conditions developed previously, grandisine B 15 was 
isolated in 71% yield after purification, Scheme 5.13.  The NMR spectroscopic data for 




Scheme 5.13  Synthesis of grandisine B 15 via the developed amination/cyclisation sequence. 
 
Conversion of a small sample of grandisine B 15 into the dipicrate salt provided 
conclusive evidence for the structure via single crystal X-ray diffraction analysis 
(Figure 5.1).  
 
 
Figure 5.1  X-ray structure of grandisine B 15.dipicrate (picrate counter anions omitted for clarity) 
depicted using ORTEP-3 (CCDC 815228). 
 
The sequence of reactions was also applied to the opposite diastereomeric series to give 
epi-grandisine B 296 in 44% yield over 2 steps, Scheme 5.14. The 1H NMR 
spectroscopic data for the compound were similar to those observed for grandisine B, 
however, a notable difference in the signals for the C-15 protons was observed. In 
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grandisine B 15, two signals for the diastereomeric protons were observed in the 1H 
NMR spectrum, however, in epi-grandisine B 296, these signals coalesced to give a 
single (broad) peak at 2.1 ppm. 
 
 
Scheme 5.14  Synthesis of epi-grandisine B 296 using the optimised sequence. 
 
5.8  The Origin of Grandisine B (15) 
 
We were intrigued by the apparent simplicity with which grandisine D 17 was 
converted into grandisine B 15; the nature of the transformation raised questions about 
the origins of the natural product. On close inspection of the isolation paper, it became 
apparent that aqueous ammonia was used during the extraction process for the 
neutralisation of acidic extracts.9 We conjectured that grandisine B 15 was actually an 
artefact of the isolation process formed from grandisine D 17 on treatment with aqueous 
ammonia. 
 
To provide evidence to support this theory, a sample of grandisine D 17 was taken up in 
dichloromethane and extracted with aqueous HCl.  On neutralisation of the acidic 
extracts with 35% aqueous ammonia and extraction into dichloromethane, two species 
were apparent in the 1H NMR spectrum of the unpurified material, consistent with 
grandisine B 15 and grandisine D 17. Although complete consumption of grandisine D 
15 did not occur, it was shown that on brief exposure to aqueous ammonia, the 
formation of grandisine B 15 readily occurs. 
 
To gain further insights/understanding of this transformation, we contacted Carroll who 
replied stating “Yes, we have certainly speculated about whether some of the 
compounds might be artefacts of the extraction and purification process. Grandisines B, 
F and G in particular are not observed by (+) ESI MS in crude methanol extracts of the 
leaves suggesting that these compounds at least are artefacts formed on treatment with 
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ammonia.”* Based on this evidence it would suggest that grandisine B does not occur 
naturally in the plant material, but is formed during the isolation process on extraction 
with aqueous ammonia.  
 
5.9  Artefact Alkaloids  
 
When considering the variety of molecular architectures found in nature, it is 
unsurprising that on subjecting compounds to ammonia-based isolation procedures, the 
formation of artefacts can occur. Such artefacts are generally indistinguishable from true 
natural products, exhibiting plausible structures found in nature. A brief overview of 
artefact alkaloids formed on treatment with aqueous ammonia follows. 
 
5.9.1  Rosmaricine (297) 
 
Although the isolation of betaine natural products from the family Labiatae was 
precedented, no alkaloids had been isolated from the family until the anomalous 
discovery of the alkaloid rosmaricine 297 in 1962 (Figure 5.2).113 
 
 
Figure 5.2  Structure of rosmaricine 297 as determined by Wenkert.113 
 
A comprehensive investigation by Wenkert in 1965 revealed the true origin of the 
species. Using a combination of synthesis and spectroscopy, the structure of rosmaricine 
297 was determined to be that depicted in Figure 5.2, containing a bridging lactone and 
primary amine functionality. The presence of the primary amine group raised questions 
about the true origin of the compound which was proposed to arise as a result of the use 
of aqueous ammonia during the isolation process. Further confirmation of this 
                                                 
* Private email communication with Prof. A.R. Carroll, Eskitis Institute, Griffith University, Brisbane, 
Queensland, Australia (23rd May 2009). 
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hypothesis was obtained when the isolation was carried out in the absence of ammonia 
and no rosmaricine 297 was obtained. Subsequent exposure of the isolated material to 
ammonia led to the formation of rosmaricine 297. The transformation was proposed to 
occur via oxidation and intramolecular cyclisation of carnosic acid 298 to give the 
quinone derivative 299, which yields rosmaricine 297 via a 1,6-conjugate addition of 
ammonia, Scheme 5.15. 
 
 
Scheme 5.15  Conversion of carnosic acid 298 into rosmaricine 297.113 
 
5.9.2  Pyridine Monoterpene Alkaloids 
 
The pyridine monoterpenoid alkaloids 301 constitute a second class of commonly 




Scheme 5.16  General synthesis of the pyridine monoterpene alkaloids 301. 
 
Although Scheme 5.16 could also represent a plausible biosynthesis of these 
compounds, studies have shown that the use of extraction methods avoiding aqueous 
ammonia generally produced no detectable levels of the alkaloid components.115 
 
The base gentianine 303 has been isolated from a number of species of the families 
Gentianaceae and Loganiaceae. The structurally related compounds gentiopicrin 302 
and swertiarmarin 304 containing a labile acetal functionality have also been isolated 
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from the same family.  Studies have shown that on treatment with aqueous ammonia 
under mild conditions both compounds 302 and 304 can be converted into gentianine 
303, Scheme 5.17.116, 117  
 
 
Scheme 5.17  Synthesis of gentianine 303 from gentiopicrin 302 and swertiarmarin 304.116, 117 
 
Subjecting plants of the family Gentainaceae, from which gentianine had been isolated, 
to ammonia-free extractions showed that only gentiana fetisowii contained gentianine in 
detectable amounts.  
 
Other monoterpene alkaloids also thought to be artefacts of the isolation process, 
include both buddamin 305 and cantleyine 306 (Scheme 5.18), neither of which are 
commonly found in plant materials when ammonia-free extractions are used.118 
 
 
Scheme 5.18  Structures of the pyridine monoterpene alkaloids buddamin 305 and cantleyine 306.118 
 
5.9.3  Decussine (307) 
 
Work by Rolfsen et al. identified biologically active compounds in extracts of the 
species Styrchnos decussate.119 Characterisation of the alkaloid components revealed a 
number of indole-type structures including decussine 307, a pentacyclic indole alkaloid, 
containing a novel azepine/pyridine fused ring system (Figure 5.3). 
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Figure 5.3  Decussine 307, an artefact alkaloid identifed by Rolfsen.119 
 
Subsequent investigations suggested that the formation of the pyridine ring occurred 
during the acid/base extraction process, with ammonia acting as the source of nitrogen.  
Rolfsen proposed that decussine 307 is formed from an indole derivative such aldehyde 
308, Scheme 5.19. 
 
 
Scheme 5.19  Proposed synthesis of the artefact alkaloid decussine 307.119 
 
5.9.4  Desmosine (311) 
 
The alkaloid desmosine 311 was isolated in 1998 by Pas and co-workers from Desmos 
dumosus.120 The unusual structure exhibited by the compound suggested the species 
could be an artefact formed from phenol 310 during the isolation process, Scheme 5.20.  
The absence of the alkaloid component in extraction procedures avoiding the use of 
aqueous ammonia provided further evidence to support this hypothesis. 
 
 
Scheme 5.20  Proposed synthesis of desmosine 311 from biological precursor 310.120 
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5.10  Synthesis of Elaeocarpus Alkaloids 
 
Having established a route to grandisine B 15, the synthesis of structurally related 
alkaloids isolated from the family Elaeocarpaceae were considered. Such studies would 
provide further insights into the origins of the Elaeocarpus alkaloids, which are 
potentially artefacts formed during the isolation process. Evidence for the formation of 
artefacts from Elaeocarpus sp. was recently provided by Carroll an co-workers,13 who 
reported that the alkaloid elaeocarpenine 24 (Figure 5.4) was only isolated when 
acid/base extraction protocols were avoided, suggesting the compound is susceptible to 
artefact formation under conditions encountered during the isolation process. 
 
 
Figure 5.4  Structure of elaeocarpenine 24 isolated by Carroll and co-workers.13 
 
The focus of initial studies were the syntheses of isoelaeocarpiline 5 and grandisine G 
20, the two alkaloids most closely related to grandisine D 17, Scheme 5.21.9,10 
 
 
Scheme 5.21  Potential applications of grandisine D 17 in the synthesis of other Elaeocarpus alkaloids. 
 
5.10.1  Grandisine G (20) 
 
Grandisine G 20, isolated in 2006 from Elaeocarpus grandis by Carroll and co-workers 
was proposed to be derived from grandisine B 15 via methoxide-promoted opening of 
the isoquinuclidinone ring.10 Grandisine G 20 was the least abundant of the grandisine 
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alkaloids isolated to date, with 3.8 mg isolated from 1.73 Kg of plant material, 
representing an isolated yield of 0.00021%. 
 
Previous work on model systems had shown that the unsubstituted isoquinuclidinone 
core unit was susceptible to ring opening on treatment with aqueous ammonia in 
methanol, to give structures analogous to grandisine G 15, Scheme 5.22. However, in 




Scheme 5.22  Ring opening of unsubstituted isoquinuclidinones 259. 
 
We initially proposed a synthesis of grandisine G 20 using the amination/cyclisation 
conditions shown in Scheme 5.23, in which methanol was employed as the solvent. 
Treatment of diketone 17 with buffered aqueous ammonia in methanol gave rise to a 
number of species including grandisine B 15 and other unidentified cyclisation products, 
however, no evidence of methyl ester 20 was observed. 
 
 
Scheme 5.23  Attempted synthesis of grandisine G 20 from grandisine D 17. 
 
Upon repeating the reaction in methanol at reflux, minor peaks were observed in the 1H 
NMR spectrum of the unpurified product, which were consistent with the ring-opened 
methyl ester 20, in particular a sharp signal at 3.6 ppm was consistent with the expected 
methoxy group. Attempts to achieve complete conversion of grandisine D 17 into 
grandisine G 20 by holding for extended periods at reflux were unsuccessful, resulting 
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in decomposition. Cyclisation of grandisine D 17 with 35% aqueous ammonia in place 
of the ammonium chloride buffered solution also failed to yield the desired methyl ester 
20.  
 
A stepwise approach was also investigated in which grandisine B 15 was initially 
prepared, then treated with ammonia in methanol, Scheme 5.24. In this instance, only 
unreacted starting material was recovered on work-up. 
 
 
Scheme 5.24  Attempted methoxide promoted ring opening of grandisine B 15. 
 
On closer inspection of the extraction procedure,10 it was noted that whilst an acid/base 
isolation procedure was used, the crude alkaloid extracts were not exposed to methanol 
until HPLC separation using a gradient of 1% TFA in H2O to 1% TFA in MeOH. We 
therefore proposed that grandisine G 20 was actually formed under acidic conditions via 
an acid-promoted ring opening of the isoquinuclidinone core in the presence of 
methanol. 
 
Due to limited supplies of grandisine B 15, initial investigations were carried out using 
the model isoquinuclidinone 263b. Treatment of the cyclohexyl substituted 
isoquinuclidinone 263b with TFA in methanol at room temperature failed to give any of 
the expected methyl ester 312, Scheme 5.25; analysis of the 1H NMR spectroscopic data 
showed only unreacted starting material. Repeating the reaction in the presence of water 
also failed to show any of the ring opened product 312. 
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Scheme 5.25  Attempted acid promoted ring-opening of model isoquinuclidinone 263b. 
 
When repeated using microwave heating, TLC analysis of the unpurified reaction 
mixture showed the presence of two compounds. On inspection of the 1H NMR 
spectrum for the unpurified material, no evidence of the methyl ester 312 was found, 
but, peaks corresponding to the starting material 263b and the hydrolysis product, 
diketone 262b were observed, Scheme 5.26. 
 
Scheme 5.26 Attempted ring opening of isoquinuclidinone 263b using microwave heating. 
 
Despite unsuccessful attempts to promote the ring opening on the model system, the 
acid promoted ring opening of grandisine B 15, was briefly investigated. 
Disappointingly, attempts to promote the ring opening of grandisine B 15 using the 
conditions investigated on the model system proved unsuccessful. On treatment with 
TFA in methanol or aqueous TFA in methanol, no evidence of grandisine G 20 was 
observed, Scheme 5.27. 
 
 
Scheme 5.27  Attempted conversion of grandisine B 15 into grandisine G 20. 
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Due to time constraints, we felt it would be counter-productive to spend further time 
investigating the synthesis of grandisine G 20.  
 
5.11  Synthesis of Elaeocarpiline (4) / Isoelaeocarpiline (5) 
 
The applications of grandisine D 17 in the synthesis of other Elaeocarpus alkaloids 
were briefly investigated. Of particular interest was isoelaeocarpiline 5, isolated 
previously from Elaeocarpus dolichostylis and Elaeocarpus grandis.5, 9 Carroll 
proposed isoelaeocarpiline 5 formed via cyclisation of the enolate of grandisine D 17 as 
shown in Scheme 5.28.  
 
 
Scheme 5.28  Proposed synthesis of isoelaeocarpiline 5 from grandisine D 17. 
 
Previous work in the group had shown that treatment of a diastereomeric mixture of 
diketones 17 and 295 with 2.0 M NH3 in isopropanol resulted in conversion into a 
mixture of cyclised products on microwave heating.56 We were keen to look for milder 
reaction conditions which could provide evidence to suggest that cyclisation occurs 
during the extraction process. 
 
Carroll previously reported the conversion of grandisine D 17 into isoelaeocarpiline 5 
on standing in DMSO.9 Attempts to replicate this transformation were unsuccessful, 
Scheme 5.29; in our hands, samples of grandisine D 17 in DMSO held at room 
temperature were found to be stable for prolonged periods.  Heating the samples to 50 
ºC and 100 ºC showed no evidence of the cyclisation product 5, however, signs of 
decomposition were observed in the latter. 
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Scheme 5.29  Attempted cyclisation of grandisine D 17 to give isoelaeocarpiline 5. 
 
Repeating the microwave conditions reported by Geyelin gave a complex mixture of 
products, Scheme 5.30.56 Spectroscopic analysis of the unpurified material showed 
peaks corresponding to starting material 17 and minor peaks consistent with cyclised 
products 314. Signals in the aromatic region were also observed suggesting 
aromatization of the cyclohexenone moiety had occurred under the reaction conditions 
to give aromatic derivatives 315. 
 
 
Scheme 5.30  Attempted cyclisation of grandisine D 17 under microwave heating. 
 
During previous investigations into the synthesis of grandisine B 15 via the amination/ 
cyclisation sequence, trace amounts of elaeocarpiline 4 were observed during a number 
of cyclisation reactions, evident from a distinct signal at 4.0 ppm in the 1H NMR 
spectrum of the unpurified product, consistent with the H-7 proton in elaeocarpiline 4, 
Scheme 5.31. It was therefore proposed that replacing aqueous ammonia with aqueous 
sodium hydroxide would yield the cyclised product 4, without the possibility of forming 
the amination/cyclisation product grandisine B 15.  
 
 
Scheme 5.31  Formation of elaeocarpiline 4 during the amination/cyclisation reaction. 
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5.11.1  Model Studies 
 
Due to limited quantities of grandisine D 17 with which to investigate the cyclisation, 




Scheme 5.32  Synthesis of model bis-enone 257d via an aldol/oxidation sequence. 
 
In an initial small-scale reaction, treatment of enone 257d with aqueous sodium 
hydroxide in acetonitrile, resulted in complete conversion into the cyclised products 316 
and 317 after 48 h at rt, Scheme 5.33. 
 
 
Scheme 5.33  Cyclisation of the model bis-enone 257d. 
 
Inspection of the 1H NMR spectrum suggested the compound was the thermodynamic 
trans-product 316. The large (11 Hz) coupling between the C-8 and C-9 protons was 
consistent with the depicted stereochemistry. Minor traces of the cis-isomer were also 
observed, evident from a signal at 4.5 ppm in the 1H NMR spectrum. Repeating the 
reaction on a larger scale gave the trans-cyclised product 316 in 54% yield after 18 h at 
room temperature, containing minor traces of the cis-product. 
 
5.11.2  Aromatic Model Cyclisation Precursor 
 
In order to further investigate the scope of the cyclisation reaction, an aromatic model 
system representative of the core structure in elaeocarpine 1 and isoelaeocarpine 2, was 
prepared. Generation of Grignard reagent 319 from bromoanisole and subsequent 
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trapping with cyclohexane carboxaldehyde 318 gave the benzylic alcohol 320 in 47% 
yield. Oxidation with Dess-Martin periodinone proceeded to afford the benzyl ketone 
316, which underwent demethylation on treatment with BCl3 in DCM to afford phenol 
317 in 24% over two steps, Scheme 5.34. 
 
Scheme 5.34  Synthesis of the elaeocarpine model 323. 
 
On treatment with aqueous sodium hydroxide in acetonitrile, rapid consumption of the 
starting material was observed, with the formation of a two species evident by TLC 
analysis. The 1H NMR spectroscopic data for the major product were consistent with 
the depicted trans-isomer 323, evident from the large coupling (11.0 Hz) between the 
H-5 and H-6 protons at the ring junction. The ~3:1 ratio of trans/cis-products observed 
in the 1H NMR spectrum of the unpurified reaction mixture could represent the 
thermodyanmic equilibrium. In order to confirm this, it would be necessary to re-subject 
a pure sample of one isomer to the cyclisation conditions to determine whether the 
equilibrium is re-established. 
 
5.11.3  Attempted Synthesis of Elaeocarpiline (4) 
 
Having demonstrated the cyclisation conditions were general to both aromatic and 
aliphatic model substrates, we were keen to apply the transformation to the synthesis of 
elaeocarpiline 4 and isoelaeocarpiline 5, Scheme 5.35. In an initial small scale reaction, 
treatment of grandisine D 17 with aqueous sodium hydroxide in acetonitrile resulted in 
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complete consumption of the starting material, with the formation of a more lipophilic 
species apparent on TLC analysis.  
 
 
Scheme 5.35  Cyclisation of grandisine D 17 on treatment with aqueous sodium hydroxide. 
 
The 1H NMR spectroscopic data were consistent with the trans-product 4, evident from 
two alkene signals at 6.25 and 5.84 ppm and a distinctive signal at 4.0 ppm consistent 
with the C-7 proton.  Traces of second product were also observed, which we proposed 
to be isoelaeocarpiline 5, based on a minor signal at 4.5 ppm corresponding to the C-7 
proton. Although the reaction proceeded cleanly on a small scale, attempts to scale up 
the transformation to enable full characterisation of the products proved unsuccessful; 
therefore, the structures of the cyclised products were not conclusively established. 
 
The reaction was also repeated using alcohol co-solvents. On treatment of grandisine D 
17 with aqueous sodium hydroxide in methanol, complete consumption of starting 
material was observed to give a single product. The 1H NMR spectroscopic data for the 
product were not consistent with isoelaeocarpiline 4 or elaeocarpiline 5, and 
furthermore, HRMS analysis failed to show a mass ion corresponding to the cyclised 
product 4. Whilst insufficient material was obtained to fully characterise the product, a 
signal at 3.30 ppm in the 1H NMR spectrum was consistent with a methoxy group. 
Based on the 1H NMR spectral data and HRMS analysis the structure was speculatively 
proposed to be tetracycle 325, Scheme 5.36. 
 
 
Scheme 5.36  Attempted cyclisation of grandisine D 17 with sodium hydroxide. 
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Repeating the reaction in EtOH resulted in the formation of a structurally similar 
product 326. Signals corresponding to an ethoxy group were observed in the 1H NMR 
spectrum, but, in this instance, HRMS analysis failed to show the mass ion 
corresponding to ethoxy derivative 326. 
 
5.11.4  Potential Strategy for the Synthesis of Grandisine C (16) 
 
Although not investigated during the course of these studies, the cyclisation approach 
could potentially provide a synthetic route to grandisine C 16. We envisaged that the 
use of benzyl alcohol in the cyclisation reaction would yield the corresponding benzyl 
derivative 327 which would give grandisine C 16 on debenzylation under hydrogenation 
conditions, Scheme 5.37. 
 
 
Scheme 5.37  Proposed synthesis of grandisine C 16 
 
5.12  Selectivity of the Cyclisation Reaction 
 
Carroll and co-workers only reported the isolation of isoelaeocarpiline 5,9 which 
features a cis-stereochemistry at the C-7/C-8 ring junction. This corresponds to the 
kinetic cyclisation product, in which protonation of the enolate intermediate 328 occurs 
on the least hindered face of the molecule (Figure 5.5).121 
 
 
Figure 5.5  Cyclisation intermediate 328. 
 
Preliminary results on model systems have shown the thermodynamic trans-
diastereoisomer to be the major product formed under the conditions investigated, with 
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only traces of the cis-diastereoisomer observed. These results are also consistent with 
studies by Danishefsky and Maloney who showed that on treatment with sodium 
hydroxide in ethanol, the kinetic cis-isomer of grandisine A 14 was readily converted 
into the more stable thermodynamic trans-diastereoisomer 329, Scheme 5.38.24 
 
 
Scheme 5.38  Epimerisation of grandisine A 14 reported by Danishefsky.24 
 
5.13  Attempted Cyclisation Under Acidic Conditions 
 
It was proposed that the cyclisation of grandisine D 17 could potentially occur on 
exposure to acid during the extraction process. Thus, diketone 17 was subjected to 
conditions encountered during the isolation procedure. On treatment with TFA in 
MeOH or aqueous TFA in MeOH no reaction was observed by TLC analysis, and the 
1H NMR spectra for the isolated material were consistent with the starting material 17. 
Exposure to aqueous H2SO4 also failed to show any evidence of the cyclisation product 
5, Scheme 5.40. 
 
 
Scheme 5.39  Attempted cyclisation of grandisine D 17 under acidic conditions. 
 
Repeating the reaction using Amberlyst H-15 acidic resin, MSA and p-TsOH in non-
protic solvents, lead to the recovery of starting material in all instances, suggesting that 
cyclisation only occurs under basic conditions. Additional work is required to gain a 
more comprehensive understanding of the cyclisation reaction. 
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5.14  Summary 
 
The racemic synthesis of grandisine B 15 has been completed using a biomimetic 
amination/cyclisation sequence to construct the isoquinuclidinone core. Initial attempts 
to use grandisine D 17 as a precursor to other Elaeocarpus alkaloids have so far proved 
inconclusive or unsuccessful. Further work towards the synthesis of these compounds 
should be undertaken in the future. Studies towards the asymmetric synthesis of (−)-
grandisine B 15 are detailed in Chapter 6. 
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Chapter 6.  Alkyne/Acetal Cyclisation Reactions in the 
Synthesis of Indolizidine Alkaloids:  The Total Synthesis of (–
)-Grandisine B (15) 
 
6.1  Retrosynthesis of (–)-Grandisine B (15) 
 
Having established a racemic route to grandisine B 15 using a biomimetic 
amination/cyclisation sequence, we were keen to develop an asymmetric synthesis of 
grandisine B 15.  Using the previously described retrosynthesis, Scheme 6.1, 
enantioselective routes to both the indolizidine aldehyde 172 and (S)-5-
methylcyclohexenone 87, would be required 
 
 
Scheme 6.1  Retrosynthesis of grandisine B 15. 
 
Whilst we envisaged the synthesis of enantio-enriched (S)-methyl-cyclohexenone 87 
would be achieved using the organocatalytic procedure recently reported by 
Jorgensen,105 the precedented routes to the indolizidine core unit suffered from a 
number of problems (long, low yields etc). Alternative strategies for the synthesis of the 
indolizidine ring system were therefore considered. 
 
Although a number of disconnections could be envisaged, we were keen to investigate 
potential biomimetic strategies for the synthesis of the indolizidine core unit. A recent 
publication by Carroll and co-workers detailed the isolation of the pyrrolidine alkaloids 
habbemines A 21 and B 22, which were proposed to be biosynthetic precursors to the 
grandisine alkaloids, Scheme 6.2.11  
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Scheme 6.2  Carroll's proposed formation of grandisine D 17 from habbemine A 21.11 
 
Intrigued by this disconnection, we proposed a route to grandisne D 17, shown 
retrosynthetically in Scheme 6.3. 
 
 
Scheme 6.3  Biomimetic retrosynthesis of grandisine D 17. 
 
Disconnection of the indolizidine core unit via an aldol condensation sequence, reveals 
the β-amino carbonyl compound 49. A similar strategy was previously used by Koizumi 
in the synthesis of the Elaeocarpus alkaloid elaeokanine A 57.122 Using an 
aldol/oxidation sequence, the 1,3-diketone substrate 49, could be prepared from 
aldehyde 330. 
 
Due to concerns regarding the stability of β-amino carbonyl compound 49 and aldehyde 
330, classes of compounds known to readily racemise, the carbonyl compound would 
ideally be masked/protected, the deprotection of which would constitute one of the 
concluding steps in the synthesis. 
 
It was proposed that the carbonyl function could be accessed via hydration of an alkyne, 
which would provide a stable precursor to the required carbonyl function, Scheme 6.4. 
 
 
Scheme 6.4  Retrosynthesis of aldehyde 330 via alkyne 331. 
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Whilst the anti-Markovnikov hydration of alkynes is precedented using transition metal 
catalysts on simple systems,123-127 classical methods for alkyne hydration are known to 
give the Markovnikov product.128-130 To overcome this problem, we proposed the 
introduction of a substituent onto the alkyne which would direct the hydration and could 
provide a handle to further functionalise the indolizidine core unit, Scheme 6.5. 
 
 
Scheme 6.5  Retrosynthesis of carbonyl compound 333. 
 
6.2  A Mercury-Mediated Alkyne Hydration Approach 
 
Although there is no literature precedent for the synthesis of compounds such as alkynyl 
cyclohexenone 335, we felt the viability of the approach could be initially confirmed by 
investigating the synthesis of simple Elaeocarpus alkaloids such as elaeokanine A 57 
and elaeocarpenine 24 (Figure 6.1). These could be potentially accessed from readily 
accessible alkyl or aryl-substituted alkynes 
 
 
Figure 6.1  Structures of elaeokanine 57 and elaeocarpenine 24. 
 
6.2.1 Synthesis of Proline Alkyne (336) 
 
To commence the asymmetric synthesis of the indolizidine core unit of grandisine B 15, 
we chose to prepare the known alkyne 336,131 an intermediate previously used by 
Gmeiner, in the synthesis of triazolopeptide derivatives 337, Scheme 6.6. 
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Scheme 6.6  Applications of alkyne 336 in the synthesis of triazolopeptide derivatives 337.131 
 
Following a literature procedure,131 commercially available (S)-proline 338 was Boc-
protected via treatment with di-tert-butyl carbonate in DCM, Scheme 6.7. Reduction of 
the carboxylic acid 339 with BH3.DMS gave alcohol 340, which was oxidised using 
Swern conditions to afford aldehyde 341 in 96% yield over 2 steps. Installation of the 
alkyne is precedented using the Corey-Fuchs protocol,131 or the Ohira-Bestmann 
reagent,132 however, the need to prepare the Ohira-Bestmann reagent led us to initially 
investigate the Corey-Fuchs route. Treatment of aldehyde 341 with CBr4 and PPh3 in 
DCM gave the dibromide 342 in 73% yield. Subsequent treatment with n-BuLi in THF 
at −78 ºC gave proline alkyne 336 in 74% yield after purification. Alternatively, 
treatment of dibromide 342 with caesium carbonate in DMSO, following the procedure 
recently reported by Yang,133 also gave alkyne 336 in 74% yield. 
 
 
Scheme 6.7  Synthesis of proline alkyne 336. 
 
6.3  Initial Cyclisation Studies 
 
Deprotection of Boc-amine 336 with conc. aqueous HCl in diethyl ether following the 
procedure of Maarseveen resulted in the removal of the Boc-group,134 however, a 
number of impurities were also evident in the 1H NMR spectrum of the product. 
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Conditions using trifluoroacetic acid in dichloromethane were superior, giving the 
amine·TFA salt 343 in quantitative yield.  
 
Acetal 345 was initially prepared via alkylation of amine 343 with the commercially 
available bromide 344. On treatment with acetal 344 and potassium carbonate in 
acetonitrile, amine 343 was converted into the corresponding N-alkylated derivative 345, 
which was obtained in 68% yield, Scheme 6.8. 
 
 
Scheme 6.8  Synthesis of acetal 345. 
 
In order to test the viability of the route, we initially chose to investigate the synthesis of 
the Elaeocarpus alklaloid elaokanine A 57, isolated from Elaeocarpus kaniensis by 
Lamberton and co-workers.33 Alkylation of alkyne 345 with n-propyl iodide in THF at 
reflux, following the procedure of Chong,135 gave the cyclisation precursor 346 in 90% 
yield, Scheme 6.9. 
 
 
Scheme 6.9  Alkylation of alkyne 345 and proposed conversion to elaeokanine 57. 
 
We envisaged that hydration of alkyne 346 would yield the intermediate ketone 347, 
which would undergo an acid-catalysed aldol condensation with the aldehyde formed on 
acetal hydrolysis, Scheme 6.10. Initially classical alkyne hydration conditions using 
mercury salts in aqueous acid were investigated. 
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Scheme 6.10  Proposed alkyne hydration/aldol condensation sequence for the synthesis of elaeokanine 57. 
 
Treatment of alkyne 346 with mercuric sulfate in aqueous sulfuric acid resulted in 
consumption of starting material, with the concomitant formation of a number of 
products, apparent by TLC analysis, Scheme 6.11.  
 
 
Scheme 6.11   Attempted mercury-mediated hydration of alkyne 346. 
 
Upon inspection of the 1H NMR spectrum of the unpurified material, peaks 
corresponding to the cyclic acetal were absent and no evidence of the deprotected 
aldehyde 348 was observed. Furthermore, a minor peak at 6.81 ppm was consistent with 
an α,β-unsaturated carbonyl compound. Disappointingly, attempts to separate the 
individual products were unsuccessful and we were unable to conclusively establish the 
identity of the products. HRMS analysis showed molecular ions corresponding to 
compounds of formula C12H19NO and C12H21NO2 suggesting that cyclisation had 
occurred to give a mixture of the aldol 59 and eliminated aldol products 57. Holding the 
reaction for prolonged periods at reflux failed to give the unsaturated ketone 57 as the 
predominant product. Reducing the temperature also proved unsuccessful, with no 
reaction observed at room temperature. 
 
In an attempt to convert the aldol product 59 into the desired unsaturated ketone 57, the 
reaction was repeated and the unpurified material was subjected to the elimination 
conditions reported by Koizumi, Scheme 6.12.122 Treatment with sodium hydroxide in 
ethanol gave a complex mixture of products, from which we were unable to isolate 
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elaeokanine A 57.  Alternative conditions using mesyl chloride and triethylamine in 
dichloromethane also failed to give elaeokanine A 57. 
 
 
Scheme 6.12  Attempted elimination of hydroxy-ketone 59 using conditions reported by Koizumi.122 
 
Following our unsuccessful cyclisation reactions using acetal 346, attempts were also 
made to deprotect acetal 346 in order to access aldehyde 348 for direct use in the 
proposed aldol condensation. Treatment with p-TsOH in aqueous acetone at reflux gave 
only recovered starting material after work-up, and similarly, treatment with 1 M 




Scheme 6.13  Attempted deprotection of cyclic acetal 346. 
 
Heating acetal 346 in TFA led to complete consumption of the starting material, 
however, the 1H NMR spectrum of the unpurified material showed multiple unidentified 
products. Conditions previously used in the Taylor group for the deprotection of cyclic 
acetals using tin(II) chloride dihydrate,137 also failed to give the deprotected aldehyde 
348, giving only recovered starting material on work-up. 
 
6.4  Alkyne/Acetal Cyclisation Reactions 
 
Due to disappointing initial results with the mercury-mediated alkyne hydration/ 
cyclisation reactions, we were keen to look for alternative conditions. The cyclisation 
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reactions of alkyne/acetals or alkyne/aldehydes have received considerable interest in 
recent years, with a range of transformations reported using transition metal, Lewis acid 
and Brønsted acid catalysts.138-145 
 
A particularly relavent paper by Saá, reported the Brønsted acid promoted 
intramolecular cyclisation of alkyne/aldehydes.146 Disappointingly, when alkyne 346 
was subjected to the reported conditions, a complex mixture of unidentified products 
was observed in the 1H NMR spectrum of the unpurified reaction mixture. Although 
one example of an alkyne/acetal cyclisation was reported by Saá, in general, the 
cyclisations were carried out with the corresponding aldehydes. We proposed that in 
this instance, the in situ deprotection of the cyclic acetal was not compatible with the 
cyclisation conditions. 
 
A mild Lewis acid catalysed cyclisation procedure was recently reported by Yu and co-
workers using iron(III) choride to catalyse the cyclisation of alkyne/acetals to prepare a 
range of heterocycles.139 Due to unsuccessful cyclisation reactions using the proline-
derived alkyne 346, a literature example from the Yu's paper was initially repeated. The 
model susbtrate 351a was prepared using a modification of the procedure reported by 
Yu;147 deprotonation of 3-phenyl-2-propyn-1-ol 349 with NaH in THF and trapping 





Scheme 6.14  Synthesis of the model cyclisation substrate 351a.147 
 
On subjecting alkyne 351a to the reported conditions,139 TLC analysis showed a number 
of products to be present after 18 h at room temperature (Lit.139 93%, 2 h). Analysis of 
the unpurified reaction mixture by 1H NMR spectroscopy confirmed the presence of a 
number of species, identified as the desired cyclisation product 352a, unreacted starting 
material 351a and aldehyde 353 resulting from acetal hydrolysis, Scheme 6.15. 
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Scheme 6.15  Attempted cyclisation of alkyne-acetal 351 using the procedure of Yu.139 
 
Based on previous work in the Taylor group, the reaction was also repeated using 
catalytic (10 mol%) tin(II) chloride dihydrate,148 which gave a product distribution 
similar to the analogous reaction using iron(III) chloride. 
 
6.5  Attempted Synthesis of Indolizidines via A Lewis Acid Mediated 
Cyclisation 
 
Having shown the cyclisation proceeded, albeit not as well as reported, we felt it would 
be instructive to apply the conditions to a model system more representative of the 
indolizidine core unit in grandisine B 15. Aromatic-substituted alkynes are commonly 
used in literature studies; we therefore chose to prepare phenyl alkyne 354 (Figure 6.2). 
The cyclic acetal was also replaced with the corresponding diethyl acetal, which we 
envisaged would be more susceptible to in situ hydrolysis. 
 
 
Figure 6.2  Alternative cyclisation substrate 354. 
 
The required alkylating agent was prepared using the procedure reported by Abad.149 
Treatment of acrolein and sodium iodide in the presence of trimethylsilyl chloride and 
subsequent addition of ethanol gave the iodo-acetal 355 in 81% yield, Scheme 6.16. 
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Scheme 6.16  Synthesis of iodo-acetal 355. 
 
Deprotection of Boc-alkyne 336 with TFA gave amine 343 which was alkylated with 
iodide 355, to give diethyl acetal 356 in 79% yield over two steps. Sonogashira 
coupling of alkyne 356 with iodobenzene 357 gave the phenyl acetylene derivative 354 
in 98% yield, Scheme 6.17. 
 
 
Scheme 6.17  Synthesis of diethyl acetal 354. 
 
Treatment of the acetal 354 with iron(III) chloride hexahydrate and tin(II) chloride 
dihydrate in acetone at 50 ºC, following the reported procedures, showed only the acetal 
hydrolysis product 359 on inspection of the 1H NMR spectra.  Repeating the reaction 
with a large excess (5 equiv.) of tin(II) chloride dihydrate also failed to give the cyclised 
product 358, Scheme 6.18. 
 
 
Scheme 6.18  Attempted cyclisation of alkyne/acetal 354 using Lewis acid catalysts. 
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6.6  A Formic Acid Mediated Alkyne Hydration Strategy 
 
A series of papers by Shvo and Menashe came to our attention reporting the hydration 
of alkynes with formic acid.150, 151 Whilst the hydration of alkynes in the presence of 
metal catalysts is precedented, the reaction was unusual in the fact that the hydration of 
alkynes was achieved by simply heating in formic acid, Scheme 6.19. 
 
 
Scheme 6.19  Formic acid mediated hydration of alkynes reported by Shvo.151  
 
The reaction was applicable to a range of simple hydrocarbon alkynes, giving the 
corresponding ketones in excellent yield. Mechanistically, Shvo proposed that the 
reaction proceeded via an initial protonation of the alkyne 360 to give the intermediate 
enol formate 363 on trapping of carbocation 362 with formic acid. Subsequent 
hydrolysis of the enol formate 363 yielded ketone 361, the formal alkyne hydration 
product, Scheme 6.20.151  
 
 
Scheme 6.20  Shvo's proposed mechanism for the formic acid mediated hydration of alkynes.151 
 
An intriguing result in the paper revealed that hydration of 1,7-octadiyne 364, did not 
give the expected diketone 365, but proceeded to give 1-acetyl-2-methylcyclopentene 
366 in 84% yield. The transformation was proposed to proceed via the intermediacy of 
diketone 365 which underwent an intramolecular aldol condensation/dehydration 
sequence in the acidic media, Scheme 6.21.151 
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Scheme 6.21  Intramolecular cyclisation of 1,7-octadiyne 364 in formic acid.151 
 
It was proposed that formic acid could potentially be used in the synthesis of the 
indolizidine core unit. In order to test the viability of the route, we initially investigated 
the cyclisation of model substrate 351a. After heating a sample of alkyne 351a in 
formic acid at 100 ºC for 2 h, the cyclisation product 352a was isolated as a crystalline 
solid in essentially quantitative yield on removal of the formic acid. 
 
 
Scheme 6.22  Cyclisation of alkyne 351a in formic acid. 
 
Analysis of the material by 1H NMR spectroscopy showed the product to be 
homogeneous, requiring no additional purification. Subsequently, it was found that 
quantitative conversion was observed in 30 min at reflux giving the cyclised product 
352a in 98% yield, Scheme 6.22. On repeating the reaction at room temperature, the 
cyclisation product 352a was again isolated in 98% yield, however, the reaction time 
was significantly increased (~24 h). 
 
6.7  Mechanism of the Formic Acid Mediated Cyclisation Reaction 
 
Interestingly, it was found that if the reaction was stopped after 15 min at room 
temperature, 4 species were apparent by in the 1H NMR spectrum of the unpurified 
reaction mixture. Two sets of signals were attributed to unreacted starting material 351a 
and the cyclised product 352a. The other two sets of signals were attributed to 
intermediates in the cyclisation reaction. 
 
  135 
Although both compounds were found to be unstable, attempts to separate the products 
by column chromatography provided samples of each product of sufficient purity to 
fully characterise them. The 1H NMR spectrum of the first compound showed two sets 
of diastereomeric protons, as well as two CH2 carbons apparent in the 
13C DEPT 
spectrum. A signal at 8.14 ppm in the 1H NMR spectrum suggested the presence of a 
formyl group. A broad peak at 3396 cm−1 in the IR spectrum was consistent with a 
hydroxyl group. Based on the spectroscopic data, the structure was proposed as enol 
formate 367 (Figure 6.3).  
 
 
Figure 6.3  Intermediates 367 and 368 isolated in the formic acid cyclisation reaction. 
  
Similarities between the two products suggested the second compound was the 
analogous ethoxy-derivative 368 with additional signals corresponding to the ethyl 
group observed in the 1H and 13C NMR spectra. HRMS analysis showed molecular ions 
corresponding to the two products, however, other species were also observed 
suggesting the compounds were unstable under HRMS conditions. Although, both the 
isolated intermediates were novel, a structurally similar compound 369 was previously 
isolated by Lu et al. during studies on the palladium-catalysed cyclisation reactions of 
alkyne/aldehydes.140    
 
When considering the cyclisation reaction, a number of plausible mechanisms could be 
proposed, Scheme 6.23-6.25. Mechanism A proceeds according to the sequence 
proposed by Shvo.151 An initial formic acid mediated alkyne hydration gives the 
intermediate formate ester 370, which upon hydrolysis, undergoes an acid-mediated 
aldol condensation/dehyderation sequence to yield the cyclised product 352a, Scheme 
6.23. 
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Scheme 6.23 Cyclisation of alkyne/acetal 351a via an intial alkyne hydration (Mechanism A). 
 
Alternatively, the reaction could proceed via an oxete intermediate 374 (Mechanism B) 
as proposed by Harding,152 and more recently Krische and Li,139, 153 Scheme 6.24. 
Alkyne addition to oxonium ion 372 and subsequent intramolecular cyclisation would 
give oxete 374 which can rearrange to yield the unsaturated ketone 352a.  
 
 
Scheme 6.24  Cyclisation of alkyne/acetal 351a via oxete intermediate 374 (Mechanism B). 
 
Finally, the reaction could proceed via addition of the alkyne to the oxonium ion 372 
consistent with the Prins-type process proposed in Mechanism B. However, in this 
instance, the resulting carbocation 373 is trapped with formic acid to yield the formate 
ester 368, which hydrolyses to give the unsaturated product 352a, Scheme 6.25.141, 147 
 
 
Scheme 6.25  Prins-type cyclisation of alkyne/acetal 351a via enol formate intermediate 368 (Mechanism 
C). 
 
The isolation of intermediates 367 and 368 in reactions carried out at room temperature 
would suggest that under these conditions, Mechanism C is operative, proceeding via 
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oxonium ion 372 or the corresponding aldehyde formed on in situ acetal hydrolysis. 
ReactIR studies could provide further insights into the mechanism of the reaction, 
however, due to time constraints we did not carry out this investigation. 
 
The selectivity for the 5-membered exo-cyclic ketone 352a can be accounted for by the 
kinetic preference for the formation of a 5-membered ring, rather than the 6-membered 
endo-cyclic ketone. The carbocation formed could also be stabilised by the aromatic π-
system, providing additional benefit for the formation of the 5-membered product. 
 
6.8  Scope of the Formic Acid Mediated Cyclisation 
 
Having developed a procedure for the synthesis of α,β-unsaturated carbonyl compounds 
using a formic acid mediated alkyne-acetal cyclisation we were keen to explore the 
scope of the reaction. A range of substrates were prepared via alkylation of the 
corresponding propargylic alcohols or amines, Scheme 6.26. 
 
 
Scheme 6.26  Synthesis of alkyne/acetal cyclisation substrates 351. 
 
Each substrate was heated in formic acid at 100 ºC for 30 min. (Scheme 6.27), with 
results shown in Table 6.1. 
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Table 6.1  Scope of the formic acid mediated alkyne/acetal cyclisation.a 






















a  All reactions were performed on 0.25 mmol scale in formic acid (1 mL). 
b  Isolated yields after column chromatography. 
c  Reaction carried out at room temperature. 
 
The phenyl-substituted alkyne 351a used in preliminary studies cyclised to give the 
corresponding unsaturated ketone 352a in 98% yield (entry 1). The cyclisation was not 
just applicable to phenyl-substituted alkynes, the ethyl ketone 352b was also prepared in 
a reasonable 70% yield (entry 2). Substituted alkynes were also tolerated in the 
cyclisation reaction; the methyl-substituted dihydrofuran 352c was prepared in 80% 
yield and the spirocyclic derivative 352d was prepared in 64% yield (entries 3 and 4). 
The reaction conditions were not just amenable to the synthesis of oxygen heterocycles, 
the 5 and 6-membered N-tosyl analogues 352e and 352f were also prepared in 77% and 
69% yield respectively (entries 5 and 6). 
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6.8.1 Aromatic-Substituted Heterocycles 
 
In the final part of this study, we investigated the synthesis of aromatic-substituted 
heterocycles. Alkylation of 2-iodophenol 375 with bromo acetaldehyde diethyl acetal 
gave acetal 376 in 99% yield. Sonogashira coupling of acetal 376 with 1-pentyne gave 
the cyclisation precursor 377 in 93% yield, Scheme 6.28. 
 
 
Scheme 6.28  Synthesis of phenol derived alkyne 377. 
 
On subjecting acetal 377 to the cyclisation conditions the formation of a single product 




Scheme 6.29  Cyclisation of phenol derived alkyne/acetal 377. 
 
The HRMS data were consistent with the expected product 378, however, the 1H NMR 
spectroscopic data were inconclusive regarding the structure of the product. Although 
previous examples had cyclised to give the corresponding exo-cyclic ketones, it was 
also conceivable that the reaction had proceeded to give the endo-cyclic ketone 379. 
Inspection of the 2D NMR spectroscopic data suggested the product was the 6-
membered exo-cyclic ketone 378. HMBC correlations between the carbonyl and propyl 
side chain were observed, however, no correlations with the aromatic ring were seen.  
Subsequent work by Unsworth confirmed the structure as the 6-membered product 
378;154 reduction with DIBAL-H gave the corresponding alcohol 380, the data for 
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which were consistent with the exo-cyclic product 380, Scheme 6.30. A correlation 
between the proton adjacent to the hydroxy group and the propyl side chain was also 
evident in the COSY spectrum. 
 
 
Scheme 6.30  Reduction of exo-cyclic ketone 378.154 
 
The same reaction conditions were also applied to the analogous N-tosyl substrate 384, 
prepared in 2 steps from 2-pentynyl aniline 382. Treatment with tosyl chloride and 
pyridine gave the corresponding N-tosyl aniline, which was coupled with glycol 
aldehyde diethyl acetal under Mitsunobu conditions to give the cyclisation precursor 
383 in 87% over 2 steps. Treatment with formic acid gave the 1,2-dihydroquinoline 384 
in 60% yield, Scheme 6.31. 
 
 
Scheme 6.31  Cyclisation of the aniline derived alkyne/acetal 383. 
 
Unfortunately, attempts to extend the methodology to enable the synthesis of 7-
membered oxepine analogues were unsuccessful. Whilst a model substrate 386 could be 
readily accessed using the previously developed sequence, Scheme 6.32, heating alkyne 
386 in formic acid gave a complex mixture of unidentifiable products. 
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Scheme 6.32  Synthesis of oxepine cyclisation precursor 386 and attempted cyclisation. 
 
6.9  Applications of Alkyne/Acetal Cyclisation Reactions in the Synthesis 
of Indolizidine Alkaloids 
 
Having demonstrated the utility of the formic acid alkyne/acetal cyclisation in the 
synthesis of a range of oxygen and nitrogen heterocycles, we were keen to apply the 
methodology to the synthesis of the indolizidine core unit in grandisine B 15. 
 
Initially, the transformation was applied to the synthesis of elaeokanine A 57 using the 
previously prepared cyclic acetal 346. When subjected to the cyclisation conditions the 
formation of predominantly one product was apparent by TLC analysis. Disappointingly, 
the 1H NMR spectroscopic data suggested the major product was aldehyde 348, formed 
by hydrolysis of the cyclic acetal, Scheme 6.33. 
 
 
Scheme 6.33  Attempted synthesis of elaeokanine A 57 via an alkyne/acetal cyclisation. 
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The corresponding diethyl acetal 388 was prepared from alkyne 356, Scheme 6.34.  
Deprotonation of alkyne 356 with n-BuLi and trapping with n-propyl iodide gave the 
cyclisation precursor 388 in 37% yield. Disappointingly, when diethyl acetal 388 was 
subjected to the cyclisation conditions the formation of a number of products was 
apparent by TLC analysis, however, no evidence of the cyclisation product 57 was 
observed in the 1H NMR spectrum of the unpurified reaction mixture. 
 
 
Scheme 6.34  Attempted synthesis of elaeokanine A 57 via diethyl acetal 388. 
 
The reaction was also repeated with the phenyl substituted alkyne 357.  In an initial 
small-scale reaction, heating alkyne 357 in formic acid led to the formation of 
predominantly one product, observed by TLC analysis, Scheme 6.35. 
 
 
Scheme 6.35  Cyclisation of phenyl substituted alkyne 357. 
 
On inspection of the 1H NMR spectroscopic data for the unpurified product, signals 
corresponding to indolizidine 358 were apparent, in particular, a mutliplet at 6.55 ppm 
was consistent with the unsaturated ketone. On scale-up the phenyl-susbstituted 
indolizidine derivative 358 was isolated in an unoptimised 37% yield.   
 
6.10  Cyclisations of Heteroatom Substituted Alkynes 
 
Although the cyclisation reaction had shown promise on the phenyl substituted alkyne 
357, attempts to cyclise aliphatic substituted alkynes had proved unsuccessful. 
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Alternative alkyne substitutuents, which could be used as a handle to further elaborate 
the indolizidine core unit, were therefore considered, Scheme 6.36. 
 
 
Scheme 6.36  Proposed synthesis of grandisine D 17. 
 
6.10.1  Bromo-Alkynes 
 
A paper by Gesson and co-workers reported the use of bromo alkynes in N-acyliminium 
ion cyclisations to give methyl esters 392 and 393 on methanolysis, Scheme 6.37.155 
 
 
Scheme 6.37 Gesson's N-acyliminium ion cyclisation using bromo-alkyne 391.155 
 
Disappointingly, attempts to prepare the bromo-alkyne 394 using a range of reported 
conditions proved unsuccessful,156-158 Scheme 6.38, Table 6.2.  
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Table 6.2  Attempted synthesis of bromo alkyne 394. 
Entry Conditions Result Ref. 
1 CBr4, PPh3, DCM, rt Complex mixture 156 
2 NBS, AgNO3, Acetone, rt Complex mixture 157 
3 Br2, KOH, H2O, 0 ºC Complex mixture 158 
 
6.10.2  Thioalkynes 
 
Publications as early as 1959 reported the conversion of thioalkynes into the 
corresponding thioesters on treatment with acid.159 More recently, the transformation 
was used by Speckamp and co-workers in the synthesis of pyrrolizidine alkaloid 
derivatives  396 and 397 via an N-acyliminium cyclisation, Scheme 6.39,160 and also by 
Maruyama and co-workers in synthetic studies towards carbapenem derivatives.161 
 
 
Scheme 6.39  Speckamp's N-acyliminium cyclisation using thioalkyne 395.160 
 
We therefore set out to prepare thioalkyne 398 in order to investigate its potential 
applications in the formic acid mediated cyclisation reaction. Following the procedure 
of Glass,162 deprotonation of alkyne 356 with n-BuLi and trapping with phenyl disulfide 
gave the thioalkyne 398 in 57% yield. Attempts to scale up the reaction gave thioalkyne 




Scheme 6.40  Attempted synthesis of S-phenyl thioalkyne 398. 
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Although the structurally-related side-product still contained the pyrrolidine ring and 
ethyl acetal, a signal at 7.14 ppm in the 1H NMR spectrum was consistent with an 
alkene.  The aromatic region integrated to double the expected value, which was 
consistent with the HRMS data, which showed the molecular formula to be 
C24H33NO2S2, suggesting the incorporation of a second thiophenyl group. The structure 
for the side product was tentatively assigned as the dithioalkene 399 based on the 
molecular formula and NMR spectroscopic data, however, the mechanism by which it 
forms remains to be established.  
 
In an attempt to overcome the formation of thioalkene 399, the reaction was repeated 
using S-phenyl benzene thiosulfonate. In this instance the desired thioalkyne was 




Scheme 6.41  Synthesis of thioalkyne 398 from alkyne 356. 
 
On treatment of alkyne 398 with formic acid at reflux, consumption of the starting 
material was observed, with the concomitant formation of a single product apparent by 
TLC analysis.  Pleasingly, 1H NMR spectroscopic analysis of the unpurified material 
showed the product to be the unsaturated thioester 400, furthermore, the material was 
homogeneous, requiring no purification. When repeated on a larger scale the phenyl 
thioester 400 was isolated in quantitative yield, Scheme 6.42.   
 
 
Scheme 6.42  Formic acid mediated cyclisation of S-phenyl thioalkyne 398. 
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The reaction sequence could also be used to prepare the analogous ethyl thioester 402, 
which was isolated in 82% yield over 2 steps, Scheme 6.43.  
 
 
Scheme 6.43  Synthesis of indolizidine thioester 402. 
 
Attempts were briefly made to extend the methodology to enable the synthesis of 5,7-
ring systems, a structural motif commonly encountered in alkaloids isolated from plants 
of the Stemonaceae family.163 The required cyclisation precursor 405 could be readily 
accessed using the sequence described previously.  Deprotection of proline alkyne 336 
and subsequent alkylation with bromide 403, prepared in 2 steps from ethyl-4-
bromobutyrate, gave acetal 404 in 47% yield. Deprotonation with n-BuLi and trapping 
with diethyl disulfide gave the cyclisation precursor 405, Scheme 6.44. 
 
 
Scheme 6.44  Synthesis of stemona alkaloid precursor 405. 
 
Disappointingly, on treatment with formic acid, consumption of the starting material 
405 was observed, however, a complex mixture of products was apparent in the 1H 
NMR spectrum of the unpurified material, with no evidence of the cyclisation product 
400, Scheme 6.45. 
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Scheme 6.45  Attempted synthesis of the stemona alkaloid skeleton 406 via an alkyne/acetal cyclisation. 
 
Despite the initial failure to prepare the stemona alkaloid skeleton 406, the 
transformation could significantly expand the utility of the cyclisation methodology and 
as such will be investigated further in due course. 
 
6.11  Fukuyama Reduction of (S)-Phenyl Thioester 
 
With thioester 400 in hand, the concluding steps in the synthesis of grandisine B 15 
were investigated. We envisaged that reduction of the thioester would give the 
indolizidine aldehyde 172 an intermediate used previously in the racemic synthesis of 
grandisine B 15. Initial attempts to reduce the thioester 400 focussed on the well 
precedented Fukuyama reduction, Scheme 6.46.164 
 
 
Scheme 6.46  Attempted reduction of thioester 400 under Fukuyama conditions.164 
 
Treatment of thioester 400 with Pd/C and triethylsilane in acetone gave no evidence of 
the desired aldehyde 172 after holding overnight at room temperature. Repeating the 
reaction in DCM, using conditions reported by Winssinger,165 also proved unsuccessful. 
Conditions for the reduction using other palladium sources such as Pd(PPh3)4 also failed 
to give the desired aldehyde 172. It was proposed that traces of thiophenol in the 
starting material may be poisoning the catalyst, however, a procedure using a high 
catalyst loading of Pd(OAc)2 (50 mol%) reported by Eberle also proved unsuccessful, 
giving only a trace of aldehyde 172 after prolonged reaction at room temperature.166 
Subjecting thioester 400 to standard hydrogenation conditions (Pd/C, H2) showed 
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neither reduction of the thioester or the double bond, providing further evidence that 
catalyst poisoning could be the problem. 
 
6.12  Alternative Methods for the Reduction of Thioester (400) 
 
Due to unsuccessful attempts to reduce the phenyl thioester 400 to aldehyde 172 using 
Fukuyama reduction conditions, methods for reducing thioester 400 directly to the 
allylic alcohol 288 were considered. Treatment of thioester 400 with NaBH4 in 
methanol or ethanol resulted in the formation of a number of products apparent by TLC 
analysis. Although attempts to separate the products proved unsuccessful, the 1H NMR 
spectroscopic data suggested the products were 1,4-reduction products, with no 
evidence of allylic alcohol 288. Interestingly, when the reduction was carried out in the 
presence of cerium(III) chloride heptahydrate using Luche conditions, no reaction was 
observed, with starting material recovered on work-up. 
 
More promising results were observed when lithium aluminium hydride was used as the 
reductant. In an initial small-scale reaction, treatment of thioester 400 with lithium 
aluminium hydride gave a mixture of indolizidine alcohol 288, along with the two 1,4-
reduction products 407 and 408, the 1H NMR spectroscopic data for which 
corresponded to the natural products tashiromine 407 and epi-tashiromine 408.167 On 
scale-up, a similar product ratio was observed, but we were unable to separate 
indolizidine alcohol 288 from the 1,4-reduction products 407 and 408, Scheme 6.47.   
 
 
Scheme 6.47  Attempted reduction of thioester 400 with LiAlH4. 
 
Although alcohol 288 could not be isolated cleanly, a sample of tashiromine 407 was 
isolated. The optical rotation of synthetic tashiromine 407 was consistent with that 
reported in the literature for the natural product [−42.6 (c 1.08, EtOH); Lit.167 +44.7 (c 
1.1, EtOH)] suggesting no loss of enantiomeric purity throughout the synthesis.  
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Conditions reported by Wang,168 for the selective reduction of unsaturated esters, using 
lithium aluminium hydride and benzyl chloride to generate AlH3 in situ, also failed to 
yield alcohol 288. Difficulties were also encountered when DIBAL-H was used as the 
reductant, which gave inseperable mixtures of 1,4 and 1,2-reduction products under a 
range of conditions. 
 
Treatment of thioester 400 with Raney Nickel in ethanol/ether resulted in complete 
reduction of the unsaturated indolizidine core unit to give a complex mixture of 1,4 and 
1,2-reduction products, including tashiromine 407. Repeating the reaction in refluxing 
acetone also resulted in complete consumption of the starting material, to give a 
complex mixture of unidentified products. In an alternative procedure, Raney Nickel 
was first deactivated by heating at reflux in acetone. Disappointingly, no reduction of 
the thioester 400 was observed under these conditions, giving only starting material on 
work-up. 
 
Due to unsuccessful attempts to reduce the phenyl thioester 400, attempts were made to 
reduce the analogous ethyl thioester 402. When subjected to the conditions previously 
investigated for the reduction of the phenyl thioester 400, the same difficulties were 
encountered. In most instances, the desired 1,2-reduction product was isolated as a 
mixture with conjugate reduction products and unreacted starting material, Scheme 6.48. 
 
 
Scheme 6.48  Attempted reduction of ethyl thioester 402. 
 
6.13  Conversion of Ethyl Thioester (402) into Methyl Ester (409) 
 
In order to overcome the problems encountered with the reduction of the thioester, we 
proposed that conversion into the known methyl ester 409 and subsequent reduction 
would provide access to the indolizidine alcohol 288.169 
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On treating ethyl thioester 288 with sodium methoxide in methanol, following the 
procedure of Krische,170 the formation of a second species was noted on TLC analysis. 
1H NMR spectroscopic analysis of the unpurified reaction mixture showed the presence 
of the desired methyl ester 409 and unreacted starting material, along with minor 
impurities. Attempts to push the reaction to completion using excess sodium methoxide 




Scheme 6.49  Attempted synthesis of methyl ester 409 using conditions reported by Krische.170 
 
A reaction using silver(I) trifluoromethanesulfonate in DCM/methanol following the 
procedure of Hanessian,171 gave more promising results. In an initial reaction, whilst 
complete consumption of the starting material 402 was not observed, the unpurified 
mixture contained only the desired product 409 and unreacted starting material 402 in a 
4:1 ratio.  It was subsequently found that if the reaction was carried out at 45 ºC in the 
presence of triethylamine, complete consumption of the starting material was observed, 
giving methyl ester 409 in 73% yield after purification, Scheme 6.50. 
 
 
Scheme 6.50  Synthesis of indolizidine alcohol 288 from ethyl thioester 402. 
 
Reduction of methyl ester 409 following the procedure of Brandi, proceeded as reported 
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6.14  Synthesis of (S)-5-methylcyclohexenone (87) 
 
With indolizidine alcohol 288 in hand, (S)-5-methylcyclohexenone 87 was prepared 
using the procedure of Jørgensen,105 via the organocatalysed conjugate addition of tert-
butyl acetoacetate into crotonaldehyde and subsequent p-TsOH-catalysed ring-
closure/decarboxylation, Scheme 6.51.  
 
 
Scheme 6.51  Jørgensen's synthesis of (S)-methyl cyclohexenone 87.105 
 
The optical rotation for the synthetic material [(+70.0 (c 0.52, CHCl3))] was similar to 
that reported by Jørgensen [(Lit.105 −74.6 (c 0.5, CHCl3))], suggesting the enantiomeric 
excess was approximately 80%, however, yields for the procedure were significantly 
lower than those published (Lit.105 93%). 
6.14.1 Resolution Approach to (S)-Methylcyclohexenone (87) 
 
An alternative resolution-based approach to methylcyclohexenone 87 was also briefly 
considered. We envisaged that condensation of 5-methyl-1,3-cyclohexanedione 236 
with an enantiomerically pure alcohol would afford a diastereomeric mixture of enones 
412 and 413.  Separation of the diastereoisomers and subsequent treatment with lithium 
aluminium hydride would enable rapid access to both enantiomers of 
methylcyclohexenone 87, Scheme 6.52. 
 
 
Scheme 6.52  Proposed synthesis of 5-methylcyclohexenone 87. 
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A similar strategy was used by Danheiser et al. in their synthesis of the natural product 
ascochlorin.172 Alkylation of the menthol-derived alkoxy ketone 414 via treatment with 
lithium diisopropyl amide and methyl iodide, gave a diastereomeric mixture of enones 
415 which were separable by fractional crystallisation. Treatment with MeLi and 




Scheme 6.53  Selected steps in Danheiser's synthesis of ascochlorin.172 
 
On treatment of 1,3-diketone 236 with (−)-menthol and catalytic p-TsOH in toluene, the 
diastereomeric alkoxy enones 417 and 418 were obtained as a 1:1 mixture, Scheme 6.54. 
Unfortunately, all efforts to separate the diastereoisomers via chromatography or 
crystallisation were unsuccessful, negating the possibility of using the sequence in the 
synthesis of enantiomerically pure (S)-5-methylcyclohexenone 87. 
 
 
Scheme 6.54  Synthesis of diastereomeric alkoxy enones 417 and 418. 
 
It was subsequently found that samples of the diastereomeric enones 417 and 418 
partially crystallised on standing for prolonged periods.  Analysis of the crystalline 
material by 1H NMR spectroscopy showed the sample to be enriched in one 
diastereoisomer, however, due to the high solubility of the compounds in most solvents, 
attempts to exploit the difference in crystallinity for the separation of the two 
diastereoisomers proved unsuccessful. Although not applicable to the synthesis of 5-
methyl-cyclohexenone 87, the route could provide a useful method for the separation of 
other cyclohexenone derivatives. 
  153 
6.15  The Synthesis of (+)-Grandisine D (17) 
 
Following the sequence developed for the racemic synthesis of grandisine B 15, 
oxidation of indolizidine alcohol 288 under Swern conditions gave the unstable 
aldehyde 172 in 88% yield, which was used immediately without purification 
(decomposition of aldehyde 172 was observed on storage). The aldol reaction of 
aldehyde 172 with the lithium enolate of (S)-5-methylcyclohexenone 87, formed on 
treatment with LDA, proceeded to give the alcohol 287 along with small amounts of the 
diasteromeric alcohol 294 derived from (R)-5-methylcyclohexenone. We were unable to 
determine the stereochemistry of the aldol products 287 and 294 from the NMR 
spectroscopic data, however this was unimportant as the stereochemistry was lost in the 
proceeding step. Oxidation of hydroxyl-ketone 287 using modified Swern conditions 
gave grandisine D 17 in 80% yield, Scheme 6.55.  
 
 
Scheme 6.55  Concluding steps in the synthesis of grandisine D 17. 
  
Conversion of grandisine D 17 into its TFA salt allowed comparison with the literature 
data which were identical to those reported in all aspects but optical rotation. Although 
our value [(+73.7 (c 0.1, MeOH))] was consistent with that reported by Tamura [(+65.7 
(c 0.09, MeOH))],25 the value reported for the natural product was considerably lower 
[(+34.6 (c 0.09, MeOH))],10 which we attributed to the natural product being of a lower 
degree of purity.  
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6.16  The Synthesis of (−)-Grandisine B (15) 
 
In the racemic series, we reported that the cyclisation of grandisine D 17 to give 
grandisine B 15 did not proceed with 35% aqueous ammonia. It was subsequently found 
that on treatment with 35% aqueous ammonia, a solution of grandisine D 17 in 1 M 
aqueous hydrochloric acid was readily converted into (−)-grandisine B 15, which was 
isolated in 72% yield after purification, Scheme 6.56. The optimised reaction procedure 
was similar to conditions used during the isolation process providing evidence to 
support the theory that grandisine B 15 is an artefact of the isolation process as 
discussed previously in Chapter 5. 
 
 
Scheme 6.56  Conversion of grandisine D 17 into grandisine B 15. 
 
The NMR spectroscopic data were consistent with those published in the isolation paper 
and the recent publication by Tamura and co-workers,9, 55 however, discrepancies were 
again noted between Carroll and Tamura regarding the optical rotation of grandisine B 
15 [(Lit.9 +11 (c 0.1, DCM)); (Lit.55 −159 (c 0.08, DCM))]. The optical rotation of our 
synthetic material [(−177.5 (c 0.08, DCM))] was consistent with that reported by 
Tamura, suggesting an error in the value reported in the original isolation paper. 
 
6.17  Applications of Thioester (400) in the Synthesis of Other 
Elaeocarpus Alkaloids 
 
With the synthesis of (−)-grandisine B 15 complete, we were in a position to investigate 
the synthesis of other Elaeocarpus alkaloids using methodology developed over the 
course of this project. We envisaged that the indolizidine thioester 400 could function as 
a general precursor to other indolizidine alkaloids as shown in Scheme 6.57. 
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Scheme 6.57  Potential applications of thioester 400 in the synthesis of other elaeocarpus alkaloids. 
 
6.18  Addition of Grignard Reagents to Thioester (400) 
 
We initially chose to investigate the coupling of thioesters with Grignard reagents in the 
presence of iron catalysts as reported by Marchese,173, 174 which we envisaged would 
provide access to ketones such as elaeokanine A 57. Pleasingly, in an initial experiment, 
treatment of thioester 400 with propyl magnesium chloride in the presence of iron(III) 
acetylacetonate, the desired product elaeokanine A 57 was isolated in an unoptimised 
38% yield, Scheme 6.58.  
 
 
Scheme 6.58  Synthesis of elaeokanine A 57 via Grignard addition to thioester 400. 
 
Although low yielding, we were encouraged by this initial result. The more complex 
target, elaeokanidine A 419, isolated from the Elaeocarpus kaniensis by Lamberton and 
co-workers in 1972,33 was selected to further test the utility of thioester 400. 
Retrosynthetically, we proposed that elaeokanidine A 57 could be obtained from enone 
420, which could be accessed via addition of propenyl magnesium bromide to thioester 
400, Scheme 6.59. 
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Scheme 6.59  Retrosynthesis of elaeokanidine A 419. 
 
Attempts to add propenyl magnesium bromide into thioester 400 following the reported 
conditions failed to give the expected enone 420, yielding only unreacted starting 
material on work-up, Scheme 6.60. The reaction was also repeated with allyl 
magnesium bromide, which we proposed could be isomerised to give enone 420.  
Disappointingly, only recovered starting material was observed in the 1H NMR 
spectrum of the unpurified reaction mixture. 
 
 
Scheme 6.60  Attempted addition of propenyl magnesium bromide into thioester 400. 
 
6.19  A Liebeskind-Srogl Approach to Elaeokanidine A (419) 
 
An alternative route to enone 420 was proposed using the Liebeskind-Srogl coupling 
reaction.175 We envisaged that coupling of thioester 400 with propenyl boronic acid 
would provide access to the enone 420. Initially the reaction was attempted with phenyl 
boronic acid in order to test the viability of the route. Coupling of thioester 400 using 
conditions reported by Liebeskind176 gave phenyl indolizidine 358 in an unoptimised 
17% yield. The transformation was also applicable to the synthesis of the styrenyl 
analogue 421 which was isolated in 56% yield, Scheme 6.61. 
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Scheme 6.61  Liebeskind-Srogl coupling of thioester 400 with phenyl and styrenyl boronic acid. 
 
On subjecting thioester 400 to the cross-coupling conditions with cis-propenyl boronic 
acid, we were pleased to observe the formation of a new product on TLC analysis.  
Analysis of the unpurified reaction mixture using 1H NMR spectroscopy, revealed the 
desired product 422 as a mixture of cis and trans-isomers. However, after purification 
on silica, only trans-422 was isolated, which was attributed to isomerisation on the 
acidic media, Scheme 6.62. 
 
 
Scheme 6.62  Liebeskind-Srogl coupling of thioester 400 with cis-propenyl boronic acid. 
 
On scale-up the enone 422 was isolated in 69% yield, containing a small amount of an 
inseparable impurity. Due to time constraints we felt it would be instructive to 
investigate the final step using the impure material. We envisaged that on treatment 
with aqueous ammonia, a double conjugate addition of ammonia would occur to give 
the piperidone skeleton. With limited quantitites of the enone 422 available, the 
conditions developed for the synthesis of grandisine B 15 were initially investigated. 
Dissolving the precursor enone 422 in 1 M aqueous HCl and subsequent treatment with 
aqueous ammonia, led to the rapid consumption of starting material, with formation of a 
number of products apparent by TLC analysis, Scheme 6.63. 
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Scheme 6.63  Synthesis of elaeokanidine A 419 via a double conjugate addition of ammonia. 
 
The 1H NMR spectrum of the unpurified reaction mixture showed peaks consistent with 
the expected product 419, isolated as a complex mixture of diastereoisomers. Although 
the 1H NMR spectra for all diastereoisomers of elaeokanidine show similarities, the C-
12 proton in elaeokanidine A 419 is shifted downfield to ~3.8 ppm, relative to 
elaeokanidines B 423 and C 424 (~3.0 ppm).33 Integration of this signal in the 
unpurified mixture suggested elaeokanidine A 419 was a minor component formed in 
the cyclisation reaction. In the isolation paper, Lamberton et al. reported the isolation of 
two other diastereoisomers, proposed to be the cis-isomer 423 and the C-12 epimer 
424,33 which could account for the other products formed during the reaction. 
 
Although attempts to completely separate the diastereoisomers by column 
chromatography were unsuccessful, we were able to obtain an enriched sample of 
elaeokanidine A 419 of sufficient purity for characterisation purposes. The 1H NMR 
spectroscopic data were consistent with those reported by Lamberton.33 Large couplings 
between the C-7 and C-8 protons (~10 Hz) and C-8 and C-9 protons (~10 Hz) 
confirmed the trans-stereochemistry at the ring junctions (Figure 6.4). 
 
                   
Figure 6.4  Structure of elaeokanidine A 419. 
        
Further evidence for the relative stereochemistry of elaeokanidine A 419 was obtained 
from nOe studies. Irradiation of the C-12 proton signal showed correlations to both C-
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11 protons as well as the C-13 methyl group, suggesting the proton was in an equatorial 
conformation. On irradiation of the C-7 proton signal, correlations to the C-5, C-9 and 
C-13 protons were observed. Finally, irradiation of the C-13 methyl signal, showed 
correlations to the C-7 and C-12 protons, however, a correlation to only one of the C-11 
protons was apparent, suggesting the methyl group adopted an axial conformation. 
Additional work is required to confirm the structures of the other diastereoisomers 423 
and 424 formed during the reaction, the results of the studies will be reported in due 
course.  
 
Based on previous observations regarding the formation of artefact alkaloids during 
isolation from Elaeocarpus sp., the natural origins of the elaeokanidines are also 
questionable. Inspection of the isolation paper revealed that aqueous ammonia was used 
during the extraction process, in a procedure similar to that employed in the isolation of 
grandisine B 15, suggesting that elaeokanidines A, B and C could also be artefacts. 
 
6.20  Summary 
 
In summary, the total synthesis of (−)-grandisine B 15 has been achieved using an 
alkyne/acetal cyclisation to efficiently construct the indolizidine core unit. A 
“biomimetic” amination/cyclisation sequence was used to assemble the 
isoquinuclidinone core unit, using the known alkaloid grandisine D 17 as a precursor. 
Results of these studies provide evidence to suggest that grandisine B 15 is an artefact 
of the isolation process formed as a consequence of using aqueous ammonia in the 
extraction procedure.  
 
Initial studies have shown that the indolizidine thioester 400 is a valuable building block 
in the synthesis of elaeocarpus alkaloids.  Preliminary results have shown that the 
thioester group can be elaborated via Grignard addition or Liebeskind-Srogl coupling, a 
strategy applied to the synthesis of elaeokanidine A 419.  The utility of thioester 400 in 
the synthesis of other elaeocarpus alkaloids is the subject of current investigations. 
 
The work described in this Chapter was recently the subject of two publications.177, 178 
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Chapter 7.  Experimental 
 
 
NMR spectra were recorded on a Jeol ECX-400 instrument at 400 MHz (1H) and 100 
MHz (13C); chemical shifts (δ) are quoted in parts per million (ppm) calibrated to 
residual non-deuterated solvent (1H NMR: CDCl3 at 7.26 ppm; 
13C NMR: CDCl3 at 
77.0 ppm). Coupling constants (J) are quoted in Hertz and are to the nearest 0.1 Hz. 
Multiplicities are given as: singlet (s), doublet (d), triplet (t), quartet (q), pentet (pent) or 
broad (br). Infrared spectra were recorded on a ThermoNicolet IR100 spectrometer with 
NaCl plates. Low resolution electrospray ionisation (ESI) mass spectra were recorded 
on a Kratos MS 25 spectrometer. High resolution mass spectra were recorded on a 
Bruker MicrOTOF spectrometer. Melting points were recorded on Gallenkamp 
apparatus and are uncorrected. Thin layer chromatography was performed on 
aluminium plates coated with Merck Silica gel 60 F254 and flash column 
chromatography was carried out using Fluka flash silica gel 60 and the specified eluent. 
Petrol refers to the fraction of petroleum ether that boils in the range 40-60 °C. Where 
necessary, solvents were dried on an Innovative Technology Inc. PureSolv® 
Purification System, and THF was distilled from sodium benzophenone ketyl 
immediately before use. Except where specified, all reagents were purchased from 
commercial sources and used without further purification. Alkyllithium reagents were 
titrated against N-benzylbenzamide before use. Unless otherwise stated all reactions 
were carried out in oven-dried glassware under an atmosphere of argon with magnetic 
stirring. Reaction temperatures of −78 °C were achieved using dry ice/acetone mixtures. 
Structural assignment was aided by the use of DEPT, COSY, HSQC and HMBC 
spectroscopy. All numbering on the structures below is for the benefit of structure 
characterisation and does not conform to IUPAC rules. 
 





 158:  To a stirred solution of 3-butynol 
(5.40 mL, 71.3 mmol, 1.0 equiv.) and 3,4-dihydro-2H-pyran (8.46 mL, 92.7 mmol, 1.3 
equiv.) in DCM (175 mL) at rt was added p-TsOH (0.14 g, 0.71 mmol, 0.01 equiv.).  
The dark blue solution was held at rt for 7 h then washed with sat. aq. NaHCO3 (2 × 100 
mL) and brine (100 mL).  The organic phase was dried (Na2SO4), then concentrated in 
vacuo to afford an orange oil which was distilled to give the title compound 158 (10.4 g, 
95%) as a colourless oil; bp. 38-41 ºC (0.5 mmHg); Rf 0.25 (DCM); δH (400 MHz, 
CDCl3) 4.64 (1 H, dd, J = 4.0, 3.0, H-5), 3.90-3.82 (1 H, m, H-9a), 3.82 (1 H, dt, J = 9.7, 
7.0, H-4a), 3.55 (1 H, dt, J = 9.7, 7.0, H-4b), 3.53-3.46 (1 H, m, H-9b), 2.49 (2 H, td, J = 
7.0, 2.7, H-3), 1.97 (1 H, t, J = 2.7, H-1), 1.87-1.47 (6 H, m, H-6, 7, 8). 
Lab Book Ref. = JDC/1/1 








 159:  To a stirred 
solution of alkyne 158 (50.0 g, 324.5 mmol, 1.0 equiv.) in diethyl ether (180 mL) at −78 
ºC was added n-BuLi (1.3 M in hexanes, 262 mL, 340.7 mmol, 1.05 equiv.) dropwise 
over 3 h.  The resulting suspension was stirred for a further 1 h at −78 ºC then 
chlorotrimethylsilane (43.2 mL, 340.7 mmol, 1.05 equiv.) was added dropwise over 1 h.  
After stirring at −78 ºC for 1 h, the reaction was warmed to rt and held overnight.  The 
reaction was quenched with water (40 mL) and the aqueous layer extracted with pentane 
(2 × 30 mL).  The combined organic extracts were dried (MgSO4), then concentrated in 
vacuo to give the title compound 159 (69.6 g, 95%) as an orange oil; Rf 0.56 (DCM); δH 
(400 MHz, CDCl3) 4.65 (1 H, dd, J = 3.5, 3.5, H-5), 3.92-3.85 (1 H, m, H-9a), 3.80 (1 H, 
dt, J = 9.6, 7.2, H-4a), 3.53 (1 H, dt, J = 9.6, 7.2, H-4b),  3.53-3.46 (1 H, m, H-9b), 2.52 
(2 H, t, J = 7.2, H-3), 1.88-1.46 (6 H, m, H-6, 7, 8), 0.13 (9 H, s, H-10). 
Lab Book Ref. = JDC/1/16 
Data were consistent with those published.
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 160:  
To a stirred solution of alkyne 159 (7.50 g, 33.2 mmol, 1.0 equiv.) in diethyl ether (25 
mL) at 0 ºC was added dropwise diisobutylaluminium hydride (1.0 M in toluene, 33.2 
mL, 33.2 mmol, 1.0 equiv.).  The reaction was warmed to rt and held for 30 min., then 
heated to 40 ºC and held for 2 h.  The colourless solution was cooled to 0 ºC, then 
pyridine (4.56 mL, 56.4 mmol, 1.7 equiv.) was added.  The yellow solution was cooled 
to −78 ºC then a solution of bromine (2.10 mL, 41.5 mmol, 1.25 equiv.) in DCM (6 mL) 
was added dropwise over 1 h.  The resulting yellow slurry was held for a further 20 min. 
at −78 ºC, then poured onto a mixture of 1 M aq. NaOH (33 mL), ice (33 g) and hexane 
(50 mL) and stirred for 45 min.  The organic phase was separated, washed with 10% aq. 
HCl (2 × 20 mL), H2O (2 × 20 mL) and brine (20 mL), then dried (Na2SO4).  The 
combined organic extracts were concentrated in vacuo to afford an orange oil, which 
was distilled to give the title compound 160 (5.60 g, 55%) as a colourless oil; bp. 93-96 
ºC (0.25 mmHg); Rf 0.32 (DCM); δH (400 MHz, CDCl3) 6.78 (1 H, t, J = 8.0, H-2), 4.58 
(1 H, dd, J = 3.9, 2.9, H-5), 3.90-3.79 (1 H, m, H-9a), 3.75 (1 H, dt, J = 9.6, 6.7, H-4a), 
3.55-3.45 (1 H, m, H-9b), 3.41 (1 H, dt, J = 9.6, 6.7, H-4b), 2.39 (2 H, dt, J = 8.0, 6.7, H-
3), 1.88-1.43 (6 H, m, H-6, 7, 8), 0.27 (9 H, s, H-10). 
Lab Book Ref. = JDC/1/6 








 161:  A stirred solution of alkene 160 
(4.50 g, 14.6 mmol, 1.0 equiv.) and pyridinium p-toluenesulfonate (0.28 g, 1.10 mmol, 
0.08 equiv.) in methanol (170 mL) was heated at 40 ºC for 20 h. After cooling to rt the 
solvent was evaporated under reduced pressure and the residue taken up in diethyl ether 
(100 mL). The resulting precipitate was filtered and washed with diethyl ether (2 × 20 
  163 
mL).  The filtrate was concentrated in vacuo to give the title compound 161 (3.30 g, 
Quant.) as a pale yellow oil; Rf 0.29 (DCM); δH (400 MHz, CDCl3) 6.76 (1 H, t, J = 8.1, 
H-2), 3.67 (2 H, t, J = 6.4, H-4), 2.37 (2 H, dt, J = 8.1, 6.4, H-3), 0.28 (9 H, s, H-5). 
Lab Book Ref. = JDC/1/7 








 162:  To a 
stirred solution of alcohol 161 (2.01 g, 9.00 mmol, 1.2 equiv.), succinimide (0.74 g, 
7.50 mmol, 1.0 equiv.) and triphenylphosphine (2.56 g, 9.75 mmol, 1.3 equiv.) in THF 
(40 mL) at 0 ºC was added diethyl azodicarboxylate (1.54 mL, 9.75 mmol, 1.3 equiv.) 
dropwise.  The yellow solution was allowed to warm to rt and held for 48 h.  The 
solvent was evaporated under reduced pressure and the residue taken up in DCM (40 
mL).  The organics phase was washed with 5 M aq. KOH (2 × 20 mL), 10% aq. HCl (2 
× 20 mL) and brine (20 mL) then dried (Na2SO4).  The organic phase was concentrated 
in vacuo to afford a yellow oil which was purified by column chromatography (SiO2, 
DCM) to give the title compound 162 (1.95 g, 85%) as a colourless oil; Rf 0.29 (DCM); 
δH (400 MHz, CDCl3) 6.67 (1 H, t, J = 8.1, H-2), 3.54 (2 H, t, J = 7.3, H-4), 2.70 (4 H, s, 
H-6), 2.38 (2 H, dt, J = 8.1, 7.3, H-3), 0.26 (9 H, s, H-7). 
Lab Book Ref. = JDC/3/71 








 163:  To 
a stirred solution of alkene 162 (1.93 g, 6.34 mmol, 1.0 equiv.) in methanol (25 mL) at 0 
ºC was added sodium borohydride (0.95 g, 25.4 mmol, 4.0 equiv.). The reaction was 
stirred at 0 ºC for 4 h then poured into a mixture of DCM (10 mL) and sat. aq. NaHCO3 
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(5 mL).  The mixture was stirred for 20 min. then the organic phase was separated and 
the aqueous phase extracted with DCM (3 × 20 mL).  The combined organic extracts 
were washed with brine (20 mL), dried (Na2SO4), then concentrated in vacuo to give the 
title compound 163 (1.80 g, 93%) as a pale yellow oil; Rf 0.38 (DCM/methanol, 9:1); δH 
(400 MHz, CDCl3) 6.70 (1 H, t, J = 8.0, H-2), 5.18 (1 H, br s, H-5), 3.46 (1 H, ddd, J = 
14.1, 8.0, 6.4, H-4a), 3.30-3.20 (1 H, m, H-4b), 2.57-2.49 (1 H, m, H-3a), 2.48-2.24 (4 H, 
m, H-6, 7), 1.93-1.86 (1 H, m, H-3b), 0.26 (9 H, s, H-9). 
Lab Book Ref. = JDC/3/85 








 164:  A solution of vinyl silane 
163 (1.80 g, 5.88 mmol, 1.0 equiv.) in trifluoroacetic acid (25 mL) was heated at reflux 
for 5 h.  The reaction mixture was cooled to rt and concentrated in vacuo to afford an 
orange oil which was purified by column chromatography (SiO2, DCM/MeOH, 98:2) to 
give the title compound 164 (1.05 g, 83%) as a pale yellow oil; Rf 0.19 (EtOAc/PE, 7:3); 
δH (400 MHz, CDCl3) 6.12 (1 H, ddd, J = 6.1, 2.3, 2.0, H-7), 4.27-4.19 (2 H, m, H-5a, 9), 
2.85 (1 H, ddd, J = 13.4, 11.5, 4.7, H-5b), 2.49-2.27 (4 H, m, H-1a, 2, 6a), 2.21-2.09 (1 H, 
m, H-6b), 1.81-1.69 (1 H, m, H-1b). 
Lab Book Ref. = JDC/3/88 








 74:  To a stirred solution of lithium 
aluminium hydride (4.0 M in Et2O, 1.70 mL, 6.80 mmol, 2.7 equiv.) in diethyl ether (60 
mL) at 0 ºC was added dropwise lactam 164 (537 mg, 2.48 mmol, 1.0 equiv.) as a 
solution in diethyl ether (15 mL).  The solution was heated to reflux and held for 4 h 
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then cooled to 0 ºC before quenching with excess sodium sulfate decahydrate.  The 
slurry was stirred at 0 ºC for 45 min., then filtered through celite and the residual solid 
washed with diethyl ether (2 × 25 mL).  The combined organic extracts were dried 
(Na2SO4), then concentrated in vacuo to give the title compound 74 (148 mg, 85%) as a 
pale yellow oil; Rf 0.31 (DCM/MeOH, 9:1); δH (400 MHz, CDCl3) 6.07-6.03 (1 H, m, 
H-7), 3.65-3.57 (1 H, m, H-9), 2.98 (1 H, ddd, J = 13.0, 5.7, 2.5, H-5a), 2.93-2.84 (2 H, 
m, H-3a, 5b), 2.83-2.77 (1 H, m, H-3b), 2.40 (1 H, ddddd, J = 17.4, 10.0, 5.9, 3.1, 3.1, H-
6a), 2.16-2.06 (1 H, m, H-1a), 2.06-1.97 (1 H, m, H-6b), 1.88-1.73 (3 H, m, H-1b, 2). 
Lab Book Ref. = JDC/3/70 






(E)-4-Bromo-4-(trimethylsilyl)but-3-enyl methanesulfonate 168:  To a stirred 
solution of alcohol 161 (100 mg, 0.45 mmol, 1.0 equiv.) and triethylamine (70 µL, 0.50 
mmol, 1.1 equiv.) in DCM (3 mL) at 0 ºC was added methanesulfonyl chloride (40 µL, 
0.50 mmol, 1.1 equiv.).  The reaction was warmed to rt and stirred for 1 h then 
quenched with sat. aq. NaHCO3 (5 mL).  The organic phase was separated and the 
aqueous phase extracted with DCM (4 × 5 mL).  The combined organics were dried 
(Na2SO4) then concentrated in vacuo to give the title compound 168 (128 mg, 94%) as a 
colourless oil; Rf 0.86 (DCM); υmax/cm
-1
 (neat) 2958, 2901, 1607, 1356, 1251, 1174, 
968; δH   (400 MHz, CDCl3) 6.70 (1 H, t, J = 8.0, H-2), 4.22 (2 H, t, J = 6.5, H-4), 3.01 
(3 H, s, H-6), 2.66 (2 H, dt, J = 8.0, 6.5, H-3), 0.28 (9 H, s, H-5); δC (125 MHz, CDCl3) 
141.0 (CH, C-2), 132.2 (C, C-1), 67.9 (CH2, C-4),  37.7 (CH3, C-6), 32.1 (CH2, C-3), 
0.2 (CH3, C-5); m/z (ESI)  323 [MNa]
+





, 322.9748 (1.5 ppm error)]. 
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(E)-(1,4-Dibromobut-1-enyl)trimethylsilane 169:  To a stirred solution of alcohol 161 
(100 mg, 0.45 mmol, 1.0 equiv.) and carbon tetrabromide (166 mg, 0.50 mmol, 1.1 
equiv.) in DCM (1 mL) at 0 ºC was added triphenylphosphine (131 mg, 0.50 mmol, 1.1 
equiv.). The reaction was stirred at 0 ºC for 30 min., then warmed to rt and held for 2 h.  
The solvent was evaporated under reduced pressure and the residue taken up in hexane 
(2 mL).  The resulting precipitate was filtered and the filtrate concentrated in vacuo to 
give a colourless oil which was purified by flash chromatography (SiO2, PE/ether, 49:1) 
to give the title compound 169 (81 mg, 63%) as a colourless oil; Rf 0.70 (PE/ether, 4:1); 
υmax/cm
-1
 (neat) 3019, 2977, 2873, 1253, 1217, 1110, 844, 759; δH (400 MHz, CDCl3) 
6.72 (1 H, t, J = 8.0, H-2), 3.36 (2 H, t, J = 7.0, H-4), 2.66 (2 H, dt, J = 8.0, 7.0, H-3), 
0.28 (9 H, s, H-5); δC (125 MHz, CDCl3) 143.8 (CH, C-2), 131.3 (C, C-1), 35.2 (CH2, 
C-4), 31.0 (CH2, C-3), 0.3 (CH3, C-5); m/z (EI)  271 (17), 205 (7), 137 (100); [HRMS 
(EI): calcd. for C7H14Si
79
Br2, 283.9232. Found: [MH]
+
, 283.9241 (3.2 ppm error)]. 






 170 and 171:  To a stirred 
solution of vinyl bromide 74 (25 mg, 0.12 mmol, 1.0 equiv.) in THF (1 mL) at −78 ºC 
was added dropwise tert-BuLi (1.6 M in pentane, 155 µL, 0.25 mmol, 2.1 equiv.).  The 
reaction was stirred at −78 ºC for 30 min. then benzaldehyde (30 µL, 0.27 mmol, 2.3 
equiv.) was added dropwise.  The reaction was stirred at −78 ºC for a further 30 min., 
then warmed to rt and held overnight.  The reaction was quenched with 2 M aq. HCl (5 
mL), then the aqueous phase was washed with diethyl ether (2 × 5 mL).  The aqueous 
phase was basified with K2CO3 then extracted with DCM (3 × 10 mL).  The combined 
organic extracts were washed with brine (10 mL), dried (Na2SO4), then concentrated in 
vacuo to afford a yellow oil which was purified by column chromatography (Al2O3, 
DCM/methanol, 95:5) to give the title compounds 170 and 171 (16 mg, 56%, 1:1 
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mixture of diastereoisomers) as a yellow oil; Rf 0.10 (DCM/MeOH, 4:1); δH (400 MHz, 
CDCl3) 7.39-7.28 (10 H, m, ArH), 5.99-5.94 (1 H, m, H-7), 5.62-5.58 (1 H, m, H-7’), 
5.18 (1 H, s, H-10’), 5.15 (1 H, s, H-10), 3.07-2.98 (1 H, m, H-9), 2.94-2.75 (5 H, m, H-
3a, 5a, 9’), 2.61-2.44 (4 H, m, H-3b, 5b), 2.36-2.29 (2 H, m, H-6), 2.29-2.20 (2 H, m, H-
6’), 1.96-1.44 (7 H, m, H-1a, 1b, 1a’, 2), 1.41-1.30 (1 H, m, H-1b’). 
Lab Book Ref. = JDC/1/31 








 154:  4-Aminocyclohexane carboxylic acid (0.50 g, 
3.34 mmol, 1.0 equiv.) was heated at 250 ºC for 30 min. then cooled to rt.  The brown 
residue was taken up in hot toluene (50 mL), then the solution was filtered. The filtrate 
was concentrated in vacuo to give the title compound 154 an off-white solid (0.37 g, 
84%); mp. 196-197 ºC (Lit. 197-198 ºC); Rf 0.36 (DCM/MeOH, 9:1); δH (400 MHz, 
CDCl3) 7.05 (1 H, br s, H-2), 3.63-3.57 (1 H, m, H-1), 2.52-2.47 (1 H, m, H-4), 1.85-
1.55 (8 H, m, H-5, 6). 
Lab Book Ref. = JDC/1/35 








 180:  To a stirred solution of piperidine (0.58 
mL, 5.87 mmol, 1.0 equiv.) and selenium dioxide (33 mg, 0.3 mmol, 0.05 equiv.) in 
acetone (15 mL) at 0 ºC was added dropwise hydrogen peroxide (30 wt% aq., 1.5 mL, 
13.0 mmol, 2.2 equiv).  The solution was stirred at 0 ºC for 30 min., then warmed to rt 
and held for a further 3 h.  The acetone was evaporated under reduced pressure and the 
organics were extracted with DCM (4 × 50 mL).  The combined organic extracts were 
dried (Na2SO4), then concentrated in vacuo to give the title compound 180 (~90% Yield 
by NMR) as an unstable yellow oil; Rf 0.10 (DCM/MeOH, 9:1); δH (400 MHz, CDCl3) 
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7.22-7.19 (1 H, m, H-1), 3.81-3.76 (2 H, m, H-5), 2.46-2.39 (2 H, m, H-2), 1.99-1.91 (2 
H, m, H-4), 1.75-1.66 (2 H, m, H-3). 
Lab Book Ref. = JDC/1/33 








 182:  To a stirred solution of 
lactam 154 (100 mg, 0.80 mmol, 1.0 equiv.) in THF (5 mL) was added lithium 
aluminium hydride (1.0 M in THF, 2.80 mL, 2.80 mmol, 3.5 equiv.).  The solution was 
heated to reflux and held for 2 h, then cooled to 0 ºC.  Sodium sulfate decahydrate was 
added slowly until effervescence ceased, then the resulting slurry was filtered through 
celite into a 25 mL round bottom flask.  To the filtrate was added Boc2O (153 mg, 0.70 
mmol, 1.0 equiv.), then the solution was stirred at rt overnight.  The reaction was 
diluted with ethyl acetate (10 mL), washed with brine (10 mL), dried (Na2SO4), then 
concentrated in vacuo to give the title compound 182 (127 mg, 75%) as a colourless oil; 
Rf 0.33 (SiO2, PE/EtOAc, 2:1); δH (400 MHz, C6D6, Rotamers observed) 4.25-4.21 (1 H, 
m, H-1), 3.89-3.84 (1 H, m, H-1’), 3.39-3.35 (2 H, m, H-3), 3.23-3.29 (2 H, m, H-3’), 
1.70-1.57 (4 H, m), 1.48 (9 H, s, H-9), 1.45 (9 H, s, H-9’), 1.30-1.07 (14 H, m). 
Lab Book Ref. = JDC/2/21 








 195:  To a stirred suspension of NaH (60 
wt%, 32 mg, 0.80 mmol, 2.0 equiv.) in THF (1 mL) at 0 ºC was added lactam 154 (50 
mg, 0.40 mmol, 1.0 equiv.).  The slurry was stirred at 0 ºC for 30 min., then warmed to 
rt and held for a further 30 min.  The slurry was re-cooled to 0 ºC, then benzyl bromide 
(92 µL, 0.80 mmol, 2.0 equiv.) was added dropwise.  The slurry was warmed to rt and 
held overnight then quenched with sat. aq. NH4Cl (5 mL). The aqueous phase was 
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separated and extracted with EtOAc (2 × 10 mL). The combined organic extracts were 
washed with brine (10 mL), dried (MgSO4), then concentrated in vacuo to give a yellow 
oil which was purified by column chromatography (SiO2, PE/EtOAc, 2:1) to give the 
title compound 195 (83 mg, 97%) as a colourless crystalline solid; mp. 90-91 ºC (Lit. 
95-97 ºC); Rf 0.39 (SiO2, DCM/MeOH, 19:1); δH (400 MHz, CDCl3) 7.33-7.22 (5 H, m, 
ArH), 4.55 (2 H, s, H-7), 3.49-3.44 (1 H, m, H-1), 2.67-2.62 (1 H, m, H-4), 1.75-1.65 (2 
H, m, H-5a), 1.75-1.65 (2 H, m, H-5b), 1.59-1.47 (4 H, m, H-6); δC (100 MHz, CDCl3) 
175.5 (CO, C-3), 137.8 (C, ArC), 128.5 (2 × CH, ArCH), 128.2 (2 × CH, ArCH), 127.4 
(CH, ArCH), 52.4 (CH, C-1), 47.6 (CH2, C-7), 38.4 (CH, C-4), 27.0 (2 × CH2, C-6), 
24.4 (2 × CH2, C-5). 
Lab Book Ref. = JDC/2/77 





tert-Butyl 3-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate 197:  To a stirred solution 
of lactam 154 (50 mg, 0.40 mmol, 1.0 equiv.) in THF (3 mL) at −78 ºC was added 
dropwise n-BuLi (2.36 M in hexanes, 0.25 mL, 0.60 mmol, 1.5 equiv.).  The solution 
was held at −78 ºC for 1 h, then Boc2O (153 mg, 0.70 mmol, 1.8 equiv.) was added as a 
solution in THF (1 mL).  The reaction was warmed to rt over 3 h then quenched with sat. 
aq. NH4Cl (5 mL).  The organic phase was extracted with diethyl ether (3 × 20 mL), 
dried (MgSO4), then concentrated in vacuo to afford a white residue which was purified 
by column chromatography (SiO2, PE/Et2O, 1:1) to give the title compound 197 (72 mg, 
80%) as a colourless crystalline solid; mp. 120-121 ºC; Rf 0.79 (DCM/MeOH, 9:1); 
υmax/cm
-1
 (thin film) 2966, 1729, 1706, 1302, 1157; δH (400 MHz, CDCl3) 4.66-4.62 (1 
H, m, H-1), 2.63-2.59 (1 H, m, H-4), 1.94-1.64 (8 H, m, H-5, 6), 1.54 (9 H, s, H-9); δC 
(100 MHz, CDCl3) 174.8 (C, C-3), 150.5 (C, C-7), 82.8 (C, C-8), 50.1 (CH, C-1), 39.9 
(CH, C-4), 28.1 (3 × CH3, C-9), 26.0 (2 × CH2, C-6), 23.1 (2 × CH2, C-5); m/z (ESI) 
248 [MNa]
+
; [HRMS (ESI): calcd. for C12H19NNaO3, 248.1257. Found: [MNa]
+
, 
248.1260 (1.2 ppm error)] 
Lab Book Ref. = JDC/3/27 
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2-Benzyl-2-azabicyclo[2.2.2]octane-3-thione 200:  A stirred solution of lactam 195 
(300 mg, 1.40 mmol, 1.0 equiv.) and Lawesson’s reagent (340 mg, 0.84 mmol, 0.6 
equiv.) in PhMe (15 mL) was heated at reflux for 5 h.  The solution was cooled to rt  
then concentrated in vacuo to afford an oily residue which was purified by column 
chromatography (SiO2, PE/DCM, 1:1) to give the title compound 200 (304 mg, 94%) as 
a colourless crystalline solid; mp. 96-98 ºC (Hexane); Rf 0.06 (SiO2, PE/EtOAc, 1:1); 
υmax/cm
-1
 (thin film) 3019, 2964, 1499, 1357, 1215, 1157, 755, 668; δH (400 MHz, 
CDCl3) 7.38-7.28 (5 H, m, ArH), 5.17 (2 H, s, H-7), 3.74 (1 H, tt, J = 3.8, 2.0, H-1), 
3.41-3.37 (1 H, m, H-4), 1.85-1.66 (4 H, m, H-5), 1.63-1.48 (4 H, m, H-6); δC (100 
MHz, CDCl3) 205.1 (CS, C-3), 136.0 (C, ArC), 128.7 (2 × CH, ArCH), 128.3 (2 × CH, 
ArCH), 127.9 (CH, ArCH), 55.3 (CH, C-1), 54.3 (CH2, C-7), 48.4 (CH, C-4), 27.0 (2 × 
CH2, C-6), 24.5 (2 × CH2, C-5); m/z (ESI) 254 [MNa]
+
; [HRMS (ESI): calcd. for 
C14H17NNaS, 254.0974. Found: [MNa]
+
, 254.0970 (1.7 ppm error)]; Anal. Calcd. for 
C14H17NS: C, 72.68; H, 7.42; N, 6.06. Found C, 72.75; H, 7.42; N, 6.03. 




2-Benzyl-3-(methylthio)-2-azoniabicyclo[2.2.2]oct-2-ene iodide 201:  To a stirred 
solution of thiolactam 200 (150 mg, 0.65 mmol, 1.0 equiv.) in diethyl ether (3 mL) was 
added dropwise methyl iodide (0.69 mL, 11.1 mmol, 17 equiv.).  The colourless 
solution was stirred at rt for 18 h, after which time the suspension was filtered and the 
filter cake washed with diethyl ether (2 × 2 mL) to give the title compound 201 (221 mg, 
91%) as a colourless crystalline solid; mp. 154-157 ºC; υmax/cm
-1
 (thin film) 2942, 1571, 
1452, 1354, 1158, 746; δH (400 MHz, CDCl3) 7.49-7.44 (2 H, m, ArH), 7.40-7.36 (3 H, 
m, ArH), 5.28 (2 H, s, H-7), 4.52-4.48 (1 H, m, H-1), 3.88-3.85 (1 H, m, H-4), 3.05 (3 H, 
s, H-8), 2.08-1.97 (2 H, m, H-5a), 1.93-1.67 (6 H, m, H-5b, 6); δC (100 MHz, CDCl3) 
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194.0 (C, C-3), 131.1 (C, ArC), 129.6 (CH, ArCH), 129.5 (2 × CH, ArCH), 129.1 (2 × 
CH, ArCH), 60.3 (CH, C-1), 58.6 (CH2, C-7), 37.0 (CH, C-4), 25.7 (2 × CH2, C-6), 24.1 
(2 × CH2, C-5), 17.2 (CH3, C-8); m/z (ESI) 246 M
+
; [HRMS (ESI): calcd. for C15H20NS, 
246.1311. Found: M
+
, 246.1319 (3.4 ppm error)]. 








 204:  A stirred solution of lactam 154 (100 mg, 
0.80 mmol, 1.0 equiv.) and Lawesson’s reagent (194 mg, 0.48 mmol, 0.6 equiv.) in 
PhMe (10 mL) was heated at reflux for 5 h.  The solution was cooled to rt, then 
concentrated in vacuo to give an oily residue which was purified by column 
chromatography (SiO2, PE/DCM, 1:1) to give the title compound 205 (92 mg, 79%) as a 
colourless crystalline solid; mp. 155-157 ºC (Lit. 152-154 ºC); Rf 0.25 (PE/EtOAc, 2:1); 
δH (400 MHz, CDCl3) 8.73 (1 H, br s, H-2), 3.77-3.71 (1 H, m, H-1), 3.23-3.19 (1 H, m, 
H-4), 1.80-1.66 (8 H, m, H-5, 6). 
Lab Book Ref. = JDC/3/32 






3-Phenyl-2-azabicyclo[2.2.2]oct-2-ene 205:  A stirred suspension of thioamide 205 (26 
mg, 0.18 mmol, 1.0 equiv.), tetrakis(triphenylphosphine)palladium (8 mg, 0.007 mmol, 
0.04 equiv.), copper thiophene carboxylate (103 mg, 0.54 mmol, 3.0 equiv.) and 
phenylboronic acid (26 mg, 0.22 mmol, 1.2 equiv.) in THF (1.8 mL) was heated in a 
microwave reactor at 100 ºC for 1 h.  The brown solution was cooled to rt, then an 
additional quantity of tetrakis(triphenylphosphine)palladium (8 mg, 0.007 mmol, 0.04 
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equiv.) was added. The reaction mixture was heated to 100 ºC and held for a further 1 h.  
The reaction was cooled to rt and the solvent was evaporated under reduced pressure, 
then the residue was taken up in CHCl3 (50 mL).  The organic phase was washed with 
25% aq. NH3 (3 × 20 mL), then the combined aqueous washes were back extracted with 
CHCl3 (3 × 20 mL).  The combined organic extracts were washed with brine (50 mL), 
dried (MgSO4), the concentrated in vacuo to afford a brown film which was purified by 
column chromatography (SiO2, PE/EtOAc, 2:1) to give the title compound 205 (9 mg, 
27%) as a yellow film; Rf 0.38 (SiO2, PE/EtOAc, 2:1); δH (400 MHz, CDCl3) 7.85-7.80 
(2 H, m, ArH), 7.43-7.38 (3 H, m, ArH), 4.40-4.36 (1 H, m, H-1), 3.35-3.31 (1 H, m, H-
4), 1.73-1.65 (4 H, m, H-5), 1.50-1.37 (4 H, m, H-6). 
Lab Book Ref. = JDC/3/37 

















 96:  To a stirred solution of lithium 
hexamethyldisilazide (1.0 M in THF, 12.5 mL, 12.5 mmol, 1.2 equiv.) in THF (20 mL) 
at 0 ºC was added cyclohexenone (1.01 mL, 10.4 mmol, 1.0 equiv.).  The solution was 
held at 0 ºC for 30 min., then trimethylsilyl chloride (2.60 mL, 20.8 mmol, 2.0 equiv.) 
was added and the solution was held at 0 ºC for a further 2 h.  The reaction was 
quenched with triethylamine (0.2 mL) and saturated aqueous NaHCO3 (6 mL).  The 
organic layer was separated, then the aqueous phase was extracted with hexane (2 × 30 
mL).  The combined organic extracts were washed with sat. aq. NaHCO3 (30 mL) and 
brine (30 mL), dried (Na2SO4), then concentrated in vacuo to afford an orange oil.  
Distillation gave the title compound 96 (1.53 g, 88%) as a colourless oil; bp. 60 ºC (9 
mmHg), (Lit.
74
 60 ºC (9 mmHg)); δH (400 MHz, CDCl3) 5.86 (1 H, ddd, J = 9.9, 4.0, 
0.8, H-3), 5.69 (1 H, ddd, J = 9.9, 3.9, 1.9, H-2), 4.88 (1 H, ddt, J = 4.5, 2.1, 0.8, H-6), 
2.20-2.04 (4 H, m, H-4, 5), 0.19 (9 H, s, H-7). 
Lab Book Ref.  JDC/1/59 









 213:  To a stirred solution of 
p-methoxyaniline (0.70 g, 5.70 mmol, 1.1 equiv.), (S)-proline (0.18 g, 1.60 mmol, 0.3 
equiv.) and formaldehyde (37 wt% aq., 0.45 mL, 5.20 mmol, 1.0 equiv.) in DMSO (20 
mL) at rt was added 2-cyclohexen-1-one (1.01 mL, 10.4 mmol, 2.0 equiv.).  The orange 
solution was heated to 50 ºC and held for 24 h before cooling to rt and diluting with 
water (200 mL).  The aqueous phase was extracted with ethyl acetate (3 × 20 mL), dried 
(MgSO4), then concentrated in vacuo to afford a dark brown oil which was purified by 
column chromatography (SiO2, PE/EtOAc, 1:2) to give the title compound 213 (429 mg, 
34%) as an off-white solid; mp. 129-131 ºC (n-hexane); Rf 0.53 (SiO2, PE/EtOAc, 2:1); 
υmax/cm
-1
 (thin film) 2949, 1726, 1513, 1248, 1212, 1040, 754; δH (400 MHz, CDCl3) 
6.85 (2 H, d, J = 9.1, ArCH), 6.64 (2 H, d, J = 9.1, ArCH), 4.23-4.18 (1 H, m, H-1), 
3.76 (3 H, s, H-13), 3.64 (1 H, ddd, J = 9.9, 2.4, 2.4, H-3a), 3.47 (1 H, br d, J = 9.9, H-
3b), 2.67 (1 H, ddd, J = 18.5, 2.9, 2.9, H-6a), 2.64-2.60 (1 H, m, H-4), 2.42 (1 H, dd, J = 
18.5, 1.9, H-6b), 2.22-2.12 (1 H, m, H-7a), 2.06-1.91 (2 H, m, H-8), 1.85-1.75 (1 H, m, 
H-7b); δC (100 MHz, CDCl3) 213.9 (CO, C-5), 151.5 (C, ArC), 142.9 (C, ArC), 115.0 (2 
× CH, ArCH), 112.9 (2 × CH, ArCH), 55.8 (CH3, C-13), 50.7 (CH2, C-3), 48.2 (CH, C-
1), 45.0 (CH2, C-6), 44.3 (CH, C-4), 25.0 (CH2, C-7), 22.2 (CH2, C-8); m/z (ESI) 254 
[MNa]
+
; [HRMS (ESI): calcd. for C14H17NNaO2, 254.1151. Found: [MNa]
+
, 254.1148 
(1.4 ppm error)]. 






 114:  To a 
stirred solution of p-methoxyaniline (1.40 g, 11.4 mmol, 1.1 equiv.), (S)-proline (0.36 g, 
3.20 mmol, 0.3 equiv.) and formaldehyde (37 wt% aq., 0.90 mL, 10.4 mmol, 1.0 equiv.) 
in DMSO (40 mL) at rt was added 4,4-dimethylcyclohexen-2-one (2.74 mL, 20.8 mmol, 
  174 
2.0 equiv.).  The orange solution was held at rt for 48 h then diluted with water (150 mL) 
and extracted with DCM (3 × 20 mL).  The combined organic extracts were washed 
with sat. aq. NaHCO3 (30 mL) and brine (30 mL), dried (Na2SO4), then concentrated in 
vacuo to afford a dark brown oil which was purified by column chromatography (SiO2, 
DCM) to give the title compound 114 (1.82 g, 67%) as an off-white solid; mp. 92-94 ºC 
(diisopropyl ether); Rf 0.66 (PE/EtOAc, 1:1); [α]
24
D −85.6 (c 0.85, CHCl3), (Lit.
50
 −71.8 
(c 1.7, CHCl3); υmax/cm
-1
 (thin film) 2956, 1730, 1514, 1244, 1039, 811; δH (400 MHz, 
CDCl3) 6.85 (2 H, d, J = 9.1, ArCH), 6.61 (2 H, d, J = 9.1, ArCH), 3.78-3.74 (4 H, m, 
H-1, 13), 3.52-3.44 (2 H, m, H-3), 2.68 (1 H, dd, J = 18.9, 2.2, H-6a), 2.63-2.60 (1 H, m, 
H-4), 2.46 (1 H, dd, J = 18.9, 3.2, H-6b), 1.81-1.72 (2 H, m, H-8), 1.08 (3 H, s, CH3), 
1.07 (3 H, s, CH3); δC (100 MHz, CDCl3) 214.0 (CO, C-5), 151.0 (C, ArC), 142.9 (C, 
ArC), 115.1 (2 × CH, ArCH), 111.7 (2 × CH, ArCH), 58.0 (CH, C-1), 55.8 (CH3, C-13), 
47.6 (CH2, C-3), 45.7 (CH, C-4), 41.0 (CH2, C-6), 38.6 (CH2, C-8), 35.8 (C, C-7), 29.9 
(CH3), 28.6 (CH3); m/z (ESI) 282 [MNa]
+
; [HRMS (ESI): calcd. for C16H21NNaO2, 
282.1465. Found: [MNa]
+
, 282.1465 (0.2 ppm error)]. 
Lab Book Ref. = JDC/3/3 






tert-Butyl 7,7-dimethyl-5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate 225:  To a 
stirred solution of isoquinuclidinone 114 (29 mg, 0.11 mmol, 1.0 equiv.) in 
acetonitrile/water (3:1, 2.8 mL) at rt was added ceric ammonium nitrate (241 mg, 0.44 
mmol, 4.0 equiv.).  After stirring at rt for 30 min., the reaction was quenched with 1 M 
NaOH (5 mL), then extracted with DCM (4 × 20 mL).  The combined extracts were 
washed with brine (20 mL), then the solvent evaporated under reduced pressure to give 
a red oil.  The oil was taken up in toluene/water (2:1, 1 mL), then Boc2O (48 mg, 0.22 
mmol, 2.0 equiv.) and 25 wt% NaOH (27 µL, 0.17 mmol, 0.15 equiv.) were added 
sequentially.  The biphasic solution was stirred at rt for 4 h, then diluted with water (2 
mL).  The organic phase was separated, then the aqueous phase extracted with ethyl 
acetate (2 × 10 mL).  The combined organics were washed with brine (10 mL), dried 
(Na2SO4), then concentrated in vacuo to afford a brown film which was purified by 
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flash chromatography (SiO2, PE/EtOAc, 2:1) to give the title compound 225 (11 mg, 
39%) as a colourless oil; Rf 0.49 (PE/EtOAc, 2:1); υmax/cm
-1
 (thin film) 2967, 2929, 
1737, 1695, 1401, 1172, 1108; δH (400 MHz, CDCl3, Rotamers observed) 4.08 (1 H, dd, 
J = 3.4, 3.4, H-1), 3.91 (1 H, dd, J = 3.3, 2.4, H-1), 3.59-3.52 (2 H, m, H-2), 3.50-3.40 
(2 H, m, H-2), 2.64 (1 H, dd, J = 19.1, 3.4, H-6a), 2.62 (1 H, dd, J = 19.1, 2.5, H-6a), 
2.55-2.51 (1 H, m, H-3), 2.43 (1 H, J = 19.1, 3.4, H-6b), 2.41 (1 H, dd, J = 19.1, 3.3, H-
6b), 1.69-1.66 (4 H, m, H-8), 1.48-1.44 (18 H, s, H-11), 1.10 (3 H, s, CH3), 1.09 (3 H, s, 
CH3), 1.03 (3 H, s, CH3), 1.02 (3 H, s, CH3); δC (100 MHz, CDCl3) 213.0 (CO, C-5), 
212.5 (CO, C-5’), 154.9 (CO, C-9), 154.8 (CO, C-9’), 79.9 (C, C-10), 79.8 (C, C-10’), 
57.2 (CH, C-1), 55.7 (CH, C-1’), 45.2 (CH, C-4), 45.0 (CH2, C-3), 44.9 (CH, C-4’), 
44.4 (CH2, C-3’), 41.6 (CH2, C-6), 41.5 (CH2, C-6’), 38.3 (CH2, C-8), 38.2 (CH2, C-8’), 
34.6 (C, C-7), 34.5 (C, C-7), 29.5 (CH3), 29.4 (CH3), 28.4 (CH3, C-11, 11’); m/z (ESI) 
276 [MNa]
+
; [HRMS (ESI): calcd. for C14H23NNaO3, 276.1570. Found: [MNa]
+
, 
276.1577 (2.3 ppm error)]. 




2-(4-Methoxyphenyl)-7,7-dimethyl-2-azabicyclo[2.2.2]octane-3,5-dione 227:  To a 
stirred solution of amine 114 (90 mg, 0.35 mmol, 1.0 equiv.) in MeCN (3 mL) at rt was 
added potassium permanganate (166 mg, 1.05 mmol, 3.0 equiv.) as a solution in H2O (1 
mL).  The reaction was held at rt for 3 h, then excess sodium metabisulfite was added 
until a colourless solution remained.  The organics were extracted with DCM (3 × 10 
mL), dried (Na2SO4), then concentrated in vacuo to give the title compound 227 (46 mg, 
48%) as a white solid; mp. 136-139 ºC; Rf 0.41 (PE/EtOAc, 1:1); [α]
24
D + 4.3 (c 1.01, 
CHCl3); υmax/cm
-1
 (thin film) 3019, 1739, 1680, 1513, 1214, 754; δH (400 MHz, CDCl3) 
7.28 (2 H, d, J = 9.0, ArCH), 6.91 (2 H, d, J = 9.0, ArCH), 3.84 (1 H, dd, J = 3.2, 2.1, 
H-1), 3.80 (3 H, s, H-13), 3.37 (1 H, dd, J = 3.4, 2.4, H-4), 2.79 (1 H, dd, J = 18.9, 2.1, 
H-6a), 2.60 (1 H, dd, J = 18.9, 3.2, H-6b), 2.06 (1 H, dd, J = 13.8, 3.4, H-8a), 1.89 (1 H, 
dd, J = 13.8, 2.4, H-8b), 1.25 (3 H, s, CH3), 1.17 (3 H, s, CH3); δC (100 MHz, CDCl3) 
205.7 (CO, C-5), 166.6 (CO, C-3), 157.8 (C, ArC), 133.7 (C, ArC), 125.1 (2 × CH, 
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ArCH), 114.4 (2 × CH, ArCH), 66.8 (CH, C-1), 59.4 (CH, C-4), 55.5 (CH3, C-13), 39.8 
(CH2, C-6), 37.3 (CH2, C-8), 36.1 (C, C-7), 29.8 (CH3), 27.8 (CH3); m/z (ESI) 296 
[MNa]
+
; [HRMS (ESI): calcd. for C16H19NNaO3, 296.1257. Found: [MNa]
+
, 296.1265 
(2.6 ppm error)]. 




7,7-Dimethyl-2-azabicyclo[2.2.2]octane-3,5-dione 228:  To a stirred solution of 
lactam 227 (5 mg, 0.018 mmol, 1.0 equiv.) in MeCN (0.75 mL) at 0 ºC was added ceric 
ammonium nitrate (44 mg, 0.08 mmol, 4.4 equiv.) as a solution in H2O (0.25 mL).  The 
solution was held at 0 ºC for 30 min. then quenched with 1 M aq. NaOH (2 mL) before 
extracting with DCM (3 × 5 mL).  The combined organic extracts were washed with 
brine (5 mL), dried (Na2SO4), then concentrated in vacuo to give the title compound 
228 (3 mg, Quant.) as an off-white film contaminated with p-benzoquinone; Rf 0.41 
(DCM/MeOH, 9:1); υmax/cm
-1
 (thin film) 3249, 2964, 1734, 1688; δH (400 MHz, CDCl3) 
7.81 (1 H, br s, H-2), 3.41 (1 H, ddd, J = 5.4, 3.2, 2.1, H-1), 3.16-3.13 (1 H, m, H-4), 
2.66 (1 H, dd, J = 18.9, 2.1, H-6a), 2.38 (1 H, dd, J = 18.9, 3.2, H-6b), 1.90 (1 H, dd, J = 
13.8, 3.3, H-8a), 1.81 (1 H, dd, J = 13.8, 2.5, H-8b), 1.18 (3 H, s, CH3), 1.13 (3 H, s, 
CH3); δC (100 MHz, CDCl3) 205.8 (CO, C-5), 170.8 (CO, C-3), 58.6 (CH, C-4), 57.7 
(CH, C-1), 39.8 (CH2, C-6), 37.4 (CH2, C-8), 35.7 (C, C-7), 29.2 (CH3), 27.6 (CH3); m/z 
(ESI) 190 [MNa]
+
; [HRMS (ESI): calcd. for C9H13NNaO2, 190.0838. Found: [MNa]
+
, 
190.0846 (3.8 ppm error)]. 

















 237:  A stirred solution of 5-
methylcyclohexane-1,3-dione (5.00 g, 39.6 mmol, 1.0 equiv.) and p-TsOH (0.23 g, 1.2 
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mmol, 0.03 equiv.) in benzene (90 mL) and ethanol (25 mL) was heated at reflux 
(Dean-Stark) for 8 h.  The reaction was cooled to rt, then the solvent was evaporated 
under reduced pressure to afford a yellow oil which was partitioned between ether (60 
mL) and sat. aq. NaHCO3 (30 mL).  The organic phase was separated and the aqueous 
phase was extracted with ether (30 mL).  The combined organic extracts were washed 
with brine (30 mL), dried (MgSO4), then concentrated in vacuo to give the title 
compound 237 (5.74 g, 94%) as a pale yellow oil; Rf 0.53 (EtOAc); δH (400 MHz, 
CDCl3) 5.32 (1 H, d, J = 1.5, H-2), 3.94-3.82 (2 H, m, H-8), 2.44-2.36 (2 H, m, H-6), 
2.26-2.09 (1 H, m, H-5), 2.13 (1 H, ddd, J = 16.8, 10.2, 1.5, H-4a), 2.02 (1 H, dd, J = 
16.8, 11.7, H-4b), 1.35 (3 H, t, J = 7.1, H-9), 1.06 (3 H, d, J = 7.1, H-7). 
Lab Book Ref. = JDC/7/87 
















 87:  To a stirred solution of lithium aluminium hydride 
(4.0 M in diethyl ether, 2.03 mL, 8.11 mmol, 1.0 equiv.) in diethyl ether (20 mL) was 
added ethoxy enone 237 (4.63 g, 30.0 mmol, 3.7 equiv.) as a solution in diethyl ether 
(15 mL) over 30 min.  The solution was held overnight at rt, then carefully quenched 
with H2O (0.35 mL), 10% aq. NaOH (1.05 mL) then H2O (0.35 mL).  The resulting 
slurry was stirred at rt for 2 h, then filtered.  To the colourless filtrate was added 10% aq. 
H2SO4 (10 mL), then the biphasic solution was stirred overnight.  The organic phase 
was separated and washed with sat. aq. NaHCO3 (25 mL), dried (Na2SO4), then 
concentrated in vacuo to afford a pale yellow oil.  Distillation gave the title compound 
87 (2.00 g, 59%) as a colourless oil; bp. 63-64 ºC (8 mmHg), (Lit.
84
 38-41 ºC (1 
mmHg)); Rf 0.58 (PE/EtOAc, 2:1); δH (400 MHz, CDCl3) 6.95 (1 H, ddd, J = 10.1, 5.6, 
2.6, H-3), 6.00 (1 H, dddd, J = 10.1, 2.5, 1.0, 1.0, H-2), 2.50-2.45 (1 H, m, H-6a), 2.45-
2.37 (1 H, m, H-4a), 2.29-2.15 (1 H, m, H-5), 2.11 (1 H, dd, J = 15.9, 12.3, H-6b), 2.03 
(1 H, dddd, J = 18.5, 9.8, 2.6, 2.5, H-4b),  1.06 (3 H, d, J = 6.5, H-7). 
Lab Book Ref. = JDC/3/14 
Data were consistent with those published.
84
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Ethyl (1R*,2S*)-4-hydroxy-2-methyl-6-oxocyclohexanecarboxylate 235: To a stirred 
solution of sodium (173 mg, 7.52 mmol, 0.03 equiv.) in EtOH (65 mL) was added ethyl 
acetoacetate (31.6 mL, 250 mmol, 1.01 equiv.).  The solution was cooled to 0 ºC, the 
crotonaldehyde (20.5 mL, 0.25 mmol, 1.0 equiv.) was added dropwise over 30 min. The 
reaction was warmed to rt and stirred for 48 h, then quenched with sat. aq. NH4Cl (20 
mL). The ethanol was removed under reduced pressure and the oil was taken up in Et2O 
(100 mL).  The aqueous phase was separated and extracted with Et2O (100 mL), then 
the combined organic extracts were washed with brine (100 mL), dried (MgSO4), then 
concentrated in vacuo to give the crude title compound 235 (Quant.) as yellow oil, 
which was used without purification. 




Ethyl-(1R*,6S*)-6-methyl-2-oxocyclohex-3-enecarboxylate 246a: To a stirred 
solution of ester 235 (5.00 g, 25.0 mmol, 1.0 equiv.) in PhMe (100 mL) at rt was added 
p-TsOH (0.95 g, 5.0 mmol, 0.2 equiv.). The solution was heated to 50 ºC and held for 
18 h, then cooled to rt and quenched with sat. aq. NaHCO3 (50 mL). The aqueous phase 
was extracted with EtOAc (2 × 50 mL), then the combined organics were washed with 
brine (50 mL), dried (MgSO4), then concentrated in vacuo to afford a brown oil which 
was purified by column chromatography (SiO2, PE/EtOAc, 4:1) to give the title 
compound 246a (1.39 g, 30%) as a pale yellow oil; Rf 0.38 (PE/Et2O, 2:1); υmax/cm
-1
 
(neat) = 2964, 2932, 1738, 1678, 1261, 1148; δH (400 MHz, CDCl3) 6.98 (1 H, ddd, J = 
10.1, 5.6, 2.6, H-4), 6.07 (1 H, ddd, J = 10.1, 2.8, 1.3, H-3), 4.25 (1 H, dq, J = 10.8, 7.1, 
H-8a), 4.25 (1 H, dq, J = 10.8, 7.1, H-8b), 3.10 (1 H, d, J = 11.7, H-1), 2.65-2.44 (2 H, m, 
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H-5a, 6), 2.12 (1 H, dddd, J = 18.9, 10.0, 2.8, 2.6, H-5b), 1.29 (3 H, t, J = 7.1, H-9), 1.08 
(3 H, d, J = 6.5, H-10); δC (100 MHz, CDCl3) 194.5 (CO, C-2), 169.9 (CO, C-7), 149.7 
(CH, C-4), 128.7 (CH, C-3), 61.6 (CH, C-1), 61.0 (CH2, C-8), 33.0 (CH2, C-5), 32.7 
(CH, C-6), 19.7 (CH3, C-10), 14.1 (CH3, C-9); m/z (ESI) 205 [MNa]
+
; [HRMS (ESI): 
calcd. for C10H14NaO3, 205.0835. Found: [MNa]
+
, 205.0832 (1.6 ppm error)] 
 Lab Book Ref. = JDC/4/29 








 246b:  To a stirred 
solution of ethyl 3-oxo-4-(triphenylphosphoranylidene)butanoate (781 mg, 2.00 mmol, 
1.0 equiv.) in THF (17.5 mL) at rt was added cinnamaldehyde (251 µL, 2.00 mmol, 1.0 
equiv.), then the solution was warmed to 35 ºC.  To the yellow solution was added NaH 
(60 wt%, 160 mg, 4.00 mmol, 2.0 equiv.), then water (1 drop) was cautiously added.  
The reaction was stirred at 35 ºC for 1 h, then quenched with 10% aq. HCl (10 mL).  
The aqueous phase was extracted with Et2O (3 × 10 mL), then the combined organics 
were washed with brine (10 mL), dried (MgSO4), then concentrated in vacuo to afford a 
yellow oil which was purified by column chromatography (SiO2, PE/EtOAc, 9:1) to 
give the title compound 246b (297 mg, 61%) as a colourless crystalline solid; mp. 53-55 
ºC; Rf 0.69 (PE/EtOAc, 2:1); δH (400 MHz, CDCl3) 7.35-7.29 (2 H, m, ArH), 7.28-7.24 
(3 H, m, ArH), 7.06 (1 H, ddd, J = 10.1, 5.7, 2.5, H-4), 6.18 (1 H, ddd, J = 10.1, 2.7, 1.2, 
H-3), 4.02 (2 H, q, J = 7.1, H-8), 3.75 (1 H, d, J = 13.1, H-1), 3.69 (1 H, ddd, J = 13.1, 
9.9, 4.8, H-6), 2.69 (1 H, dddd, J = 18.8, 5.7, 4.8, 1.2, H-5a), 2.62 (1 H, dddd, J =18.8, 
9.9, 2.7, 2.5, H-5b), 1.01 (3 H, t, J = 7.1, H-9). 
Lab Book Ref. = JDC/11/3 
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Ethyl 5,5-dimethyl-2-oxocyclohex-3-enecarboxylate 246c: To a stirred solution of 
diisopropylamine (0.70 mL, 4.95 mmol, 1.5 equiv.) in THF (10 mL) at 0 ºC was added 
dropwise n-BuLi (1.6 M in hexanes, 2.89 mL, 4.62 mmol, 1.4 equiv.).  The colourless 
solution was stirred at 0 ºC for 30 min. then cooled to −78 ºC, before adding 4,4-
dimethyl-2-cyclohexenone (0.43 mL, 3.3 mmol, 1.0 equiv.) as a pre-cooled in 
THF/DMPU (5:1, 6 mL) via cannula.  The resulting yellow solution was stirred at −78 
ºC for 1 h, then ethyl cyanoformate (0.49 mL, 4.95 mmol, 1.5 equiv.) was added.  The 
solution was stirred at −78 ºC for a further 1 h, then quenched with sat. aq. NH4Cl (5 
mL).  The aqueous phase was extracted with EtOAc (3 × 10 mL), then the combined 
organic extracts were washed with H2O (20 mL) and brine (20 mL), dried (MgSO4), 
then concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, PE/Et2O, 6:1) to give the title compound 246c (481 mg, 74%) as 
a pale yellow oil as a mixture of keto and enol tautomers; Rf 0.54 (PE/EtOAc, 2:1); 
υmax/cm
-1
 (neat) 2962, 1740, 1683, 1302, 1238; δH (400 MHz, CDCl3, Keto) 6.66 (1 H, 
dd, J = 10.1, 2.0, H-4), 5.87 (1 H, d, J = 10.1, H-3), 4.23 (1 H, dq, J = 10.8, 7.1, H-8a), 
4.22 (1 H, dq, J = 10.8, 7.1, H-8b), 3.52 (1 H, dd, J = 13.7, 4.8, H-1), 2.29 (1 H, dd, J = 
13.7, 13.5, H-6a), 1.97 (1 H, ddd, J = 13.5, 4.8, 2.0, H-6b), 1.29 (3 H, t, J = 7.1, H-9), 
1.19 (3 H, s, CH3), 1.04 (3 H, s, CH3); δC (100 MHz, CDCl3, Keto) 194.0 (CO, C-2), 
170.4 (CO, C-7), 159.5 (CH, C-4), 126.0 (CH, C-3), 61.2 (CH2, C-8), 50.8 (CH, C-1), 
38.8 (CH2, C-6), 33.0 (C, C-5), 30.0 (CH3), 25.7 (CH3), 14.1 (CH3, C-9); δH (400 MHz, 
CDCl3, Enol) 6.03 (1 H, d, J = 9.8, H-4), 5.82 (1 H, d, J = 9.8, H-3), 4.29-4.16 (2 H, m, 
H-8), 2.33 (2 H, s, H-6), 1.31 (3 H, t, J = 7.1, H-9), 1.19 (6 H, s, CH3); δC (100 MHz, 
CDCl3, Enol) 170.4 (CO, C-7), 165.0 (C, C-2), 149.6 (CH, C-4), 121.2 (CH, C-3), 93.2 
(C, C-1), 60.2 (CH2, C-8), 34.3 (CH2, C-6), 32.4 (C, C-5), 27.7 (2 × CH3), 14.3 (CH3, 
C-9); m/z (ESI) 197 [MH]
+
; [HRMS (ESI): calcd. for C11H17O3, 197.1172. Found: 
[MH]
+
, 197.1167 (2.5 ppm error)]. 
Lab Book Ref. = JDC/10/25 




Using the procedure described for the preparation of compound 246c, the title 
compound 246d (209 mg, 28%) was isolated as a colourless oil; Rf 0.39 (PE/EtOAc, 
2:1); [α]
21
D = −46.4 (c 1.00, CHCl3); υmax/cm
-1
 (neat) 2983, 2939, 1736, 1679, 1307, 
1226, 1166; δH (400 MHz, CDCl3) 6.77-6.73 (1 H, m, H-4), 4.83-4.81 (2 H, m, H-12), 
4.19 (1 H, dq, J = 13.8, 6.9, H-8a), 4.18 (1 H, dq, J = 13.8, 6.9, H-8b), 3.46 (1 H, d, J = 
13.0, H-1), 3.11 (1 H, ddd, J = 13.0, 11.0, 4.9, H-6), 2.46 (1 H, dddd, J = 18.7, 6.1, 4.9, 
1.4, H-5a), 2.38-2.27 (1 H, m, H-5b), 1.78 (3 H, ddd, J = 2.6, 1.4, 1.4, H-13), 1.74 (3 H, 
m, H-11), 1.24 (3 H, t, J = 6.9, H-9); δC (100 MHz, CDCl3) 194.7 (CO, C-2), 169.7 (CO, 
C-7), 144.5 (C, C-10), 144.3 (CH, C-4), 134.7 (C, C-3), 112.8 (CH2, C-12), 60.8 (CH2, 
C-8), 58.4 (CH, C-1), 45.6 (CH, C-6), 30.7 (CH2, C-5), 19.6 (CH3, C-11), 15.7 (CH3, C-
13), 14.1 (CH3, C-9); m/z (ESI) 223 [MH]
+
; [HRMS (ESI): calcd. for C13H19O3, 
223.1329. Found: MH
+
, 223.1321 (3.4 ppm error)]. 




Ethyl 2-oxocyclohex-3-enecarboxylate 246e: Using the procedure described for the 
preparation of compound 246c, the title compound 246e (239 mg, 43%) was isolated as 
a pale yellow oil; Rf 0.38 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2979, 2924, 1740, 1674, 
1370, 1257, 1182, 1152; δH (400 MHz, CDCl3) 6.99 (1 H, ddd, J = 10.2, 3.6, 3.6, H-4), 
6.05 (1 H, ddd, J = 10.2, 2.0, 2.0, H-3), 4.20 (1 H, dq, J = 10.8, 7.1, H-8a), 4.20 (1 H, dq, 
J = 10.8, 7.1, H-8b), 3.38 (1 H, dd, J = 10.0, 4.9, H-1), 2.54-2.43 (1 H, m, H-5a), 2.43-
2.32 (2 H, m, H-5b, 6a), 2.24-2.16 (1 H, m, H-6b), 1.26 (3 H, t, J = 7.1, H-9); δC (100 
MHz, CDCl3) 193.9 (CO, C-2), 169.9 (CO, C-7), 150.5 (CH, C-4), 129.0 (CH, C-3), 
61.1 (CH2, C-8), 53.3 (CH, C-1), 25.5 (CH2, C-6), 24.2 (CH2, C-5), 14.0 (CH3, C-9); 
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m/z (ESI) 169 [MH]
+
; [HRMS (ESI): calcd. for C9H13O3, 169.0859. Found: [MH]
+
, 
169.0862 (1.6 ppm error)]. 
Lab Book Ref. = JDC/10/28 








8-Methyl-2-azabicyclo[2.2.2]octane-3,5-dione 248a: A stirred solution of β-ketoester 
246a (46 mg, 0.25 mmol, 1.0 equiv.) in 35% aq. NH3 (1 mL) was held at rt until 
consumption of the starting material was observed by TLC (DCM/MeOH, 9:1). The 
solution was concentrated in vacuo to afford a pale yellow solid was purified by column 
chromatography (SiO2, DCM/MeOH, 98:2) to give the title compound 248a (36 mg, 
93%) as a colourless crystalline solid; mp. 135-137 ºC; Rf 0.40 (DCM/MeOH, 9:1); 
υmax/cm
-1
 (thin film) 3244, 2961, 1730, 1681, 1335, 1105; δH (400 MHz, CDCl3) 7.92 (1 
H, br s, NH), 3.98-3.93 (1 H, m, H-1), 3.08-3.05 (1 H, m, H-4), 2.49-2.40 (2 H, m, H-6a, 
8), 2.32 (1 H, dddd, J = 13.0, 10.8, 3.9, 2.8, H-7a), 2.20 (1 H, dd, J = 18.5, 1.9, H-6b), 
1.31 (1 H, ddd, J = 13.0, 4.6, 1.0, H-7b), 1.06 (3 H, d, J = 7.1, H-9); δC (100 MHz, 
CDCl3) 205.1 (CO, C-5), 171.8 (CO, C-3), 64.4 (CH, C-4), 47.0 (CH, C-1), 43.8 (CH2, 
C-6), 35.4 (CH2, C-7), 29.4 (CH, C-8), 20.8 (CH3, C-9); m/z (ESI) 154 [MH]
+
; [HRMS 
(ESI): calcd. for C8H12NO2, 154.0863. Found: [MH]
+
, 154.0864 (0.6 ppm error)]; Anal. 
Calcd. for C8H11NO2: C, 62.73; H, 7.24; N, 9.14. Found: C, 62.50; H, 7.18; N, 9.11. 




8-Phenyl-2-azabicyclo[2.2.2]octane-3,5-dione 248b: Using the procedure described 
for the preparation of compound 248a, the title compound 248b (41 mg, 76%) was 
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isolated as a colourless crystalline solid; mp. 188-191 ºC; Rf 0.44 (DCM/MeOH, 9:1); 
υmax/cm
-1
 (thin film) 3413, 1727, 1678, 1025; δH (400 MHz, CDCl3) 7.26-7.21 (2 H, m, 
ArH), 7.18-7.13 (1 H, m, ArH), 7.08-7.02 (2 H, m, ArH), 4.06-4.01 (1 H, m, H-1), 3.57 
(1 H, ddd, J = 11.2, 6.0, 2.3, H-8), 3.30 (1 H, dd, J = 2.3, 2.3 H-4), 2.62-2.53 (1 H, m, 
H-7a), 2.52 (1 H, ddd, J = 18.1, 3.1, 3.1 H-6a), 2.35 (1 H, dd, J = 18.1, 2.0, H-6b), 1.93 
(1 H, ddd, J = 13.3, 6.0, 1.1, H-7b); δC (100 MHz, CDCl3) 204.4 (CO, C-5), 170.6 (CO, 
C-3), 140.5 (C, ArC), 128.7 (2 × CH, ArCH), 127.1 (CH, ArCH), 126.8 (2 × CH, 
ArCH), 64.9 (CH, C-4), 46.6 (CH, C-1), 44.6 (CH2, C-6), 40.2 (CH, C-8), 34.4 (CH2, C-
7); m/z (ESI) 216 [MH]
+
; [HRMS (ESI): calcd. for C13H14NO2, 216.1019. Found: 
[MH]
+
, 216.1017 (1.0 ppm error)]. 














7,7-Dimethyl-2-azabicyclo[2.2.2]octane-3,5-dione 248c: Using the procedure 
described for the preparation of compound 248a, the title compound 248c (35 mg, 80%) 
was isolated as a colourless crystalline solid; mp. 182-185 ºC; Rf 0.41 (DCM/MeOH, 
9:1); υmax/cm
-1
 (thin film) 3249, 2964, 1734, 1688; δH (400 MHz, CDCl3) 7.81 (1 H, br s, 
NH), 3.43-3.39 (1 H, m, H-1), 3.16-3.13 (1 H, m, H-4), 2.66 (1 H, dd, J = 18.9, 2.0, H-
6a), 2.38 (1 H, dd, J = 18.9, 3.3, H-6b), 1.90 (1 H, dd, J = 13.8, 3.3, H-8a), 1.81 (1 H, dd, 
J = 13.8, 2.5, H-8b), 1.18 (3 H, s, CH3), 1.13 (3 H, s, CH3); δC (100 MHz, CDCl3) 205.8 
(CO, C-5), 170.8 (CO, C-3), 58.6 (CH, C-4), 57.7 (CH, C-1), 39.8 (CH2, C-6), 37.4 
(CH2, C-8), 35.7 (C, C-7), 29.2 (CH3), 27.6 (CH3); m/z (ESI) 168 [MH]
+
; [HRMS (ESI): 
calcd. for C9H14NO2, 168.1019. Found: [MH]
+
, 168.1022 (1.6 ppm error)]; Anal. Calcd. 
for C9H13NO2: C, 64.65; H, 7.84; N, 8.38. Found: C, 64.67; H, 7.81; N, 8.42. 
Lab Book Ref. = JDC/10/84 
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6-Methyl-8-(prop-1-en-2-yl)-2-azabicyclo[2.2.2]octane-3,5-dione 248d: Using the 
procedure described for the preparation of compound 248a, the title compound 248d 
(47 mg, 98%, ~4:1) was isolated as a colourless crystalline solid; mp. 112-115 ºC; Rf 
0.51 (Major), 0.47 (Minor) (DCM/MeOH, 9:1); υmax/cm
-1
 (thin film) 3273, 2939, 1729, 
1679, 1073; δH (400 MHz, CDCl3, Major) 7.81 (1 H, br s, NH), 4.83 (1 H, br s, H-10a), 
4.76 (1 H, br s, H-10b), 3.68 (1 H, dddd, J = 5.6, 4.0, 1.7, 1.5, H-1), 3.36-3.31 (1 H, dd, 
J = 2.4, 1.6, H-4), 2.89-2.81 (1 H, m, H-8), 2.35 (1 H, ddd, J = 13.5, 11.3, 4.0, H-7a), 
2.17 (1 H, qd, J = 7.2, 1.5, H-6), 1.79 (1 H, ddd, J = 13.5, 5.6, 1.7, H-7b), 1.73 (3 H, s, 
H-11), 1.15 (3 H, d, J = 7.2, H-12); δC (100 MHz, CDCl3, Major) 207.7 (CO, C-5), 
171.0 (CO, C-3), 144.3 (C, C-9), 111.6 (CH2, C-10), 61.7 (CH, C-4), 52.6 (CH, C-1), 
46.7 (CH, C-6), 40.4 (CH, C-8), 32.8 (CH2, C-7), 22.0 (CH3, C-11), 14.4 (CH3, C-12); 
δH (400 MHz, CDCl3, Minor) 8.07 (1 H, br s, NH), 4.85 (1 H, br s, H-10a), 4.77 (1 H, 
br s, H-10b), 3.79-3.74 (1 H, m, H-1), 3.38 (1 H, dd, J = 1.9, 1.9, H-4), 2.90-2.81 (1 H, 
m, H-8), 2.44 (1 H, qdd, J = 7.4, 2.7, 1.8, H-6), 2.25-2.15 (1 H, m, H-7a), 1.89 (1 H, ddd, 
J = 13.7, 6.7, 1.1, H-7b), 1.73 (3 H, s, H-11), 1.09 (3 H, d, J = 7.4, H-12); δC (100 MHz, 
CDCl3, Minor) 207.6 (CO, C-5), 172.1 (CO, C-3), 143.6 (C, C-9), 111.9 (CH2, C-10), 
61.2 (CH, C-4), 52.0 (CH2, C-1), 48.0 (CH, C-6), 41.9 (CH, C-8), 26.7 (CH2, C-7), 22.3 
(CH3, C-11), 12.1 (CH3, C-12); m/z (ESI) 194 [MH]
+
; [HRMS (ESI): calcd. for 
C11H16NO2, 194.1176. Found: [MH]
+
, 194.1181 (2.6 ppm error)]; Anal. Calcd. for 
C11H15NO2: C, 68.37; H, 7.82; N, 7.25. Found: C, 68.37; H, 7.81; N, 7.25. 




2-Azabicyclo[2.2.2]octane-3,5-dione 248e: Using the procedure described for the 
preparation of compound 248a, the title compound 248e (21 mg, 60%) was isolated as a 
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colourless crystalline solid; mp. 207-209 ºC (Lit.
45
 143-144 ºC); Rf 0.39 (DCM/MeOH, 
9:1); υmax/cm
-1
 (thin film) 3189, 1733, 1697, 1096; δH (400 MHz, CDCl3) 7.81 (1 H, br s, 
NH), 4.04-3.99 (1 H, m, H-1), 3.26 (1 H, dd, J = 4.8, 2.7, H-4), 2.47 (1 H, ddd, J = 18.6, 
3.1, 3.1, H-6a), 2.29 (1 H, dd, J = 18.6, 2.0, H-6b), 2.18-1.97 (3 H, m, H-7a, 8), 1.88-1.79 
(1 H, m, H-7b); δC (100 MHz, CDCl3) 205.7 (CO, C-5), 171.2 (CO, C-3), 57.3 (CH, C-
4), 47.3 (CH, C-1), 43.3 (CH2, C-6), 26.6 (CH2, C-7), 21.0 (CH2, C-8); m/z (ESI) 140 
[MH]
+
; [HRMS (ESI): calcd. for C7H10NO2, 140.0706. Found: [MH]
+
, 140.0704 (1.2 
ppm error)]. 
Lab Book Ref. = JDC/11/25 






Ethyl 4-methyl-2-oxocyclohex-3-enecarboxylate 249: Using the procedure described 
for the preparation of compound 246c, the title compound 249 (376 mg, 62%) was 
isolated as a pale yellow oil; Rf 0.39 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2982, 1734, 1675, 
1258, 1183; δH (400 MHz, CDCl3) 5.91-5.89 (1 H, m, H-3), 4.19 (1 H, dq, J = 10.8, 7.1, 
H-8a), 4.19 (1 H, dq, J = 10.8, 7.1, H-8b), 3.29 (1 H, dd, J = 9.8, 5.1, H-1), 2.44-2.24 (3 
H, m, H-5, 6a), 2.22-2.13 (1 H, m, H-6b), 1.95 (3 H, s, H-10), 1.26 (3 H, t, J = 7.1, H-9); 
δC (100 MHz, CDCl3) 193.7 (CO, C-2), 170.2 (CO, C-7), 162.8 (C, C-4), 125.7 (CH, C-
3), 61.1 (CH2, C-8), 52.4 (CH, C-1), 29.3 (CH2, C-5), 25.4 (CH2, C-6), 24.3 (CH3, C-
10), 14.0 (CH3, C-9); m/z (ESI) 183 [MH]
+
; [HRMS (ESI): calcd. for C10H15O3, 
183.1016. Found: [MH]
+
, 183.1011 (2.5 ppm error)]. 




Ethyl-(1R*,6R*)-1,6-dimethyl-2-oxocyclohex-3-enecarboxylate 251:  To a stirred 
suspension of NaH (60 wt%, 60 mg, 1.51 mmol, 1.1 equiv.) in THF (5 mL) at 0 ºC was 
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added ester 246a (250 mg, 1.37 mmol, 1.0 equiv.) as a solution in THF (1 mL).  The 
suspension was stirred at 0 ºC for 30 min, then methyl iodide (102 µL, 1.64 mmol, 1.2 
equiv.) was added dropwise.  The suspension was held at 0 ºC for a further 30 min., 
then warmed to rt and held for 8 h. The reaction was quenched with sat. aq. NH4Cl (5 
mL), then the aqueous phase was extracted with Et2O (3 × 10 mL).  The combined 
organic extracts were washed with brine (10 mL), dried (MgSO4), then concentrated in 
vacuo to afford a yellow oil which was purified by column chromatography (SiO2, 
PE/Et2O, 9:1) to give the title compound 251 (103 mg, 38%) as a colourless oil; Rf 0.54 
(PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2982, 1734, 1674, 1191, 1113; δH (400 MHz, CDCl3) 
6.95 (1 H, ddd, J = 10.1, 5.7, 2.4, H-4), 6.07 (1 H, ddd, J = 10.1, 2.7, 1.1, H-3), 4.14 (1 
H, dq, 10.8, 7.1, H-8a), 4.08 (1 H, dq, J = 10.8, 7.1, H-8b), 2.40 (1 H, dddd, J = 19.2, 
10.8, 2.7, 2.4, H-5a), 3.24-3.25 (1 H, dddd, J = 19.2, 5.7, 4.9, 1.1, H-5b), 2.14-2.03 (1 H, 
dqd, J = 10.8, 6.9, 4.9, H-6), 1.40 (3 H, s, H-11), 1.20 (3 H, t, J = 7.1, H-9), 1.12 (3 H, d, 
J = 6.9, H-10); δC (100 MHz, CDCl3) 197.0 (CO, C-2), 170.7 (CO, C-7), 149.5 (CH, C-
4), 128.8 (CH, C-3), 60.9 (CH2, C-8), 57.1 (C, C-1), 38.7 (CH, C-6), 32.4 (CH2, C-5), 
18.4 (CH3, C-11), 16.4 (CH3, C-10), 14.1 (CH3, C-9); m/z (ESI) 219 [MNa]
+
; [HRMS 
(ESI): calcd. for C11H16NaO3, 219.0992. Found: [MNa]
+
, 219.0999 (3.5 ppm error)]. 




4,8-Dimethyl-2-azabicyclo[2.2.2]octane-3,5-dione 252: Using the procedure described 
for the preparation of compound 248a, the title compound 252 (35 mg, 83%) was 
isolated as a colourless crystalline solid; mp. 97-99 ºC; Rf 0.42 (DCM/MeOH, 9:1); 
υmax/cm
-1
 (thin film) 3239, 1731, 1686, 1443, 1056; δH (400 MHz, CDCl3) 8.05 (1 H, br 
s, NH), 3.98-3.93 (1 H, m, H-1), 2.44 (1 H, ddd, J = 18.5, 3.4, 3.3, H-6a), 2.31 (1 H, dd, 
J = 18.5, 1.9, H-6b), 2.16 (1 H, ddd, J = 13.0, 9.8, 1.9, H-7a), 2.07-1.97 (1 H, m, H-8), 
1.58 (1 H, dddd, J = 13.0, 4.6, 3.4, 3.3, H-7b), 1.21 (3 H, s, H-10), 1.02 (3 H, d, J = 6.9, 
H-9); δC (100 MHz, CDCl3) 207.7 (CO, C-5), 171.7 (CO, C-3), 61.0 (C, C-4), 45.9 (CH, 
C-1), 42.4 (CH2, C-6), 36.8 (CH2, C-7), 33.4 (CH, C-8) 18.9 (CH3, C-9), 10.4 (CH3, C-
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10); m/z (ESI) 168 [MH]
+
; [HRMS (ESI): calcd. for C9H14NO2, 168.1019. Found: 
[MH]
+
, 168.1023 (2.2 ppm error)]. 




2,5-Dimethyl-8-(methylimino)-2-azabicyclo[2.2.2]octan-3-one 253 and 254:  A 
stirred solution of β-ketoester 247a (46 mg, 0.25 mmol, 1.0 equiv.) in aq. MeNH2 (40 
wt%, 1 mL) was held at rt for 24 h, then concentrated in vacuo to afford the title 
compound 253/254 (44 mg, 98%, 4:1 ratio of diastereoisomers) as a yellow oil; Rf 0.55 
(DCM/MeOH, 9:1); υmax/cm
-1
 (neat) 2958, 1729, 1679, 1398, 1249; δH (400 MHz, 
CDCl3, Major) 3.69-3.64 (1 H, m, H-1), 3.08 (1 H, d, J = 2.5, H-4), 3.06-3.02 (3 H, s, 
H-11), 2.92 (3 H, s, H-10), 2.44-2.37 (1 H, m, H-6a), 2.30-2.31 (3 H, m, H-6b, 7a, 8), 
1.12-0.99 (1 H, m, H-7b), 0.97 (3 H, d, J = 6.7, H-9); δC (100 MHz, CDCl3, Major) 
171.5 (CN, C-5), 167.6 (CO, C-3), 59.1 (CH, C-4), 54.7 (CH, C-1), 39.0 (CH3, C-11), 
34.5 (CH2, C-7), 34.1 (CH2, C-6), 31.4 (CH3, C-10), 29.5 (CH, C-8), 20.5 (CH3, C-9); 
δH (400 MHz, CDCl3, Minor) 3.69-3.65 (1 H, m, H-4), 3.61-3.57 (1 H, m, H-1), 3.15 (3 
H, dd, J = 1.8, 1.8, H-11), 2.92 (3 H, s, H-10), 2.53-2.38 (2 H, m, H-6a, 7a), 2.30-2.14 (2 
H, m, H-6b, 8), 1.14-1.02 (1 H, m, H-7b), 0.97 (3 H, d, J = 6.7, H-9); δC (100 MHz, 
CDCl3, Minor) 170.4 (CN, C-5), 166.7 (CO, C-3), 55.2 (CH, C-1), 50.5 (CH, C-4), 
40.1 (CH2, C-6), 38.5 (CH3, C-11), 34.1 (CH2, C-7), 31.5 (CH3, C-10), 30.2 (CH, C-8), 
20.2 (CH3, C-9); m/z (ESI) 181 [MH]
+
; [HRMS (ESI): calcd. for C10H17N2O, 181.1335. 
Found: [MH]
+
, 181.1335 (0.2 ppm error)]. 
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2,8-Dimethyl-2-azabicyclo[2.2.2]octane-3,5-dione 255a: To a stirred solution of β-
ketoester 246a (46 mg, 0.25 mmol, 1.0 equiv.) in H2O (1 mL) at rt was added amine (22 
µL, 0.25 mmol, 1.0 equiv.).  The solution was stirred at rt until consumption of the 
starting material was observed by TLC (DCM/MeOH, 9:1), then concentrated in vacuo 
to afford a yellow oil which was purified by column chromatography (SiO2, 
DCM/MeOH, 98:2) to give the title compound 255a (26 mg, 62%) as a colourless 
crystalline solid; mp. 131-133 ºC; Rf 0.54 (DCM/MeOH, 9:1); υmax/cm
-1
 (thin film) 
2970, 2932, 1728, 1668, 1396; δH (400 MHz, CDCl3) 3.81-3.77 (1 H, m, H-1), 3.15 (1 
H, d, J = 2.8, H-4), 3.00 (3 H, s, H-10), 2.49 (1 H, ddd, J = 18.5, 3.2, 3.2, H-6a), 2.45-
2.30 (2 H, m, H-7a, 8), 2.21 (1 H, dd, J = 18.5, 2.0, H-6b), 1.31 (1 H, ddd, J = 13.2, 4.4, 
1.6, H-7b), 1.06 (3 H, d, J = 7.0, H-9); δC (100 MHz, CDCl3) 204.9 (CO, C-5), 168.6 
(CO, C-3), 64.3 (CH, C-4), 54.8 (CH, C-1), 42.9 (CH2, C-6), 34.2 (CH2, C-7), 31.8 
(CH3, C-10), 29.8 (CH, C-8), 20.9 (CH3, C-9); m/z (ESI) 168 [MH]
+
; [HRMS (ESI): 
calcd. for C9H14NO2, 168.1019. Found: [MH]
+
, 168.1017 (1.1 ppm error)]; Anal. Calcd. 
for C9H13NO2: C, 64.65; H, 7.84; N, 8.38. Found: C, 64.58; H, 7.90; N, 8.33. 




8-Methyl-2-propyl-2-azabicyclo[2.2.2]octane-3,5-dione 255b: Using the procedure 
described for the preparation of compound 255a, the title compound 255b (24 mg, 49%) 
was isolated as a yellow film; Rf 0.60 (DCM/MeOH, 9:1); υmax/cm
-1
 (thin film) 2962, 
1730, 1672, 1463; δH (400 MHz, CDCl3) 3.85-3.81 (1 H, m, H-1), 3.42-3.26 (2 H, m, H-
10), 3.15 (1 H, d, J = 2.8, H-4), 2.47-2.38 (1 H, m, H-8), 2.42 (1 H, ddd, J = 18.5, 3.1, 
3.1, H-6a), 2.30 (1 H, dddd, J = 13.5, 10.8, 3.7, 3.1, H-7a), 2.22 (1 H, dd, J = 18.5, 2.0, 
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H-6b), 1.60-1.49 (2 H, m, H-11), 1.32 (1 H, ddd, J = 13.5, 4.7, 1.4, H-7b), 1.05 (3 H, d, J 
= 7.1, H-9), 0.90 (3 H, t, J = 7.4, H-12); δC (100 MHz, CDCl3) 205.2 (CO, C-5), 168.2 
(CO, C-3), 64.7 (CH, C-4), 52.8 (CH, C-1), 46.3 (CH2, C-10), 43.6 (CH2, C-6), 34.9 
(CH2, C-7), 29.7 (CH, C-8), 21.5 (CH2, C-11), 20.8 (CH3, C-9), 11.2 (CH3, C-12); m/z 
(ESI) 196 [MH]
+
; [HRMS (ESI): calcd. for C11H18NO2, 196.1332. Found: [MH]
+
, 
196.1329 (1.6 ppm error)]. 




2-Allyl-8-methyl-2-azabicyclo[2.2.2]octane-3,5-dione 255c: Using the procedure 
described for the preparation of compound 255a, the title compound 255c (21 mg, 43%) 
was isolated as a yellow film; Rf 0.59 (DCM/MeOH, 9:1); υmax/cm
-1
 (thin film) 2961, 
1729, 1668, 1461; δH (400 MHz, CDCl3) 5.74 (1 H, ddt, J = 17.0, 10.0, 6.5, H-11), 5.25 
(1 H, dd, J = 17.0, 1.5, H-12), 5.23 (1 H, dd, J = 10.0, 1.5, H-12), 4.07 (1 H, dd, J = 
14.9, 6.5, H-10a), 3.95 (1 H, dd, J = 14.9, 6.5, H-10b), 3.85-3.81 (1 H, m, H-1), 3.18 (1 
H, d, J = 2.8, H-4), 2.50-2.41 (1 H, m, H-8), 2.41 (1 H, ddd, J = 18.5, 3.2, 3.2, H-6a), 
2.29 (1 H, dddd, J = 13.5, 10.7, 3.8, 3.2, H-7a), 2.21 (1 H, dd, J = 18.5, 1.9, H-6b), 1.30 
(1 H, ddd, J = 13.5, 4.8, 1.9, H-7b), 1.06 (3 H, d, J = 7.1, H-9); δC (100 MHz, CDCl3) 
205.1 (CO, C-5), 168.1 (CO, C-3), 132.4 (CH, C-11), 119.2 (CH2, C-12), 64.8 (CH, C-
4), 51.8 (CH, C-1), 47.0 (CH2, C-10), 43.5 (CH2, C-6), 34.8 (CH2, C-7), 29.9 (CH, C-8), 
20.9 (CH3, C-9); m/z (ESI) 194 [MH]
+
; [HRMS (ESI): calcd. for C11H16NO2, 194.1176. 
Found: [MH]
+
, 194.1168 (3.8 ppm error)]. 




8-Methyl-3-thioxo-2-azabicyclo[2.2.2]octan-5-one 208:  To a stirred solution of 
lactam 248a (50 mg, 0.33 mmol, 1.0 equiv.) in PhMe (2 mL) at rt was added 
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Lawesson’s reagent (73 mg, 0.18 mmol, 0.55 equiv.). The solution was heated to 60 ºC 
and held for 30 min., then cooled to rt.  The solution was concentrated in vacuo to 
afford an orange residue which was purified by column chromatography (SiO2, 
PE/EtOAc, 2:1) to give the title compound 208 (21 mg, 38%) as a yellow film; Rf 0.51 
(DCM/MeOH, 9:1); υmax/cm
-1
 (thin film) 3203, 2959, 2925, 1729, 1509, 1330, 1096; δH 
(400 MHz, CDCl3) 9.36 (1 H, s, NH), 4.11 (1 H, br s, H-1), 3.74-3.72 (1 H, m, H-4), 
2.49-2.32 (3 H, m, H-6a, 7a, 8), 2.24 (1 H, dd, J = 18.6, 1.6, H-6b), 1.42-1.33 (1 H, m, H-
7b), 1.09 (3 H, d, J = 6.8, H-9); δC (100 MHz, CDCl3) 203.4 (C), 199.8 (C), 72.0 (CH, 
C-4), 50.6 (CH, C-1), 41.8 (CH2, C-6), 35.0 (CH2, C-7), 30.7 (CH, C-8), 20.6 (CH3, C-
9); m/z (ESI) 170 [MH]
+
; [HRMS (ESI): calcd. for C8H12NOS, 170.0634. Found: [MH]
+
, 
170.0632 (1.0 ppm error)]. 




(6S*)-6-[(R*)-Hydroxy(phenyl)methyl]cyclohex-2-en-1-one 260a: To a stirred 
solution of diisopropylamine (1.76 mL, 12.5 mmol, 1.2 equiv.) in THF (50 mL) at 0 ºC 
was added n-BuLi (1.38 M in hexane, 9.00 mL, 12.5 mmol, 1.2 equiv.).  The solution 
was stirred at 0 ºC for 30 min., then cooled to −78 ºC before adding cyclohexenone 
(1.00 mL, 10.4 mmol, 1.0 equiv.).  The solution was held at −78 ºC for 1 h, then 
benzaldehyde (1.10 mL, 10.9 mmol, 1.05 equiv.) was added dropwise.  The solution 
was held at −78 ºC for a further 2 h, then quenched with 10% aq. HCl (10 mL).  After 
warming to rt, the organic phase was separated, then the aqueous phase was extracted 
with DCM (3 × 50 mL).  The combined organic extracts were washed with sat. aq. 
NaHCO3 (50 mL) and brine (50 mL), dried (MgSO4), then concentrated in vacuo to 
give a yellow oil which was purified by column chromatography (SiO2, PE/EtOAc, 9:1) 
to give the title compound 260a (1.49 g, 71%) as a colourless oil; Rf 0.34 (PE/EtOAc, 
4:1); υmax/cm
-1
 (neat) 3443 (br), 2925, 2869, 1666, 1423, 1223, 1045; δH (400 MHz, 
CDCl3) 7.37-7.29 (5 H, m, ArH), 7.02 (1 H, dddd, J = 10.0, 5.2, 3.1, 1.0, H-3), 6.08 (1 
H, ddd, J = 10.0, 2.6, 1.5, H-2), 4.82, (1 H, dd, J = 9.6, 1.6, H-7), 2.61-2.53 (1 H, m, H-
6), 2.33-2.26 (2 H, m, H-4), 1.57-1.48 (2 H, m, H-5); δC (100 MHz, CDCl3) 203.6 (CO, 
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C-1), 151.6 (CH, C-3), 140.9 (C, ArC), 129.5 (CH, C-2), 128.3 (2 × CH, ArCH), 127.9 
(CH, ArCH), 127.1 (2 × CH, ArCH), 75.4 (CH, C-7), 52.6 (CH, C-6), 25.6 (CH2), 25.3 
(CH2); m/z (ESI) 225 [MNa]
+
; [HRMS (ESI): calcd. for C13H14NaO2, 225.0886. Found: 
[MNa]
+
, 225.0894 (3.7 ppm error)]. 
Lab Book Ref. = JDC/2/53 
 
 
6-Benzoylcyclohex-2-en-1-one 257a: To a stirred solution of DMSO (0.35 mL, 5.00 
mmol, 2.0 equiv.) in DCM (5 mL) at −78 ºC was added dropwise trifluoroacetic 
anhydride (0.53 mL, 3.75 mmol, 1.5 equiv.).  The solution was held at −78 ºC for 30 
min. before adding alcohol 260a (0.51 g, 2.50 mmol, 1.0 equiv.) as a pre-cooled 
solution in DCM (1.5 mL) via cannula.  The yellow solution was held at −78 ºC for 1 h, 
then Et3N (1.74 mL, 12.5 mmol, 5.0 equiv.) was added dropwise.  The solution was 
held at −78 ºC for a further 15 min., then warmed to rt and held for 1 h.  The reaction 
was quenched with H2O (20 mL), then the aqueous phase was separated and extracted 
with Et2O (3 × 20 mL).  The combined organic extracts were washed with 1 M aq. HCl 
(20 mL), sat. aq. NaHCO3 (20 mL) and brine (20 mL), dried (MgSO4), then 
concentrated in vacuo to afford a brown oil which was purified by column 
chromatography (SiO2, PE/Et2O, 4:1) to give the title compound 257a (0.41 g, 81%) as 
a pale yellow oil; Rf 0.33 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2935, 1686, 1667, 1448, 
1290; δH (400 MHz, CDCl3, ~1:1(keto/enol)) 16.15 (1 H, s, OH), 7.98-7.93 (2 H, m, 
ArH), 7.61-7.50 (3 H, m, ArH), 7.50-7.39 (5 H, m, ArH), 7.06 (1 H, ddd, J = 10.1, 4.0, 
4.0, H-3keto), 6.82 (1 H, ddd, J = 10.0, 4.3, 4.3, H-3enol), 6.19 (1 H, ddd, J = 10.0, 1.9, 
1.9, H-2enol), 6.10 (1 H, ddd, J = 10.1, 2.0, 2.0, H-2keto), 4.42 (1 H, dd, J = 8.9, 5.0, H-
6keto), 2.67 (2 H, t, J = 7.3, H-5enol), 2.65-2.37 (3 H, m, H-4keto, 5a keto), 2.32-2.20 (3 H, m, 
H-4enol, 5b keto); δC (100 MHz, CDCl3, Keto) 198.0 (CO), 195.9 (CO), 150.8 (CH, C-3), 
136.6 (C, ArC), 133.3 (CH, C-2), 129.5 (CH, ArCH), 128.8 (2 × CH, ArCH), 128.5 (2 × 
CH, ArCH), 54.6 (CH, C-6), 25.5 (CH2), 24.4 (CH2); δC (100 MHz, CDCl3, Enol) 188.7 
(C), 177.9 (C), 146.7 (CH, C-3), 135.3 (C, ArC), 130.1 (CH, C-2), 129.0 (CH, ArCH), 
128.1 (2 × CH, ArCH), 128.0 (2 × CH, ArCH), 104.7 (C, C-6), 24.8 (CH2), 23.7 (CH2); 
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m/z (ESI) 223 [MNa]
+
; [HRMS (ESI): calcd. for C13H12NaO2, 223.0730. Found: 
[MNa]
+
, 223.0736 (2.9 ppm error)]. 




(6S*)-6-[(S*)-Cyclohexyl(hydroxy)methyl]cyclohex-2-en-1-one 260b: Using the 
procedure described for the preparation of compound 260a, the title compound 260b 
(1.67 g, 76%) was isolated as a pale yellow oil; Rf 0.40 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 
3486 (br), 2926, 2852, 1661, 1449, 1390, 1223; δH (400 MHz, CDCl3) 7.01-6.95 (1 H, 
m, H-3), 6.01-5.97 (1 H, m, H-2), 3.90 (1 H, br s, OH), 3.61 (1 H, dd, J = 7.8, 2.2, H-7), 
2.48-2.38 (3 H, m, H-4, 6), 2.05-1.97 (1 H, m), 1.80-1.57 (5 H, m), 1.54-1.40 (3 H, m), 
1.29-1.12 (4 H, m); δC (100 MHz, CDCl3) 204.5 (CO, C-1), 150.8 (CH, C-3), 129.9 (CH, 
C-2), 75.6 (CH, C-7), 48.9 (CH, C-6), 39.5 (CH, CyCH), 30.2 (CH2), 26.7 (CH2), 26.4 
(CH2), 26.3 (CH2), 25.8 (CH2), 25.2 (CH2), 25.1 (CH2); m/z (ESI) 209 [MH]
+
; [HRMS 
(ESI): calcd. for C13H21O2, 209.1536. Found: [MH]
+
, 209.1535 (0.4 ppm error)]. 




6-(Cyclohexanecarbonyl)cyclohex-2-en-1-one 257b: To a stirred solution of alcohol 
260b (100 mg, 0.48 mmol, 1.0 equiv.) in DCM (5 mL) at rt, was added in one portion 
DMP (246 mg, 0.58 mmol, 1.2 equiv.).  The reaction mixture was stirred at rt for 2 h, 
then additional DMP (102 mg, 0.24 mmol, 1.0 equiv.) was added.  The reaction mixture 
was held for 18 h, then diluted with diethyl ether (5 mL) before quenching with sat. aq. 
NaHCO3/Na2S2O4 (1:1, 5 mL).  The organic phase was separated, then the aqueous 
phase was extracted with ether (3 × 10 mL).  The combined organic extracts were 
washed with brine (20 mL), dried (MgSO4), then concentrated in vacuo to give a pale 
yellow oil which was purified by column chromatography (SiO2, PE/EtOAc, 9:1) to 
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give the title compound 257b (54 mg, 55%, keto/enol, ~1:2) as a yellow oil; Rf 0.65 
(keto) and 0.50 (enol) (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2929, 2854, 1713, 1672, 1449; 
δH (400 MHz, CDCl3) 7.00 (1 H, ddd, J = 10.1, 3.7, 3.7, H-3keto), 6.67 (1 H, dd, J = 9.9, 
4.3, 4.3, H-3enol), 6.07 (1 H, ddd, J = 9.9, 1.9, 1.9, H-2enol), 6.02 (1 H, ddd, J = 10.1, 2.0, 
2.0, H-2keto), 3.66 (1 H, dd, J = 8.4, 4.9, H-6keto), 2.69-2.47 (4 H, m), 2.40-2.27 (4 H, m), 
2.10-2.02 (1 H, m), 1.94-1.61 (10 H, m), 1.53-1.41 (2 H, m), 1.37-1.18 (10 H, m); δC 
(100 MHz, CDCl3, Keto) 210.5 (CO, C-7), 195.9 (CO, C-1), 151.1 (CH, C-3), 129.2 
(CH, C-2), 57.6 (CH, C-6), 50.4 (CH, CyCH), 28.7 (CH2), 27.5 (CH2), 25.7 (CH2), 25.2 
(CH2), 24.2 (CH2); δC (100 MHz, CDCl3, Enol) 192.5 (C), 183.4 (C), 144.8 (CH, C-3), 
127.9 (CH, C-2), 102.8 (C, C-6), 41.8 (CH, CyCH), 28.9 (CH2), 25.8 (CH2), 24.5 (CH2), 
21.3 (CH2), 25.9 (CH2); m/z (ESI) 207 [MH]
+
; [HRMS (ESI): calcd. for C13H19O2, 
207.1380. Found: [MH]
+
, 207.1379 (0.5 ppm error)]. 




3-Cyclohexyl-2-azabicyclo[2.2.2]oct-2-en-5-one 259b: A stirred solution of enone 
257b (5 mg, 0.03 mmol, 1.0 equiv.) in 35 % aq. NH3 (1 mL) was held at rt, then 
concentrated in vacuo to afford the title compound 259b (5 mg, Quant.) as a yellow film; 
Rf 0.45 (DCM/MeOH/NH3, 190:9:1); υmax/cm
-1
 (neat) 2927, 2852, 1728, 1623; δH (400 
MHz, CDCl3) 4.58-4.54 (1 H, m, H-1), 3.41-3.39 (1 H, dd, J = 3.0, 1.9, H-4), 2.12-2.08 
(2 H, m, H-6), 1.96-1.06 (15 H, m); δC (100 MHz, CDCl3) 209.6 (CO, C-5), 178.8 (CN, 
C-4), 55.2 (CH, C-4), 52.2 (CH, C-1), 46.7 (CH, CyCH), 39.1 (CH2), 29.3 (CH2), 29.3 
(CH2), 25.9 (CH2), 25.7 (CH2), 25.7 (CH2), 23.3 (CH2), 21.1 (CH2); m/z (ESI) 206 
[MH]
+
; [HRMS (ESI): calcd. for C13H20NO, 206.1539. Found: [MH]
+
, 206.1544 (2.3 
ppm error)]. 
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To a stirred solution of diisopropylamine (364 µL, 2.60 mmol, 1.3 equiv.) in THF (10 
mL) at 0 ºC was added dropwise n-BuLi (1.53 M in hexane, 1.57 mL, 2.40 mmol, 1.2 
equiv.). The colourless solution was stirred at 0 ºC for 30 min., then cooled to −78 ºC 
before adding cyclohexenone 87 (220 mg, 2.00 mmol, 1.0 equiv.) dropwise.  The 
solution was held at −78 ºC for 1 h, then benzaldehyde (304 µL, 3.00 mmol, 1.5 equiv.) 
was added dropwise.  The solution was held at −78 ºC for 2 h before quenching with 
AcOH (0.5 mL).  The reaction was diluted with water (10 mL), then the aqueous phase 
was extracted with EtOAc (3 × 20 mL).  The combined organic extracts were washed 
with brine (10 mL), dried (MgSO4), then concentrated in vacuo to afford the crude 
product which was purified by column chromatography (SiO2, PE/EtOAc, 9:1) to give 
the syn-isomer syn-261a (50 mg, 12%) as a colourless oil and the title compound anti-
261a (289 mg, 67%) as a colourless crystalline solid; mp. 115-117 ºC; Rf 0.24 
(PE/EtOAc, 2:1); υmax/cm
-1
 (thin film) 3430 (br), 2918, 1666, 1454, 1391, 1049; δH (400 
MHz, CDCl3) 7.40-7.28 (5 H, m, ArH), 6.90 (1 H, dddd. J = 10.1, 4.8, 3.1, 1.0, H-3), 
6.07 (1 H, dddd, J = 10.1, 2.3, 1.6, 0.5, H-2), 4.83 (1 H, dd, J = 8.4, 4.3, H-8), 2.94 (1 H, 
d, J = 4.3, OH), 2.59 (1 H, dddd, J = 19.7, 5.6, 3.1, 2.3, H-4a), 2.52 (1 H, dd, J = 8.4, 4.3, 
H-6), 2.08 (1 H, dddd, J = 19.7, 4.8, 3.7, 1.6, H-4b), 1.99-1.98 (1 H, m, H-5), 1.01 (3 H, 
d, J = 7.1, H-7); δC (100 MHz, CDCl3) 201.2 (CO, C-1), 148.1 (CH, C-3), 142.1 (C, 
ArC), 128.5 (2 × CH, ArH), 128.5 (CH, C-2), 128.0 (CH, ArH), 126.3 (2 × CH, ArCH), 
73.3 (CH, C-8), 60.5 (CH, C-6), 30.8 (CH2, C-4), 30.0 (CH, C-5), 19.9 (CH3, C-7); m/z 
(ESI) 239 [MNa]
+
; [HRMS (ESI): calcd. for C14H16NaO2, 239.1043. Found: [MNa]
+
, 
239.1044 (0.6 ppm error)]. 
 
 




A colourless oil; 50 mg (12%); Rf 0.30 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 3410 (br), 
2959, 2920, 1665, 1390, 1050; δH (400 MHz, CDCl3) 7.32-7.21 (5 H, m, ArH), 6.91 (1 
H, ddd, J = 10.0, 4.7, 3.5, H-3), 5.99 (1 H, ddd, J = 10.0, 2.3, 1.7, H-2), 5.06 (1 H, d, J = 
5.3, H-8), 2.62 (1 H, dd, J = 8.3, 5.3, H-6), 2.51 (1 H, dddd, J = 18.7, 4.8, 4.7, 1.7, H-4a), 
2.23-2.12 (1 H, m, H-5), 2.10 (1 H, dddd, J = 18.7, 7.4, 3.5, 2.3, H-4b), 1.04 (3 H, d, J = 
6.6, H-7); δC (100 MHz, CDCl3) 202.1 (CO, C-1), 150.2 (CH, C-3), 141.8 (C, ArC), 
129.7 (CH, C-2), 128.2 (2 × CH, ArH), 127.4 (CH, ArH), 126.7 (2 × CH, ArH), 73.9 
(CH, C-8), 58.7 (CH, C-6), 32.9 (CH2, C-4), 29.9 (CH, C-5), 19.9 (CH3, C-7); m/z (ESI) 
239 [MNa]
+
; [HRMS (ESI): calcd. for C14H16NaO2, 239.1043. Found: [MNa]
+
, 
239.1045 (1.1 ppm error)]. 















261b: Using the procedure described for the preparation of compound 261a, the title 
compound anti-261b (444 mg, 67%) was isolated as a colourless oil; Rf 0.32 
(PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 3469 (br), 2926, 1666, 1450, 1391, 1258, 1096; δH 
(400 MHz, CDCl3) 6.84 (1 H, ddd, J = 10.1, 4.0, 4.0, H-3), 5.95 (1 H, ddd, J = 10.1, 2.0, 
2.0, H-2), 3.51-3.44 (1 H, m, H-8), 2.50 (1 H, dddd, J = 19.2, 4.6, 4.0, 2.0, H-4a), 2.41-
2.30 (1 H, m, H-5), 2.29 (1 H, dd, J = 8.1, 4.5, H-6), 2.16 (1 H, d, J = 7.8, OH), 2.16-
2.06 (1 H, m, H-4b), 1.94-1.87 (1 H, m, CyH), 1.80-1.68 (3 H, m, CyH), 1.67-1.53 (2 H, 
m, CyH), 1.29-0.96 (5 H, m, CyH), 1.08 (3 H, d, J = 6.6, H-7); δC (100 MHz, CDCl3) 
202.3 (CO, C-1), 148.3 (CH, C-3), 129.5 (CH, C-2), 74.4 (CH, C-8), 55.3 (CH, C-6), 
41.7 (CH, CyCH), 33.0 (CH2, C-4), 31.3 (CH, C-5), 30.2 (CH2, CyCH2), 27.9 (CH2, 
CyCH2), 26.3 (CH2, CyCH2), 26.2 (CH2, CyCH2), 25.9 (CH2, CyCH2), 19.8 (CH3, C-7); 
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m/z (ESI) 245 [MNa]
+
; [HRMS (ESI): calcd. for C14H22NaO2, 245.1512. Found: 
[MNa]
+
, 245.1512 (0.1 ppm error)]. 




6-(1-Hydroxyhexyl)-5-methylcyclohex-2-en-1-one 261c: Using the procedure 
described for the preparation of compound 261a, the title compound 261c (287 mg, 
45%, ~2.5:1(anti/syn)) was isolated as a yellow oil; Rf 0.44 (PE/EtOAc, 2:1); υmax/cm
-1
 
(neat) 3442 (br), 2956, 2929, 1665, 1390; δH (400 MHz, CDCl3, ~2.5:1(anti/syn)) 6.95 
(1 H, ddd, J = 10.1, 5.6, 2.4, H-3syn), 6.85 (1 H, ddd, J = 10.1, 4.7, 4.0, H-3anti), 6.00-
5.95 (2 H, m, H-2), 3.88-3.73 (2 H, m, H-8), 2.51 (1 H, dddd, J = 19.2, 4.8, 4.7, 1.8, H-
4a anti), 2.47-2.31 (3 H, m, H-4a syn, 5anti, 6syn), 2.21-2.08 (3 H, m, H-4b, 5syn), 2.14 (1 H, 
dd, J = 8.2, 4.5, H-6 anti), 1.79-1.68 (2 H, m, H-9a), 1.66-1.55 (2 H, m, H-9b), 1.54-1.40 
(2 H, m, H-11a), 1.40-1.19 (10 H, m, H-10, 11b, 12), 1.12 (3 H, d, J = 6.8, H-7anti), 1.05 
(3 H, d, J = 6.2, H-7syn), 0.88 (3 H, t, J = 6.8, H-13anti), 0.87 (3 H, t, J = 6.9, H-13syn); δC 
(400 MHz, CDCl3, Anti) 201.9 (CO, C-1), 148.5 (CH, C-3), 129.6 (CH, C-2), 70.5 (CH, 
C-8), 58.4 (CH, C-6), 36.4 (CH2, C-9), 33.1 (CH2, C-4), 31.7 (CH2, C-11), 31.6 (CH, C-
5), 25.7 (CH2, C-10), 22.6 (CH2, C-12), 20.0 (CH3, C-7), 14.0 (CH3, C-13); δC (400 
MHz, CDCl3, Syn) 203.5 (CO, C-1), 150.1 (CH, C-3), 130.1 (CH, C-2), 71.1 (CH, C-8), 
57.8 (CH, C-6), 36.4 (CH2, C-9), 34.2 (CH2, C-4), 31.9 (CH2, C-11), 31.7 (CH, C-5), 
25.9 (CH2, C-10), 22.6 (CH2, C-12), 19.0 (CH3, C-7), 14.0 (CH3, C-13); m/z (ESI) 233 
[MNa]
+
; [HRMS (ESI): calcd. for C13H22NaO2, 233.1512. Found: [MNa]
+
, 233.1503 
(4.0 ppm error)]. 









anti-261d: Using the procedure described for the preparation of compound 261a, the 
syn-isomer syn-261d (25 mg, 2%) was isolated as a colourless oil and the title 
compound anti-261d (491 mg, 50%) was isolated as a colourless oil; 0.31 (PE/EtOAc, 
2:1); υmax/cm
-1
 (neat) 3438 (br), 2926, 1666; δH (400 MHz, CDCl3) 6.82 (1 H, dddd, J = 
10.0, 5.5, 2.6, 1.2, H-3), 5.97 (1 H, dddd, J = 10.0, 2.8, 1.2, 0.7, H-2), 5.72-5.68 (1 H, m, 
H-9), 4.08 (1 H, d, J = 9.7, H-7), 2.52 (1 H, dddd, J = 19.7, 5.5, 2.8, 2.6, H-4a), 2.26 (1 
H, dd, J = 9.7, 2.8, H-6), 2.20-2.06 (2 H, m H-5, 13a), 2.06-1.97 (3 H, m, H-4b, 10), 
1.79-1.69 (1 H, m, H-13b), 1.67-1.54 (3 H, m, H-11a, 12), 1.54-1.43 (1 H, m, H-11b), 
1.02 (3 H, d, J = 7.2, H-14); δC (100 MHz, CDCl3) 201.7 (CO, C-1), 147.9 (CH, C-3), 
137.6 (C, C-8), 128.0 (CH, C-2), 126.2 (CH, C-9), 75.9 (CH, C-7), 56.2 (CH, C-6), 29.7 
(CH, C-5), 29.6 (CH2, C-4), 24.9 (CH2, C-10), 22.3 (CH2), 22.3 (CH2), 22.0 (CH2, C-
13), 19.8 (CH3, C-14); m/z (ESI) 243 [MNa]
+
; [HRMS (ESI): calcd. for C14H20NaO2, 
243.1356. Found: [MNa]
+





261d: A colourless oil; 25 mg (2%); 0.41 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 3438 (br), 
2926, 1666; δH (400 MHz, CDCl3) 6.91 (1 H, ddd, J = 10.1, 4.7, 3.8, H-3), 5.99 (1 H, 
ddd, J = 10.1, 2.0, 2.0, H-2), 5.64-5.61 (1 H, m, H-9), 4.28 (1 H, d, J = 6.6, H-7), 2.58 
(1 H, dddd, J = 19.1, 4.8, 4.7, 2.0, H-4a), 2.41 (1 H, dd, J = 7.6, 6.6, H-6), 2.27 (1 H, 
ddqd, J = 7.6, 6.8, 6.8, 4.8, H-5), 2.09 (1 H, dddd, J = 19.1, 6.8, 3.8, 2.0, H-4b), 2.05-
1.96 (3 H, m, H-10, 13a), 1.88-1.78 (1 H, m, H-13b), 1.70-1.40 (4 H, m, H-11, 12), 1.05 
(3 H, d, J = 6.8, H-14); δC (100 MHz, CDCl3) 202.2 (CO, C-1), 149.4 (CH, C-3), 137.7 
(C, C-8), 129.5 (CH, C-2), 125.6 (CH, C-9), 76.7 (CH, C-7), 55.6 (CH, C-6), 32.2 (CH2, 
C-4), 29.8 (CH, C-5), 25.0 (CH2, C-10), 24.4 (CH2, C-13), 22.5 (CH2), 22.3 (CH2), 19.7 
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(CH3, C-14); m/z (ESI) 243 [MNa]
+
; [HRMS (ESI): calcd. for C14H20NaO2, 243.1356. 
Found: [MNa]
+
, 243.1348 (3.0 ppm error)]. 





2-en-1-one anti-261e: Using the procedure described for the preparation of compound 
261a, the title compound anti-261e (1.97 g, Quant.) was isolated as a colourless 
crystalline solid; mp. 87-89 ºC Rf 0.44 (PE/EtOAc, 4:1); [α]
21
D +75.1 (c 1.02, CHCl3); 
υmax/cm
-1
 (thin film) 3501, 2923, 1656, 1448, 1370; δH (400 MHz, CDCl3) 6.61 (1 H, 
ddd, J = 5.5, 2.8, 1.4, H-3), 4.85-4.82 (1 H, m, H-10a), 4.82-4.80 (1 H, m, H-10b), 3.16 
(1 H, ddd, J = 10.0, 8.6, 2.0, H-7), 2.96 (1 H, ddd, J = 11.8, 10.2, 5.1, H-5), 2.56 (1 H, 
dd, J = 11.8, 2.0, H-6), 2.46-2.35 (1 H, m, H-4a), 2.33-2.22 (1 H, m, H-4b), 2.27-2.19 (1 
H, d, J = 10.0, OH), 2.08-2.00 (1 H, m, CyH), 1.93-1.82 (1 H, m, CyH), 1.72-1.54 (4 H, 
m, CyH), 1.70-1.67 (3 H, m, H-11), 1.63 (3 H, br s, H-9), 1.25-1.11 (3 H, m, CyH), 1.05 
(2 H, m, CyH); δC (100 MHz, CDCl3) 202.0 (CO, C-1), 144.8 (C, C-8), 143.5 (CH, C-3), 
135.6 (C, C-2), 114.0 (CH2, C-10), 75.2 (CH, C-7), 50.0 (CH, C-6), 46.2 (CH, C-7), 
42.0 (CH, CyCH), 30.8 (CH2, C-4), 30.2 (CH2, CyCH2), 29.5 (CH2, CyCH2), 26.2 (CH2, 
CyCH2), 26.0 (CH2, CyCH2), 25.7 (CH2, CyCH2), 18.6 (CH3, C-9), 15.5 (CH3, C-11); 
m/z (ESI) 263 [MH]
+
; [HRMS (ESI): calcd. for C17H27O2, 263.2006. Found: [MH]
+
, 
263.2006 (0.2 ppm error)]; Anal. Calcd. for C17H26O2: C, 77.82; H, 9.99. Found: C, 
77.98; H, 9.96. 
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3-Ethoxy-5-propylcyclohex-2-en-1-one:  To a stirred solution of 5-propylcyclohexane-
1,3-dione (1.75 g, 11.3 mmol, 1.0 equiv.) in PhMe (40 mL) and EtOH (10 mL) at rt was 
added p-TsOH (65 mg, 0.34 mmol, 0.03 equiv). The yellow solution was heated to 
reflux (Dean-Stark) and held for 48 h before cooling to rt and quenching with sat. aq. 
NaHCO3 (20 mL).  The aqueous phase was separated and extracted with EtOAc (2 × 20 
mL), then the combined organic extracts were washed with brine (20 mL), dried 
(MgSO4), then concentrated in vacuo to afford the title compound 3-ethoxy-5-
propylcyclohex-2-enone (1.60 g, 78%) as a pale yellow oil; Rf 0.53 (EtOAc); υmax/cm
-1
 
(neat) 2958, 2873, 1655, 1605, 1380, 1212, 1140; δH (400 MHz, CDCl3) 5.29 (1 H, s, 
H-2), 3.88 (1 H, dq, J = 9.7, 7.1, H-7a), 3.84 (1 H, dq, J = 9.7, 7.1, H-7b), 2.44-2.35 (2 H, 
m, H-4a, 6a), 2.16-1.94 (3 H, m, H-4b, 5, 6b), 1.35-1.29 (7 H, m, H-8, 9, 10), 0.87 (3 H, t, 
J = 7.0, H-11); δC (100 MHz, CDCl3) 200.3 (CO, C-1), 178.0 (C, C-3), 102.2 (CH, C-2), 
64.3 (CH2, C-7), 43.1 (CH2, C-6), 37.6 (CH2, C-9), 35.4 (CH2, C-4), 33.3 (CH, C-5), 
19.5 (CH2, C-10), 14.0 (CH3), 13.9 (CH3); m/z (ESI) 205 [MNa]
+
; [HRMS (ESI): calcd. 
for C11H18NaO2, 205.1199. Found: [MNa]
+
, 205.1190 (4.2 ppm error)]. 




5-Propylcyclohex-2-en-1-one:  To a stirred solution of LiAlH4 (4.0 M in Et2O, 0.58 mL, 
2.30 mmol, 1.0 equiv.) in Et2O (6 mL) at 0 ºC was added dropwise enone 3-ethoxy-5-
propylcyclohex-2-enone (1.56 g, 8.60 mmol, 3.7 equiv.) as a solution in Et2O (4 mL).  
The resulting white slurry was held at 0 ºC for 30 min. before warming to rt and holding 
for 18 h.  The reaction was cooled to 0 ºC, then sodium sulfate decahydrate was 
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carefully added until effervescence ceased.  The slurry was filtered, then to the filtrate 
was added 10% aq. H2SO4 (5 mL).  The biphasic solution was stirred at rt for 18 h, then 
the aqueous phase was separated and extracted with Et2O (3 × 10 mL).  The combined 
organic extracts were washed with sat. aq. NaHCO3 (10 mL) and brine (10 mL), dried 
(MgSO4), then concentrated in vacuo to afford a yellow oil which was purified by 
column chromatography (SiO2, PE/Et2O, 9:1) to give the title compound 5-
propylcyclohex-2-enone (421 mg, 36%) as a colourless oil; Rf 0.58 (PE/EtOAc, 2:1); 
υmax/cm
-1
 (neat) 2958, 2926, 2873, 1681, 1388, 1247; δH (400 MHz, CDCl3) 6.92 (1 H, 
ddd, J = 10.0, 5.7, 2.4, H-3), 5.95 (1 H, dddd, J = 10.0, 2.7, 1.0, 1.0, H-2), 2.52-2.34 (2 
H, m, H-4a, 6a), 2.11-1.93 (3 H, m, H-4b, 5, 6b), 1.36-1.25 (4 H, m, H-7, 8), 0.85 (3 H, t, 
J = 7.1, H-9); δC (100 MHz, CDCl3) 200.0 (CO, C-1), 149.9 (CH, C-3), 129.5 (CH, C-2), 
44.3 (CH2, C-6), 37.8 (CH2, C-7), 34.8 (CH, C-5), 32.1 (CH2, C-4), 19.5 (CH2, C-8), 
13.9 (CH3, C-9); m/z (ESI) 161 [MNa]
+
; [HRMS (ESI): calcd. for C9H14NaO, 161.0937. 
Found: [MNa]
+
, 161.0937 (0.2 ppm error)]. 





Using the procedure described for the preparation of compound 261a, the syn-isomer 
syn-261f (61 mg, 13%) was isolated as a colourless oil and the title compound anti-261f 
(356 mg, 73%) was isolated as an amorphous yellow solid; Rf 0.29 (PE/EtOAc, 2:1); 
υmax/cm
-1
 (thin film) 3415 (br), 2957, 2927, 1661, 1392; δH (400 MHz, CDCl3) 7.42-
7.27 (5 H, m, ArH), 6.88 (1 H, dddd, J = 9.9, 5.3, 2.6, 1.1, H-3), 6.08-6.02 (1 H, m, H-
2), 4.79 (1 H, d, J = 9.3, H-7), 3.02 (1 H, br s, OH), 2.60 (1 H, dd, J = 9.3, 2.8, H-6), 
2.55 (1 H, dddd, J = 19.8, 5.6, 2.8, 2.6, H-4a), 2.14-2.06 (1 H, m, H-4b), 1.70-1.62 (1 H, 
m, H-5), 1.38-1.06 (4 H, m, H-8, 9), 0.71 (3 H, t, J = 7.2, H-10); δC (400 MHz, CDCl3) 
201.3 (CO, C-1), 148.3 (CH, C-3, 141.9 (C, ArC), 128.6 (2 × CH, ArCH), 128.3 (CH, 
C-2), 128.1 (CH, ArCH), 126.4 (2 × CH, ArCH), 73.6 (CH, C-7), 58.7 (CH, C-6), 35.3 
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(CH2, C-8), 34.4 (CH, C-5), 28.3 (CH2, C-4), 19.9 (CH2, C-9), 13.6 (CH3, C-10); m/z 
(ESI) 267 [MNa]
+
; [HRMS (ESI): calcd. for C16H20NaO2, 267.1356. Found: [MNa]
+
, 





A colourless oil; 61 mg (13%); Rf 0.45 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 3431 (br), 
2957, 2926, 1668, 1391, 1029; δH (400 MHz, CDCl3) 7.38-7.23 (5 H, m, ArH), 6.94-
6.88 (1 H, m, H-3), 5.99 (1 H, ddd, J = 10.1, 1.9, 1.9, H-2), 5.06 (1 H, dd, J = 6.1, 5.7, 
H-7), 3.54 (1 H, d, J = 6.1, OH), 2.70-2.59 (1 H, m, H-4a), 2.68 (1 H, dd, J = 6.0, 5.7, 
H-6), 2.23-2.09 (2 H, m, H-4b, 5), 1.49-1.39 (1 H, m, H-8a) 1.37-1.15 (3 H, m, H-8b, 9). 
0.81 (3 H, t, J = 7.2, H-10); δC (400 MHz, CDCl3) 201.5 (CO, C-1), 149.9 (CH, C-3), 
141.9 (C, ArC), 129.6 (CH, C-2), 128.3 (2 × CH, ArCH), 127.7 (CH, ArCH), 126.5 (2 × 
CH, ArCH), 74.5 (CH, C-7), 57.6 (CH, C-6), 35.6 (CH2, C-8), 33.9 (CH, C-5), 29.5 
(CH2, C-4), 19.7 (CH2, C-9), 13.9 (CH3, C-10); m/z (ESI) 267 [MNa]
+
; [HRMS (ESI): 
calcd. for C16H20NaO2, 267.1356. Found: [MNa]
+
, 267.1350 (1.9 ppm error)]. 
Lab Book Ref. = JDC/13/27/B 
 














3-Ethoxy-5-phenylcyclohex-2-en-1-one:  To a stirred solution of 5-
phenylcyclohexane-1,3-dione (5.00 g, 26.6 mmol, 1.0 equiv.) in PhMe (90 mL) and 
EtOH (25 mL) at rt was added p-TsOH (152 mg, 0.80 mmol, 0.03 equiv). The yellow 
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solution was heated to reflux (Dean-Stark) and held for 18 h before cooling to rt and 
quenching with sat. aq. NaHCO3 (25 mL).  The aqueous phase was separated and 
extracted with EtOAc (2 × 25 mL), then the combined organic extracts were washed 
with brine (25 mL), dried (MgSO4), then concentrated in vacuo to afford the title 
compound 3-ethoxy-5-phenylcyclohex-2-enone (3.86 g, 67%) as a pale yellow oil; Rf 
0.58 (EtOAc); υmax/cm
-1
 (neat) 2982, 2941, 1655, 1603, 1379, 1350, 1210; δH (400 MHz, 
CDCl3) 7.36-7.30 (2 H, m, ArH), 7.27-7.21 (3 H, m, ArH), 5.42 (1 H, s, H-2), 3.94 (1 H, 
dq, J = 9.8, 7.0, H-7a), 3.90 (1 H, dq, J = 9.8, 7.0, H-7b), 3.34 (1 H, dddd, J = 12.4, 10.4, 
5.0, 5.0, H-5), 2.71-2.56 (3 H, m, H-4, 6a), 2.54 (1 H, dd, J = 16.4, 12.4, H-6b), 1.36 (3 
H, t, J = 7.0, H-8); δC (100 MHz, CDCl3) 198.6 (CO, C-1), 176.8 (C, C-3), 142.6 (C, 
ArC), 128.6 (2 × CH, ArCH), 126.9 (CH, ArCH), 126.5 (2 × CH, ArCH), 102.3 (CH, C-
2), 64.4 (CH2, C-7), 43.7 (CH2, C-6), 39.2 (CH, C-5), 36.5 (CH2, C-4), 14.0 (CH3, C-8). 
m/z (ESI) 239 [MNa]
+
; [HRMS (ESI): calcd. for C14H16NaO2, 239.1043. Found: 
[MNa]
+
, 239.1042 (0.2 ppm error)]. 
Lab Book Ref. = JDC/12/87 






5-Phenylcyclohex-2-en-1-one:  To a stirred solution of LiAlH4 (4.0 M in Et2O, 1.18 mL, 
4.70 mmol, 1.0 equiv.) in Et2O (11 mL) at 0 ºC was added dropwise enone 3-ethoxy-5-
phenylcyclohex-2-enone (3.77 g, 17.4 mmol, 3.70 equiv.) as a solution in Et2O (9 mL).  
The resulting white slurry was held at 0 ºC for 30 min. before warming to rt and holding 
for 18 h.  The reaction was cooled to 0 ºC, then sodium sulfate decahydrate was 
carefully added until effervescence ceased.  The slurry was filtered, then to the filtrate 
was added 10% aq. H2SO4 (5 mL).  The biphasic solution was stirred at rt for 18 h, then 
the aqueous phase was separated and extracted with Et2O (3 × 10 mL).  The combined 
organic extracts were washed with sat. aq. NaHCO3 (10 mL) and brine (10 mL), dried 
(MgSO4), then concentrated in vacuo to afford a yellow oil which was purified by 
column chromatography (SiO2, PE/Et2O, 9:1) to give the title compound 5-
phenylcyclohex-2-enone (1.95 g, 65%) as a colourless oil; Rf 0.47 (PE/EtOAc, 2:1); δH 
  203 
(400 MHz, CDCl3) 7.38-7.33 (2 H, m, ArH), 7.29-7.23 (3 H, m, ArH), 7.06 (1 H, ddd, J 
= 10.1, 5.7, 2.5, H-3), 6.13 (1 H, dd, J = 10.1, 2.8, H-2), 3.36 (1 H, dddd, J = 12.5, 10.8, 
4.9, 4.9, H-5), 2.76-2.60 (3 H, m, H-4a, 6), 2.54 (1 H, dddd, J = 18.7, 10.8, 2.8, 2.5, H-
4b). 
Lab Book Ref. = JDC/13/2 







Using the procedure described for the preparation of compound 261a, the syn-isomer 
syn-261g (129 mg, 15%) was isolated as a colourless crystalline solid and the title 
compound anti-261g (558 mg, 67%) was isolated as a colourless crystalline solid; mp. 
140-143 ºC; Rf 0.21 (PE/EtOAc, 2:1); υmax/cm
-1
 (thin film) 3433 (br), 3029, 1657, 1452, 
1392; δH (400 MHz, CDCl3) 7.36-7.28 (6 H, m, ArH), 7.28-7.21 (4 H, m, ArH), 6.97 (1 
H, ddd, J = 10.1, 4.6, 3.5, H-3), 6.10 (1 H, ddd, J = 10.1, 2.0, 1.7, H-2), 4.69 (1 H, dd, J 
= 8.5, 4.2, H-7), 3.42 (1 H, ddd, J = 9.6, 8.0, 5.7, H-5), 3.24 (1 H, d, J = 8.5, OH), 3.22 
(1 H, dd, J = 9.6, 4.2, H-6), 2.76 (1 H, dddd, J = 19.5, 5.7, 4.6, 1.7, H-4a), 2.67 (1 H, 
dddd, J = 19.5, 8.0, 3.5, 2.0, H-4b); δC (400 MHz, CDCl3) 200.7 (CO, C-1), 148.5 (CH, 
C-3), 143.1 (C, ArC), 142.4 (C, ArC), 130.0 (CH, C-2), 128.9 (CH, ArCH), 128.2 (2 × 
CH, ArCH), 127.5 (2 × CH, ArCH), 127.2 (2 × CH, ArCH), 127.1 (CH, ArCH), 125.7 
(2 × CH, ArCH), 72.4 (CH, C-7), 58.3 (CH, C-6), 43.3 (CH, C-5), 33.1 (CH2, C-4); m/z 
(ESI) 301 [MNa]
+
; [HRMS (ESI): calcd. for C19H18NaO2, 301.1199. Found: [MNa]
+
, 
301.1203 (1.4 ppm error)]; Anal. Calcd. for C19H18O2: C, 81.99; H, 6.52. Found: C, 
81.87; H, 6.54. 
 




A colourless crystalline solid; 129 mg (15%); mp. 79-82 ºC; Rf 0.36 (PE/EtOAc, 2:1); 
υmax/cm
-1
 (thin film) 3475 (br), 1664, 1389, 908; δH (400 MHz, CDCl3) 7.35-7.30 (2 H, 
m, ArH), 7.29-7.21 (4 H, m, ArH), 7.19-7.15 (2 H, m, ArH), 7.12-7.07 (2 H, m, ArH), 
6.98 (1 H, ddd, J = 10.0, 5.5, 2.9, H-3), 6.12 (1 H, ddd, J = 10.0, 2.4, 1.2, H-2), 5.05 (1 
H, d, J = 9.5, OH), 4.74 (1 H, dd, J = 9.5, 4.6, H-7), 3.39 (1 H, dd, J = 11.8, 4.6, H-6), 
3.06 (1 H, ddd, J = 11.8, 9.9, 5.4, H-5), 2.58 (1 H, dddd, J = 19.1, 5.5, 5.4, 1.2, H-4a), 
2.50 (1 H, dddd, J = 19.1, 9.9, 2.9, 2.4, H-4b); δC (400 MHz, CDCl3) 202.5 (CO, C-1), 
150.2 (CH, C-3), 141.9 (C, ArC), 141.2 (C, ArC), 130.3 (CH, C-2), 128.8 (2 × CH, 
ArCH), 128.0 (2 × CH, ArCH), 127.6 (2 × CH, ArCH), 127.4 (CH, ArCH), 127.4 (2 × 
CH, ArCH), 127.1 (CH, ArCH), 74.3 (CH, C-7), 55.5 (CH, C-6), 42.4 (CH, C-5), 35.0 
(CH2, C-4); m/z (ESI) 301 [MNa]
+
; [HRMS (ESI): calcd. for C19H18NaO2, 301.1199. 
Found: [MNa]
+
, 301.1194 (1.6 ppm error)]. 
Lab Book Ref. = JDC/13/28/B 
 




(5S*,6R*)-6-Benzoyl-5-methylcyclohex-2-en-1-one 262a: To a stirred solution of 
DMSO (0.20 mL, 2.80 mmol, 2.0 equiv.) in DCM (10 mL) at −78 ºC was added 
dropwise trifluoroacetic anhydride (294 µL, 2.10 mmol, 1.5 equiv.).  The solution was 
held at −78 ºC for 30 min. before adding alcohol 261a (300 mg, 1.40 mmol, 1.0 equiv.) 
as a pre-cooled solution in DCM (5 mL) via cannula.  The yellow solution was held at 
−78 ºC for 1 h, then Et3N (0.98 mL, 7.00 mmol, 5.0 equiv.) was added dropwise.  The 
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solution was held at −78 ºC for a further 15 min., then warmed to rt and held for 1 h.  
The reaction was quenched with H2O (20 mL), then the aqueous phase was separated 
and extracted with Et2O (3 × 20 mL).  The combined organic extracts were washed with 
1 M aq. HCl (20 mL), sat. aq. NaHCO3 (20 mL) and brine (20 mL), dried (MgSO4), then 
concentrated in vacuo to afford a brown oil which was purified by column 
chromatography (SiO2, PE/Et2O, 4:1) to give the title compound 262a (258 mg, 86%) as 
a colourless oil; Rf 0.44 (PE/EtOAc, 2:1), υmax/cm
-1
 (neat) 2961, 1685, 1663, 1448, 1388, 
1298; δH (400 MHz, CDCl3) 7.95-7.89 (2 H, m, ArH), 7.57-7.52 (1 H, m, ArH), 7.47-
7.42 (2 H, m, ArH), 7.01 (1 H, ddd, J = 10.1, 5.5, 2.8, H-3), 6.07 (1 H, ddd, J = 10.1, 
2.6, 1.4, H-2), 4.14 (1 H, d, J = 10.7, H-6), 2.87-2.74 (1 H, m, H-5), 2.59 (1 H, dddd, J 
= 19.1, 5.5, 5.2, 1.4, H-4a), 2.19 (1 H, dddd, J = 19.1, 9.6, 2.8, 2.6, H-4b), 1.00 (3 H, d, J 
= 6.6, H-7); δC (100 MHz, CDCl3) 198.7 (CO), 196.5 (CO), 149.9 (CH, C-3), 137.7 (C, 
ArC), 133.1 (CH, ArCH), 129.1 (CH, C-2), 128.6 (2 × CH, ArCH), 128.5 (2 × CH, 
ArCH), 61.8 (CH, C-6), 32.9 (CH2, C-4), 32.6 (CH, C-5), 19.8 (CH3, C-7); m/z (ESI) 
215 [MH]
+
; [HRMS (ESI): calcd. for C14H15O2, 215.1067. Found: [MH]
+
, 215.1064 (1.2 
ppm error)]. 
Lab Book Ref. = JDC/9/91 
 




(5S*,6S*)-6-(Cyclohexanecarbonyl)-5-methylcyclohex-2-en-1-one 262b:  To a 
stirred solution of alcohol 261b (444 mg, 2.00 mmol, 1.0 equiv.) in DCM (20 mL) at 0 
ºC was added DMP (1.02 g, 2.40 mmol, 1.2 equiv.).  The solution was held at 0 ºC for 
30 min., then warmed to rt and held for 2 h.  The reaction was diluted with Et2O (20 mL) 
before quenching with sat. aq. NaHCO3/sat. aq. Na2S2O3 (1:1, 20 mL).  The biphasic 
solution was stirred vigourously for 30 min., then the aqueous phase was separated and 
extracted with Et2O (3 × 20 mL).  The combined organic extracts were washed with 
brine (20 mL), dried (MgSO4), then concentrated in vacuo to afford the title compound 
262b (433 mg, 99%) as a colourless oil; Rf 0.56 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2929, 
  206 
2855, 1713, 1668, 1449, 1386, 1255; δH (400 MHz, CDCl3) 6.95 (1 H, ddd, J = 10.1, 5.3, 
2.9, H-3), 6.00 (1 H, ddd, J = 10.1, 2.6, 1.4, H-2), 3.45 (1 H, d, J = 10.5, H-6), 2.68-2.47 
(3 H, m, H-4a, 5, CyH), 2.10 (1 H, dddd, J = 19.0, 9.3, 2.9, 2.6, H-4b), 1.95-1.73 (4 H, m, 
CyH), 1.73-1.62 (1 H, m, CyH), 1.33-1.13 (5 H, m, CyH), 0.97 (3 H, d, J = 6.5, H-7); δC 
(100 MHz, CDCl3) 211.3 (CO, C-8), 193.5 (CO, C-1), 149.9 (CH, C-3), 129.1 (CH, C-
2), 64.6 (CH, C-6), 52.2 (CH, CyCH), 32.8 (CH2, C-4), 31.4 (CH, C-5), 28.1 (CH2, 
CyCH2), 27.2 (CH2, CyCH2), 25.8 (2 × CH2, CyCH2), 25.3 (CH2, CyCH2) 19.9 (CH3, C-
7); m/z (ESI) 221 [MH]
+
; [HRMS (ESI): calcd. for C14H21O2, 221.1536. Found: [MH]
+
, 
221.1533 (1.3 ppm error)]. 




(5S*,6S*)-6-(Cyclohexanecarbonyl)-5-methylcyclohex-2-en-1-one 262c: Using the 
procedure described for the preparation of compound 262b, the title compound 262c 
(276 mg, 98%) was isolated as a pale yellow oil; Rf 0.59 (PE/EtOAc, 2:1); υmax/cm
-1
 
(neat) 2959, 1717, 1672; δH (400 MHz, CDCl3) 6.93 (1 H, ddd, J = 10.1, 5.3, 2.9, H-3), 
5.98 (1 H, ddd, J = 10.1, 2.6, 1.5, H-2), 3.20 (1 H, d, J = 10.3, H-6), 2.64-2.48 (3 H, m, 
H-4a, 5, 9a), 2.47-2.36 (1 H, m, H-9b), 2.07 (1 H, dddd, J = 18.9, 9.0, 2.9, 2.6, H-4b), 
1.66-1.51 (2 H, m, H-10), 1.33-1.20 (4 H, m, H-11, 12), 0.97 (3 H, d, J = 6.6, H-7), 0.84 
(3 H, t, J = 7.0, H-13); δC (100 MHz, CDCl3) 207.9 (CO, C-8), 196.2 (CO, C-1), 149.9 
(CH, C-3), 128.8 (CH, C-2), 66.6 (CH, C-6), 43.9 (CH2, C-9), 32.7 (CH2, C-4), 31.6 
(CH, C-5), 25.5 (CH2, C-11), 22.7 (CH2, C-10), 22.4 (CH2, C-12), 19.6 (CH3, C-7), 13.8 
(CH3, C-13); m/z (ESI) 209 [MH]
+
; [HRMS (ESI): calcd. for C13H21O2, 209.1536. 
Found: [MH]
+
, 209.1536 (0.2 ppm error)]. 
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(5S*,6R*)-6-(Cyclohex-1-enecarbonyl)-5-methylcyclohex-2-en-1-one 262d: Using 
the procedure described for the preparation of compound 262b, the title compound 262d 
(98 mg, Quant.) was isolated as a colourless oil; Rf 0.29 (PE/EtOAc, 2:1); υmax/cm
-1
 
(neat) 2930, 1675, 1655, 1387, 1290, 1176; δH (400 MHz, CDCl3) 6.94 (1 H, ddd, J = 
10.1, 5.5, 2.8, H-3), 6.85-6.81 (1 H, m, H-10), 6.00 (1 H, ddd, J = 10.1, 2.7, 1.4, H-2), 
3.84 (1 H, d, J = 10.7, H-6), 2.71-2.58 (1 H, m, H-5), 2.53 (1 H, dddd, J = 19.0, 5.5, 5.2, 
1.4, H-4a), 2.36-2.16 (4 H, m, H-11, 14), 2.11 (1 H, dddd, 19.0, 9.7, 2.8, 2.7, H-4b), 
1.68-1.54 (4 H, m, H-12, 13), 0.94 (1 H, d, J = 6.6, H-7); δC (100 MHz, CDCl3) 199.2 
(CO), 196.9 (CO), 149.5 (CH, C-3), 141.9 (CH, C-10), 140.7 (C, C-9), 129.2 (CH, C-2), 
60.1 (CH, C-6), 33.0 (CH2, C-4), 32.7 (CH, C-5), 26.1 (CH2, CyCH2), 22.9 (CH2, 
CyCH2), 21.7 (CH2, CyCH2), 21.3 (CH2, CyCH2), 19.8 (CH3, C-7); m/z (ESI) 219 
[MH]
+
; [HRMS (ESI): calcd. for C14H19O2, 219.1380. Found: [MH]
+
, 219.1381 (0.8 
ppm error)]. 





262e: Using the procedure described for the preparation of compound 262a, the title 
compound 262e (0.92 g, 93%) was isolated as a colourless oil; [α]
24
D −103.2 (c 1.25, 
CHCl3); Rf 0.79 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2923, 1712, 1661, 1449, 1366; δH 
(400 MHz, CDCl3, ~1.6:1 (keto/enol)) 6.71 (1 H, ddq, J = 5.6, 2.7, 1.3, H-3keto), 6.21-
6.17 (1 H, m, H-3enol), 4.81-4.78 (1 H, m, H-10a keto), 4.76-4.74 (1 H, m, H-10a enol), 4.74 
(1 H, br s, H-10b keto), 4.63 (1 H, br s, H-10b enol), 3.78 (1 H, d, J = 11.3, H-6keto), 3.29 (1 
H, br d, J = 8.1, H-5enol), 3.14 (1 H, ddd, J = 11.3, 10.1, 5.1, H-5keto), 2.60-2.40 (3 H, m), 
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2.39-2.27 (2 H, m), 1.91-1.42 (24 H, m), 1.41-1.09 (9 H, m); δC (100 MHz, CDCl3, 
Keto) 210.9 (CO, C-7), 196.9 (CO, C-1), 145.2 (C, C-8), 144.6 (CH, C-3), 135.0 (C, C-
2), 112.7 (CH2, C-10), 61.7 (CH, C-6), 51.8 (CH, CyCH), 44.0 (CH, C-5), 30.1 (CH2), 
28.5 (CH2), 28.1 (CH2), 27.4 (CH2), 25.7 (CH2), 25.4 (CH2), 20.6 (CH3, C-9), 15.6 (CH3, 
C-11); δC (100 MHz, CDCl3, Enol) 193.6 (CO, C-1), 185.0 (C, C-7), 147.0 (C, C-8), 
137.1 (CH, C-3), 133.9 (C, C-2), 112.0 (CH2, C-10), 105.1 (C, C-6), 41.6 (CH, CyCH), 
39.0 (CH, C-5), 30.3 (CH2), 28.5 (CH2), 26.0 (CH2), 25.8 (CH2), 25.7 (CH2), 25.6 (CH2), 
21.0 (CH3, C-9), 15.6 (CH3, C-11); m/z (ESI) 261 [MH]
+
; [HRMS (ESI): calcd. for 
C17H25O2, 261.1849. Found: [MH]
+
, 261.1856 (2.5 ppm error)]. 




(5S*,6R*)-6-Benzoyl-5-propylcyclohex-2-en-1-one 262f: Using the procedure 
described for the preparation of compound 262b, the title compound 262f (201 mg, 83%) 
was isolated as a colourless crystalline solid; mp. 61-63 ºC; Rf 0.48 (PE/EtOAc, 2:1); 
υmax/cm
-1
 (thin film) 2959, 2929, 1687, 1664, 1388, 1298, 1190; δH (400 MHz, CDCl3) 
7.96-7.88 (2 H, m, ArH), 7.56-7.50 (1 H, m, ArH), 7.49-7.39 (2 H, m, ArH), 7.00 (1 H, 
ddd, J = 10.0, 5.1, 3.1, H-3), 6.07 (1 H, ddd, J = 10.0, 2.3, 1.6, H-2), 4.23 (1 H, d, J = 
9.6, H-6), 2.75-2.65 (1 H, m, H-5), 2.65 (1 H, dddd, J = 18.9, 5.1, 5.1, 1.6, H-4a), 2.16 
(1 H, dddd, J = 18.9, 8.3, 3.1, 2.3 H-4b), 1.41-1.18 (4 H, m, H-8, 9), 0.81 (3 H, t, J = 5.6, 
H-10); δC (400 MHz, CDCl3) 198.8 (CO, C-1), 196.6 (CO, C-7), 149.8 (CH, C-3), 137.5 
(C, ArC), 133.1 (CH, ArCH), 129.1 (CH, C-2), 128.5 (4 × CH, ArCH), 60.4 (CH, C-6), 
37.0 (CH, C-5), 36.1 (CH2, C-8), 29.9 (CH2, C-4), 19.5 (CH2, C-9), 13.8 (CH3, C-10); 
m/z (ESI) 243 [MH]
+
; [HRMS (ESI): calcd. for C16H19O2, 243.1380. Found: [MH]
+
, 
243.1381 (0.6 ppm error)]. 
Lab Book Ref. = JDC/13/32 
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(5S*,6R*)-6-Benzoyl-5-phenylcyclohex-2-en-1-one 262g: Using the procedure 
described for the preparation of compound 262b, the title compound 262g (401 mg, 
93%) was isolated as a colourless crystalline solid; mp. 148-151 ºC; Rf 0.32 (PE/EtOAc, 
2:1); υmax/cm
-1
 (thin film) 3030, 1687, 1666, 1449, 1294; δH (400 MHz, CDCl3) 7.82-
7.75 (2 H, m, ArH), 7.53-7.46 (1 H, m, ArH), 7.41-7.35 (2 H, m, ArH), 7.24-7.19 (4 H, 
m, ArH), 7.18-7.13 (1 H, m, ArH), 7.11 (1 H, ddd, J = 10.1, 5.0, 2.3, H-3), 6.20 (1 H, 
ddd, J = 10.1, 2.6, 1.3, H-2), 4.81 (1 H, d, J = 11.8, H-6), 3.99 (1 H, ddd, J = 11.8, 10.4, 
5.2, H-5), 2.81 (1 H, dddd, J = 19.2, 5.2, 5.0, 1.3, H-4a), 2.69 (1 H, dddd, J = 19.2, 10.4, 
2.6, 2.3, H-4b); δC (100 MHz, CDCl3) 198.0 (CO), 196.1 (CO), 149.5 (CH, C-3), 141.6 
(C, ArC), 137.9 (C, ArC), 133.0 (CH, ArCH), 129.5 (CH, C-2), 128.7 (2 × CH, ArCH), 
128.4 (4 × CH, ArCH), 127.2 (2 × CH, ArCH), 127.1 (CH, ArCH), 60.1 (CH, C-6), 43.5 
(CH, C-5), 33.6 (CH2, C-4); m/z (ESI) 299 [MNa]
+
; [HRMS (ESI): calcd. for 
C19H16NaO2, 299.1043. Found: [MNa]
+
, 299.1040 (0.7 ppm error)]; Anal. Calcd. for 
C19H16O2: C, 82.58; H, 5.84. Found: C, 82.08; H, 5.84. 
Lab Book Ref. = JDC/11/33 
 




8-Methyl-3-phenyl-2-azabicyclo[2.2.2]oct-2-en-5-one 263a: To a stirred solution of 
diketone (54 mg, 0.25 mmol, 1.0 equiv.) in MeOH (1 mL) at 0 ºC was added dropwise 
35% aqueous NH3 (0.5 mL).  The resulting yellow solution was held at 0 ºC for 30 min. 
then warmed to rt and held until consumption of starting material was observed by TLC 
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(DCM/MeOH, 95:5).  The reaction mixture was diluted with water (5 mL), then 
extracted with DCM (3 × 10 mL).  The combined organic extracts were washed with 
brine (10 mL), dried (MgSO4), then concentrated in vacuo to afford a yellow oil  which 
was purified by column chromatography (SiO2, DCM/MeOH, 98:2) to give the title 
compound 263a (49 mg, 91%) as a yellow oil; Rf 0.53 (DCM/MeOH, 95:5); υmax/cm
-1
 
(neat) 2957, 2871, 1730, 1600, 1572, 1447, 1346; δH (400 MHz, CDCl3) 7.81-7.77 (2 H, 
m, ArH), 7.45-7.38 (3 H, m, ArH), 4.79-4.76 (1 H, m, H-1), 3.87 (1 H, d, J = 2.8, H-4), 
2.22 (1 H, ddd, J = 19.0, 3.0, 3.0, H-6a), 2.13 (1 H, dd, J = 19.0, 1.9, H-6b), 2.11-1.98 (2 
H, m, H-7a, 8), 1.37-1.32 (1 H, m, H-7b), 1.12 (3 H, d, J = 6.8, H-9); δC (100 MHz, 
CDCl3) 208.3 (CO, C-5), 171.6 (CN, C-3), 135.7 (C, ArC), 130.8 (CH, ArCH), 128.6 (2 
× CH, ArCH), 126.2 (2 × CH, ArCH), 57.7 (CH, C-4), 56.1 (CH, C-1), 39.5 (CH2, C-6), 
32.3 (CH2, C-7), 29.4 (CH, C-8), 21.2 (CH3, C-9); m/z (ESI) 214 [MH]
+
; [HRMS (ESI): 
calcd. for C14H16NO, 214.1226. Found: [MH]
+
, 214.1231 (2.1 ppm error)]. 




3-Cyclohexyl-8-methyl-2-azabicyclo[2.2.2]oct-2-en-5-one 263b: Using the procedure 
described for the preparation of compound 263a, the title compound 263b (49 mg, 89%) 
was isolated as a yellow oil; Rf 0.56 (DCM/MeOH, 95:5); υmax/cm
-1
 (neat) 2928, 2853, 
1730, 1624, 1450; δH (400 MHz, CDCl3) 4.51 (1 H, br s, H-1), 3.23 (1 H, d, J = 3.1, H-
4), 2.30-2.22 (1 H, m, CyH), 2.09 (1 H, ddd, J = 19.0, 3.0, 3.0, H-6a), 2.00 (1 H, dd, J = 
19.0, 1.8, H-6b), 1.99-1.90 (1 H, m, H-7a), 1.91-1.83 (1 H, m, H-8), 1.82-1.73 (4 H, m, 
CyH), 1.71-1.64 (1 H, m, CyH), 1.34-1.15 (6 H, m, H-7b, CyH), 1.02 (3 H, d, J = 7.0, 
H-9); δC (100 MHz, CDCl3) 209.0 (CO, C-5), 179.7 (CN, C-3), 59.3 (CH, C-4), 55.3 
(CH, C-1), 46.6 (CH, CyCH), 39.7 (CH2, C-6), 32.4 (CH2, C-7), 29.3 (2 × CH2, CyCH2), 
29.1 (CH, C-8), 25.9 (CH2, CyCH2), 25.7 (2 × CH2, CyCH2), 21.3 (CH3, C-9); m/z (ESI) 
220 [MH]
+
; [HRMS (ESI): calcd. for C14H22NO, 220.1696. Found: [MH]
+
, 220.1702 
(2.6 ppm error)]. 
Lab Book Ref. = JDC/9/84 
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8-Methyl-3-pentyl-2-azabicyclo[2.2.2]oct-2-en-5-one 263c: Using the procedure 
described for the preparation of compound 263a, the title compound 263c (34 mg, 65%) 
was isolated as a yellow oil; Rf 0.60 (DCM/MeOH, 95:5); υmax/cm
-1
 (neat) 2956, 2930, 
2871, 1731, 1628; δH (400 MHz, CDCl3) 4.51-4.47 (1 H, m, H-1), 3.13 (1 H, d, J = 3.0, 
H-4), 2.35-2.30 (2 H, m, H-10), 2.13-2.06 (1 H, ddd, J = 19.0, 3.4, 2.4, H-6a), 1.99 (1 H, 
dd, J = 19.0, 1.8, H-6b), 1.99-1.84 (2 H, m, H-7a, 8), 1.57-1.47 (2 H, m, H-11), 1.33-
1.18 (5 H, m, H-7b, 12, 13), 1.01 (3 H, d, J = 6.7, H-9), 0.85 (3 H, t, J = 7.0, H-14); δC 
(100 MHz, CDCl3) 208.6 (CO, C-5), 176.7 (CN, C-3), 60.6 (CH, C-4), 55.5 (CH, C-1), 
39.6 (CH2, C-6), 38.3 (CH2, C-10), 32.5 (CH2, C-7), 31.4 (CH2, C-13), 28.9 (CH, C-8), 
25.3 (CH2, C-11), 22.3 (CH2, C-12), 21.2 (CH3, C-9), 13.9 (CH3, C-14); m/z (ESI) 208 
[MH]
+
; [HRMS (ESI): calcd. for C13H22NO, 208.1696. Found: [MH]
+
, 208.1697 (0.6 
ppm error)]. 




3-Cyclohexenyl-8-methyl-2-azabicyclo[2.2.2]oct-2-en-5-one 263d: Using the 
procedure described for the preparation of compound 263a, the title compound 263d 
(44 mg, 80%) was isolated as a yellow oil; Rf 0.49 (DCM/MeOH, 95:5); υmax/cm
-1
 (neat) 
2930, 2868, 1731, 1576, 1340; δH (400 MHz, CDCl3) 6.41 (1 H, m, H-11), 4.60 (1 H, 
dddd, J = 3.6, 3.6, 1.8, 1.8, H-1), 3.62 (1 H, d, J = 3.1, H-4), 2.30-2.25 (2 H, m, H-15), 
2.21-2.15 (2 H, m, H-12), 2.12 (1 H, ddd, J = 19.0, 3.6, 3.0, H-6a), 2.02 (1 H, dd, J = 
19.0, 1.8, H-6b), 2.01-1.93 (1 H, m, H-7a), 1.91-1.81 (1 H, m, H-8), 1.67-1.54 (4 H, m, 
H-13, 14), 1.24 (1 H, ddd, J = 12.8, 4.4, 1.8, H-7b), 1.03 (3 H, d, J = 7.0, H-9); δC (100 
MHz, CDCl3) 209.2 (CO, C-5), 172.2 (CN, C-4), 135.3 (C, C-10), 133.0 (CH, C-11), 
55.8 (CH, C-4), 55.6 (CH, C-1), 39.8 (CH2, C-6), 32.7 (CH2, C-7), 29.2 (CH, C-8), 26.0 
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(CH2, C-12), 24.0 (CH2, C-15), 22.1 (CH2, CyCH2), 21.8 (CH2, CyCH2), 21.3 (CH3, C-
9); m/z (ESI) 218 [MH]
+
; [HRMS (ESI): calcd. for C14H20NO, 218.1539. Found: [MH]
+
, 
218.1540 (0.4 ppm error)]. 





Using the procedure described for the preparation of compound 263a, the title 
compound 263e (49 mg, 75%, 3:1) was isolated as a yellow oil; Rf 0.63 (DCM/MeOH, 
95:5); υmax/cm
-1
 (neat) 2929, 2853, 1725, 1623, 1450; δH (400 MHz, CDCl3) 4.82 (1 H, 
d, J = 1.0, H-10a minor), 4.79 (1 H, d, J = 1.0, H-10a major), 4.78 (1 H, d, J = 1.0, H-10b 
minor), 4.76 (1 H, d, J = 1.0, H-10b major), 4.41-4.38 (1 H, m, H-1major), 4.33-4.30 (1 H, m, 
H-1minor), 3.52 (1 H, d, J = 2.7, H-4major), 3.51 (1 H, d, J = 2.5, H-4minor), 2.34-2.23 (4 H, 
m, H-8major, 8minor, CyHmajor, CyHminor), 2.05-1.91 (4 H, m, H-6major, 6minor, 7a major, 7a 
minor), 1.91-1.61 (14 H, m, H- 7b major, 7b minor, CyH), 1.73 (3 H, s, H-11minor), 1.72 (3 H, s, 
H-11major), 1.40-1.14 (8 H, m, CyH), 1.05 (3 H, d, J = 7.3, H-12major), 1.04 (3 H, d, J = 
7.4, H-12minor); δC (100 MHz, CDCl3, Major) 211.4 (CO, C-5), 178.5 (CN, C-3), 145.4 
(C, C-9), 111.0 (CH2, C-10), 61.2 (CH, C-1), 57.3 (CH, C-4), 46.5 (CH, CyCH), 44.7 
(CH, C-6), 40.5 (CH, C-8), 29.8 (CH2, C-7), 29.5 (CH2, CyCH2), 29.4 (CH2, CyCH2), 
25.8 (CH2, CyCH2), 25.7 (2 × CH2, CyCH2), 22.1 (CH3, C-11), 15.7 (CH3, C-12); δC 
(100 MHz, CDCl3, Minor) 211.4 (CO, C-5), 180.2 (CN, C-3), 144.5 (C, C-9), 111.5 
(CH2, C-10), 61.0 (CH, C-1), 55.9 (CH, C-4), 46.6 (CH, CyCH), 43.1 (CH, C-6), 42.4 
(CH, C-8), 29.4 (CH2, CyCH2), 25.8 (CH2, CyCH2), 25.7 (2 × CH2, CyCH2), 23.7 (CH2, 
CyCH2), 22.5 (CH3, C-11), 11.7 (CH3, C-12); m/z (ESI) 260 [MH]
+
; [HRMS (ESI): 
calcd. for C17H26NO, 260.2009. Found: [MH]
+
, 260.2007 (0.9 ppm error)]. 
Lab Book Ref. = JDC/9/97 
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3-Phenyl-8-propyl-2-azabicyclo[2.2.2]oct-2-en-5-one 263f: Using the procedure 
described for the preparation of compound 263a, the title compound 263f (48 mg, 80%) 
was isolated as a yellow oil; Rf 0.54 (DCM/MeOH, 95:5); υmax/cm
-1
 (neat) 2956, 2929, 
2871, 1731, 1601, 1446, 1346; δH (400 MHz, CDCl3) 7.81-7.77 (2 H, m, ArH), 7.46-
7.38 (3 H, m, ArH), 4.86-4.77 (1 H, m, H-1), 3.96 (1 H, d, J = 3.1, H-4), 2.25-2.18 (1 H, 
ddd, J = 19.0, 3.0, 2.5 H-6a), 2.14 (1 H, dd, J = 19.0, 1.9, H-6b), 2.02 (1 H, dddd, J = 
13.2, 10.9, 3.7, 2.5, H-7a), 1.93-1.84 (1 H, m, H-8), 1.46-1.28 (5 H m, H-7b, 9, 10), 0.90 
(3 H, t, J = 7.1, H-11); δC (100 MHz, CDCl3) 208.3 (CO, C-5), 171.4 (CN, C-3), 135.8 
(C, ArC), 130.8 (CH, ArCH), 128.6 (2 × CH, ArCH), 126.2 (2 × CH, ArCH), 56.2 (2 × 
CH, C-1, 4), 39.5 (CH2, C-6), 38.3 (CH2, C-9), 34.6 (CH, C-8), 31.1 (CH2, C-7), 20.5 
(CH2, C-10), 13.8 (CH3, C-11); m/z (ESI) 242 [MH]
+
; [HRMS (ESI): calcd. for 
C16H20NO, 242.1539. Found: [MH]
+
, 242.1543 (1.6 ppm error)]. 




3,8-Diphenyl-2-azabicyclo[2.2.2]oct-2-en-5-one 263g: Using the procedure described 
for the preparation of compound 263a, the title compound 263g (~50% by 
1
H NMR 
Spectroscopy) was isolated as a yellow oil; Rf 0.64 (DCM/MeOH, 95:5); δH (400 MHz, 
CDCl3) 7.87-7.83 (2 H, m, ArH), 7.53-7.42 (3 H, m, ArH), 7.38-7.31 (2 H, m, ArH), 
7.29-7.21 (1 H, m, ArH), 7.21-7.17 (2 H, m, ArH), 4.98-4.95 (1 H, m, H-1), 4.17 (1 H, d, 
J = 2.8, H-4), 3.24 (1 H, ddd, J = 11.6, 5.9, 2.8, H-8), 2.47-2.42 (1 H, m, H-7a), 2.41-
2.38 (2 H, m, H-6), 2.06 (1 H, ddd, J = 13.1, 5.9, 1.2, H-7b); δC (100 MHz, CDCl3) 
207.5 (CO, C-5), 171.7 (CN, C-3), 141.1 (C, ArC), 135.4 (C, ArC), 131.0 (CH, ArCH), 
128.9 (2 × CH, ArCH), 128.7 (2 × CH, ArCH), 127.3 (2 × CH, ArCH), 127.2 (CH, 
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ArCH), 126.3 (2 × CH, ArCH), 57.8 (CH, C-4), 56.1 (CH, C-1), 41.0 (CH, C-8), 40.6 
(CH2, C-6), 31.3 (CH2, C-7); m/z (ESI) 276 [MH]
+
; [HRMS (ESI): calcd. for C19H18NO, 
276.1383. Found: [MH]
+
, 276.1382 (0.5 ppm error)]. 




(5S*,6R*)-6-(Cyclohexanecarbonyl)-5,6-dimethylcyclohex-2-en-1-one 264:  To a 
stirred solution of diketone 262b (189 mg, 0.86 mmol, 1.0 equiv.) in acetone (2 mL) at 
rt were added K2CO3 (178 mg, 1.29 mmol, 1.5 equiv.) and MeI (67 µL, 1.08 mmol, 1.25 
equiv.).  The suspension was heated to reflux and held for 24 h, then cooled to rt and 
diluted with H2O (5 mL).  The aqueous solution was extracted with Et2O (3 × 10 mL), 
then the combined organic extracts were washed with brine (10 mL), dried (MgSO4), 
then concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, PE/Et2O, 9:1) to give the title compound 264 (53 mg, 26%) as a 
colourless oil; Rf 0.64 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2930, 2855, 1674, 1450, 1386, 
987; δH (400 MHz, CDCl3) 6.94 (1 H, ddd, J = 10.1, 5.5, 2.4, H-3), 6.01 (1 H, ddd, J = 
10.1, 2.9, 1.2, H-2), 2.68 (1 H, dddd, J = 19.9, 10.7, 2.9, 2.4, H-4a), 2.63-2.55 (1 H, m, 
CyH), 2.27 (1 H, dddd, J = 19.9, 5.5, 5.4, 1.2, H-4b), 2.01 (1 H, dqd, J = 10.7, 7.0, 5.4, 
H-5), 1.73-1.55 (4 H, m, CyH), 1.47-1.41 (1 H, m, CyH), 1.41 (3 H, s, H-9), 1.35-1.10 
(5 H, m, CyH), 1.18 (3 H, d, J = 7.0, H-8); δC (100 MHz, CDCl3) 212.0 (CO, C-7), 
198.5 (CO, C-1), 150.9 (CH, C-3), 128.5 (CH, C-2), 63.3 (C, C-6), 47.0 (CH, CyCH), 
38.9 (CH, C-5), 32.8 (CH2, C-4), 29.8 (CH2, CyCH2), 29.5 (CH2, CyCH2), 25.5 (CH2, 
CyCH2), 25.3 (2 × CH2, CyCH2), 17.9 (CH3, C-9), 16.0 (CH3, C-8); m/z (ESI) 235 
[MH]
+
; [HRMS (ESI): calcd. for C15H23O2, 235.1693. Found: [MH]
+
, 235.1694 (0.6 
ppm error)]. 
Lab Book Ref. = JDC/10/67 
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6-(1-Hydroxyhexyl)cyclohex-2-en-1-one 260c: Using the procedure described for the 
preparation of compound 260a, the title compound 260c (1.06 g, 72%, ~3.5:1 (anti:syn)) 
was isolated as a yellow oil; Rf 0.54anti and 0.26syn (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 
3455 (br), 2929, 2860, 1667, 1389; δH (400 MHz, CDCl3) 7.02-6.94 (2 H, m, H-3), 
6.03-5.97 (2 H, m, H-2), 4.20-4.13 (1 H, m, H-7syn), 3.85 (1 H, ddd, J = 7.7, 7.6, 2.9, H-
7anti), 2.47-2.38 (5 H, m, H-4, 6 syn), 2.32 (1 H, ddd, J = 13.5, 7.6, 4.7, H-6anti), 2.12-1.94 
(3 H, m, H-5a, 5b syn), 1.76-1.65 (1 H, ddd, J = 13.5, 13.4, 9.2, 7.1, H-5b anti), 1.59-1.19 
(16 H, m, H-8, 9, 10, 11), 0.87 (6 H, t, J = 6.9, H-12); δC (400 MHz, CDCl3, Anti) 203.8 
(CO, C-1), 150.9 (CH, C-3), 129.8 (CH, C-2), 71.7 (CH, C-7), 51.5 (CH, C-6), 33.6 
(CH2, C-8), 31.9 (CH2, C-10), 25.8 (CH2, C-4), 25.0 (CH2, C-5), 24.5 (CH2, C-9), 22.6 
(CH2, C-11), 14.0 (CH3, C-12); δC (400 MHz, CDCl3, Syn) 202.1 (CO, C-1), 150.7 (CH, 
C-3), 130.1 (CH, C-2), 69.8 (CH, C-7), 51.5 (CH, C-6), 32.8 (CH2, C-8), 31.7 (CH2, C-
10), 25.9 (CH2, C-4), 22.6 (CH2, C-9), 22.6 (CH2, C-11), 22.3 (CH2, C-5), 14.0 (CH3, 
C-12); m/z (ESI) 219 [MNa]
+
; [HRMS (ESI): calcd. for C12H20NaO2, 219.1361. Found: 
[MNa]
+
, 219.1359 (1.0 ppm error)]. 




6-Hexanoylcyclohex-2-en-1-one 257c: Using the procedure described for the 
preparation of compound 262a, the title compound 257c (0.88 g, 88%, 1:1 (keto:enol)) 
was isolated as an orange oil; Rf 0.55 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2956, 2931, 
1716, 1674, 1634, 1582; δH (400 MHz, CDCl3) 6.99 (1 H, ddd, J = 10.0, 3.9, 3.9, H-
3keto), 6.66 (1 H, ddd, J = 9.9, 4.3, 4.3, H-3enol), 6.04 (1 H, ddd, J = 9.9, 1.9, 1.9, H-2enol), 
6.00 (1 H, ddd, J = 10.0, 2.0, 2.0, H-2keto), 3.46 (1 H, dd, J = 8.3, 5.0, H-6keto), 2.65-2.44 
(6 H, m, H-4a, 5enol, 8keto), 2.39-2.27 (5 H, m, H-4b, 5a keto, 8enol), 2.11-2.01 (1 H, m, 5b 
keto), 1.64-1.51 (4 H, m, H-9), 1.38-1.18 (8 H, m, H-10, 11), 0.88 (3 H, t, J = 7.0, H-12), 
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0.86 (3 H, t, J = 7.0, H-12); δC (100 MHz, CDCl3) 207.3 (CO, C-7keto), 195.6 (C, C-
1keto), 188.7 (C, C-1enol), 183.3 (C, C-7enol), 151.3 (CH, C-3keto), 145.1 (CH, C-3enol), 
129.1 (CH, C-2keto), 127.9 (CH, C-2enol), 103.8 (C, C-6enol), 59.4 (CH, C-6keto), 42.7 
(CH2, C-8keto), 34.2 (CH2, C-8enol), 31.5 (CH2), 31.2 (CH2), 25.4 (CH2, C-9enol), 24.5 
(CH2), 24.3 (CH2), 24.2 (CH2), 23.0 (CH2), 22.4 (2 × CH2), 21.6 (CH2, C-5enol), 13.9 
(CH3), 13.8 (CH3); m/z (ESI) 217 [MNa]
+
; [HRMS (ESI): calcd. for C12H18NaO2, 
217.1204. Found: [MNa]
+
, 217.1197 (3.6 ppm error)]. 




(6S*)-6-[(R*)-Cyclohexenyl(hydroxy)methyl]cyclohex-2-en-1-one 260d: Using the 
procedure described for the preparation of compound 260a, the title compound 260d 
(190 mg, 61%) was isolated as a colourless oil; Rf 0.38 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 
3469 (br), 2926, 2858, 1658, 1390, 1222, 1017; δH (400 MHz, CDCl3) 7.03-6.98 (1 H, 
m, H-3), 6.00 (1 H, ddd, J = 10.0, 2.4, 1.6, H-2), 5.67-5.64 (1 H, m, H-9), 4.40 (1 H, d, J 
= 1.4, OH), 4.13 (1 H, d, J = 9.2, H-7), 2.45-2.33 (3 H, m, H-4, 6), 2.25-2.15 (1 H, m, 
H-13a), 2.08-1.94 (2 H, m, H-10), 1.85-1.72 (2 H, m, H-5, 13b), 1.67-1.58 (3 H, m, H-
11a, 12), 1.57-1.44 (2 H, m, H-5, 11b); δC (100 MHz, CDCl3) 204.5 (CO, C-1), 151.5 
(CH, C-3), 136.1 (C, C-8), 129.6 (CH, C-2), 126.9 (CH, C-9), 77.9 (CH, C-7), 48.6 (CH, 
C-6), 25.8 (CH2, C-4), 25.2 (CH2, C-5), 24.9 (CH2, C-10), 22.4 (2 × CH2), 22.4 (CH2); 
m/z (ESI) 229 [MNa]
+
; [HRMS (ESI): calcd. for C13H18NaO2, 229.1199. Found: 
[MNa]
+
, 229.1195 (1.9 ppm error)]. 





6-(Cyclohexanecarbonyl)cyclohex-2-en-1-one 257d: Using the procedure described 
for the preparation of compound 262a, the title compound 257d (171 mg, 91%) was 
isolated as a colourless crystalline solid; mp. 77-79 ºC; Rf 0.46 (PE/EtOAc, 2:1); 
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υmax/cm
-1
 (thin film) 2937, 2867, 1672, 1650, 1127; δH (400 MHz, CDCl3) 6.97 (1 H, 
ddd, J = 10.1, 4.4, 3.4, H-3), 6.90-6.86 (1 H, m, H-2), 5.98 (1 H, ddd, J = 10.1, 1.9, 1.9, 
H-2), 4.09 (1 H, dd, J = 8.9, 5.1, H-6), 2.57-2.45 (1 H, m, H-4a), 2.38-2.10 (6 H, m, H-
4b, 5a, 10, 13), 2.10-2.01 (1 H, m, H-5b), 1.66-1.51 (4 H, m, H-11, 12); δC (100 MHz, 
CDCl3) 198.5 (CO), 196.4 (CO), 150.6 (CH, C-3), 142.3 (CH, C-9), 139.1 (C, C-8), 
129.4 (CH, C-2), 52.8 (CH, C-6), 26.1 (CH2, C-10), 25.7 (CH2, C-5), 24.4 (CH2, C-4), 
22.9 (CH2, C-13), 21.7 (CH2), 21.3 (CH2); m/z (ESI) 205 [MH]
+
; [HRMS (ESI): calcd. 
for C13H17O2, 205.1223. Found: [MH]
+
, 205.1230 (3.5 ppm error)]. 
Lab Book Ref. = JDC/8/69 
 




Methyl 2-(6-phenyl-2,3,4,5-tetrahydropyridin-2-yl)acetate 266a: To a stirred 
solution of diketone 257a (50 mg, 0.25 mmol, 1.0 equiv.) in MeOH (1 mL) at 0 ºC was 
added dropwise 35% aqueous NH3 (0.5 mL).  The resulting yellow solution was held at 
0 ºC for 30 min., then warmed to rt and held until consumption of starting material was 
observed by TLC (DCM/MeOH, 95:5).  The reaction mixture was diluted with water (5 
mL), then extracted with DCM (3 × 10 mL).  The combined organic extracts were 
washed with brine (10 mL), dried (MgSO4), then concentrated in vacuo to afford the 
title compound 266a (42 mg, 72%) as a yellow; Rf 0.54 (DCM/MeOH, 9:1); υmax/cm
-1
 
(neat) 2931, 2858, 1735, 1604, 1279, 1173; δH (400 MHz, CDCl3) 7.80-7.75 (2 H, m, 
ArH), 7.39-7.32 (3 H, m, ArH), 4.09-3.98 (1 H, m, H-5), 3.74 (3 H, s, H-8) 2.79 (1 H, 
dd, J = 14.9, 6.9, H-6a), 2.74-2.65 (1 H, m, H-2a), 2.55-2.46 (1 H, m, H-2b), 2.52 (1 H, 
dd, J = 14.9, 7.8, H-6b), 2.00-1.89 (2 H, m, H-3a, 4a), 1.82-1.68 (1 H, m, H-3b), 1.35-
1.24 (1 H, m, H-4b); δC (400 MHz, CDCl3) 172.8 (CO, C-7), 165.4 (CN, C-1), 139.7 (C, 
ArC), 129.6 (CH, ArCH), 128.1 (2 × CH2, ArCH), 126.1 (2 × CH2, ArCH), 55.7 (CH, 
C-5), 51.5 (CH3, C-8), 42.5 (CH2, C-6), 27.0 (CH2, C-4), 26.5 (CH2, C-2), 18.9 (CH2, 
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C-3); m/z (ESI) 232 [MH]
+
; [HRMS (ESI): calcd. for C14H18NO2, 232.1332. Found: 
[MH]
+
, 232.1336 (1.6 ppm error)]. 




Methyl 2-(6-cyclohexyl-2,3,4,5-tetrahydropyridin-2-yl)acetate 266b: Using the 
procedure described for the preparation of compound 266a, the title compound 266b (6 
mg, Quant. (0.03 mmol scale)) was isolated as a yellow oil; Rf 0.48 (DCM/MeOH/NH3, 
190:9:1); υmax/cm
-1
 (neat) 2927, 2852, 1739, 1657, 1170; δH (400 MHz, CDCl3) 3.79-
3.70 (1 H, m, H-5), 3.68 (3 H, s, H-8), 2.70 (1 H, dd, J = 15.0, 5.9, H-6a), 2.37 (1 H, dd, 
J = 15.0, 8.5, H-6b), 2.11-1.97 (2 H, m), 1.87-1.48 (8 H, m), 1.35-1.07 (7 H, m); δC (100 
MHz, CDCl3) 175.3 (CO, C-7), 172.8 (CN, C-1), 54.6 (CH, C-5), 51.4 (CH3, C-8), 49.0 
(CH, CyCH), 42.3 (CH2, C-6), 30.3 (CH2), 30.2 (CH2), 27.1 (CH2), 26.2 (CH2), 26.2 
(CH2), 26.2 (CH2), 26.1 (CH2), 18.5 (CH2); m/z (ESI) 238 [MH]
+
; [HRMS (ESI): calcd. 
for C14H24NO2, 238.1802. Found: [MH]
+
, 238.1804 (1.2 ppm error)]. 




Methyl 2-(6-pentyl-2,3,4,5-tetrahydropyridin-2-yl)acetate 266c: Using the procedure 
described for the preparation of compound 266a, the title compound 266c  (50 mg, 89%) 
as a yellow oil; Rf 0.38 (DCM/MeOH, 95:5); υmax/cm
-1
 (neat) 2931, 2869, 1740, 1660, 
1437, 1280, 1172; δH (400 MHz, CDCl3) 3.83-3.71 (1 H, m, H-5), 3.69 (3 H, s, H-8), 
2.73 (1 H, dd, J = 15.1, 5.9, H-6a), 2.38 (1 H, dd, J = 15.1, 8.6, H-6b), 2.19-2.01 (4 H m, 
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H-2, 9), 1.86-1.70 (2 H, m, H-3a, 4a), 1.65-1.45 (3 H, m, H-3b, 10), 1.37-1.14 (5 H, m, 
H-4b, 11, 12), 0.88 (3 H, t, J = 7.0, H-13); δC (400 MHz, CDCl3) 172.7 (CO, C-7), 172.0 
(CN, C-1), 54.7 (CH, C-5), 51.5 (CH3, C-8), 42.2 (CH2, C-6), 40.9 (CH2, C-9), 31.6 
(CH2, C-11), 28.5 (CH2, C-2), 26.9 (CH2, C-4), 26.4 (CH2, C-10), 22.5 (CH2, C-12), 
18.5 (CH2, C-3), 14.0 (CH3, C-13); m/z (ESI) 226 [MH]
+
; [HRMS (ESI): calcd. for 
C13H24NO2, 226.1802. Found: [MH]
+
, 226.1803 (0.7 ppm error)]. 




Methyl 2-(6-cyclohexenyl-2,3,4,5-tetrahydropyridin-2-yl)acetate 266d: Using the 
procedure described for the preparation of compound 266a, the title compound 266d 
(11  mg, 96% (0.05 mmol scale)) was isolated as a yellow oil; Rf 0.52 (DCM/MeOH, 
9:1); υmax/cm
-1
 (neat) 2931, 2858, 1738, 1617, 1435, 1172; δH (400 MHz, CDCl3) 6.29-
6.24 (1 H, m, H-10), 3.95-3.84 (1 H, m, H-5), 3.69 (3 H, s, H-8), 2.64 (1 H, dd, J = 14.7, 
7.0, H-6a), 2.43 (1 H, dd, J = 14.7, 7.8, H-6b), 2.43-2.34 (1 H, m, H-2a), 2.32-2.06 (5 H, 
m, H-2b, 11, 14), 1.86-1.75 (2 H, m, H-3a, 4a), 1.70-1.52 (5 H, m, H-3b, 12, 13), 1.22-
1.11 (1 H, m, H-4b); δC (400 MHz, CDCl3) 173.0 (CO, C-7), 166.4 (CN, C-1), 139.0 (C, 
C-9), 129.7 (CH, C-10), 55.3 (CH, C-5), 51.4 (CH3, C-8), 42.6 (CH2, C-6), 27.2 (CH2, 
C-4), 25.9 (CH2, C-11), 24.9 (CH2, C-2), 24.5 (CH2, C-14), 22.6 (CH2, C-12), 22.2 
(CH2, C-13), 18.9 (CH2, C-3); m/z (ESI) 235 [MH]
+
; [HRMS (ESI): calcd. for 
C14H22NO2, 236.1645. Found: [MH]
+
, 236.1641 (1.8 ppm error)]. 
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Methyl 2-[(2S*,6S*)-6-pentylpiperidin-2-yl)acetate 267:  To a stirred solution of 
imine 266c (104 mg, 0.46 mmol, 1.0 equiv.) in MeOH (3 mL) at 0 ºC was added NaBH4 
(28 mg, 0.74 mmol, 1.6 equiv.).  The colourless solution was held at 0 ºC for 30 min. 
before warming to rt and holding for 1 h. The reaction was quenched with 1 M aq. 
NaOH (1 mL), then the aqueous phase was extracted with DCM (3 × 5 mL).  The 
combined organic extracts were washed with brine (5 mL), dried (Na2SO4), then 
concentrated in vacuo to afford the title compound 267 (98 mg, 93%, Inseparable 
mixture of diastereoisomers (~3:1 – cis/trans)) as a yellow oil; Rf 0.50 (DCM/MeOH, 
9:1); δH (400 MHz, CDCl3, cis-isomer) 3.68 (3 H, s, H-8), 2.93 (1 H, dddd, J = 10.5, 7.7, 
5.5, 2.6, H-5), 2.55-2.46 (1 H, m, H-1), 2.42 (1 H, dd, J = 16.2, 5.5, H-6a), 2.37 (1 H, dd, 
J = 16.2, 7.7, H-6b), 1.82-1.72 (1 H, m), 1.69-1.55 (3 H, m), 1.38-1.23 (8 H, m), 1.16-
0.94 (2 H, m), 0.88 (3 H, t, J = 6.6, H-13). 
Lab Book Ref. = JDC/10/19 






(3S)-4-Acetyl-3-methyl-5-oxohexanal 274:  To a stirred solution of acetylacetone 
(0.82 mL, 8.00 mmol, 1 equiv.) and catalyst 275 (50 mg 0.08 mmol, 0.01 equiv.) at r.t 
was added crotonaldehyde (0.98 mL, 12.0 mmol, 1.5 equiv.).  The solution was stirred 
at rt for 24 h, then concentrated in vacuo to give the title compound 274 (1.35 g, 99 %) 
as a pale yellow oil which was used without further purification; Rf 0.13 (PE/Et2O, 1:1); 
υmax/cm
-1
 (neat) 2969, 1723, 1698, 1359, 1159; δH (400 MHz, CDCl3) 9.71 (1 H, dd, J = 
2.0, 1.1, H-9), 3.69 (1 H, d, J = 9.4, H-3), 2.90 (1 H, ddqd, J = 9.4, 8.4, 6.8, 4.1, H-6), 
2.48 (1 H, ddd, J = 17.3, 4.1, 1.1, H-8a), 2.33 (1 H, ddd, J = 17.3, 8.4, 2.0, H-8b), 2.18 (6 
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H, s, H-1, 5), 0.97 (3 H, d, J = 6.8, H-7); δC (100 MHz, CDCl3) 203.8 (CO), 203.5 (CO), 
200.8 (CO, C-9), 73.8 (CH, C-3), 48.0 (CH2, C-8), 30.2 (CH3), 29.6 (CH3), 28.1 (CH, 
C-6), 17.9 (CH3, C-7); m/z (ESI) 171 [MH]
+
; [HRMS (ESI): calcd. for C9H15O3, 
171.1016. Found: [MH]
+
, 171.1020 (2.7 ppm error)]. 
Lab Book Ref. = JDC/6/46 






(5S,6S)-6-Acetyl-5-methylcyclohex-2-enone 51:  To a stirred solution of aldehyde 272 
(125 mg, 0.73 mmol, 1.0 equiv.) in PhMe (5 mL) at rt was added p-TsOH (15 mg, 0.07 
mmol, 0.1 equiv.).  The solution was heated to 50 ºC and held for 18 h, before cooling 
to rt and diluting with ether (5 mL).  The organic phase was washed with sat. aq. 
NaHCO3 (2 × 5 mL) and brine (5 mL), dried (MgSO4) then concentrated in vacuo to 
afford a brown oil which was purified by column chromatography (SiO2, PE/Et2O, 4:1) 
to give the title compound 51 (82 mg, 74%) as a pale yellow oil; Rf 0.71 (PE/EtOAc, 
1:1); υmax/cm
-1
 (neat) 2961, 1716, 1672, 1425, 1280; δH (400 MHz, CDCl3) 6.96 (1 H, 
ddd, J = 10.2, 5.3, 2.9, H-3keto), 6.52 (1 H, dddd, J = 9.9, 6.3, 2.3, 1.2, H-3enol), 6.01 (1 
H, ddd, J = 9.9, 3.1, 0.7, H-2enol), 6.00 (1 H, ddd, J = 10.2, 2.6, 1.4, H-2keto), 3.18 (1 H, d, 
J = 10.6, H-6keto), 2.81 (1 H, dqdd, J = 7.0, 7.0, 1.3, 1.3, H-5enol), 2.62-2.49 (3 H, m, H-
4a keto, 4a enol, 5keto), 2.22 (1 H, dddd, J = 18.2, 6.3, 1.3, 0.7, H-4b enol), 2.20 (3 H, s, H-
9enol), 2.14-2.11 (1 H, m, H-4keto), 2.09 (3 H, s, H-9keto), 1.08 (3 H, d, J = 7.0, H-7enol), 
1.03 (3 H, d, J = 6.5, H-7keto); δC (100 MHz, CDCl3, Keto) 205.8 (CO, C-8), 196.0 (CO, 
C-1), 150.1 (CH, C-3), 128.8 (CH, C-2), 67.6 (CH, C-6), 32.8 (CH2, C-4), 31.9 (CH, C-
5), 30.5 (CH3, C-9), 19.6 (CH3, C-7); δC (100 MHz, CDCl3, Enol) 187.2 (CO, C-8), 
181.6 (C, C-2), 142.9 (CH, C-3), 126.7 (CH, C-2), 109.9 (C, C-6), 31.8 (CH2, C-4), 27.1 
(CH, C-5), 21.1 (CH3, C-9), 20.5 (CH3, C-7); m/z (ESI) 175 [MNa]
+
; [HRMS (ESI): 
calcd. for C9H12NaO2, 175.0730. Found: [MNa]
+
, 175.0727 (1.4 ppm error)]. 
Lab Book Ref. = JDC/5/2 
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1,7-Dimethyl-2,9-dioxabicyclo[3.3.1]nonan-3-one 279: To a stirred solution of 
aldehyde 272 (125 mg, 0.73 mmol, 1.0 equiv.) in PhMe (5 mL) at rt was added p-TsOH 
(15 mg, 0.07 mmol, 0.1 equiv.).  The solution was heated to 50 ºC and held for 18 h, 
before cooling to rt and diluting with ether (5 mL).  The organic phase was washed with 
sat. aq. NaHCO3 (2 × 5 mL) and brine (5 mL), dried (MgSO4) then concentrated in 
vacuo to afford a brown oil which was purified by column chromatography (SiO2, 
PE/Et2O, 4:1) to give enone 51 (68 mg, 61%) as a pale yellow oil and the title 
compound 279 (10 mg, 8%) as a colourless oil; Rf 0.60 (PE/Et2O, 1:1); υmax/cm
-1
 (neat) 
2921, 1736, 1290, 1253, 1124, 1037; δH (400 MHz, CDCl3) 4.47 (1 H, ddd, J = 8.0, 4.6, 
1.8, H-3), 2.92 (1 H, ddd, J = 18.1, 8.0, 0.9, H-2a), 2.37 (1 H, d, J = 18.1, H-2b), 2.01 (1 
H, ddd, J = 13.5, 4.2, 1.9, H-6a), 1.98-1.84 (1 H, m, H-5), 1.66 (1 H, dddd , J = 13.7, 4.0, 
1.9, 1.8, H-4a), 1.62-1.55 (1 H, m, H-4b), 1.53 (3 H, s, H-8), 1.30 (1 H, dd, J = 13.5, 
11.9, H-6b), 0.95 (3 H, d, J = 6.4, H-9); δC (100 MHz, CDCl3) 168.5 (CO, C-1), 104.4 
(C, C-7), 68.1 (CH, C-3), 43.1 (CH2, C-6), 37.5 (CH2, C-4), 33.8 (CH2, C-2), 27.6 (CH3, 
C-8), 21.2 (CH/CH3, C-5/9); m/z (ESI) 171 [MH]
+
; [HRMS (ESI): calcd. for C9H15O3, 
171.1016. Found: [MH]
+
, 171.1015 (0.5 ppm error)]. 




3,8-Dimethyl-2-azabicyclo[2.2.2]oct-2-en-5-one 27:  To a stirred solution of enone 51 
(76 mg, 0.50 mmol, 1.0 equiv.) in MeOH (1 mL) at 0 ºC was added 35% aq. NH3 (0.5 
mL).  The resulting yellow solution was held at 0 ºC for 30 min., then warmed to rt and 
held for 2 h.  The reaction was diluted with water (5 mL) then extracted with DCM (3 × 
10 mL).  The combined organic extracts were washed with brine (5 mL), dried 
(Na2SO4), then concentrated in vacuo to afford the title compound 27 (64 mg, 84%) as 
yellow oil which partially solidified on storage at −20 ºC; Picrate mp. 208-210 ºC (Lit.
42
 
212-213 ºC); Rf 0.33 (DCM/MeOH, 95:5); [α]
24
D −252.7 (c 0.51, DCM), [Lit.
42
 −34.5 (c 
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0.50, DCM)]; υmax/cm
-1
 (neat) 2957, 1729, 1633, 1379; δH (400 MHz, CDCl3) 4.50 (1 H, 
dddd, J = 3.5, 3.5, 1.9, 1.9, H-1), 3.13 (1 H, d, J = 2.9, H-4), 2.17-2.08 (1 H, m, H-6a), 
2.12 (3 H, s, H-10), 2.01 (1 H, dd, J = 19.0, 1.9, H-6b), 1.99-1.91 (2 H, m, H-7a, 8), 
1.27-1.19 (1 H, m, H-7b), 1.04 (3 H, d, J = 6.9, H-9); δC (100 MHz, CDCl3) 208.4 (CO, 
C-5), 173.7 (CN, C-3), 61.4 (CH, C-4), 55.5 (CH, C-1), 39.5 (CH2, C-6), 32.4 (CH2, C-
7), 28.8 (CH, C-8), 24.5 (CH3, C-10), 21.0 (CH3, C-9); m/z (ESI) 152 [MH]
+
; [HRMS 
(ESI): calcd. for C9H14NO, 152.1070. Found: [MH]
+
, 152.1070 (0.1 ppm error)]; HPLC 
Analysis (Phenomenex Lux Cellulose-2 column, 95:5 iso-hexane/EtOH, flow rate 1.0 
mL/min,; RT = 9.51 (minor, 9.5%) and 10.62 (major, 90.5%)). 
Lab Book Ref. = JDC/9/32 






3,5,8-Trimethyl-2,6-diazabicyclo[2.2.2]octa-2,5-diene 285:  A stirred solution of 
aldehyde 274 (10 mg, 0.06 mmol, 1.0 equiv.) in 35% aq. NH3 (1 mL) was held at rt for 
2 h, then diluted with water (5 mL).  The organic phase was separated and the aqueous 
phase extracted with DCM (4 × 5 mL). The combined organic extracts were washed 
with brine (5 mL), dried (Na2SO4), then concentrated in vacuo to afford the title 
compound 285 (9 mg, Quant.) as yellow film; Rf 0.39 (DCM/MeOH, 9:1); υmax/cm
-1
 
(thin film) 2958, 1658, 1433, 1380, 1280; δH (400 MHz, CDCl3) 6.24 (1 H, dd, J = 2.4, 
2.4, H-1), 3.71 (1 H, d, J = 2.3, H-4), 2.12 (3 H, s, CH3), 2.11 (3 H, s, CH3), 1.71 (1 H, 
ddd, J = 12.1, 9.3, 2.4, H-7a), 1.48 (1 H, dqdd, J = 9.3, 6.9, 4.6, 2.3, H-8), 0.92 (1 H, 
ddd, J = 12.1, 4.6, 2.4, H-7b), 0.87 (3 H, d, J = 6.9, H-9); δC (100 MHz, CDCl3) 172.3 
(CN), 170.3 (CN), 76.6 (CH, C-1), 55.5 (CH, C-4), 32.2 (CH2, C-7), 27.2 (CH, C-8), 
25.3 (CH3), 22.7 (CH3), 20.5 (CH3, C-9); m/z (ESI) 151 [MH]
+
; [HRMS (ESI): calcd. 
for C9H15N2, 151.1230. Found: [MH]
+
, 151.1232 (1.7 ppm error)]. 
Lab Book Ref. = JDC/4/90  
 





 291:  To a stirred solution of sodium (58 mg, 
2.50 mmol, 0.01 equiv.) in absolute ethanol (50 mL) at rt, was added in one portion 
succinimide (24.8 g, 250 mmol, 1.0 equiv.).  The suspension was stirred at rt for 5 min., 
then acrolein (16.7 mL, 250 mmol, 1.0 equiv.) was added dropwise over 2 h, ensuring 
the internal temperature remained below 30 ºC.  The resulting yellow solution was 
stirred at rt for a further 2 h, then quenched with glacial acetic acid (1 mL).  The 
solution was concentrated in vacuo to give a yellow oil, which was passed through a 
plug of silica (50 g, CHCl3:Acetone, 95:5) to give the semi-pure aldehyde 291 (36.1 g, 
93%) as a viscous yellow oil; Rf 0.25 (DCM/MeOH, 95:5); δH (400 MHz, CDCl3) 9.76 
(1 H, t, J = 1.4, H-6), 3.85 (2 H, t, J = 7.0, H-4), 2.77 (2 H, td, J = 7.0, 1.4, H-5), 2.71 (4 
H, s, H-1). 
Lab Book Ref. = JDC/5/75 







Methyl (E)-5-(2,5-dioxopyrrolidin-1-yl)pent-2-enoate 293:  To a stirred solution of 
K2CO3 (10.4 g, 75.1 mmol, 1.05 equiv.) in H2O (50 mL) at 0 ºC was added dropwise 
trimethyl phosphonoacetate (12.2 mL, 75.1 mmol, 1.05 equiv.). The solution was stirred 
at 0 ºC for 30 min., then aldehyde 291 (11.1 g, 71.5 mmol, 1.0 equiv.) was added as a 
solution in THF (50 mL).  The solution was held at 0 ºC for 30 min., then warmed to rt 
and held for 18 h. The reaction was diluted with ether (50 mL) and H2O (50 mL), then 
the aqueous phase was extracted with EtOAc (3 × 50 mL).  The combined organic 
extracts were washed with 1 M aq. HCl (50 mL) and brine (50 mL), dried (MgSO4), 
then concentrated in vacuo to afford the title compound 293 (14.3 g, 95%) as a yellow 
oil which partially solidified on standing; Rf 0.68 (DCM/MeOH, 95:5); δH (400 MHz, 
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CDCl3) 6.85 (1 H, dt, J = 15.7, 7.1, H-6), 5.86 (1 H, dt J = 15.7, 1.6, H-7), 3.72 (3 H, s, 
H-9), 3.65 (2 H, t, J = 7.2, H-4), 2.71 (4 H, s, H-1), 2.50 (2 H, tdd, J = 7.2, 7.1, 1.6, H-5). 
Lab Book Ref. = JDC/6/61 








 64b:  To a stirred 
solution of imide 293 (16.6 g, 78.6 mmol, 1.0 equiv.), in MeOH (150 mL) at 0 ºC, was 
added NaBH4 (5.94 g, 157.2 mmol, 2.0 equiv.) portionwise over 2 h.  The colourless 
solution was stirred at 0 ºC for a further 2 h, then carefully quenched with conc. HCl (50 
mL). The reaction mixture was diluted with water (100 mL), then extracted with DCM 
(3 × 150 mL). The combined organic extracts were washed with brine (150 mL), dried 
(MgSO4), then concentrated in vacuo to afford the title compound 64b (17.9 g, Quant.) 
as a pale yellow oil; Rf 0.46 (CHCl3/acetone, 4:1); δH (400 MHz, CDCl3) 6.91 (1 H, dt, J 
= 15.7, 7.1, H-7), 5.88 (1 H, dt, J = 15.7, 1.6, H-8), 4.90 (1 H, dd, J = 6.3, 1.4, H-9), 
3.73 (3 H, s, H-11), 3.58 (1 H, ddd, J = 13.8, 7.8, 6.3, H-5a), 3.26 (3 H, s, H-12), 2.59-
2.41 (3 H, m, H-2a, 6), 2.37-2.27 (2 H, m, H-2b, 5b), 2.19-2.06 (1 H, m, H-1a), 2.00 (1 H, 
dddd, J = 14.0, 9.6, 3.1, 1.4, H-1b). 
Lab Book Ref. = JDC/6/98 








 65:  To a stirred solution 
of ester 64b (2.29 g, 10.1 mmol, 1.0 equiv.) in 1,2-dichloroethane (40 mL) at 0 ºC, was 
added SnCl4 (2.96 mL, 25.3 mmol, 2.5 equiv.).  The reaction was held at 0 ºC for 30 
min., then warmed to 70 ºC and held for 18 h.  The reaction mixture was cooled to 0 ºC, 
then quenched with 10% aq. NaOH (20 mL).  The aqueous phase was extracted with 
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DCM (4 × 50 mL), then the combined extracts were washed with water (50 mL) and 
brine (50 mL), dried (Na2SO4), then concentrated in vacuo to afford the title compound 
65 (1.75 g, 75%)  as a complex mixture of diastereoisomers which was used directly 
without further purification; Rf 0.24 (CHCl3/acetone, 4:1); δH (400 MHz, CDCl3) 4.25-
4.11 (2 H, m), 3.79 (3 H, s), 3.63-3.56 (1 H, m), 2.78-2.68 (1 H, m), 2.56-2.12 (4 H, m), 
1.90-1.66 (3 H, m). 
Lab Book Ref. = JDC/5/94 








 66:  To a stirred 
solution of ester 65 (2.35 g, 10.0 mmol, 1.0 equiv.) in PhMe (35 mL) at rt, was added 
DBN (2.47 mL, 20.0 mmol, 2.0 equiv.).  The solution was heated to reflux and held for 
18 h, before cooling to rt and diluting with DCM (50 mL). The organic phase was 
washed with 10% aq. HCl (50 mL) and water (50 mL), then the combined aqueous 
washes were back extracted with DCM (50 mL).  The combined organic extracts were 
washed with brine (50 mL), dried (Na2SO4), then concentrated in vacuo to give a brown 
oil which was purified by column chromatography (SiO2, DCM/MeOH, 9:1) to give the 
title compound 66 (0.73 g, 37%) as a pale yellow oil; Rf 0.65 (DCM/MeOH, 9:1); δH 
(400 MHz, CDCl3) 7.08-7.04 (1 H, m, H-7), 4.44-4.37 (1 H, m, H-9), 4.27 (1 H, dd, J = 
13.1, 6.4, H-5a), 3.77 (3 H, s, H-11), 2.79-2.69 (1 H, m, H-5b), 2.64 (1 H, dddd, J = 12.5, 
8.6, 6.8, 1.7, H-1a), 2.56-2.45 (1 H, m, H-2a), 2.44-2.23 (3 H, m, H-2b, 6), 1.60 (1 H, 
ddd, J = 12.5, 12.5, 11.3, 9.5, H-1b). 
Lab Book Ref. = JDC/5/97 











 288: To a stirred solution of ester 
66 (0.95 g, 4.90 mmol, 1.0 equiv.) in THF (16 mL) at 0 ºC was added dropwise DIBAL-
H (1.2 M in toluene, 22.5 mL, 27.0 mmol, 5.5 equiv.) over 30 min.  The resulting white 
suspension was held at 0 ºC for 30 min., then warmed to rt and held for 4 h.  The 
reaction was cooled to 0 ºC and quenched with MeOH (5 mL), then sat. aq. Rochelle’s 
salt (20 mL) was added. The viscous solution was stirred vigourously for 2 h, then 
extracted with DCM (4 × 50 mL).  The combined organic extracts were washed with 
brine (50 mL), dried (Na2SO4), then concentrated in vacuo to afford an orange oil which 
was purified by column chromatography (SiO2, DCM/MeOH/NH3, 40:9:1) to give the 
title compound 288 (399 mg, 53%) as an orange oil; Rf 0.10 (DCM/MeOH, 4:1); δH 
(400 MHz, CDCl3) 5.68-5.64 (1 H, m, H-7), 4.05-4.03 (2 H, m, H-10), 3.35 (1 H, br s, 
OH), 3.19-3.12 (1 H, m, H-9), 2.91 (1 H, ddd, J = 10.5, 8.1, 3.8, H-3a), 2.80 (1 H, ddd, J 
= 11.3, 5.7, 5.7, H-5a), 2.67 (1 H, ddd, J = 10.5, 8.9, 7.9, H-3b), 2.53 (1 H, ddd, J = 11.3, 
6.0, 6.0, H-5b), 2.27-2.13 (2 H, m, H-6), 2.03 (1 H, dddd, J = 12.1, 9.5, 6.9, 3.6, H-1a), 
1.89 (1 H, ddddd, J = 12.8, 10.5, 8.1, 7.9, 3.6, H-2a), 1.75 (1 H, ddddd, J = 12.8, 9.5, 8.9, 
7.3, 3.8, H-2b), 1.54 (1 H, dddd, J = 12.1, 10.5, 10.5, 7.3, H-1b). 
Lab Book Ref. = JDC/6/70 








 172:  To a stirred solution of 
oxalyl chloride (201 µL, 2.38 mmol, 1.2 equiv.) in DCM (10 mL) at −78 ºC was added 
dropwise DMSO (337 µL, 4.76 mmol, 2.4 equiv.).  The colourless solution was held at 
−78 ºC for 30 min., then alcohol 288 (304 mg, 1.98 mmol, 1.0 equiv.) was added via 
cannula as a pre-cooled solution in DCM (5 mL).  The reaction was held at −78 ºC for 1 
h, then Et3N (1.38 mL, 9.90 mmol, 5.0 equiv.) was added dropwise.  The yellow 
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solution was held at −78 ºC for a further 30 min. then warmed to rt and held for 1 h.  
The reaction was quenched with sat. aq. NaHCO3 (20 mL) then the aqueous phase was 
extracted with DCM (4 × 20 mL).  The combined organic extracts were washed with sat. 
aq. NaHCO3 (20 mL) and brine (20 mL), dried (Na2SO4), then concentrated in vacuo to 
afford the title compound 172 (198 mg, 66%) as a yellow oil which was used 
immediately without further purification; Rf 0.28 (DCM/MeOH, 9:1); δH (400 MHz, 
CDCl3) 9.41 (1 H, s, H-10), 6.84 (1 H, ddd, J = 4.0, 3.9, 1.7, H-7), 3.45-3.37 (1 H, m, 
H-9), 2.97-2.90 (1 H, m, H-5a), 2.90 (1 H, ddd, J = 10.1, 7.9, 4.8, H-3a), 2.74 (1 H, ddd, 
J = 10.1, 8.5, 7.3, H-3b), 2.68-2.61 (1 H, m, H-5b), 2.61-2.51 (1 H, m, H-6a), 2.48-2.38 
(1 H, m, H-6b), 2.40-2.31 (1 H, m, H-1a), 1.94-1.75 (2 H, m, H-2), 1.45 (1 H, dddd, J = 
12.8, 10.2, 9.4, 7.6, H-1b). 
Lab Book Ref. = JDC/7/68 


























methylcyclohex-2-en-1-one 287:  To a stirred solution of diisopropylamine (62 µL, 
0.44 mmol, 1.3 equiv.) in THF (5 mL) at 0 ºC was added dropwise n-BuLi (1.53 M in 
hexanes, 0.27 mL, 0.41 mmol, 1.2 equiv.).  The colourless solution was held at 0 ºC for 
30 min., then cooled to −78 ºC before the addition of enone 87 (41 mg, 0.37 mmol, 1.1 
equiv.) as a pre-cooled solution in THF (1 mL).  The resulting pale yellow solution was 
held at −78 ºC for 1 h, before the addition of aldehyde 172 (51 mg, 0.34 mmol, 1.0 
equiv.) as a pre-cooled solution in THF (1.5 mL).  The reaction was held at −78 ºC for a 
further 30 min., then quenched with AcOH (0.25 mL).  The organic phase was basified 
(sat. aq. NaHCO3) then extracted with DCM (4 × 5 mL).  The combined organic 
extracts were washed with brine (5 mL), dried (MgSO4), then concentrated in vacuo to 
afford an orange oil which was purified by column chromatography (SiO2, 
DCM/MeOH/NH3, 110:9:1) to give the title compound 287 and diastereoisomer 294 (57 
mg, 73% BRSM, 1:1.5 – 287:294) as a yellow oil and recovered aldehyde 172 (6 mg, 
12%) as a yellow film; Rf 0.49 (DCM/MeOH/NH3, 40:9:1); υmax/cm
-1
 (neat) 3399 (br), 
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2957, 2918, 1676, 1389, 1026, 730; δH (400 MHz, CDCl3) 6.86 (1 H, dddd, J = 10.1, 5.2, 
2.8, 1.1, H-14), 6.03 (1 H, dddd, J = 10.1, 2.6, 1.5, 0.7, H-13), 5.77 (1 H, ddd, J = 3.8, 
3.8, 1.3, H-7), 4.25 (1 H, d, J = 9.5, H-10), 3.06-2.99 (1 H, m, H-9), 2.95 (1 H, ddd, J = 
10.5, 8.4, 3.4, H-3a), 2.84 (1 H, ddd, J = 11.3, 5.7, 5.7, H-5a), 2.72-2.63 (1 H, m, H-3b), 
2.56 (1 H, dddd, J = 19.7, 5.6, 2.8, 2.6, H-15a), 2.50 (1 H, ddd, J = 11.3, 5.6, 5.3, H-5b), 
2.38 (1 H, dd, J = 9.5, 3.2, H-11), 2.44-2.11 (4 H, m, H-1a, 6, 16), 2.07 (1 H, dddd, J = 
19.7, 5.2, 2.3, 1.5, H-15b), 2.00-1.86 (1 H, m, H-2a), 1.82-1.67 (2 H, m, H-1b, 2b), 1.07 
(3 H, d, J = 7.1, H-17); δC (100 MHz, CDCl3) 201.4 (CO, C-12), 147.9 (CH, C-14), 
139.1 (C, C-8), 128.3 (CH, C-13), 124.5 (CH, C-7), 74.7 (CH, C-10), 59.8 (CH, C-9), 
56.6 (CH, C-11), 53.0 (CH2, C-3), 46.3 (CH2, C-5), 30.1 (CH, C-16), 30.0 (CH2, C-15), 
29.6 (CH2, C-1), 25.5 (CH2, C-6), 22.3 (CH2, C-2), 19.9 (CH3, C-17); m/z (ESI) 262 
[MH]
+
; [HRMS (ESI): calcd. for C16H24NO2, 262.1802. Found: [MH]
+


























methylcyclohex-2-en-1-one 294: A yellow oil; Rf 0.35 (DCM/MeOH/NH3, 40:9:1); 
υmax/cm
-1
 (neat) 3340 (br), 2956, 2915, 1668, 730; δH (400 MHz, CDCl3) 6.82-6.77 (1 H, 
m, H-14), 5.95 (1 H, ddd, J = 10.1, 2.4, 1.6, H-13), 5.74-5.71 (1 H, m, H-7), 4.26 (1 H, 
d, J = 7.9, H-10), 3.12-3.05 (1 H, m, H-9), 2.88 (1 H, ddd, J = 10.6, 8.5, 3.5, H-3a), 2.76 
(1 H, ddd, J = 11.3, 5.7, 5.7 H-5a), 2.63-2.48 (2 H, m, H-3b, 15a), 2.47 (1 H, ddd, J = 
11.3, 5.6, 5.6, H-5b), 2.31 (1 H, dd, J = 7.9, 4.3, H-11), 2.28-2.19 (3 H, m, H-6, 16), 
2.09-1.98 (2 H, m, H-1a, 15b), 1.93-1.80 (1 H, m, H-2a), 1.78-1.66 (1 H, m, H-2b), 1.53-
1.42 (1 H, m, H-1b), 1.02 (3 H, d, J = 7.0, H-17); δC (100 MHz, CDCl3) 201.0 (CO, C-
12), 147.6 (CH, C-14), 139.6 (C, C-8), 128.5 (CH, C-13), 122.1 (CH, C-7), 73.4 (CH, 
C-10), 60.1 (CH, C-9), 57.5 (CH, C-11), 52.7 (CH2, C-3), 46.3 (CH2, C-5), 30.8 (CH, 
C-16), 30.4 (CH2, C-15), 28.2 (CH2, C-1), 25.4 (CH2, C-6), 22.0 (CH2, C-2), 19.9 (CH3, 
C-17); m/z (ESI) 262 [MH]
+
; [HRMS (ESI): calcd. for C16H24NO2, 262.1802. Found: 
MH
+
, 262.1803 (0.5 ppm error)]. 
Lab Book Ref. = JDC/8/2 























methylcyclohex-2-en-1-one 17:  To a stirred solution of DMSO (10 µL, 0.14 mmol, 2.0 
equiv.) in DCM (1 mL) at −78 ºC was added dropwise trifluoroacetic anhydride (15 µL, 
0.11 mmol, 1.5 equiv.).  The colourless solution was held at −78 ºC for 30 min., before 
adding alcohol 287 (17 mg, 0.07 mmol, 1.0 equiv.) as a pre-cooled solution in DCM (1 
mL) via cannula.  The reaction was held at −78 ºC for 1 h, then Et3N (48 µL, 0.35 mmol, 
5.0 equiv.) was added dropwise.  The yellow solution was held at −78 ºC for a further 
15 min., then warmed to rt and held for 1 h.  The reaction was quenched with sat. aq. 
NaHCO3 (10 mL), then the aqueous phase was extracted with DCM (4 × 5 mL).  The 
combined organic extracts were washed with brine (5 mL), dried (Na2SO4), then 
concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 190:9:1) to give the title compound 17 (12 
mg, 71%) as a colourless oil. To a solution of the product 17 (11 mg, 0.05 mmol, 1.0 
equiv.) in DCM (0.5 mL) at 0 ºC was added dropwise TFA (3 µL, 0.06 mmol, 1.2 
equiv.). The colourless solution was held at 0 ºC for 30 min., then warmed to rt and held 
for 2 h.  The pale yellow solution was concentrated in vacuo to afford the title 
compound 17·TFA (16 mg, Quant.) as a pale yellow film; Rf 0.69 (DCM/MeOH/NH3, 
40:9:1); υmax/cm
-1
 (neat) 2959, 1676, 1656, 1390, 1190; δH (400 MHz, DMSO-d6) 10.37 
(1 H, br s, NH
+
), 7.35 (1 H, dd, J = 3.8, 3.8, H-7), 7.16 (1 H, ddd, J = 9.9, 5.5, 2.2, H-
14), 5.97 (1 H, dd, J = 9.9, 2.1, H-13), 4.40 (1 H, dd, J = 8.7, 8.7, H-9), 4.33 (1 H, d, J = 
11.5, H-11), 3.62-3.50 (1 H, m, H-3a), 3.41-3.27 (2 H, m, H-3b, 5a), 3.18-3.05 (1 H, m, 
H-5b), 2.66-2.59 (2 H, m, H-6), 2.53-2.37 (3 H, m, H-1a, 15a, 16), 2.27-2.15 (1 H, m, H-
15b), 2.08-1.98 (2 H, m, H-2), 1.71-1.58 (1 H, m, 1b) 0.86 (3 H, d, J = 6.2, H-17); δC 
(100 MHz, DMSO-d6) 198.3 (CO, C-10), 196.7 (CO, C-12), 151.6 (CH, C-14), 140.1 
(CH, C-7), 137.2 (C, C-8), 128.3 (CH, C-13), 59.2 (CH, C-11), 57.9 (CH, C-9), 52.9 
(CH2, C-3), 43.1 (CH2, C-5), 33.0 (CH, C-16), 32.6 (CH2, C-15), 28.1 (CH2, C-1), 22.9 
(CH2, C-6), 20.2 (CH2, C-2), 19.1 (CH3, C-17); m/z (ESI) 260 [MH]
+
; [HRMS (ESI): 
calcd. for C16H22NO2, 260.1645. Found: [MH]
+
, 260.1644 (0.4 ppm error)]. 
Lab Book Ref. = JDC/8/16 and JDC/8/18 
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en-5-one 15:  To a stirred solution of diketone 17 (7 mg, 0.03 mmol, 1.0 equiv.) in 1 M 
aq. HCl (1 mL) at 0 ºC was added dropwise pH 10 NH3/NH4Cl aq. solution (1 mL).  
The yellow solution was held at rt for 1 h, then extracted with DCM (3 × 5 mL).  The 
combined organic extracts were washed with brine (5 mL), dried (Na2SO4), then 
concentrated in vacuo to afford a yellow film which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 90:9:1) to give the title compound 17 (5 mg, 
71%) as a yellow film; Rf 0.33 (DCM/MeOH/NH3, 90:9:1); υmax/cm
-1
 (neat) 2954, 2872, 
1730, 1578, 1341, 1102; δH (400 MHz, CDCl3) 6.41 (1 H, ddd, J = 4.2, 4.2, 1.5, H-7), 
4.63 (1 H, dddd, J = 3.6, 3.3, 1.8, 1.8, H-14), 3.70-3.63 (1 H, m, H-9), 3.55 (1 H, d, J = 
3.1, H-11), 2.92 (1 H, ddd, J =10.2, 7.7, 4.7, H-3a), 2.87 (1 H, ddd, J = 11.0, 3.2, 3.2, H-
5a), 2.77 (1 H, ddd, J = 10.2, 8.2, 7.5, H-3b), 2.64 (1 H, ddd, J = 11.0, 7.0, 5.1, H-5b), 
2.47-2.36 (1 H, m, H-6a), 2.36-2.24 (2 H, m, H-1a, 6b), 2.16 (1 H, ddd, J = 18.8, 3.3, 2.7, 
H-13a), 2.06 (1 H, dd, J = 18.8, 1.8, H-13b), 2.00-1.92 (1 H, m, H-15a), 1.91-1.72 (3 H, 
m, H-2, 16), 1.35 (1 H, dddd, J = 12.7, 10.3, 9.3, 7.6, H-1b), 1.27 (1 H, ddd, J = 12.6, 
4.5, 1.8, H-15b), 1.06 (3 H, d, J = 7.0, H-17); δC (100 MHz, CDCl3) 208.9 (CO, C-12), 
171.1 (CN, C-10), 138.6 (C, C-8), 130.2 (CH, C-7), 58.9 (CH, C-9), 56.5 (CH, C-11), 
55.6 (CH, C-14), 52.6 (CH2, C-3), 45.2 (CH2, C-5), 40.0 (CH2, C-13), 32.2 (CH2, C-15), 
30.0 (CH2, C-1), 29.2 (CH, C-16), 24.9 (CH2, C-6), 22.4 (CH2, C-2), 21.2 (CH3, C-17); 
m/z (ESI) 259 [MH]
+
; [HRMS (ESI): calcd. for C16H23N2O, 259.1805. Found: [MH]
+
, 
259.1810 (2.1 ppm error)]. 
Lab. Book Ref. = JDC/8/10 




Grandisine B Dipicrate: An aqueous solution of grandisine B 15 (ca. 10 mg in 1 mL) 
was treated with a slight excess of 1% aqueous picric acid solution (~1.25 equiv.) to 
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give grandisine B dipicrate as an orange crystalline solid. A crystal suitable for X-ray 
























methylcyclohex-2-en-1-one 295:  To a stirred solution of DMSO (21 µL, 0.30 mmol, 
2.0 equiv.) in DCM (4 mL) at −78 ºC was added dropwise trifluoroacetic anhydride (32 
µL, 0.23 mmol, 1.5 equiv.).  The colourless solution was held at −78 ºC for 30 min., 
before adding alcohol 294 (40 mg, 0.15 mmol, 1.0 equiv.) as a pre-cooled solution in 
DCM (2 mL) via cannula.  The reaction was held at −78 ºC for 1 h, then Et3N (105 µL, 
0.75 mmol, 5.0 equiv.) was added dropwise.  The yellow solution was held at −78 ºC 
for a further 15 min., then warmed to rt and held for 1 h.  The reaction was quenched 
with sat. aq. NaHCO3 (20 mL), then the aqueous phase was extracted with DCM (4 × 10 
mL).  The combined organic extracts were washed with brine (10 mL), dried (Na2SO4), 
then concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 190:9:1) to give the title compound 295 (32 
mg, 80%) as a colourless oil. To a stirred solution of the product 295 (30 mg, 0.12 
mmol, 1.0 equiv.) in DCM (1 mL) at 0 ºC was added dropwise TFA (12 µL, 0.15 mmol, 
1.3 equiv.). The solution was stirred at 0 ºC for 30 min., then warmed to rt and held for 
2 h.  The solution was concentrated in vacuo to afford the title compound 295 (45 mg, 
Quant.) as a yellow oil; Rf 0.34 (DCM/MeOH/NH3, 190:9:1); υmax/cm
-1
 (neat) = 2958, 
2927, 2874, 1677, 1656, 1389; δH (400 MHz, DMSO-d6) 10.60 (1 H, br s, NH
+
), 7.33 (1 
H, dd, J = 4.0, 4.0 H-7), 7.16 (1 H, ddd, J = 10.0, 5.7, 2.2, H-14), 5.94 (1 H, dd, J = 10.0, 
2.0, H-13), 4.46-4.38 (1 H, m, H-9), 4.38 (1 H, d, J = 11.8, H-11), 3.60-3.48 (1 H, m, H-
3a), 3.39-3.28 (2 H, m, H-3b, 5a), 3.21-3.09 (1 H, m, H-5b), 2.66-2.59 (2 H, m, H-6), 
2.53-2.34 (3 H, m, H-1a, 15a, 16), 2.29-2.16 (1 H, m, H-15b), 2.09-1.97 (2 H, m, H-2), 
1.77 (1 H, dddd, J = 13.2, 9.6, 9.5, 7.3, H-1b), 0.87 (3 H, d, J = 6.3, H-17); δC (100 MHz, 
DMSO-d6) 198.4 (CO, C-10), 196.7 (CO, C-12), 151.9 (CH, C-14), 138.9 (CH, C-7), 
137.3 (C, C-8), 128.3 (CH, C-13), 59.0 (CH, C-11), 57.9 (CH, C-9), 52.6 (CH2, C-3), 
42.9 (CH2, C-5), 32.6 (CH2, C-15), 32.3 (CH, C-16), 27.9 (CH2, C-1) 22.3 (CH2, C-6), 
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20.4 (CH2, C-2), 19.0 (CH3, C-17); m/z (ESI) 260 [MH]
+
; [HRMS (ESI): calcd. for 
C16H22NO2, 260.1645. Found: [MH]
+
, 260.1636 (3.5 ppm error)]. 
Lab Book Ref. = JDC/7/60 







en-5-one 296:  A stirred solution of diketone 295 (13 mg, 0.05 mmol, 1.0 equiv.) in 1 M 
aq. HCl (0.5 mL) was basified with 35 % aq. NH3 (1 mL) and the resulting yellow 
solution held at rt for 1 h.  The reaction mixture was extracted with DCM (4 × 5 mL), 
then the combined organics were washed with brine (5 mL), dried (Na2SO4), then 
concentrated in vacuo to afford a yellow film which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 90:9:1) to give the title compound 296 (8 mg, 
62%) as a yellow film; Rf 0.33 (DCM/MeOH/NH3, 90:9:1); υmax/cm
-1
 (thin film) 2954, 
2872, 1730, 1577, 1399, 1101; δH (400 MHz, CDCl3) 6.40 (1 H, dd, J = 4.2, 4.2, H-7), 
4.66-4.62 (1 H, m, H-14), 3.75 (1 H, dd, J = 7.9, 7.9, H-9), 3.60 (1 H, d, J = 3.0, H-11), 
2.93-2.83 (2 H, m, H-3), 2.79 (1 H, ddd, J = 11.6, 5.7, 5.7, H-5a), 2.66 (1 H, ddd, J = 
11.6, 5.6, 5.6, H-5b), 2.39-2.33 (2 H, m, H-6), 2.32-2.23 (1 H, m, H-1a), 2.11-2.08 (2 H, 
m, H-13), 2.07-1.72 (3 H, m, H-2, 15a, 16), 1.39-1.32 (1 H, m, H-1b), 1.28 (1 H, ddd, J 
= 12.3, 4.0, 1.7, H-15b), 1.06 (3 H, d, J = 6.9, H-17); δC (100 MHz, CDCl3) 209.0 (CO, 
C-12), 170.8 (CN, C-10), 138.1 (C, C-8), 130.0 (CH, C-7), 58.7 (CH, C-9), 56.4 (CH, 
C-11), 55.8 (CH, C-14), 52.9 (CH2, C-3), 44.9 (CH2, C-5), 39.5 (CH2, C-13), 33.0 (CH2, 
C-15), 29.8 (CH2, C-1), 29.4 (CH, C-16), 25.2 (CH2, C-6), 22.5 (CH2, C-2), 21.3 (CH3, 
C-17); m/z (ESI) 259 [MH]
+
; [HRMS (ESI): calcd. for C16H23N2O, 259.1805. Found: 
[MH]
+
, 259.1805 (0.1 ppm error)]. 
Lab Book Ref. = JDC/8/14 
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(4aR*,9aR*)-1,2,3,4,4a,7,8,9a-octahydro-9H-xanthen-9-one 316: To a stirred 
solution of diketone 257d (50 mg, 0.24 mmol, 1.0 equiv.) in MeCN (5 mL) at rt was 
added 10% aq. NaOH (0.5 mL).  The resulting yellow solution was held at rt for 18 h, 
then diluted with H2O (10 mL) before extracting with Et2O (3 × 10 mL).  The combined 
organic extracts were washed with brine (10 mL), dried (MgSO4), then concentrated in 
vacuo to afford a yellow oil which was purified by column chromatography (SiO2, 
PE/Et2O, 98:2) to give the title compound 316 (27 mg, 54%) as a colourless crystalline 
solid; mp. 75-78 ºC; Rf 0.54 (PE/EtOAc, 4:1); υmax/cm
-1
 (thin film) 2928, 2859, 1634, 
1566, 1428, 1185; δH (400 MHz, CDCl3) 6.40 (1 H, ddd, J = 9.9, 4.3, 4.3, H-3), 5.91 (1 
H, ddd, J = 9.9, 2.0, 2.0, H-2), 3.97 (1 H, ddd, J = 13.5, 11.3, 4.4, H-9), 2.53-2.32 (3 H, 
m, H-5, 13a), 2.30-2.11 (4 H, m, H-4, 8, 10a), 1.89-1.75 (2 H, m, H-11a, 13b), 1.67-1.56 
(1 H, m, H-10b), 1.37-1.15 (2 H, m, H-11b, 12a), 1.14-1.01 (1 H, m, H-12b); δC (100 
MHz, CDCl3) 193.3 (CO, C-7), 164.6 (C, C-1), 140.2 (CH, C-3), 123.0 (CH, C-2), 
107.6 (C, C-6), 81.3 (CH, C-9), 47.8 (CH, C-8), 31.8 (CH2, C-10), 24.8 (CH2), 24.1 
(CH2), 24.0 (CH2), 23.4 (CH2), 17.6 (CH2, C-5); m/z (ESI) 205 [MH]
+
; [HRMS (ESI): 
calcd. for C13H17O2, 205.1223. Found: [MH]
+
, 205.1222 (0.3 ppm error)]. 




Cyclohexenyl(2-methoxyphenyl)methanol 320:  To a stirred suspension of Mg 
turnings (78 mg, 3.20 mmol, 1.0 equiv.) in THF (5 mL) at rt was added dropwise 2-
bromoanisole (333 µL, 3.20 mmol, 1.0 equiv.).  The resulting orange solution was held 
at rt for 1 h then transferred via cannula into a cooled (−78 ºC) solution of cyclohexene 
carboxaldehyde (353 mg, 3.20 mmol, 1.0 equiv.) in THF (5 mL).  The solution was held 
at −78 ºC for 30 min., then warmed to rt and held for 18 h.  The reaction was quenched 
with sat. aq. NH4Cl (5 mL), then the aqueous phase was extracted with Et2O (3 × 10 
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mL).  The combined organic extracts were washed with brine (10 mL), dried (MgSO4), 
then concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, PE/Et2O, 9:1) to give the title compound 320 (326 mg, 47%) as 
a colourless oil; Rf 0.40 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 3400 (br), 2926, 1489, 1241; 
δH (400 MHz, CDCl3) 7.27 (1 H, dd, J = 7.5, 1.8, H-9), 7.23 (1 H, dd, J = 7.7, 1.8, H-
11), 6.94 (1 H, ddd, J = 7.7, 7.5, 1.1, H-10), 6.89-6.86 (1 H, m, H-12), 5.78-5.75 (1 H, 
m, H-5), 5.31 (1 H, d, J = 5.1, H-7), 3.83 (3 H, s, H-14), 2.64 (1 H, d, J = 5.1, OH), 
2.09-2.03 (2 H, m, H-4), 1.95-1.89 (2 H, m, H-1), 1.65-1.52 (4 H, m, H-2, 3); δC (100 
MHz, CDCl3) 157.1 (C, C-13), 138.6 (C, C-6), 130.8 (C, C-8), 128.4 (CH, ArCH), 
127.8 (CH, ArCH), 122.5 (CH, C-1), 120.6 (CH, C-12), 110.7 (CH, C-12), 73.4 (CH, C-
7), 55.5 (CH3, C-14), 25.2 (CH2, C-1), 25.0 (CH2, C-4), 22.6 (CH2), 22.5 (CH2); m/z 
(ESI) 241 [MNa]
+
; [HRMS (ESI): calcd. for C14H18NaO2, 241.1199. Found: [MNa]
+
, 
241.1203 (1.5 ppm error)]. 
Lab Book Ref = JDC/11/1 
 
 
Cyclohexenyl(2-methoxyphenyl)methanone 321:  To a stirred solution of alcohol 320 
(298 mg, 1.37 mmol, 1.0 equiv.) in DCM (15 mL) at 0 ºC was added in one portion 
DMP (721 mg, 1.70 mmol, 1.2 equiv.). The solution was stirred at 0 ºC for 30 min. 
before warming to rt and holding for 2 h.  The reaction was diluted with Et2O (20 mL), 
then quenched with sat. aq. NaHCO3/sat. aq. thiosulfate (1:1, 20 mL).  The biphasic 
solution was stirred for 30 min., then the aqueous phase was extracted with Et2O (2 × 20 
mL).  The combined organic extracts were washed with brine (20 mL), dried (Na2SO4), 
then concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, PE/Et2O, 9:1) to give the title compound 321 (102 mg, 34%) as 
a colourless oil; Rf 0.44 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2934, 1653, 1388, 1435, 1243; 
δH (400 MHz, CDCl3) 7.38-7.32 (1 H, m, H-11), 7.15 (1 H, dd, J = 7.4, 1.8, H-9), 6.97-
6.91 (2 H, m, H-10, 12), 6.65-6.51 (1 H, m, H-5), 3.78 (3 H, s, H-14), 2.23-2.17 (2 H, m, 
H-1), 1.74-1.60 (2 H, m, H-4), 2.42-2.37 (4 H, m, H-2, 3); δC (100 MHz, CDCl3) 197.8 
(CO, C-7), 156.7 (C, C-13), 145.7 (CH, C-5), 140.0 (C, C-6), 130.5 (CH, C-11), 129.6 
(C, C-8), 128.6 (CH, C-9), 120.0 (CH, C-10), 111.3 (CH, C-12), 55.7 (CH3, C-14), 26.3 
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(CH2, C-4), 22.9 (CH2, C-1), 21.9 (CH2), 21.6 (CH2); m/z (ESI) 217 [MH]
+
; [HRMS 
(ESI): calcd. for C14H17O2, 217.1223. Found: [MH]
+
, 217.1214 (4.3 ppm error)]. 


















Cyclohexenyl(2-hydroxyphenyl)methanone 322:  To a stirred solution of ketone 321 
(76 mg, 0.35 mmol, 1.0 equiv.) in DCM (2 mL) at 0 ºC was added dropwise BCl3 (1.0 
M in DCM, 0.70 mL, 2.0 equiv.).  The solution was stirred at 0 ºC for 30 min. before 
warming to rt and holding for 4 h.  The reaction was quenched by pouring onto ice, then 
the aqueous phase was extracted with DCM (3 × 10 mL).  The combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), then concentrated in vacuo to 
afford a yellow oil which was purified by column chromatography (SiO2, PE/EtOAc, 
9:1) to give the title compound 322 (50 mg, 71%) as a colourless oil; Rf 0.89 
(DCM/MeOH, 95:5); υmax/cm
-1
 (neat) 2934, 1692, 1621, 1597, 1239; δH (400 MHz, 
CDCl3) 7.67 (1 H, dd, J = 8.0, 1.7, H-9), 7.44 (1 H, ddd, J = 8.4, 7.3, 1.7, H-11), 6.99 (1 
H, dd, J = 8.4, 1.2, H-12), 6.85 (1 H, ddd, J = 8.0, 7.3, 1.2, H-10), 6.38-6.35 (1 H, m, H-
5), 2.43-2.37 (2 H, m, H-1), 2.31-2.25 (2 H, m, H-4), 1.80-1.67 (4 H, m, H-2, 3); δC 
(100 MHz, CDCl3) 202.8 (CO, C-7), 162.6 (C, C-13), 139.5 (CH, C-5), 137.4 (C, C-6), 
135.6 (CH, C-11), 132.5 (CH, C-9), 119.0 (C, C-8), 118.2 (CH, ArCH), 118.1 (CH, 
ArCH), 25.5 (CH2, C-4), 24.6 (CH2, C-1), 21.9 (CH2), 21.5 (CH2); m/z (ESI) 241 
[MNa]
+
; [HRMS (ESI): calcd. for C13H14NaO2, 225.0886. Found: [MNa]
+
, 225.0885 
(0.5 ppm error)]. 




(4aS*,9aS*)-1,2,3,4,4a,9a-Hexahydro-9H-xanthen-9-one 323:  To a stirred solution 
of phenol 322 (27 mg, 0.13 mmol, 1.0 equiv.) in MeCN (2 mL) at rt was added 10% aq. 
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NaOH (0.1 mL).  The resulting yellow solution was held at rt for 1 h, then diluted with 
H2O (5 mL) before extracting with Et2O (3 × 10 mL).  The combined organic extracts 
were washed with brine (10 mL), dried (MgSO4), then concentrated in vacuo to afford a 
yellow oil which was purified by column chromatography (SiO2, PE/EtOAc, 49:1) to 
give the title compound 323 (15 mg, 56%) as a colourless oil containing traces of the 
cis-diastereoisomer; Rf 0.37 (PE/EtOAc, 9:1); υmax/cm
-1
 (neat) 2937, 2862, 1686, 1605, 
1322, 766; δH (400 MHz, CDCl3) 7.87 (1 H, dd, J = 7.9, 1.8, H-9), 7.45 (1 H, ddd, J = 
8.5, 7.2, 1.8, H-11), 7.00 (1 H, ddd, J = 7.9, 7.2, 1.0, H-10), 6.95 (1 H, ddd, J = 8.5, 1.0, 
0.5, H-12), 4.09 (1 H, ddd, J = 12.5, 11.0, 4.5, H-5), 2.48 (1 H, ddd, J = 12.2, 11.0, 4.0, 
H-6), 2.46-2.37 (1 H, m, H-1a), 2.30-2.23 (1 H, m, H-4a), 1.93-1.82 (2 H, m, H-2a, 3a), 
1.72 (1 H, dddd, J = 12.5, 12.5, 11.2, 5.4, H-4b), 1.40-1.17 (3 H, m, H-1b, 2b, 3b); δC 
(100 MHz, CDCl3) 194.2 (CO, C-7), 161.4 (C, C-13), 135.6 (CH, C-11), 127.1 (CH, C-
9), 121.1 (CH, C-10), 120.9 (C, C-8), 117.6 (CH, C-12), 80.5 (CH, C-5), 49.6 (CH, C-6), 
32.4 (CH2, C-4), 24.7 (CH2), 23.8 (CH2), 23.6 (CH2); m/z (ESI) 203 [MH]
+
; [HRMS 
(ESI): calcd. for C13H15O2, 203.1067. Found: [MH]
+
, 203.1061 (2.8 ppm error)]. 




(S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid 339:  To a stirred solution 
of (S)-proline (10.0 g, 86.7 mmol, 1.0 equiv.) and triethylamine (12.7 mL, 91.0 mmol, 
1.05 equiv.) in DCM (200 mL) at 0 ºC was added dropwise ditert-butyl dicarbonate 
(20.8 g, 95.4 mmol, 1.1 equiv.) as a solution in DCM (20 mL).  The colourless solution 
was held at 0 ºC for 3 h, then quenched with sat. aq. citric acid (100 mL).  The aqueous 
phase was separated and extracted with DCM (2 × 100 mL), then the combined organic 
extracts were washed with brine (100 mL), dried (Na2SO4), then concentrated in vacuo 
to afford a colourless oil.  The oil was taken up in hot EtOAc (10 mL) and the product 
precipitated by slow addition of hexane (500mL).  The resulting suspension was filtered 
and dried to afford the title compound 339 (17.7 g, 95%) as a colourless crystalline solid; 
mp. 134-136 ºC [(Lit.
184
 135-137 ºC)]; Rf 0.37 (DCM/MeOH, 9:1); [α]
20
D −102.5 (c 
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1.05, CHCl3), (Lit.
184
 −80.0 (c 1.375, CHCl3)); δH (400 MHz, CDCl3, Rotamers 
observed) 4.39-4.21 (2 H, m, H-5, 5’), 3.61-3.29 (4 H, m, H-3, 3’), 2.45-2.22 (2 H, m, 
H-1), 2.12-1.84 (6 H, m, H-1’, 2, 2’), 1.49 (9 H, s, H-9), 1.43 (9 H, s, H-9’). 
Lab Book Ref. = JDC/13/53 
Melting Point and 
1






tert-Butyl (S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 340:  To a stirred 
solution of acid 339 (17.50 g, 81.3 mmol, 1.0 equiv.) in THF (200 mL) at 0 ºC as added 
dropwise BH3·DMS (8.48 mL, 89.4 mmol, 1.1 equiv.) over 1 h via syringe pump.  The 
colourless solution was held at 0 ºC for 30 min., then heated to reflux and held for 3 h.  
The reaction was cooled to 0 ºC and carefully quenched with H2O (100 mL).  The 
aqueous phase was extracted with EtOAc (2 × 100 mL), then the combined organic 
extracts were washed with brine (100 mL), dried (MgSO4), then concentrated in vacuo 
to afford the title compound 340 (16.3 g, Quant.) as a colourless crystalline solid; mp. 
56-59 ºC (Lit.
185
 58-59 ºC); Rf 0.37 (DCM/MeOH, 9:1); [α]
24
D −48.4 (c 1.01, CHCl3), 
(Lit.
185
 −47.0 (c 1.0, CHCl3)); δH (400 MHz, CDCl3) 3.95 (1 H, dddd, J = 7.9, 7.7, 5.6, 
3.3, H-5), 3.64 (1 H, dd, J = 11.1, 3.3, H-6a), 3.58 (1 H, dd, J = 11.1, 7.7, H-6b), 3.46 (1 
H, ddd, J = 10.9, 7.1, 6.6, H-3a), 3.31 (1 H, ddd, J = 10.9, 7.1, 6.5, H-3b), 2.06-1.96 (1 H, 
m, H-1a), 1.90-1.71 (2 H, m, H-2), 1.63-1.54 (1 H m, H-1b), 1.47 (9 H, s, H-9).  
Lab Book Ref. = JDC/13/60 
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tert-Butyl (S)-2-formylpyrrolidine-1-carboxylate 341:  To a stirred solution of oxalyl 
chloride (7.76 mL, 91.7 mmol, 1.2 equiv.) in DCM (450 mL) at −78 ºC was added 
dropwise DMSO (13.0 mL, 183.4 mmol, 2.4 equiv.) over 45 min. via syringe pump.  
The colourless solution was held at −78 ºC for 30 min., then alcohol 340 (15.38 g, 76.4 
mmol, 1.0 equiv.) was added as a pre-cooled solution in DCM (50 mL) via cannula.  
The reaction was held at −78 ºC for 1 h, then triethylamine (53.3 mL, 382.0 mmol, 5.0 
equiv.) was added dropwise.  The reaction was held at −78 ºC for a further 15 min., then 
warmed to rt and held for 1 h.  The reaction was quenched with H2O (50 mL), then the 
aqueous phase was extracted with DCM (2 × 150 mL).  The combined organic extracts 
were washed with H2O (150 mL) and brine (150 mL), dried (Na2SO4), then 
concentrated in vacuo to afford the title compound 341 (14.5 g, 96%) as a colourless oil 
that was used without further purification; Rf 0.19 (PE/EtOAc, 4:1); δH (400 MHz, 
CDCl3, Rotamers observed) 9.55 (1 H, d, J = 1.8, H-6), 9.46 (1 H, d, J = 3.0, H-6’), 
4.25-4.16 (1 H, m, H-5), 4.04 (1 H, ddd, J = 8.9, 6.2, 3.0, H-5’), 3.60-3.35 (4 H, m, H-3, 
3’), 2.18-1.77 (8 H, m, H-1, 1’, 2, 2’), 1.47 (9 H, s, H-9), 1.42 (9 H, s, H-9’). 
Lab Book Ref. = JDC/13/71  






tert-Butyl (S)-2-(2,2-dibromovinyl)pyrrolidine-1-carboxylate 342:  To a stirred 
solution of triphenylphosphine (57.4 g, 219.0 mmol, 3.0 equiv.), in DCM (450 mL) at 0 
ºC was added dropwise carbon tetrabromide (36.3 g, 109.5 mmol, 1.5 equiv.) as a 
solution in DCM (15 mL) via syringe pump over 45 min.  The resulting orange solution 
was held at 0 ºC for 30 min., then aldehyde 341 (14.5 g, 73.0 mmol, 1.0 equiv.) was 
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added dropwise as a solution in DCM (40 mL) over 45 min.  The solution was held at 0 
ºC for 3 h, then quenched with sat. aq. NaHCO3 (300 mL).  The aqueous phase was 
extracted with DCM (2 × 150 mL), then the combined organic extracts were washed 
with brine (150 mL), dried (Na2SO4), then concentrated in vacuo to afford a yellow 
solid, which was purified by column chromatography (SiO2, PE/EtOAc, 9:1) to give the 
title compound 342 (18.8 g, 73%) as a colourless crystalline solid; mp. 61-63 ºC (Lit.
187
 
61-62 ºC); Rf 0.38 (PE/EtOAc, 4:1); [α]D +26.4 (c 1.01, CHCl3), (Lit.
188
 +30.6 (c 1.04, 
CHCl3); δH (400 MHz, CDCl3) 6.47-6.30 (1 H, m, H-6), 4.50-4.28 (1 H, m, H-5), 3.51-
3.34 (2 H, m, H-3), 2.23-2.11 (1 H, m, H-1a), 1.90-1.79 (2 H, m, H-2), 1.78-1.68 (1 H, 
m, H-1b), 1.46 (9 H, s, H-9). 
Lab Book Ref. = JDC/13/76 
















tert-Butyl (S)-2-ethynylpyrrolidine-1-carboxylate 336:  To a stirred solution of 
bromide 342 (5.32 g, 15.0 mmol, 1.0 equiv.) in DMSO (180 mL) at rt was added 
Cs2CO3 (12.2 g, 37.5 mmol, 2.5 equiv.).  The suspension was heated to 115 ºC and held 
for 18 h, then cooled to rt and poured into H2O (500 mL).  The aqueous phase was 
extracted with EtOAc (3 × 150 mL), then the combined organic extracts were washed 
with H2O (150 mL) and brine (150 mL), dried (MgSO4), then concentrated in vacuo to 
afford a brown oil which was purified by column chromatography (SiO2, PE/EtOAc, 
9:1) to give the title compound 336 (2.16 g, 74%) as a colourless oil; Rf 0.38 (PE/EtOAc, 
4:1); [α]
24
D –102.1 (c 1.03, MeOH), (Lit.
187
 –99.0 (c 1.0, MeOH)); δH (400 MHz, CDCl3, 
Rotamers observed) 4.58-4.36 (1 H, m, H-5), 3.54-3.22 (2 H, m, H-3), 2.26-2.17 (1 H, 
m, H-1a), 2.14-1.98 (3 H, m, H-2, 6), 1.96-183 (1 H, m, H-1b), 1.48 (9 H, s, H-10). 
Lab Book Ref. = JDC/13/84 
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(S)-2-Ethynylpyrrolidine 2,2,2-trifluoroacetate 343:  To a stirred solution of alkyne 
336 (2.00 g, 10.2 mmol, 1.0 equiv.) in DCM (50 mL) at 0 ºC was added dropwise TFA 
(5 mL).  The resulting orange solution was held at 0 ºC for 30 min., then warmed to rt 
and held until consumption of the starting material was observed by TLC (~4 h).  The 
orange solution was concentrated in vacuo to afford the crude product as an orange oil 
which was purified by column chromatography (SiO2, DCM/MeOH, 9:1) to give the 
title compound 343 (2.13 g, Quant) as a colourless oil; Rf 0.18 (DCM/MeOH, 9:1); 
[α]
24
D –33.6 (c 0.88, CHCl3); υmax/cm
-1
 (neat) 3307, 3250, 2968, 1674, 1201, 1134; δH 
(400 MHz, CDCl3) 4.33 (1 H, ddd, J = 6.8, 6.5, 2.3, H-5), 3.45 (1 H, ddd, J = 11.5, 8.2, 
6.9, H-3a), 3.34 (1 H, ddd, J = 11.5, 8.2, 5.8, H-3b), 2.58 (1 H, d, J = 2.3, H-7), 2.39-
2.29 (1 H, m, H-1a), 2.26-2.03 (3 H, m, H-1b, 2); δC (100 MHz, CDCl3) 77.2 (CH, C-7), 
76.4 (C, C-6), 49.0 (CH, C-5), 44.5 (CH2, C-3), 32.2 (CH2, C-1), 23.5 (CH2, C-2); m/z 
(ESI) 96 [MH]
+
; [HRMS (ESI): calcd. for C6H10N, 96.0813. Found: [MH]
+
, 96.0811 
(2.8 ppm error)]. 




(S)-1-(2-(1,3-Dioxolan-2-yl)ethyl)-2-ethynylpyrrolidine 345:  To a stirred solution of 
amine 343 (1.07 g, 5.10 mmol, 1.0 equiv.) in MeCN (25 mL) at rt were added 
successively K2CO3 (2.11 g, 15.3 mmol, 3.0 equiv.) and 2-(2-bromoethyl)-1,3-
dioxolane (0.90 mL, 7.70 mmol, 1.5 equiv.).  The suspension was heated to 50 ºC and 
held for 24 h, then cooled to rt and the solvent removed under reduced pressure.  The 
residue was taken up in EtOAc (20 mL) and the organic phase was washed with H2O 
(10 mL) and brine (10 mL), dried (MgSO4), then concentrated in vacuo to afford a 
brown oil which was purified by column chromatography (SiO2, DCM/MeOH, 98:2) to 
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give the title compound 345 (677 mg, 68%) as an orange oil; Rf 0.51 (DCM/MeOH, 
9:1); [α]
20
D –108.3 (c 0.99, CHCl3); υmax/cm
-1
 (neat) 2957, 2881, 2813, 1140, 1033; δH 
(400 MHz, CDCl3) 4.92 (1 H, t, J = 4.9, H-7), 3.98-3.92 (2 H, m, H-11a, 11a’), 3.86-3.81 
(2 H, m, H-11b, 11b’), 3.42-3.38 (1 H, m, H-9), 2.91 (1 H, ddd, J = 11.9, 9.0, 7.1, H-5a), 
2.75 (1 H, ddd, J = 8.8, 8.1, 5.4, H-3a), 2.55-2.46 (2 H, m, H-3b, 5b), 2.26 (1 H, d, J = 
2.1, H-10), 2.14-2.03 (1 H, m, H-1a), 1.96-1.71 (5 H, m, H-1b, 2, 6); δC (100 MHz, 
CDCl3) 103.3 (CH, C-7), 82.9 (C, C-8), 72.3 (CH, C-10), 64.8 (2 × CH2, C-11, 11’), 
54.1 (CH, C-9), 51.7 (CH2, C-3), 48.1 (CH2, C-5), 33.0 (CH2, C-6), 31.6 (CH2, C-1), 
22.0 (CH2, C-2); m/z (ESI) 196 [MH]
+
; [HRMS (ESI): calcd. for C11H18NO2, 196.1332. 
Found: [MH]
+
, 196.1334 (1.2 ppm error)]. 




(S)-1-(2-(1,3-Dioxolan-2-yl)ethyl)-2-(pent-1-ynyl)pyrrolidine 346: To a stirred 
solution of alkyne 345 (195 mg, 1.00 mmol, 1.0 equiv.) in THF (5 mL) at −78 ºC was 
added dropwise n-BuLi (1.6 M, 0.69 mL, 1.10 mmol, 1.1 equiv.).  The yellow solution 
was held at −78 ºC for 1 h, then warmed to rt before adding n-propyl iodide (117 µL, 
1.20 mmol, 1.2 equiv.).  The reaction was heated to reflux and held for 18 h, then 
cooled to rt and quenched with sat. aq. NH4Cl (5 mL).  The aqueous phase was 
extracted with EtOAc (3 × 10 mL), then the combined organic extracts were washed 
with brine (10 mL), dried (MgSO4), then concentrated in vacuo to afford the title 
compound 346 (214 mg, 90%) as a pale yellow oil; Rf 0.49 (DCM/MeOH, 9:1); [α]
24
D –
93.3 (c 1.00, CHCl3); υmax/cm
-1
 (neat) 2960, 2876, 1141, 1034; δH (400 MHz, CDCl3) 
4.94 (1 H, t, J = 4.9, H-7), 4.00-3.91 (2 H, m, H-11a, 11a’), 3.90-3.80 (2 H, m, H-11b, 
11b’), 3.34-3.27 (1 H, m, H-9), 2.96 (1 H, ddd, J = 11.6, 9.7, 6.6, H-5a), 2.81 (1 H, ddd, 
J = 8.8, 8.7, 4.8, H-3a), 2.49-2.37 (2 H, m, H-3b, 5b), 2.16 (2 H, td, J = 7.0, 1.9, H-12), 
2.12-2.01 (1 H, m, H-1a), 1.98-1.68 (5 H, m, H-1b, 2, 6), 1.57-1.45 (2 H, qt, J = 7.4, 7.0, 
H-13), 0.96 (3 H, t, J = 7.4, H-14); δC (100 MHz, CDCl3) 103.4 (CH, C-7), 84.5 (C, C-
10), 79.0 (C, C-8), 64.8 (2 × CH2, C-11, 11’), 54.9 (CH, C-9), 51.9 (CH2, C-3), 48.4 
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(CH2, C-5), 33.1 (CH2, C-6), 32.0 (CH2, C-1), 22.3 (CH2, C-13), 22.0 (CH2, C-2), 20.7 
(CH2, C-12), 13.5 (CH3, C-14); m/z (ESI) 238 [MH]
+
; [HRMS (ESI): calcd. for 
C14H24NO2, 238.1802. Found: [MH]
+
, 238.1803 (0.5 ppm error)]. 






 351a:  To a stirred suspension of 
sodium hydride (60 wt%, 600 mg, 15.0 mmol, 1.0 equiv.) in DMF (12 mL) at 0 ºC was 
added dropwise 3-phenyl-2-propyn-1-ol (1.87 mL, 15.0 mmol, 1.0 equiv.).  The 
resulting yellow slurry was held at 0 ºC for 1 h, then bromo acetaldehyde diethyl acetal 
(2.26 ml, 15.0 mmol, 1.0 equiv.) was added dropwise.  The solution was held at 0 ºC for 
30 min., then heated to 100 ºC and held for 18 h.  The brown solution was cooled to rt 
then quenched with H2O (50 mL).  The aqueous phase was extracted with Et2O (3 × 25 
mL), then the combined organic extracts were washed with brine (25 mL), dried 
(MgSO4), then concentrated in vacuo to afford an orange oil which was purified by 
column chromatography (SiO2, PE/Et2O, 19:1) to give the title compound 351a (1.21 g, 
32%) as a pale yellow oil; Rf 0.45 (PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.46-7.42 (2 
H, m, ArH), 7.34-7.29 (3 H, m, ArH), 4.71 (1 H, t, J = 5.2, H-5), 4.45 (2 H, s, H-3), 
3.73 (2 H, dq, J = 9.3, 7.1, H-6a, 6a’), 3.66 (2 H, d, J = 5.2, H-4), 3.60 (2 H, dq, J = 9.3, 
7.1, H-6b, 6b’), 1.24 (6 H, t, J = 7.1, H-7, 7’). 
Lab Book Ref. = JDC/12/93 















 355: To a stirred solution of acrolein (3.35 mL, 50.0 
mmol, 1.0 equiv.) and NaI (8.99 g, 60.0 mmol, 1.2 equiv.) in MeCN (125 mL) at 0 ºC 
was added dropwise TMSCl (7.62 mL, 60.0 mmol, 1.2 equiv.).  The resulting slurry was 
stirred at 0 ºC for 5 min., then EtOH (7.5 mL) was added.  The yellow slurry was held at 
0 ºC for a further 20 min., then quenched with sat. aq. NaHCO3 (200 mL). The aqueous 
phase was diluted with water (100 mL), then extracted with hexane (3 × 150 mL).  The 
combined organic extracts were washed with brine (150 mL), dried (MgSO4), then 
concentrated in vacuo to afford the title compound 355 (10.5 g, 81%) as a colourless oil; 
Rf 0.60 (PE/EtOAc, 9:1); δH (400 MHz, CDCl3) 4.58 (1 H, t, J = 5.5, H-3), 3.68 (2 H, dq, 
J = 9.4, 7.1, H-4a, 4a’), 3.53 (2 H, dq, J = 9.4, 7.1, H-4b, 4b’), 3.19 (2 H, t, J = 7.0, H-1), 
2.13 (2 H, td, J = 7.0, 5.5, H-2), 1.21 (6 H, t, J = 7.1, H-5, 5’). 
Lab Book Ref. = JDC/13/93 






(S)-1-(3,3-Diethoxypropyl)-2-ethynylpyrrolidine 356:  To a stirred solution of amine 
343 (2.13 g, 10.2 mmol, 1.0 equiv.) in MeCN (130 mL) at rt were added successively 
K2CO3 (4.23 g, 30.6 mmol, 3.0 equiv.) and 1,1-diethoxy-3-iodopropane 355 (2.76 g, 
10.7 mmol, 1.05 equiv.).  The suspension was heated to reflux and held for 18 h, then 
cooled to rt and the solvent removed under reduced pressure.  The residue was taken up 
in H2O (100 mL) and the aqueous phase extracted with DCM (3 × 50 mL).  The 
combined organic extracts were washed with brine (50 mL), dried (Na2SO4), then 
concentrated in vacuo to afford an orange oil which was purified by column 
chromatography (SiO2, DCM/MeOH, 99:1-98:2) to give the title compound 356 (1.81 g, 
79%) as a pale yellow oil; Rf 0.56 (DCM/MeOH, 9:1); [α]
24
D –101.0 (c 0.70, CHCl3); 
υmax/cm
-1
 (neat) 2973, 2879, 2877, 1126, 1062; δH (400 MHz, CDCl3) 4.60 (1 H, t, J = 
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5.8, H-7), 3.66 (1 H, dq, J = 9.3, 7.0, H-11a), 3.64 (1 H, dq, J = 9.3, 7.0, H-11a’), 3.52 (1 
H, dq, J = 9.3, 7.0, H-11b), 3.49 (1 H, dq, J = 9.3, 7.0, H-11b’), 3.38 (1 H, ddd, J = 7.9, 
4.5, 2.1, H-9), 2.86 (1 H, ddd, J = 11.9, 8.7, 7.3, H-5a), 2.77 (1 H, ddd, J = 9.3, 7.7, 5.1, 
H-3a), 2.49 (1 H, ddd, J = 9.3, 8.0, 5.6, H-3b), 2.44-2.39 (1 H, m, H-5b), 2.25 (1 H, d, J = 
2.1, H-10), 2.15-2.03 (1 H, m, H-1a), 1.97-1.71 (5 H, m, H-1b, 2, 6), 1.20 (6 H, t, J = 7.0, 
H-12, 12’); δC (100 MHz, CDCl3) 101.5 (CH, C-7), 83.1 (C, C-8), 72.1 (CH, C-10), 
61.1 (CH2, C-11), 60.9 (CH2, C-11’), 54.2 (CH, C-9), 51.8 (CH2, C-3), 48.7 (CH2, C-5), 
32.7 (CH2, C-6), 31.7 (CH2, C-1), 22.0 (CH2, C-2), 15.3 (2 × CH3, C-12, 12’); m/z (ESI) 
226 [MH]
+
; [HRMS (ESI): calcd. for C13H24NO2, 226.1802. Found: [MH]
+
, 226.1805 
(1.7 ppm error)]. 




(S)-1-(3,3-Diethoxypropyl)-2-(phenylethynyl)pyrrolidine 354:  To a stirred solution 
of alkyne 356 (140 mg, 0.62 mmol, 1.0 equiv.), CuI (11 mg, 0.06 mmol, 0.1 equiv.) and 
Pd(PPh3)2Cl (21 mg, 0.03 mmol, 0.05 equiv.) in Et3N (2 mL, degassed) at rt was added 
iodobenzene (139 µL, 1.24 mmol, 2.0 equiv.).  The dark brown solution was held at rt 
for 18 h, then concentrated in vacuo to afford a dark brown residue which was purified 
by column chromatography (SiO2, DCM/MeOH, 98:2) to give the title compound 354 
(185 mg, 98%) as a yellow oil; Rf 0.66 (DCM/MeOH, 9:1); [α]
24
D –95.0 (c 1.05, CHCl3); 
υmax/cm
-1
 (neat) 2973, 2895, 1444, 1126, 1061; δH (400 MHz, CDCl3) 7.54-7.41 (2 H, m, 
ArH), 7.36-7.27 (3 H, m, ArH), 4.63 (1 H, t, J = 5.2, H-7), 4.22 (1 H, br s, H-9), 3.65 (2 
H, dq, J = 9.4, 7.1, H-11a, 11a’), 3.52 (1 H, dq, J = 9.4, 7.1, H-11b), 3.51 (1 H, dq, J = 
9.4, 7.1, H-11b’), 3.27-3.08 (2 H, m, H-3a, 5a), 3.06-2.90 (2 H, m, H-3b, 5b), 2.51-2.36 (1 
H, m, 1a), 2.24-2.00 (5 H, m, H-1b, 2, 6), 1.17 (6 H, t, J = 7.1, H-12, 12’); δC (100 MHz, 
CDCl3) 131.8 (2 × CH, ArCH), 128.8 (CH, ArCH), 128.3 (2 × CH, ArCH), 121.9 (C, 
ArC), 100.9 (CH, C-7), 87.5 (C), 84.2 (C), 61.9 (CH2, C-11), 61.8 (CH2, C-11’), 55.9 
(CH, C-9), 52.1 (CH2, C-3), 48.6 (CH2, C-5), 31.6 (CH2), 31.3 (CH2), 21.8 (CH2, C-2), 
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15.2 (2 × CH3, C-12, 12’); m/z (ESI) 302 [MH]
+
; [HRMS (ESI): calcd. for C19H28NO2, 
302.2115. Found: [MH]
+
, 302.2116 (0.3 ppm error)]. 
Lab Book Ref. = JDC/14/80 
 




(2,5-Dihydrofuran-3-yl)(phenyl)methanone 352a: A stirred solution of alkyne 351a 
(62 mg, 0.25 mmol, 1.0 equiv.) in formic acid (1 mL) was heated at 100 ºC (oil-bath 
pre-heated) for 30 min. The brown solution was cooled to rt then concentrated in vacuo 
to afford an orange oil which was purified by column chromatography (SiO2, PE/EtOAc, 
9:1) to give the title compound 352a (43 mg, 98%) as a colourless crystalline solid; mp. 
67-69 ºC (Lit.
153
 48-50 ºC); Rf 0.23 (SiO2, PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.82-
7.78 (2 H, m, ArH), 7.61-7.56 (1 H, m, ArH), 7.50-7.45 (2 H, m, ArH), 6.64-6.61 (1 H, 
m, H-5), 5.04-4.99 (2 H, m, H-3a, 4a), 4.95-4.91 (2 H, m, H-3b, 4b). 
Lab Book Ref. = JDC/13/85 
1






(4-Hydroxydihydrofuran-3(2H)-ylidene)(phenyl)methyl formate 367: A stirred 
solution of alkyne 351a (248 mg, 1.00 mmol, 1.0 equiv.) in formic acid (5 mL) was held 
at rt for 30 min., then concentrated in vacuo to afford an orange oil which was purified 
by column chromatography (SiO2, PE/EtOAc, 9:1-2:1) to give formate 368 (15 mg, 6%) 
as an unstable colourless oil and the title compound 367 (45 mg, 20%) as an unstable 
yellow oil; Rf 0.07 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 3396 (br), 1737, 1125, 1069; δH 
(400 MHz, CDCl3) 8.14 (1 H, s, H-6), 7.70-7.65 (2 H, m, ArH), 7.45-7.37 (3 H, m, 
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ArH), 4.69 (1 H, d, J = 3.5, H-5), 4.63 (1 H, d, J = 14.5, H-3a), 4.40 (1 H, d, J = 14.5, H-
3b), 4.07 (1 H, d, J = 10.1, H-4a), 3.80 (1 H, dd, J = 10.1, 3.5, H-4b); δC (100 MHz, 
CDCl3) 158.4 (CH, C-6), 142.4 (C, C-1), 133.3 (C, ArC), 131.0 (C, C-2), 129.4 (CH, 
ArCH), 128.6 (2 × CH, ArCH), 127.0 (2 × CH, ArCH), 77.1 (CH2, C-4), 71.4 (CH, C-5), 
68.7 (CH2, C-3); m/z (ESI) 243 [MNa]
+
; [HRMS (ESI): calcd. for C12H12NaO4, 
243.0628. Found: [MNa]
+




(4-Ethoxydihydrofuran-3(2H)-ylidene)(phenyl)methyl formate 368: A colourless oil; 
Rf 0.24 (PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 8.14 (1 H, s, H-8), 7.62-7.58 (2 H, m, 
ArH), 7.43-7.36 (3 H, m, ArH), 4.63 (1 H, d, J = 14.3, H-3a), 4.42 (1 H, d, J = 14.3, H-
3b), 4.41 (1 H, d, J = 3.6, H-5), 4.20 (1 H, d, J = 10.2, H-4a), 3.75 (1 H, dd, J = 10.2, 3.6, 
H-4b), 3.53 (1 H, dq, J = 9.0, 7.0, H-6a), 3.45 (1 H, dq, J = 9.0, 7.0, H-6b), 1.22 (3 H, t, J 
= 7.0, H-7); δC (100 MHz, CDCl3) 158.3 (CH, C-8), 142.8 (C, C-1), 134.0 (C, ArC), 
129.7 (C, C-2), 128.7 (CH, ArCH), 128.4 (2 × CH, ArCH), 127.3 (2 × CH, ArCH), 78.0 
(CH, C-5), 73.5 (CH2, C-4), 68.9 (CH2, C-3), 63.6 (CH2, C-6), 15.4 (CH3, C-7); m/z 
(ESI) 271 [MNa]
+
; [HRMS (ESI): calcd. for C14H16NaO4, 271.0941. Found: [MNa]
+
, 
271.0929 (4.2 ppm error)]. 




1-(2,2-Diethoxyethoxy)pent-2-yne 351b:  To a stirred suspension of sodium hydride 
(60 wt%, 220 mg, 5.50 mmol, 1.1 equiv.) in DMF (5 mL) at 0 ºC was added dropwise 
2-pentyn-1-ol (0.51 mL, 5.50 mmol, 1.1 equiv.).  The resulting yellow slurry was held 
at 0 ºC for 30 min., then bromo acetaldehyde diethyl acetal (0.76 ml, 5.00 mmol, 1.0 
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equiv.) was added dropwise.  The solution was held at 0 ºC for 30 min., then heated to 
reflux and held for 18 h.  The brown solution was cooled to rt then quenched with H2O 
(25 mL).  The aqueous phase was extracted with Et2O (3 × 10 mL), then the combined 
organic extracts were washed with brine (10 mL), dried (MgSO4), then concentrated in 
vacuo to afford an orange oil which was purified by column chromatography (SiO2, 
PE/Et2O, 9:1) to give the title compound 351b (495 mg, 49%) as a pale yellow oil; Rf 
0.67 (PE/EtOAc, 2:1); υmax/cm
-1
 (neat) 2977, 2935, 1135, 1102; δH (400 MHz, CDCl3) 
4.66 (1 H, t, J = 5.3, H-5), 4.19 (2 H, t, J = 2.2, H-3), 3.71 (2 H, dq, J = 9.4, 7.1, H-6a. 
6a’), 3.58 (2 H, dq, J = 9.4, 7.1, H-6b, 6b’), 3.56 (2 H, d, J = 5.3, H-4), 2.22 (2 H, qt, J = 
7.5, 2.2, H-8), 1.23 (6 H, t, J = 7.1, H-7, 7’), 1.13 (3 H, t, J = 7.5, H-9); δC (100 MHz, 
CDCl3) 100.8 (CH, C-5), 88.5 (C, C-1), 74.9 (C, C-2), 69.7 (CH2, C-4), 62.1 (2 × CH2, 
C-6, 6’), 59.0 (CH2, C-3), 15.2 (2 × CH3, C-7, 7’), 13.7 (CH3, C-9), 12.3 (CH2, C-8); 
m/z (ESI) 223 [MNa]
+
; [HRMS (ESI): calcd. for C11H20NaO3, 223.1305. Found: 
[MNa]
+
, 223.1305 (0.3 ppm error)]. 




(3-(2,2-Diethoxyethoxy)but-1-ynyl)benzene 351c:  To a stirred suspension of sodium 
hydride (60 wt%, 136 mg, 3.40 mmol, 1.0 equiv.) in DMF (4 mL) at 0 ºC was added 
dropwise 4-phenyl-3-butyn-2-ol (500 mg, 3.40 mmol, 1.0 equiv.).  The resulting orange 
solution was held at 0 ºC for 1 h, then bromo acetaldehyde diethyl acetal (2.26 ml, 15.0 
mmol, 1.0 equiv.) and TBAI (126 mg, 0.34 mmol, 0.1 equiv.) were added.  The solution 
was held at 0 ºC for 30 min., then heated to 100 ºC and held for 18 h.  The brown 
solution was cooled to rt then quenched with H2O (50 mL).  The aqueous phase was 
extracted with Et2O (3 × 20 mL), then the combined organic extracts were washed with 
brine (20 mL), dried (MgSO4), then concentrated in vacuo to afford an orange oil which 
was purified by column chromatography (SiO2, PE/Et2O, 19:1-9:1) to give the title 
compound 351c (152 mg, 17%) as a pale yellow oil; Rf 0.53 (PE/EtOAc, 4:1); υmax/cm
-1
 
(neat) 2977, 2876, 1328, 1110; δH (400 MHz, CDCl3) 7.46-7.39 (2 H, m, ArH), 7.33-
7.28 (3 H, m, ArH), 4.70 (1 H, dd, J = 5.7, 4.9, H-5), 4.49 (1 H, q, J = 6.6, H-3), 3.83 (1 
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H, dd, J = 10.4, 4.9, H-4a), 3.74 (1 H, dq, J = 10.7, 7.1, H-6a), 3.73 (1 H, dq, J = 10.7, 
7.1, H-6a’), 3.64-3.55 (2 H, m, H-6b, 6b’), 3.56 (1 H, dd, J = 10.4, 5.7, H-4b), 1.53 (3 H, 
d, J = 6.6, H-8), 1.23 (3 H, t, J = 7.1, H-7), 1.22 (3 H, t, J = 7.1, H-7’); δC (100 MHz, 
CDCl3) 131.7 (2 × ArCH), 128.3 (ArCH), 128.2 (2 × ArCH), 122.7 (ArC), 101.0 (CH, 
C-5), 88.8 (C, C-2), 85.0 (C, C-1), 68.9 (CH2, C-4), 66.2 (CH, C-3), 62.4 (CH2, C-6), 
61.8 (CH2, C-6’), 22.0 (CH3, C-8), 15.3 (2 × CH3, C-7, 7’); m/z (ESI) 285 [MNa]
+
; 
[HRMS (ESI): calcd. for C16H22NaO3, 285.1461. Found: [MNa]
+
, 285.1463 (0.5 ppm 
error)]. 




((1-(2,2-Diethoxyethoxy)cyclohexyl)ethynyl)benzene 351d:  To a stirred suspension 
of sodium hydride (60 wt%, 100 mg, 2.50 mmol, 1.0 equiv.) in DMF (2 mL) at 0 ºC was 
added dropwise 1-(phenylethynyl)cyclohexanol (0.50 g, 2.50 mmol, 1.0 equiv.) as a 
solution in DMF (1 mL).  The resulting yellow slurry was held at 0 ºC for 1 h, then 
bromo acetaldehyde diethyl acetal (0.37 ml, 2.50 mmol, 1.0 equiv.) was added dropwise.  
The solution was held at 0 ºC for 30 min., then heated to 100 ºC and held for 18 h.  The 
brown solution was cooled to rt then quenched with H2O (50 mL).  The aqueous phase 
was extracted with Et2O (3 × 25 mL), then the combined organic extracts were washed 
with brine (25 mL), dried (MgSO4), then concentrated in vacuo to afford an orange oil 
which was purified by column chromatography (SiO2, PE/Et2O, 19:1) to give the title 
compound 351d (303 mg, 38%) as a pale yellow oil; Rf 0.53 (PE/EtOAc, 4:1); υmax/cm
-1
 
(neat) 2934, 1135, 1092, 756; δH (400 MHz, CDCl3) 7.45-7.39 (2 H, m, ArH), 7.33-7.27 
(3 H, m, ArH), 4.68 (1 H, t, J = 5.3, H-5), 3.74 (2 H, dq, J = 9.4, 7.1, H-6a, 6a’), 3.71 (2 
H, d, J = 5.3, H-4), 3.60 (2 H, dq, J = 9.4, 7.1, H-6b, 6b’), 2.02-1.93 (2 H, m, CyH), 
1.76-1.64 (4 H, m, CyH), 1.64-1.47 (3 H, m, CyH), 1.41-1.26 (1 H, m, CyH), 1.22 (6 H, 
t, J = 7.1, H-7, 7’); δC (100 MHz, CDCl3) 131.6 (2 × CH, ArCH), 128.2 (2 × CH, 
ArCH), 128.1 (CH, ArCH), 123.0 (C, ArC), 101.4 (CH, C-5), 90.5 (C, C-2), 86.0 (C, C-
1), 74.2 (C, C-3), 64.2 (CH2, C-4), 61.9 (2 × CH2, C-6, 6’), 37.1 (2 × CH2, CyCH), 25.4 
  250 
(CH2, CyCH), 22.8 (2 × CH2, CyCH), 15.3 (2 × CH3, C-7, 7’); m/z (ESI) 339 [MNa]
+
; 
[HRMS (ESI): calcd. for C20H28NaO3, 339.1931. Found: [MNa]
+
, 339.1928 (0.8 ppm 
error)]. 
Lab Book Ref. = JDC/13/96 
 
Synthesis of -(2,2-Diethoxyethyl)-4-methyl--(3-phenylprop-2-






:  To a stirred solution of 2,2-
diethoxyethanamine (3.64 mL, 25.0 mmol, 1.0 equiv.) and Et3N (6.97 mL, 50.0 mmol, 
2.0 equiv.) in DCM (50 mL) at 0 ºC was added dropwise p-toluenesulfonyl chloride 
(5.24 g, 27.5 mmol, 1.1 equiv.) as a solution in DCM (50 mL). The reaction was held at 
0 ºC for 2 h, then diluted with H2O (100 mL). The aqueous phase was extracted with 
DCM (50 mL), then the combined organic extracts were washed with 1 M aq. HCl (25 
mL), sat. aq. NaHCO3 (50 mL) and brine (50 mL), dried (Na2SO4), then concentrated in 
vacuo to afford the title compound (7.20 g, Quant.) as a colourless crystalline solid; Rf 
0.38 (PE/EtOAc, 2:1); mp. 65-67 ºC (Lit. 67-68 ºC) δH (400 MHz, CDCl3) 7.74 (2 H, d, 
J = 8.3, H-6), 7.31 (2 H, d, J = 8.3, H-7), 4.59 (1 H, t, J = 6.2, NH), 4.47 (1 H, t, J = 5.7, 
H-2), 3.64 (2 H, dq, J = 9.4, 7.1, H-3a, 3a’), 3.47 (2 H, dq, J = 9.4, 7.1, H-3b, 3b’), 3.02 
(2 H, dd, J = 6.2, 5.7, H-1), 2.43 (3 H, s, H-9), 1.17 (6 H, t, J = 7.1, H-4, 4’).  
Lab Book Ref. = JDC/13/24 
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-(2,2-Diethoxyethyl)-4-methyl--(3-phenylprop-2-ynyl)benzenesulfonamide 351e:  
To a stirred suspension of -(2,2-Diethoxyethyl)-4-methylbenzenesulfonamide (431 mg, 
1.50 mmol, 1.0 equiv.) and K2CO3 (442 mg, 3.20 mmol, 2.1 equiv.) in DMF (5 mL) at 
rt was added 3-phenyl-2-propynyl methanesulfonate (315 mg, 1.50 mmol, 1.0 equiv.).  
The viscous slurry was heated to 80 ºC and held for 24 h, then cooled to rt and diluted 
with water (50 mL).  The aqueous phase was extracted with Et2O (3 × 20 mL), then the 
combined organic extracts were washed with brine (20 mL), dried (MgSO4), then 
concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, PE/EtOAc, 9:1) to give the title compound 351e (500 mg, 83%) 
as a pale yellow oil; Rf 0.18 (PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.79 (2 H, d, J = 
8.3, H-9), 7.27-7.21 (5 H, m ArH), 7.03 (2 H, d, J = 8.3, H-10), 4.74 (1 H, t, J = 5.6, H-
5), 4.49 (2 H, s, H-3), 3.79 (2 H, dq, J = 9.3, 7.1, H-6a, 6a’), 3.60 (2 H, dq, J = 9.3, 7.1, 
H-6b, 6b’), 3.32 (2 H, d, J = 5.6, H-4), 2.32 (3 H, s, H-12), 1.24 (6 H, t, J = 7.1, H-7, 7’). 
Lab Book Ref. = JDC/13/31 









tert-Butyl 3-phenylprop-2-ynyl(tosyl)carbamate:  To a stirred suspension of NaH 
(60wt%, 336 mg, 8.40 mmol, 1.4 equiv.) in DMF (9 mL) at 0 ºC was added tert butyl 
tosylcarbamate (1.95 g, 7.20 mmol, 1.2 equiv.) as a solution in DMF (4 mL).  The 
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suspension was held at 0 ºC for 30 min., then 3-phenyl-2-propynyl bromide (1.17 g, 
6.00 mmol, 1.0 equiv.) was added as a solution in DMF (2 mL). The solution was 
allowed to warm to rt, then heated to 100 ºC and held for 4 h.  The brown solution was 
cooled to rt and poured into H2O (50 mL).  The aqueous phase was extracted with Et2O 
(3 × 20 mL), then the combined organic extracts were washed with brine (2 × 20 mL), 
dried (MgSO4), then concentrated in vacuo to afford a brown oil which was purified by 
column chromatography (SiO2, PE/EtOAc, 19:1-9:1) to give the title compound (1.70 g, 
61%) as a pale yellow oil; Rf 0.41 (PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.98 (2 H, d, 
J = 8.4, H-5), 7.42-7.25 (7 H, m, ArH), 4.85 (2 H, s, H-3), 2.42 (3 H, s, H-8), 1.37 (9 H, 
s, H-11). 
Lab Book Ref. = JDC/13/38 








 : To a stirred solution of 
tert-Butyl 3-phenylprop-2-ynyl(tosyl)carbamate (1.69 g, 4.40 mmol, 1.0 equiv.) in 
DCM (10 mL) at 0 ºC was added dropwise TFA (1.69 mL, 22.0 mmol, 5.0 equiv.).  The 
brown solution was held at 0 ºC for 30 min., then warmed to rt and held for 4 h. The 
reaction was carefully quenched with sat. aq. NaHCO3, then the aqueous phase was 
extracted with EtOAc (3 × 20 mL)  The combined organic extracts were washed with 
brine (20 mL), dried (MgSO4), then concentrated in vacuo to afford a yellow oil which 
was purified by column chromatography (SiO2, PE/Et2O, 9:1-4:1) to give the title 
compound (0.88 g, 70%) as an off-white amorphous solid; (Lit.
192
 121-123 ºC); Rf 0.24 
(PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.81 (2 H, d, J = 8.3, H-5), 7.35-7.22 (5 H, m, 
ArH), 7.13 (2 H, d, J = 8.3, H-6) 4.08 (2 H, d, J = 6.2, H-3), 2.36 (3 H, s, H-8). 
Lab Book Ref. = JDC/13/43 









351f:  To a stirred suspension of sodium hydride (60 wt%, 50 mg, 1.30 mmol, 1.05 
equiv.) in DMF (2 mL) at 0 ºC was added dropwise 4-Methyl--(3-phenylprop-2-
ynyl)benzenesulfonamide (342 mg, 1.20 mmol, 1.0 equiv.). The resulting yellow slurry 
was held at 0 ºC for 30 min., then acetal 355 (248 mg, 1.30 mmol, 1.05 equiv.) was 
added dropwise.  The solution was held at 0 ºC for 30 min., then warmed to rt and held 
for 4 h.  The brown solution was quenched with sat. aq. NH4Cl (5 mL), then diluted 
with H2O (25 mL).  The aqueous phase was extracted with Et2O (3 × 10 mL), then the 
combined organic extracts were washed with brine (2 × 20 mL), dried (MgSO4), then 
concentrated in vacuo to afford an orange oil which was purified by column 
chromatography (SiO2, PE/EtOAc, 9:1) to give the title compound 351f (462 mg, 93%) 
as a colourless oil; Rf 0.32 (PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.77 (2 H, d, J = 8.3, 
H-10), 7.31-7.20 (5 H, m, ArH), 7.06 (2 H, d, J = 8.3, H-11), 4.63 (1 H, t, J = 5.6, H-6), 
4.35 (2 H, s, H-3), 3.67 (2 H, dq, J = 9.3, 7.1, H-7a, 7a’), 3.53 (2 H, dq, J = 9.3, 7.1, H-7b, 
7b’), 3.36-3.32 (2 H, m, H-4), 2.34 (3 H, s, H-13), 1.98-1.92 (2 H, m, H-5), 1.20 (6 H, t, 
J = 7.1, H-8, 8’). 
Lab Book Ref. = JDC/13/50 






1-(2,5-Dihydrofuran-3-yl)propan-1-one 352b:  Using the procedure described for the 
preparation of compound 352a, the title compound 352b (22 mg, 70%) was isolated as a 
pale yellow oil; Rf 0.21 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2855, 1641, 1124, 1074; δH 
(400 MHz, CDCl3) 6.74-6.71 (1 H, m, H-5), 4.88-4.80 (4 H, m, H-3, 4), 2.72 (2 H, q, J 
= 7.3, H-6), 1.13 (3 H, t, J = 7.3, H-7); δC (100 MHz, CDCl3) 197.0 (CO, C-1), 141.0 (C, 
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C-2), 136.3 (CH, C-5), 76.3 (CH2), 74.4 (CH2), 32.7 (CH2, C-6), 7.9 (CH3, C-7); m/z 
(ESI) 127 [MH]
+
; [HRMS (ESI): calcd. for C7H11O2, 127.0754. Found: [MH]
+
, 
127.0757 (2.7 ppm error)]. 




(2-Methyl-2,5-dihydrofuran-3-yl)(phenyl)methanone 352c:  Using the procedure 
described for the preparation of compound 352a, the title compound 352c (38 mg, 80%) 
was isolated as a pale yellow oil; Rf 0.33 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2973, 2848, 
1644, 1359, 1276, 1240, 1084; δH (400 MHz, CDCl3) 7.81-7.77 (2 H, m, ArH), 7.60-
7.54 (1 H, m, ArH), 7.49-7.44 (2 H, m, ArH), 6.56-6.54 (1 H, m, H-5), 5.38-5.30 (1 H, 
m, H-3), 4.93 (1 H, ddd, J = 16.1, 5.6, 1.9, H-4a), 4.77 (1 H, ddd, J = 16.1, 4.9, 1.9, H-
4b), 1.45 (3 H, d, J = 6.3, H-6); δC (100 MHz, CDCl3) 191.4 (CO, C-1), 143.5 (C, C-2), 
139.5 (CH, C-5), 138.2 (C, ArC), 132.6 (CH, ArCH), 128.8 (2 × CH, ArCH), 128.4 (2 × 
CH, ArCH), 82.2 (CH, C-3), 74.5 (CH2, C-4), 20.5 (CH3, C-6); m/z (ESI) 189 [MH]
+
; 
[HRMS (ESI): calcd. for C12H13O2, 189.0910. Found: [MH]
+
, 189.0912 (1.2 ppm error)]. 




Phenyl(1-oxaspiro[4.5]dec-3-en-4-yl)methanone 352d:  Using the procedure 
described for the preparation of compound 352a, the title compound 352d (39 mg, 64%) 
was isolated as a yellow oil; Rf 0.49 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2929, 1646, 1317, 
1240, 1089; δH (400 MHz, CDCl3) 7.77-7.73 (2 H, m, ArH), 7.58-7.53 (1 H, m, ArH), 
7.47-7.42 (2 H, m, ArH), 6.45 (1 H, t, J = 1.9, H-5), 4.75 (2 H, d, J = 1.9, H-4), 2.11-
2.00 (2 H, m, CyH), 1.76-1.61 (7 H, m, CyH), 1.36-1.23 (1 H, m, CyH); δC (100 MHz, 
CDCl3) 192.4 (CO, C-1), 145.5 (C, C-2), 139.9 (CH, C-5), 139.1 (C, ArC), 132.4 (CH, 
ArCH), 128.9 (2 × CH2, ArCH), 128.3 (2 × CH2, ArCH), 90.4 (C, C-3), 71.9 (CH2, C-4), 
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34.1 (2 × CH2, CyCH), 25.0 (CH2, CyCH), 22.3 (2 × CH2, CyCH); m/z (ESI) 265 
[MNa]
+
; [HRMS (ESI): calcd. for C16H18NaO2, 265.1199. Found: [MNa]
+
, 265.1192 
(2.5 ppm error)]. 




Phenyl(1-tosyl-2,5-dihydro-1H-pyrrol-3-yl)methanone 352e:  Using the procedure 
described for the preparation of compound 352a, the title compound 352e (63 mg, 77%) 
was isolated as a colourless crystalline solid; mp. 147-149 ºC, (Lit.
153 
134-136 ºC); Rf 
0.18 (PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.77 (2 H, d, J = 8.3, H-7), 7.68-7.64 (2 H, 
m, ArH), 7.59-7.53 (1 H, m, ArH), 7.46-7.41 (2 H, m, ArH), 7.35 (2 H, d, J = 8.3, H-8), 
6.35 (1 H, dddd, J = 1.9, 1.9, 1.8, 1.8, H-5), 4.48-4.39 (4 H, m, H-3, 4), 2.44 (3 H, s, H-
10). 
Lab Book Ref. = JDC/13/87 






Phenyl(1-tosyl-1,2,5,6-tetrahydropyridin-3-yl)methanone 352f:  Using the procedure 
described for the preparation of compound 352a, the title compound 352f (59 mg, 69%) 
was isolated as a yellow oil; Rf 0.16 (PE/EtOAc, 4:1); δH (400 MHz, CDCl3) 7.74 (2 H, 
d, J = 8.3, H-8), 7.63-7.46 (3 H, m, ArH), 7.45-7.40 (2 H, m, ArH), 7.35 (2 H, d, J = 8.3, 
H-9), 6.66-6.40 (1 H, m, H-6), 3.96 (2 H, dd, J = 4.5, 2.4, H-3), 3.24 (2 H, t, J = 5.8, H-
4), 2.53-2.46 (2 H, m, H-5), 2.44 (3 H, s, H-11). 
Lab Book Ref. = JDC/13/90 
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1-(2,2-Diethoxyethoxy)-2-iodobenzene 376: To a stirred solution of 2-iodophenol (660 
mg, 3.00 mmol, 1.0 equiv.) in DMF (3 mL) at rt were added K2CO3 (1.66 g, 12.0 mmol, 
4.0 equiv.) and bromo acetaldehyde diethyl acetal (0.50 mL, 3.30 mmol, 1.1 equiv.).  
The suspension was heated to 140 ºC and held for 5 h, then cooled to rt and poured into 
H2O (50 mL).  The aqueous phase was extracted with Et2O (3 × 20 mL), then the 
combined organic extracts were washed with brine (20 mL), dried (MgSO4), then 
concentrated in vacuo to afford the title compound 376 (1.00 g, 99%) as a yellow oil; Rf 
0.58 (PE/EtOAc); υmax/cm
-1
 (neat) 2975, 1475, 1135, 1075, 749; δH (400 MHz, CDCl3) 
7.76 (1 H, dd, J = 7.8, 1.6, H-3), 7.30-7.25 (1 H, ddd, J = 8.4, 7.4, 1.6, H-5), 6.82 (1 H, 
dd, J = 8.4, 1.3, H-6), 6.74 (1 H, ddd, J = 7.8, 7.4, 1.3, H-4), 4.89 (1 H, t, J = 5.2, H-8), 
4.04 (2 H, d, J = 5.2, H-7), 3.82 (2 H, dq, J = 9.3, 7.1, H-9a, 9a’), 3.72 (2 H, dq, J = 9.3, 
7.1, H-9b, 9b’), 1.27 (6 H, t, J = 7.1, H-10, 10’); δC (100 MHz, CDCl3) 157.2 (C, C-1), 
139.4 (CH, C-3), 129.4 (CH, C-5), 122.8 (CH, C-4), 112.2 (CH, C-6), 100.7 (CH, C-8), 
86.4 (C, C-2), 70.1 (CH2, C-7), 63.4 (2 × CH2, C-9, 9’), 15.4 (2 × CH3, C-10, 10’); m/z 
(ESI) 359 [MNa]
+
; [HRMS (ESI): calcd. for C12H17INaO3, 359.0115. Found: [MNa]
+
, 
359.0120 (1.9 ppm error)]. 




1-(2,2-Diethoxyethoxy)-2-(pent-1-ynyl)benzene 377: To a stirred suspension of iodide 
376 (336 mg, 1.00 mmol, 1.0 equiv.), CuI (19 mg, 0.10 mmol, 0.1 equiv.) and 
Pd(PPh3)2Cl2 (35 mg, 0.05 mmol, 0.05 equiv.) in Et3N (3 mL, degassed) at rt under 
argon (flask purged via 5 × vacuum/argon cycles) was added 1-pentyne (229 µL, 2.00 
mmol, 2.0 equiv.). The dark brown solution was stirred at rt for 18 h, then concentrated 
in vacuo to afford a brown residue which was purified by column chromatography 
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(SiO2, PE/Et2O, 19:1) to give the title compound 377 (258 mg, 93%) as a yellow oil; Rf 
0.60 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2972, 2932, 2874, 1493, 1445, 1292, 1119, 1074; 
δH (400 MHz, CDCl3) 7.36 (1 H, dd, J = 7.6, 1.7, H-3), 7.20 (1 H, ddd, J = 8.3, 7.5, 1.7, 
H-5), 6.87 (1 H, ddd, J = 7.6, 7.5, 1.0, H-4), 6.84 (1 H, dd, J = 8.3, 1.0, H-6), 4.87 (1 H, 
t, J = 5.2, H-8), 4.05 (2 H, d, J = 5.2, H-7), 3.81 (2 H, dq, J = 9.4, 7.1, H-9a, 9a’), 3.70 (2 
H, dq, J = 9.4, 7.1, H-9b, 9b’), 2.41 (2 H, t, J = 7.0, H-13), 1.63 (2 H, qt, J = 7.4, 7.0, H-
14), 1.25 (6 H, t, J = 7.1, H-10, 10’), 1.06 (3 H, t, J = 7.4, H-15); δC (100 MHz, CDCl3) 
159.0 (C, C-1), 133.4 (CH, C-3), 128.7 (CH, C-5), 120.7 (CH, C-4), 113.7 (C, C-2), 
112.1 (CH, C-6), 100.9 (CH, C-8), 94.2 (C, C-12), 76.7 (C, C-11), 69.9 (CH2, C-7), 63.3 
(2 × CH2, C-9, 9’)  22.2 (CH2, C-14), 21.6 (CH2, C-13), 15.3 (2 × CH3, C-10, 10’), 13.5 
(CH3, C-15); m/z (ESI) 299 [MNa]
+
; [HRMS (ESI): calcd. for C17H24NaO3, 299.1618. 
Found: [MNa]
+
, 299.1617 (0.4 ppm error)]. 




1-(2H-Chromen-4-yl)butan-1-one 378: Using the procedure described for the 
preparation of compound 352a, the title compound 378 (29 mg, 57%) was isolated as a 
yellow oil; Rf 0.48 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2964, 1682, 1485, 1456, 1226; δH 
(400 MHz, CDCl3) 7.25 (1 H, dd, J = 7.8, 1.6, H-3), 7.18 (1 H, ddd, J = 8.0, 7.6, 1.6, H-
5), 6.95 (1 H, ddd, J = 7.8, 7.6, 1.3, H-4), 6.87 (1 H, dd, J = 8.0, 1.3, H-6), 6.56 (1 H, t, 
J = 4.1, H-8), 4.82 (2 H, d, J = 4.1, H-7), 2.75 (2 H, t, J = 7.3, H-11), 1.72 (2 H, qt, J = 
7.4, 7.3, H-12), 0.98 (3 H, t, J = 7.4, H-13); δC (100 MHz, CDCl3) 200.7 (CO, C-10), 
154.3 (C, C-1), 135.1 (C, C-9), 129.8 (CH, C-5), 128.9 (CH, C-8), 126.6 (CH, C-3), 
121.6 (CH, C-4), 119.7 (C, C-2), 116.3 (CH, C-6), 64.3 (CH2, C-7), 41.6 (CH2, C-11), 
17.9 (CH2, C-12), 13.8 (CH3, C-13); m/z (ESI) 225 [MNa]
+
; [HRMS (ESI): calcd. for 
C13H14NaO2, 225.0886. Found: [MNa]
+
, 286.0890 (1.8 ppm error)]. 
Lab Book Ref. = JDC/13/87 
 





 382:  To a stirred suspension of 2-iodoaniline (500 mg, 2.28 
mmol, 1.0 equiv.), CuI (19 mg, 0.10 mmol, 0.05 equiv.) and Pd(PPh3)2Cl2 (35 mg, 0.05 
mmol, 0.02 equiv.) in Et3N (5 mL, degassed) at rt under argon (flask purged via 5 × 
vacuum/argon cycles) was added 1-pentyne (450 µL, 4.56 mmol, 2.0 equiv.).  The dark 
brown solution was stirred at rt for 18 h, then concentrated in vacuo to afford a brown 
residue which was purified by column chromatography (SiO2, PE/Et2O, 19:1-9:1) to 
give the title compound 382 (335 mg, 92%) as a colourless oil; Rf 0.48 (PE/EtOAc, 4:1); 
υmax/cm
-1
 (neat) 3470, 3377, 2962, 1613, 1492, 1455, 1306; δH (400 MHz, CDCl3) 7.25 
(1 H, dd, J = 7.6, 1.5, H-3), 7.08 (1 H, ddd, J = 8.1, 7.5, 1.5, H-5), 6.70-6.67 (1 H, m, H-
6), 6.66 (1 H, ddd, J = 7.6, 7.5, 1.1, H-4), 4.17 (2 H, br s, NH2), 2.45 (2 H, t, J = 7.0, H-
9), 1.65 (2 H, qt, J = 7.4, 7.0, H-10), 1.06 (3 H, t, J = 7.4, H-11); δC (100 MHz, CDCl3) 
147.6 (C, C-1), 132.0 (CH, C-3), 128.8 (CH, C-5), 117.8 (CH, C-4), 114.1 (CH, C-6), 
108.9 (C, C-2), 95.6 (C, C-8), 77.1 (C, C-7), 22.4 (CH2, C-10), 21.6 (CH2, C-9), 13.6 
(CH3, C-11); m/z (ESI) 160 [MH]
+
; [HRMS (ESI): calcd. for C11H14N, 160.1121. Found: 
[MH]
+
, 160.1125 (2.9 ppm error)]. 
Lab Book Ref. = JDC/14/39 
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4-Methyl--(2-(pent-1-ynyl)phenyl)benzenesulfonamide 382a:  To a stirred solution 
of aniline 382 (300 mg, 1.88 mmol, 1.0 equiv.), in pyridine (4 mL) at rt was added p-
toluenesulfonyl chloride (395 mg, 2.07 mmol, 1.1 equiv.).  The brown solution was 
stirred at rt for 5 h, then the solvent was removed under reduced pressure.  The residue 
was taken up in EtOAc (30 mL), then washed with 1 M aq. HCl (20 mL), sat. aq. 
NaHCO3 (20 mL) and brine (20 mL), dried (MgSO4), then concentrated in vacuo to 
afford the title compound 382a (580 mg, 98%) as an off-white solid; mp. 84-86 ºC; Rf 
0.38 (PE/EtOAc, 4:1); υmax/cm
-1
 (thin film) 3255, 2961, 1487, 1397, 1330, 1167, 1092; 
δH (400 MHz, CDCl3) 7.66 (2 H, d, J = 8.3, H-13), 7.56 (1 H, dd, J = 8.2, 1.2, H-6), 
7.26-7.17 (4 H, m, H-3, 5, 14), 6.97 (1 H, ddd, J = 7.6, 7.6, 1.2, H-4), 2.39 (2 H, t, J = 
7.1, H-9), 2.35 (3 H, s, H-16), 1.62 (2 H, qt, J = 7.4, 7.1, H-10), 1.04 (3 H, t, J = 7.4, H-
11); δC (100 MHz, CDCl3) 143.9 (C, C-15), 137.5 (C, C-1), 136.0 (C, C-12), 131.8 (CH, 
C-3), 129.5 (2 × CH, C-14), 128.7 (CH, C-5), 127.2 (2 × CH, C-13), 124.1 (CH, C-4), 
119.3 (CH, C-6), 114.8 (C, C-2), 97.7 (C, C-7), 75.4 (C, C-8), 22.0 (CH2, C-10), 21.5 
(CH3, C-16), 21.4 (CH2, C-9), 13.6 (CH3, C-11); m/z (ESI) 314 [MH]
+
; [HRMS (ESI): 
calcd. for C18H20NO2S, 314.1209. Found: [MH]
+
, 314.1208 (0.4 ppm error)]. 
Lab Book Ref. = JDC/14/40 
  
 


























To a stirred solution of tosylate 382a (500 mg, 1.60 mmol, 1.0 equiv.), glycoaldehyde 
diethyl acetal (215 mg, 1.60 mmol, 1.0 equiv.) and triphenylphosphine (462 mg, 1.76 
mmol, 1.1 equiv.) in THF (4 mL) at 0 ºC was added dropwise DIAD (0.35 mL, 1.76 
mmol, 1.1 equiv.).  The orange solution was held at 0 ºC for 30 min., then warmed to rt 
and held for 18 h.  The reaction mixture was concentrated in vacuo to afford an orange 
oil which was purified by column chromatography (SiO2, PE/EtOAc, 19:1) to give the 
title compound 383 (610 mg, 89%) as a colourless oil; Rf 0.40 (PE/EtOAc, 4:1); 
υmax/cm
-1
 (neat) 2974, 2932, 1485, 1350, 1162, 1095, 1067; δH (400 MHz, CDCl3) 7.56 
(2 H, d, J = 8.2, H-13), 7.39-7.34 (1 H, m, H-3), 7.30 (1 H, dd, J = 7.4, 1.8, H-5), 7.27-
7.17 (4 H, m, H-4, 6, 14), 4.73 (1 H, t, J = 5.6, H-18), 3.93-3.63 (6 H, m, H-17, 19, 19’), 
2.39 (3 H, s, H-16), 2.01 (2 H, t, J = 7.2, H-9), 1.40 (2 H, qt, J = 7.4, 7.2, H-10), 1.22-
0.97 (6 H, m, H-20, 20’), 0.92 (3 H, t, J = 7.4, H-11); δC (100 MHz, CDCl3) 142.9 
(ArC), 140.5 (ArC), 137.1 (ArC), 133.4 (CH, C-5), 132.5 (CH, C-3), 129.2 (2 × CH, C-
14), 127.7 (4 × CH, C-4, 6, 13), 123.5 (C, C-2), 101.8 (CH, C-18), 95.6 (C, C-8), 77.2 
(C, C-7), 62.1 (2 × CH2, C-19, 19’), 52.1 (CH2, C-17), 21.9 (CH2, C-10), 21.5 (CH3, C-
16), 21.4 (CH2, C-9), 15.1 (2 × CH3, C-20, 20’), 13.6 (CH3, C-11); m/z (ESI) 452 
[MNa]
+
; [HRMS (ESI): calcd. for C24H31NNaO4S, 452.1866. Found: [MNa]
+
, 452.1872 
(1.3 ppm error)]. 
Lab Book Ref. = JDC/14/42 
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1-(1-Tosyl-1,2-dihydroquinolin-4-yl)butan-1-one 384: Using the procedure described 
for the preparation of compound 352a, the title compound 384 (54 mg, 60%) was 
isolated as a yellow oil; Rf 0.33 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2964, 1683, 1354, 
1165, 1089; δH (400 MHz, CDCl3) 7.73 (1 H, dd, J = 8.1, 1.6, H-3), 7.61 (1 H, dd, J = 
7.8, 1.4, H-6), 7.37 (1 H, ddd, J = 7.8, 7.7, 1.6, H-5), 7.30-7.25 (1 H, m, H-4), 7.27 (2 H, 
d, J = 8.3, H-15), 7.08 (2 H, d, J = 8.3, H-16), 6.24 (1 H, t, J = 4.6, H-8), 4.47 (2 H, d, J 
= 4.6, H-7), 2.30 (3 H, s, H-18), 2.24 (2 H, t, J = 7.3, H-11), 1.47 (2 H, qt, J = 7.4, 7.3, 
H-12), 0.85 (3 H, t, J = 7.4, H-13); δC (100 MHz, CDCl3) 199.7 (CO, C-8), 143.7 (C, C-
17), 136.5 (ArC), 136.1 (ArC), 135.6 (ArC), 130.7 (CH, C-8), 129.3 (2 × CH, C-16), 
128.9 (CH, C-5), 127.7 (CH, C-3), 127.2 (2 × CH, C-15), 126.9 (CH, C-6), 126.8 (C, C-
2), 126.7 (CH, C-4), 44.8 (CH2, C-7), 41.2 (CH2, C-11), 21.4 (CH3, C-18) 17.5 (CH2, C-
12), 13.7 (CH3, C-13); m/z (ESI) 356 [MH]
+
; [HRMS (ESI): calcd. for C20H22NO3S, 
356.1315. Found: [MH]
+
, 356.1313 (0.6 ppm error)]. 




1-(3,3-Diethoxypropoxy)-2-iodobenzene 385:  To a stirred suspension of iodide 355 
(852 mg, 3.30 mmol, 1.1 equiv.) and K2CO3 (1.66 g, 12.0 mmol, 4.0 equiv.) in DMF (3 
mL) at rt was added 2-iodophenol (660 mg, 3.00 mmol, 1.0 equiv.).  The slurry was 
heated to 140 ºC and held for 18 h, then cooled to rt and poured into H2O (50 mL). The 
aqueous phase was extracted with Et2O (3 × 20 mL), then the combined organic extracts 
were washed with H2O (20 mL) and brine (20 mL), dried (MgSO4), then concentrated 
in vacuo to afford the title compound 385 (929 mg, 88%) as an orange oil; Rf 0.47 
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(PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2973, 1464, 1123, 1057; δH (400 MHz, CDCl3) 7.76 
(1 H, dd, J = 7.8, 1.6, H-3), 7.28 (1 H, ddd, J = 8.3, 7.5, 1.6, H-5), 6.81 (1 H, dd, J = 8.3, 
1.3, H-6), 6.70 (1 H, ddd, J = 7.8, 7.5, 1.3, H-4), 4.91 (1 H, t, J = 5.7, H-9), 4.10 (2 H, t, 
J = 5.9, H-7), 3.73 (2 H, dq, J = 9.4, 7.1, H-10a, 10a’), 3.57 (2 H, dq, J = 9.4, 7.1, H-10b, 
10b’), 2.14 (2 H, td, J = 5.9, 5.7, H-8), 1.21 (6 H, t, J = 7.1, H-11, 11’); δC (100 MHz, 
CDCl3) 157.3 (C, C-1), 139.3 (CH, C-3), 129.4 (CH, C-5), 122.4 (CH, C-4), 111.9 (CH, 
C-6), 100.5 (CH, C-9), 86.5 (C, C-2), 65.3 (CH2, C-7), 62.2 (2 × CH2, C-10, 10’), 33.8 
(CH2, C-8), 15.4 (2 × CH3, C-11, 11’); m/z (ESI) 373 [MNa]
+
; [HRMS (ESI): calcd. for 
C13H19INaO3, 373.0277. Found: [MNa]
+
, 373.0261 (4.3 ppm error)]. 




1-(3,3-Diethoxypropoxy)-2-(pent-1-ynyl)benzene 386:  To a stirred suspension of 
iodide 385 (350 mg, 1.00 mmol, 1.0 equiv.), CuI (19 mg, 0.10 mmol, 0.1 equiv.) and 
Pd(PPh3)2Cl2 (35 mg, 0.05 mmol, 0.05 equiv.) in Et3N (5 mL, degassed) at rt under 
argon (flask purged via 5 × vacuum/argon cycles) was added 1-pentyne (197 µL, 2.00 
mmol, 2.0 equiv.).  The dark brown solution was stirred at rt for 18 h, then concentrated 
in vacuo to afford a brown residue which was purified by column chromatography 
(SiO2, PE/Et2O, 19:1-9:1) to give the title compound 386 (252 mg, 87%) as a colourless 
oil; Rf 0.49 (PE/EtOAc, 4:1); υmax/cm
-1
 (neat) 2971, 2933, 2876, 1492, 1447, 1261, 1120, 
1060; δH (400 MHz, CDCl3) 7.35 (1 H, dd, J = 7.6, 1.6, H-3), 7.21 (1 H, ddd, J = 8.0, 
7.9, 1.6, H-5), 6.89-6.83 (2 H, m, H-4, 6), 4.84 (1 H, t, J = 5.8, H-9), 4.10 (2 H, t, J = 
6.2, H-7), 3.71 (2 H, dq, J = 9.4, 7.1, H-10a, 10a’), 3.54 (2 H, dq, J = 9.4, 7.1, H-10b 
10b’), 2.43 (2 H, t, J = 7.0, H-14), 2.13 (1 H, td, J = 6.2, 5.8, H-8), 1.64 (2 H, qt, J = 7.4, 
7.0, H-15), 1.21 (6 H, t, J = 7.1, H-11, 11’), 1.07 (3 H, t, J = 7.4, H-16); δC (100 MHz, 
CDCl3) 159.3 (C, C-1), 133.3 (CH, C-3), 128.7 (CH, C-5), 120.4 (CH, C-4), 113.5 (C, 
C-2), 111.8 (CH, C-6), 100.6 (CH, C-9), 94.2 (C, C-13), 76.8 (C, C-12), 64.7 (CH2, C-
7), 62.1 (2 × CH2, C-10, 10’), 33.9 (CH2, C-8), 22.3 (CH2, C-15), 21.7 (CH2, C-14), 
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15.3 (2 × CH3, C-11, 11’), 13.5 (CH3, C-16); m/z (ESI) 313 [MNa]
+
; [HRMS (ESI): 
calcd. for C18H26NaO3, 313.1774. Found: [MNa]
+
, 313.1766 (2.5 ppm error)]. 




(S)-1-(3,3-diethoxypropyl)-2-(pent-1-ynyl)pyrrolidine 388:  To a stirred solution of 
alkyne 356 (200 mg, 0.89 mmol, 1.0 equiv.) in THF (5 mL) at –78 ºC was added 
dropwise n-BuLi (1.6 M, 0.61 mL, 0.98 mmol, 1.1 equiv.).  The yellow solution was 
held at –78 ºC for 1 h, then warmed to 0 ºC before adding n-propyl iodide (104 µL, 1.07 
mmol, 1.2 equiv.).  The reaction was allowed to warm to rt, the heated to reflux and 
held for 18 h.  The reaction was cooled to rt, then quenched with sat. aq. NH4Cl (5 mL).  
The aqueous phase was extracted with DCM (3 × 10 mL), then the combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), then concentrated in vacuo to 
afford a yellow oil which was purified by column chromatography (SiO2, DCM/MeOH, 
99:1-98:2) to give the title compound 388 (87 mg, 37%) as a colourless oil; Rf 0.50 
(DCM/MeOH, 9:1); [α]
20
D –99.7 (c 1.15, CHCl3); υmax/cm
-1
 (neat) 2966, 1457, 1375, 
1127, 1063; δH (400 MHz, CDCl3) 4.58 (1 H, t, J = 5.7, H-7), 3.65 (1 H, dq, J = 9.4, 7.1, 
H-14a), 3.64 (1 H, dq, J = 9.4, 7.1, H-14a’), 3.50 (1 H, qd, J = 9.4, 7.1, H-14b), 3.49 (1 H, 
dq, J = 9.4, 7.1, H-14b’), 3.35 (1 H, br s, H-9), 2.92 (1 H, ddd, J = 11.9, 8.7, 7.8, H-5a), 
2.82 (1 H, ddd, J = 8.8, 8.7, 5.2, H-3a), 2.50-2.34 (2 H, m, H-3b, 5b), 2.15 (2 H, td, J 
=7.0, 2.0, H-11), 2.13-2.02 (1 H, m, H-1a), 1.94-1.70 (4 H, m, H-1b, 2a, 6), 1.50 (2 H, qt, 
J = 7.4, 7.0, H-12), 1.19 (6 H, t, J = 7.1, H-15, 15’), 0.96 (3 H, t, J = 7.4, H-13); δC (100 
MHz, CDCl3) 101.6 (CH, C-7), 84.4 (C, C-10), 79.1 (C, C-8), 61.0 (CH2, C-14), 60.7 
(CH2, C-14’), 54.9 (CH, C-9), 51.9 (CH2, C-3), 48.9 (CH2, C-5), 32.6 (CH2, C-6), 32.0 
(CH2, C-1), 22.3 (CH2, C-12), 21.9 (CH2, C-2), 20.7 (CH2, C-11), 15.3 (2 × CH3, C-15, 
15’), 13.5 (CH3, C-13); m/z (ESI) 268 [MH]
+
; [HRMS (ESI): calcd. for C16H30NO2, 
268.2271. Found: [MH]
+
, 268.2272 (0.3 ppm error)]. 
Lab Book Ref. = JDC/12/73 
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(S)-(1,2,3,5,6,8a-Hexahydroindolizin-8-yl)(phenyl)methanone 358:  A solution of 
alkyne 357 (75 mg, 0.25 mmol, 1.0 equiv.) in formic acid (1 mL) was heated at 100 ºC 
(oil-bath pre-heated) for 2 h, then cooled to rt and the solution concentrated under 
reduced pressure.  The residue was dissolved in DCM (10 mL) and washed with sat. aq. 
NaHCO3 (10 mL), then the aqueous washes were back extracted with DCM (3 × 10 
mL).  The combined organic extracts were washed with brine (10 mL), dried (Na2SO4), 
then concentrated in vacuo to afford an orange oil which was purified by column 
chromatography (SiO2, DCM/MeOH, 95:5) to give the title compound 358 (21 mg, 37%) 
as a yellow film; Rf 0.28 (DCM/MeOH, 9:1); υmax/cm
-1
 (neat) 2954, 1645, 1272, 710; δH 
(400 MHz, CDCl3) 7.69-7.65 (2 H, m, ArH), 7.54-7.49 (1 H, m, ArH), 7.44-7.39 (2 H, 
m, ArH), 6.55 (1 H, ddd, J = 4.1, 4.1, 1.8, H-7), 3.77-3.71 (1 H, m, H-9), 3.08-2.99 (2 H, 
m, H-3a, 5a), 2.87 (1 H, ddd, J = 10.0, 8.7, 7.6, H-3b), 2.74 (1 H, ddd, J = 11.9, 7.6, 5.1, 
H-5b), 2.64-2.53 (1 H, m, H-6a), 2.47-2.35 (2 H, m, H-1a, 6b), 2.01-1.83 (2 H, m, H-2), 
1.58-1.47 (1 H, m, H-1b); δC (100 MHz, CDCl3) 196.4 (C, C-10), 140.3 (C, C-8), 140.0 
(CH, C-7), 137.9 (C, ArC), 131.9 (CH, ArCH), 129.2 (2 × CH, ArCH), 128.2 (2 × CH, 
ArCH), 59.5 (CH, C-9), 52.5 (CH2, C-3), 45.5 (CH2, C-5), 28.9 (CH2, C-1), 25.0 (CH2, 
C-6), 22.1 (CH2, C-2); m/z (ESI) 228 [MH]
+
; [HRMS (ESI): calcd. for C15H18NO, 
228.1383. Found: [MH]
+
, 228.1380 (1.4 ppm error)]. 




(S)-1-(3,3-Diethoxypropyl)-2-(phenylthioethynyl)pyrrolidine 398:  To a stirred 
solution of alkyne 356 (750 mg, 3.30 mmol, 1.0 equiv.) in THF (12 mL) at −78 ºC was 
added dropwise n-BuLi (1.58 M, 2.30 mL, 3.63 mmol, 1.1 equiv.).  The pale yellow 
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solution was held at −78 ºC for 30 min., then (S)-phenyl benzenethiosulfonate (909 mg, 
3.63 mmol, 1.1 equiv.) was added dropwise as a solution in THF (3 mL).  The solution 
was held at −78 ºC for a further 30 min., before warming to rt and holding for 2 h.  The 
reaction was quenched with sat. aq. NH4Cl (10 mL), then the aqueous phase was 
extracted with DCM (3 × 10 mL).  The combined organic extracts were washed with 
brine (20 mL), dried (Na2SO4), then concentrated in vacuo to afford a yellow oil which 
was purified by column chromatography (SiO2, PE/EtOAc, 2:1-1:1) to give the title 
compound 398 (0.94 g, 85%) as a yellow oil; Rf 0.38 (DCM/MeOH, 95:5); [α]
20
D –
106.2 (c 1.00, CHCl3); υmax/cm
-1
 (neat) 2973, 2877, 2808, 1478, 1126, 1062, 739; δH 
(400 MHz, CDCl3) 7.42-7.37 (2 H, m, ArH), 7.35-7.29 (1 H, m, ArH), 7.22-7.17 (2 H, 
m, ArH), 4.60 (1 H, t, J = 5.8, H-7), 3.67-3.63 (1 H, m, H-9), 3.65 (1 H, dq, J = 9.4, 7.1, 
H-11a), 3.64 (1 H, dq, J = 9.4, 7.1, H-11a’), 3.50 (1 H, dq, J = 9.4, 7.1, H-11b), 3.49 (1 H, 
dq, J = 9.4, 7.1, H-11b’), 2.89 (1 H, ddd, J = 11.9, 8.7, 7.1, H-5a), 2.80 (1 H, ddd, J = 8.8, 
8.7, 5.5, H-3a), 2.56 (1 H, ddd J = 8.8, 7.7, 5.3, H-3b), 2.49 (1 H, ddd, J = 11.9, 8.5, 6.3, 
H-5b), 2.22-2.12 (1 H, m, H-1a), 2.05-1.76 (5 H, m, H-1b, 2, 6), 1.19 (3 H, t, J = 7.1, H-
12), 1.17 (3 H, t, J = 7.1, H-12’); δC (100 MHz, CDCl3) 133.2 (C, ArC), 129.0 (2 × CH, 
ArCH), 126.2 (CH, ArCH), 125.9 (2 × CH, ArCH), 101.4 (CH, C-7), 98.5 (C, C-8), 
69.8 (C, C-10), 61.2 (CH2, C-11), 60.9 (CH2, C-11’), 55.7 (CH, C-9), 51.8 (CH2, C-3), 
48.8 (CH2, C-5), 32.8 (CH2, C-6), 31.8 (CH2, C-1), 22.1 (CH2, C-2), 15.3 (2 × CH3, C-
12, 12’); m/z (ESI) 334 [MH]
+
; [HRMS (ESI): calcd. for C19H28NO2S, 334.1835. Found: 
[MH]
+
, 334.1837 (0.4 ppm error)]. 




(S)-2-(1,2-bis(Phenylthio)vinyl)-1-(3,3-diethoxypropyl)pyrrolidine 399:  To a stirred 
solution of alkyne 356 (1.17 g, 5.20 mmol, 1.0 equiv.) in THF (35 mL) at −78 ºC was 
added dropwise n-BuLi (1.6 M, 3.40 mL, 5.50 mmol, 1.05 equiv.).  The pale yellow 
solution was held at −78 ºC for 30 min., then diphenyl disulfide (1.20 g, 5.50 mmol, 
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1.05 equiv.) was added dropwise as a pre-cooled solution in THF (5 mL).  The solution 
was held at −78 ºC for a further 30 min., before warming to rt and holding for 2 h.  The 
reaction was quenched with sat. aq. NH4Cl (25 mL), then the aqueous phase was 
extracted with DCM (3 × 20 mL).  The combined organic extracts were washed with 
brine (20 mL), dried (Na2SO4), then concentrated in vacuo to afford an orange oil which 
was purified by column chromatography (SiO2, DCM/MeOH, 99:1-95:5) to give 
thioalkyne 398 (624 mg, 36%) as a yellow oil and the title compound 399 (653 mg, 
28%) as a yellow oil; Rf 0.56 (DCM/MeOH, 9:1); [α]
24
D +85.9 (c 1.00, CHCl3); 
υmax/cm
-1
 (neat) 2971, 2875, 2799, 1581, 1478, 1440, 1125, 1063, 742; δH (400 MHz, 
CDCl3) 7.43-7.38 (2 H, m, ArH), 7.34-7.20 (7 H, m, ArH), 7.20-7.13 (1 H, m, ArH), 
7.14 (1 H, s, H-10), 4.56 (1 H, t, J = 5.7, H-7), 3.61 (2 H, dq, J = 9.3, 7.1, H-11a, 11a’), 
3.47 (1 H, dq, J = 9.3, 7.1, H-11b), 3.45 (1 H, dq, J = 9.3, 7.1, H-11b’), 3.23-3.15 (1 H, 
m, H-3a), 3.01 (1 H, dd, J = 7.7, 6.2, H-9), 2.83 (1 H, ddd, J = 11.9, 8.5, 7.4, H-5a), 
2.19-2.10 (2 H m, H-3b, 5b), 1.98-1.87 (1 H, m, H-1a), 1.85-1.62 (5 H, m, H-1b, 2, 6), 
1.19 (3 H, t, J = 7.1, H-12), 1.18 (3 H, t, J = 7.1, H-12’); δC (100 MHz, CDCl3) 135.7 (C, 
ArC), 134.8 (C, ArC), 134.2 (CH, C-10), 132.8 (C, C-8), 129.9 (2 × CH, ArCH), 129.0 
(2 × CH, ArCH), 128.8 (2 × CH, ArCH), 128.7 (2 × CH, ArCH), 126.9 (CH, ArCH), 
125.9 (CH, ArCH), 101.4 (CH, C-7), 70.9 (CH, C-9), 61.0 (CH2, C-11), 60.9 (CH2, C-
11’), 53.6 (CH2, C-3), 49.9 (CH2, C-5), 32.9 (CH2, C-6), 31.8 (CH2, C-1), 22.8 (CH2, C-
2), 15.4 (2 × CH3, C-12, 12’); m/z (ESI) 444 [MH]
+
; [HRMS (ESI): calcd. for 
C25H34NO2S2, 444.2025. Found: [MH]
+
, 444.2033 (1.8 ppm error)]. 




S-Phenyl (S)-1,2,3,5,6,8a-hexahydroindolizine-8-carbothioate 400:  A stirred 
solution of alkyne 398 (300 mg, 0.90 mmol, 1.0 equiv.) in formic acid (10 mL) was 
heated to 100 ºC (oil-bath pre-heated) and held for 2 h.  The brown solution was cooled 
to rt then concentrated in vacuo.  The residue was taken up in DCM (20 mL) and 
washed with sat. aq. NaHCO3 (20 mL).  The aqueous phase was back-extracted with 
DCM (3 × 10 mL), then the combined organic extracts were washed with brine (20 mL), 
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dried (Na2SO4), then concentrated in vacuo to afford the title compound 400 (232 mg, 
99%) as an orange oil; Rf 0.34 (DCM/MeOH, 9:1); [α]
24
D −67.3 (c 1.30, CHCl3); 
υmax/cm
-1
 (neat) 2956, 1670, 1163, 949, 746; δH (400 MHz, CDCl3) 7.45-7.39 (5 H, m, 
ArH), 7.17 (1 H, ddd, J = 4.9, 3.8, 1.7, H-7), 3.60-3.54 (1 H, m, H-9), 2.97-2.88 (2 H, m, 
H-3a, 5a), 2.75 (1 H, ddd, J = 10.0, 8.3, 6.9, H-3b), 2.70-2.63 (1 H, m, H-5b), 2.56-2.45 
(1 H, m, H-6a), 2.37 (1 H, m, H-6b), 2.27 (1 H, dddd, J = 13.0, 9.4, 7.4, 3.8, H-1a), 1.98-
1.71 (2 H, m, H-2), 1.52 (1 H, dddd, J = 13.0, 10.4, 8.8, 7.6, H-1b); δC (100 MHz, 
CDCl3) 189.8 (CO, C-10), 141.1 (C, C-8), 137.0 (CH, C-7), 135.0 (2 × CH, ArCH), 
129.2 (CH, ArCH), 129.1 (2 × CH, ArCH), 127.5 (C, ArC), 58.9 (CH, C-9), 52.1 (CH2, 
C-3), 45.0 (CH2, C-5), 29.3 (CH2, C-1), 24.6 (CH2, C-6), 22.5 (CH2, C-2); m/z (ESI) 
260 [MH]
+
; [HRMS (ESI): calcd. for C15H18NOS, 260.1104. Found: [MH]
+
, 260.1109 
(1.9 ppm error)]. 




(S)-1-(3,3-Diethoxypropyl)-2-(ethylthioethynyl)pyrrolidine 401:  To a stirred 
solution of alkyne 356 (1.50 g, 6.66 mmol, 1.0 equiv.) in THF (20 mL) at −78 ºC was 
added dropwise n-BuLi (1.58 M, 4.64 mL, 7.33 mmol, 1.1 equiv.).  The pale yellow 
solution was held at −78 ºC for 30 min., then diethyl disulfide (902 µL, 7.33 mmol, 1.1 
equiv.) was added dropwise.  The solution was held at −78 ºC for a further 30 min., 
before warming to rt and holding for 2 h.  The reaction was quenched with sat. aq. 
NH4Cl (10 mL), then the aqueous phase was extracted with DCM (3 × 20 mL).  The 
combined organic extracts were washed with brine (20 mL), dried (Na2SO4), then 
concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, DCM/MeOH, 98:2-97:3) to give the title compound 401 (1.61 g, 
85%) as a colourless oil; Rf 0.38 (DCM/MeOH, 95:5); [α]
20
D –124.4 (c 1.07, CHCl3); 
υmax/cm
-1
 (neat) 2973, 2929, 2877, 1126, 1062; δH (400 MHz, CDCl3) 4.58 (1 H, t, J = 
5.8, H-7), 3.65 (1 H, dq, J = 9.3, 7.0, H-13a), 3.63 (1 H, dq, J = 9.3, 7.0, H-13a’), 3.51 (1 
H, dq, J = 9.3, 7.0, H-13b), 3.50-3.45 (1 H, m, H-9), 3.48 (1 H, dq, J = 9.3, 7.0, H-13b’), 
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2.84 (1 H, ddd, J = 11.9, 8.8, 7.1, H-5a), 2.80-2.73 (1 H, m, H-3a), 2.70 (1 H, dq, J = 
12.4, 7.3, H-11a), 2.66 (1 H, dq, J = 12.4, 7.3, H-11b), 2.47 (1 H, ddd, J = 8.8, 8.7, 5.6, 
H-3b), 2.44-2.35 (1 H, m, H-5b), 2.14-2.02 (1 H, m, H-1a), 1.94-1.70 (5 H, m, H-1b, 2, 6), 
1.37 (3 H, t, J = 7.3, H-12), 1.20 (3 H, t, J = 7.0, H-14), 1.19 (3 H, t, J = 7.0, H-14’); δC 
(100 MHz, CDCl3) 101.5 (CH, C-7), 93.4 (C, C-8), 73.2 (C, C-10), 61.1 (CH2, C-13), 
60.9 (CH2, C-13’), 55.6 (CH, C-9), 51.8 (CH2, C-3), 48.8 (CH2, C-5), 32.7 (CH2, C-6), 
31.7 (CH2, C-1), 29.6 (CH2, C-11), 22.0 (CH2, C-2), 15.3 (2 × CH3, C-14, 14’), 14.6 
(CH3, C-12); m/z (ESI) 286 [MH]
+
; [HRMS (ESI): calcd. for C15H28NO2S, 286.1835. 
Found: [MH]
+
, 286.1836 (0.3 ppm error)]; Anal. Calcd. for C15H27NO2S: C, 63.12; H, 
9.53; N, 4.91. Found: C, 63.05; H, 9.08; N, 4.88. 




S-Ethyl (S)-1,2,3,5,6,8a-hexahydroindolizine-8-carbothioate 402:  A stirred solution 
of alkyne 401 (800 mg, 2.80 mmol, 1.0 equiv.) in formic acid (20 mL) was heated at 
100 ºC (oil-bath pre-heated) for 2 h, then cooled to rt and the solution concentrated 
under reduced pressure.  The residue was dissolved in DCM (20 mL) and washed with 
sat. aq. NaHCO3 (20 mL), then the aqueous washes were back extracted with DCM (3 × 
20 mL).  The combined organic extracts were washed with brine (20 mL), dried 
(Na2SO4), then concentrated in vacuo to afford the title compound 402 (575 mg, 97%) 
as a pale yellow oil; Rf 0.32 (DCM/MeOH, 9:1); [α]
21
D –86.9 (c 0.97, CHCl3); υmax/cm
-1
 
(neat) 2930, 1655, 1165, 954, 764; δH (400 MHz, CDCl3) 6.95 (1 H, ddd, J = 5.1, 3.8, 
1.7, H-7), 3.62-3.53 (1 H, m, H-9), 2.98-2.81 (4 H, m, H-3a, 5a, 11), 2.73 (1 H, ddd, J = 
10.0, 8.3, 6.9, H-3b), 2.62 (1 H, ddd, J = 11.5, 7.6, 5.0, H-5b), 2.47-2.36 (1 H, m, H-6a), 
2.31-2.21 (2 H, m, H-1a, 6b), 1.90-1.71 (2 H, m, H-2), 1.47 (1 H, dddd, J = 12.7, 10.3, 
8.7, 7.6, H-1b), 1.25 (3 H, t, J = 7.4, H-12); δC (100 MHz, CDCl3) 192.1 (CO, C-10), 
141.6 (C, C-8), 135.5 (CH, C-7), 58.8 (CH, C-9), 52.1 (CH2, C-3), 45.0 (CH2, C-5), 
29.3 (CH2, C-1), 24.4 (CH2, C-6), 22.8 (CH2, C-11), 22.5 (CH2, C-2), 14.8 (CH3, C-12); 
m/z (ESI) 212 [MH]
+
; [HRMS (ESI): calcd. for C11H18NOS, 212.1104. Found: [MH]
+
, 
212.1106 (1.2 ppm error)]. 
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Lab Book Ref. = JDC/14/4 






:  To a stirred solution of ethyl-4-bromobutyrate (0.73 mL, 5.10 
mmol, 1.0 equiv.) in DCM (10 mL) at –78 ºC was added dropwise DIBAL-H (1.0 M in 
hexane, 5.36 mL, 5.36 mmol, 1.05 equiv.) over 30 min. via syringe pump.  The solution 
was held at –78 ºC for 1 h, before quenching with MeOH (2 mL).  The solution was 
warmed to rt and held for 30 min., then poured into sat. aq. Rochelle’s salt (20 mL) and 
ether (20 mL).  The biphasic solution was stirred vigourously for 2 h, then the aqueous 
phase was separated and extracted with Et2O (3 × 20 mL).  The combined organic 
extracts were washed with brine (20 mL), dried (MgSO4), then concentrated in vacuo to 
afford the title compound (0.77 g, Quant.) as a pale yellow oil which was sufficiently 
pure to use without further purification; Rf 0.19 (PE/EtOAc, 9:1); δH (400 MHz, CDCl3) 
9.82 (1 H, t, J = 0.9, H-1), 3.46 (2 H, t, J = 6.4, H-4), 2.68 (2 H, td, J = 7.0, 0.9, H-2), 
2.19 (2 H, tt, J = 7.0, 6.4, H-3). 
Lab Book Ref. = JDC/14/59 






4-Bromo-1,1-diethoxybutane 403: To a stirred solution of 4-bromobutanal (770 mg, 
5.10 mmol, 1.0 equiv.) in EtOH (7 mL) at rt was added NH4Cl (20 mg).  The solution 
was heated to reflux and held for 2 h, before cooling to rt and quenching with sat. aq. 
NaHCO3 (10 mL).  The aqueous phase was extracted with Et2O (3 × 10 mL), then the 
combined organics were washed with brine (10 mL), dried (MgSO4), then concentrated 
in vacuo to afford a colourless oil which was purified by column chromatography (SiO2, 
PE/Et2O, 19:1) to give the title compound 403 (802 mg, 70%) as a colourless oil; Rf 
0.49 (PE/EtOAc, 9:1); υmax/cm
-1
 (neat) 2975, 2930, 2878, 1127, 1062; δH (400 MHz, 
CDCl3) 4.49 (1 H, t, J = 5.6, H-1), 3.63 (2 H, dq, J = 9.4, 7.1, H-5a, 5a’), 3.47 (2 H, dq, J 
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= 9.4, 7.1, H-5b, 5b’), 3.42 (2 H, t, J = 6.7, H-4), 1.96-1.88 (2 H, m, H-3), 1.78-1.71 (2 H, 
m, H-2), 1.18 (6 H, t, J = 7.1, H-6, 6’); δC (100 MHz, CDCl3) 102.1 (CH, C-1), 61.2 (2 
× CH2, C-5, 5’), 33.6 (CH2, C-4), 32.2 (CH2, C-2), 28.0 (CH2, C-3), 15.3 (2 × CH3, C-6, 
6’); m/z (ESI) 247 [MNa]
+
; [HRMS (ESI): calcd. for C8H17
79
BrNaO2, 247.0304. Found: 
[MNa]
+
, 247.0312 (3.2 ppm error)]. 




(S)-1-(4,4-Diethoxybutyl)-2-ethynylpyrrolidine 404:  To a stirred solution of alkyne 
356 (250 mg, 1.20 mmol, 1.0 equiv.) in MeCN (15 mL) at rt were added successively 
K2CO3 (498 mg, 3.60 mmol, 3.0 equiv.) and acetal 403 (297 mg, 1.32 mmol, 1.1 equiv.).  
The suspension was heated to reflux and held for 18 h, then cooled to rt and the solvent 
removed under reduced pressure.  The residue was taken up in H2O (20 mL) and the 
aqueous phase was extracted with DCM (3 × 10 mL).  The combined organic extracts 
were washed with brine (10 mL), dried (Na2SO4), then concentrated in vacuo to afford 
an orange oil which was purified by column chromatography (SiO2, DCM/MeOH, 99:1-
98:2) to give the title compound 404 (133 mg, 47%) as a pale yellow oil; Rf 0.52 
(DCM/MeOH, 9:1); υmax/cm
-1
 (neat) 2974, 2877, 2808, 1376, 1128, 1065; δH (400 MHz, 
CDCl3) 4.50 (1 H, t, J = 5.6, H-8), 3.63 (1 H, dq, J = 9.4, 7.1, H-12a), 3.63 (1 H, dq, J = 
9.4, 7.1, H-12a’), 3.48 (2 H, dq, J = 9.4, 7.1, H-12b, 12b’), 3.41-3.34 (1 H, m, H-10), 
2.82-2.73 (2 H, m, H-3a, 5a), 2.48 (1 H, ddd, J = 8.8, 8.8, 5.6, H-3b), 2.40-2.32 (1 H, m, 
H-5b), 2.24 (1 H, d, J = 2.1, H-11), 2.14-2.03 (1 H, m, H-1a), 1.96-1.82 (2 H, m, H-1b, 
2a), 1.82-1.69 (1 H, m, H-2b), 1.69-1.52 (4 H, m, H-6, 7), 1.19 (6 H, t, J = 7.1, H-13, 
13’); δC (100 MHz, CDCl3) 102.7 (CH, C-8), 83.2 (C, C-9), 72.0 (CH, C-11), 60.9 (2 × 
CH2, C-12, 12’), 54.2 (CH, C-10), 52.9 (CH2, C-5), 51.6 (CH2, C-3), 31.6 (2 × CH2, C-1, 
7), 23.9 (CH2, C-6), 22.0 (CH2, C-2), 15.3 (2 × CH3, C-13, 13’); m/z (ESI) 240 [MH]
+
; 
[HRMS (ESI): calcd. for C14H26NO2, 240.1964. Found: [MH]
+
, 240.1961 (1.2 ppm 
error)]. 
Lab Book Ref. = JDC/14/67 
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(S)-1-(4,4-diethoxybutyl)-2-(ethylthioethynyl)pyrrolidine 405:  To a stirred solution 
of alkyne 404 (96 mg, 0.40 mmol, 1.0 equiv.) in THF (2.5 mL) at –78 ºC was added 
dropwise n-BuLi (1.58 M, 0.28 mL, 0.44 mmol, 1.1 equiv.).  The pale yellow solution 
was held at –78 ºC for 30 min., then diethyl disulfide (54 µL, 0.44 mmol, 1.1 equiv.) 
was added dropwise.  The solution was held at –78 ºC for a further 30 min., before 
warming to rt and holding for 2 h.  The reaction was quenched with sat. aq. NH4Cl (5 
mL), then the aqueous phase was extracted with DCM (3 × 10 mL).  The combined 
organic extracts were washed with brine (20 mL), dried (Na2SO4), then concentrated in 
vacuo to afford a yellow oil which was purified by column chromatography (SiO2, 
DCM/MeOH, 98:2) to give the title compound 405 (112 mg, 93%) as a colourless oil; 
Rf 0.55 (DCM/MeOH, 9:1); [α]
24
D –107.1 (c 1.35, CHCl3); υmax/cm
-1
 (neat) 2972, 2928, 
2875, 1375, 1127, 1062; δH (400 MHz, CDCl3) 4.49 (1 H, t, J = 5.4, H-8), 3.67-3.58 (2 
H, m, H-14a, 14a’), 3.52-3.43 (3 H, m, H-10, 14b, 14b’), 2.80-2.72 (2 H, m, H-3a, 5a), 
2.72-2.63 (2 H, m, H-12), 2.45 (1 H, ddd, J = 8.7, 8.5, 5.4, H-3b), 2.33 (1 H, ddd, J = 
11.7, 6.7, 6.7, H-5b), 2.12-2.01 (1 H, m, H-1a), 1.93-1.80 (2 H, m, 1b, 2a), 1.80-1.68 (1 H 
m, H-2b), 1.68-1.50 (4 H, m, H-6, 7), 1.36 (3 H, t, J = 7.3, H-13), 1.18 (6 H, t, J = 7.1, 
H-15, 15’); δC (100 MHz, CDCl3) 102.8 (CH, C-8), 93.5 (C, C-9), 73.1 (C, C-11), 61.0 
(CH2, C-14), 60.9 (CH2, C-14’), 55.5 (CH, C-10), 53.0 (CH2, C-5), 51.6 (CH2, C-3), 
31.7 (2 × CH2, C-1, 7), 29.6 (CH2, C-12), 23.9 (CH2, C-6), 22.0 (CH2, C-2), 15.3 (2 × 
CH3, C-15, 15’), 14.6 (CH3, C-13); m/z (ESI) 300 [MH]
+
; [HRMS (ESI): calcd. for 
C16H30NO2S, 300.1992. Found: [MH]
+
, 300.1993 (0.3 ppm error)]. 
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(8R,8aS)-Octahydroindolizin-8-ylmethanol 407:  To a stirred solution of LiAlH4 (4.0 
M in Et2O, 0.19 mL, 0.76 mmol, 4.0 equiv.) in Et2O (5 mL) at 0 ºC was added thioester 
400 (50 mg, 0.19 mmol, 1.0 equiv.) as a solution in THF (1 mL).  The solution was 
stirred at 0 ºC for 30 min., then warmed to rt and held for 2 h.  The reaction was cooled 
to 0 ºC and quenched with excess sodium sulfate decahydrate.  The slurry was filtered, 
then the filtrate was concentrated in vacuo to afford a yellow oil which was purified by 
column chromatography (SiO2, DCM/MeOH/NH3, 90:9:1) to give allylic alcohol 288 (7 
mg, 24%) as a yellow film and the title compound 407 (6 mg, 21%) as a yellow film; Rf 
0.05 (DCM/MeOH, 9:1); [α]
23
D −42.6 (c 1.08, EtOH), (Lit.
167
 +44.7 (c 1.1, EtOH)); 
υmax/cm
-1
 (neat) 3365, 2930, 1444, 1164, 1042; δH (400 MHz, CDCl3) 3.65 (1 H, dd, J = 
10.8, 4.7, H-10a), 3.50 (1 H, dd, J = 10.8, 6.3, H-10b), 3.17-3.08 (2 H, m, H-3a, 5a), 2.12 
(1 H, ddd, J = 9.1, 9.1, 9.1, H-3b), 1.97-1.80 (3 H, m, H-1a, 5b, 7a), 1.80-1.54 (5 H, m, 
H-2, 6, 9), 1.55-1.43 (2 H, m, H-1b, 8), 1.05 (1 H, m, H-7b); δC (100 MHz, CDCl3) 66.4 
(CH, C-9), 65.6 (CH2, C-10), 54.0 (CH2, C-3), 52.5 (CH2, C-5), 44.2 (CH, C-8), 28.9 
(CH2, C-1), 27.3 (CH2, C-7), 24.9 (CH2, C-6), 20.6 (CH2, C-2); m/z (ESI) 156 [MH]
+
; 
[HRMS (ESI): calcd. for C9H18NO, 156.1383. Found: [MH]
+
, 156.1386 (1.7 ppm error)]. 
Lab Book Ref. = JDC/12/7 






Methyl (S)-1,2,3,5,6,8a-hexahydroindolizine-8-carboxylate 409: To a stirred solution 
of thioester 402 (1.04 g, 4.92 mmol, 1.0 equiv.) and Et3N (3.43 mL, 24.6 mmol, 5.0 
equiv.) in DCM/MeOH (1:1, 40 mL) at rt was added in one portion AgOTf (3.80 g, 14.8 
mmol, 3.0 equiv.).  The brown solution was heated to 45 ºC and held for 18 h, then 
cooled to rt and filtered through a short plug of silica, washing with DCM/MeOH (100 
mL, 9:1).  The organic phase was washed with sat. aq. NaHCO3 (100 mL), then the 
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aqueous washings were back-extracted with DCM (3 × 100 mL). The combined organic 
extracts were washed with brine (100 mL), dried (Na2SO4), then concentrated in vacuo 
to afford a brown oil which was purified by column chromatography (SiO2, 
DCM/MeOH, 19:1-4:1) to give the title compound 409 (0.65 g, 73%) as a pale yellow 
oil; Rf 0.12 (DCM/MeOH, 9:1); [α]
20
D –55.6 (c 0.35, CHCl3); υmax/cm
-1
 (neat) 2951, 
1713, 1435, 1260, 1100, 1036; δH (400 MHz, CDCl3) 6.98-6.94 (1 H, m, H-7), 3.69 (3 
H, s, H-11), 3.61-3.53 (1 H, m, H-9), 2.93-2.80 (3 H, m, H-3, 5a), 2.67 (1 H, ddd, J = 
11.9, 6.0, 6.0, H-5b), 2.38-2.26 (3 H, m, H-1a, 6), 1.92-1.73 (2 H, m, H-2), 1.55-1.44 (1 
H, m, H-1b); δC (100 MHz, CDCl3) 166.3 (CO, C-10), 137.4 (CH, C-7), 132.2 (C, C-8), 
58.7 (CH, C-9), 52.5 (CH2, C-3), 51.5 (CH3, C-11), 44.9 (CH2, C-5), 29.8 (CH2, C-1), 
24.4 (CH2, C-6), 22.3 (CH2, C-2); m/z (ESI) 182 [MH]
+
; [HRMS (ESI): calcd. for 
C10H16NO2, 182.1176. Found: [MH]
+
, 182.1179 (1.8 ppm error)]. 
Lab Book Ref. = JDC/14/48 







 288: To a stirred solution of 
ester 409 (394 mg, 2.17 mmol, 1.0 equiv.) in THF (30 mL) at 0 ºC was added dropwise 
DIBAL-H (1.0 M in hexane, 8.68 mL, 8.68 mmol, 4.0 equiv.) over 20 min. via syringe 
pump.  The solution was held at 0 ºC for 30 min., then warmed to rt and held for 2 h.  
The reaction was cooled to 0 ºC before quenching with MeOH (1 mL), then diluted with 
sat. aq. Rochelle’s salt (25 mL) and EtOAc (25 mL). The biphasic solution was stirred 
vigourously for 2 h, then the aqueous phase was separated and extracted with EtOAc (4 
× 25 mL).  The combined organic extracts were washed with brine (25 mL), dried 
(MgSO4), then concentrated in vacuo to afford the title compound 288 (228 mg, 69%) 
as a pale orange oil; Rf 0.04 (DCM/MeOH, 9:1); [α]
20
D –54.6 (c 1.03, CHCl3); υmax/cm
-1
 
(neat) 3352 (br), 2909, 2875, 1458, 1062, 1018; δH (400 MHz, CDCl3) 5.68-5.64 (1 H, 
m, H-7), 4.05-4.03 (2 H, m, H-10), 3.35 (1 H, br s, OH), 3.19-3.12 (1 H, m, H-9), 2.91 
(1 H, ddd, J = 10.5, 8.1, 3.8, H-3a), 2.80 (1 H, ddd, J = 11.3, 5.7, 5.7, H-5a), 2.67 (1 H, 
ddd, J = 10.5, 8.9, 7.9, H-3b), 2.53 (1 H, ddd, J = 11.3, 6.0, 6.0, H-5b), 2.27-2.13 (2 H, m, 
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H-6), 2.03 (1 H, dddd, J = 12.1, 9.5, 6.9, 3.6, H-1a), 1.89 (1 H, ddddd, J = 12.8, 10.5, 
8.1, 7.9, 3.6, H-2a), 1.75 (1 H, ddddd, J = 12.8, 9.5, 8.9, 7.3, 3.8, H-2b), 1.54 (1 H, dddd, 
J = 12.1, 10.5, 10.5, 7.3, H-1b); δC (100 MHz, CDCl3) 139.4 (C, C-8), 120.5 (CH, C-7), 
64.7 (CH2, C-10), 60.4 (CH, C-9), 52.9 (CH2, C-3), 46.6 (CH2, C-5), 28.0 (CH2, C-1), 
25.0 (CH2, C-6), 22.1 (CH2, C-2); m/z (ESI) 154 [MH]
+
; [HRMS (ESI): calcd. for 
C9H16NO, 154.1226. Found: [MH]
+
, 154.1226 (0.3 ppm error)]. 
Lab Book Ref. = JDC/14/79 
















 87: To a stirred solution of organocatalyst 275 (299 
mg, 0.50 mmol, 0.05 equiv.) in crotonaldehyde (1.24 mL, 15.0 mmol, 1.5 equiv.) at rt 
was added tert-butyl acetoacetate (1.66 mL, 10.0 mmol, 1.0 equiv.).  The yellow 
solution was stirred at rt for 24 h, then excess crotonaldehyde was removed under 
reduced pressure. The yellow oil was taken up in PhMe (40 mL), then p-TsOH (380 mg, 
2.00 mmol, 0.2 equiv.) was added.  The solution was heated to 80 ºC and held for 18 h, 
then cooled to rt and quenched with sat. aq. NaHCO3 (20 mL).  The aqueous phase was 
separated, then extracted with Et2O (3 × 20 mL). The combined organic extracts were 
washed with brine (20 mL), dried (MgSO4), then concentrated in vacuo to afford a 
brown oil which was purified by column chromatography (SiO2, PE/Et2O, 9:1) to give 
the title compound 87 (510 mg, 46%) as a pale yellow oil; Rf 0.32 (PE/EtOAc, 4:1); 
[α]
21
D +70.4 (c 0.52, CHCl3), (Lit.
105
 −74.6 (c 0.50, CHCl3, 80% ee); δH (400 MHz, 
CDCl3) 6.95 (1 H, ddd, J = 10.1, 5.6, 2.6, H-3), 6.00 (1 H, dddd, J = 10.1, 2.5, 1.0, 1.0, 
H-2), 2.50-2.45 (1 H, m, H-6a), 2.45-2.37 (1 H, m, H-4a), 2.29-2.15 (1 H, m, H-5), 2.11 
(1 H, dd, J = 15.9, 12.3, H-6b), 2.03 (1 H, dddd, J = 18.5, 9.8, 2.6, 2.5, H-4b), 1.06 (3 H, 
d, J = 6.5, H-7). 
Lab Book Ref. = JDC/14/30 








417 and 418:  To a stirred suspension of 5-methyl-1,3-cyclohexanedione (0.92 g, 7.30 
mmol, 1.0 equiv.) and (−)-menthol (1.14 g, 7.30 mmol, 1.0 equiv.) in PhMe (25 mL) at 
rt was added p-TsOH (70 mg, 0.37 mmol, 0.05 equiv.).  The suspension was heated to 
reflux (Dean-Stark) and held for 24 h.  The orange solution was cooled to rt, then 
quenched with sat. aq. NaHCO3 (20 mL).  The organic phase was separated, then the 
aqueous phase was extracted with ether (3 × 25 mL).  The combined organic extracts 
were washed with brine (25 mL), dried (MgSO4), then concentrated in vacuo to afford a 
yellow oil which was purified by column chromatography (SiO2, PE/EtOAc, 10:0-9:1) 
to give the title compounds 417 and 418 (1.64 g, 85%, 1:1 ratio of diastereoisomers) as 
a colourless oil; Rf 0.40 (PE/Et2O, 1:1); υmax/cm
-1
 (neat) 2954, 2871, 1655, 1600, 1377, 
1208; δH (400 MHz, CDCl3) 5.38 (2 H, s, H-12, 12’), 4.00-3.91 (2 H, m, H-9, 9’), 2.45-
2.31 (4 H, m, H-14a, 14a’, 16a, 16a’), 2.28-1.89 (10 H, m, H-6, 6’, 10a, 10a’, 14b, 14b’, 15, 
15’, 16b, 16b’), 1.72-1.63 (4 H, m, H-3a, 3a’, 4a, 4a’), 1.50-1.31 (4 H, m, H-2, 2’, 5, 5’), 
1.06 (3 H, d, J = 1.8, CH3), 1.05 (3 H, d, J = 1.7, CH3), 0.91-0.86 (12 H, m, CH3), 0.73 
(3 H, d, J = 4.4, CH3), 0.72 (3 H, d, J = 4.4, CH3); δC (100 MHz, CDCl3) 200.0 (CO, C-
13), 199.9 (CO, C-13), 176.8 (C, C-11), 176.5 (C, C-11), 102.2 (CH, C-12), 101.9 (CH, 
C-12), 78.4 (CH, C-9), 77.9 (CH, C-9), 47.4 (CH, C-5), 47.3 (CH, C-5), 45.0 (2 × CH2, 
C-14), 39.4 (CH2, C-10), 38.9 (CH2, C-10), 37.7 (CH2, C-16), 37.5 (CH2, C-16), 34.2 (2 
× CH2, C-3), 31.2 (2 × CH, C-2), 28.8 (CH, C-15), 28.7 (CH, C-15), 26.4 (CH, C-6), 
26.3 (CH, C-6), 23.8 (CH2, C-4), 23.7 (C-4), 21.9 (2 × CH3, C-1), 20.9 (CH3), 20.8 
(CH3), 20.5 (CH3), 20.4 (CH3), 16.7 (CH3), 16.6 (CH3); m/z (ESI) 265 [MH]
+
; [HRMS 
(ESI): calcd. for C17H29O2, 265.2162. Found: [MH]
+
, 265.2153 (3.4 ppm error)]. 
Lab Book Ref. = JDC/6/97 
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(S)-1,2,3,5,6,8a-Hexahydroindolizine-8-carbaldehyde 172:  To a stirred solution of 
oxalyl chloride (105 µL, 1.24 mmol, 1.2 equiv.) in DCM (5 mL) at −78 ºC was added 
dropwise DMSO (176 µL, 2.48 mmol, 2.4 equiv.).  The colourless solution was held at 
−78 ºC for 30 min., then alcohol 288 (158 mg, 1.03 mmol, 1.0 equiv.) was added via 
cannula as a pre-cooled solution in DCM (3 mL).  The reaction was held at −78 ºC for 1 
h, then Et3N (718 µL, 5.15 mmol, 5.0 equiv.) was added dropwise.  The yellow solution 
was held at −78 ºC for a further 30 min., then warmed to rt and held for 1 h.  The 
reaction was quenched with sat. aq. NaHCO3 (10 mL) then the aqueous phase was 
extracted with DCM (4 × 10 mL).  The combined organic extracts were washed with sat. 
aq. NaHCO3 (20 mL) and brine (20 mL), dried (Na2SO4), then concentrated in vacuo to 
afford the title compound 172 (137 mg, 88%) as a yellow oil which was used 
immediately without further purification; Rf 0.28 (DCM/MeOH, 9:1); δH (400 MHz, 
CDCl3) 9.41 (1 H, s, H-10), 6.84 (1 H, ddd, J = 4.0, 3.9, 1.7, H-7), 3.45-3.37 (1 H, m, 
H-9), 2.97-2.90 (1 H, m, H-5a), 2.90 (1 H, ddd, J = 10.1, 7.9, 4.8, H-3a), 2.74 (1 H, ddd, 
J = 10.1, 8.5, 7.3, H-3b), 2.68-2.61 (1 H, m, H-5b), 2.61-2.51 (1 H, m, H-6a), 2.48-2.38 
(1 H, m, H-6b), 2.40-2.31 (1 H, m, H-1a), 1.94-1.75 (2 H, m, H-2), 1.45 (1 H, dddd, J = 
12.8, 10.2, 9.4, 7.6, H-1b). 
Lab Book Ref. = JDC/14/18 



























methylcyclohex-2-en-1-one 287:  To a stirred solution of diisopropylamine (119 µL, 
0.85 mmol, 1.3 equiv.) in THF (7 mL) at 0 ºC was added dropwise n-BuLi (1.58 M in 
hexanes, 0.49 mL, 0.77 mmol, 1.2 equiv.).  The colourless solution was held at 0 ºC for 
30 min., then cooled to −78 ºC before the addition of enone 87 (72 mg, 0.65 mmol, 1.0 
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equiv.) as a pre-cooled solution in THF (1 mL).  The resulting pale yellow solution was 
held at −78 ºC for 1 h, before the addition of aldehyde 172 (137 mg, 0.91 mmol, 1.4 
equiv.) as a pre-cooled solution in THF (1 mL).  The reaction was held at −78 ºC for a 
further 2 h, then quenched with AcOH (0.5 mL).  The organic phase was diluted with 
water (20 mL) and basified (K2CO3) then extracted with DCM (4 × 10 mL).  The 
combined organic extracts were washed with brine (10 mL), dried (Na2SO4), then 
concentrated in vacuo to afford an orange oil which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 120:9:1-90:9:1) to give the minor 
diastereoisomer 294 (18 mg, 10%) as an off-white solid and the title compound 287 (94 
mg, 51%) as an off-white solid; mp. 113-116 ºC; Rf 0.49 (DCM/MeOH/NH3, 40:9:1); 
[α]
20
D –20.4 (c 0.99, CHCl3); υmax/cm
-1
 (thin film) 3399 (br), 2957, 2918, 1676, 1389, 
1026, 730; δH (400 MHz, CDCl3) 6.86 (1 H, dddd, J = 10.1, 5.2, 2.8, 1.1, H-14), 6.03 (1 
H, dddd, J = 10.1, 2.6, 1.5, 0.7, H-13), 5.77 (1 H, ddd, J = 3.8, 3.8, 1.3, H-7), 4.25 (1 H, 
d, J = 9.5, H-10), 3.06-2.99 (1 H, m, H-9), 2.95 (1 H, ddd, J = 10.5, 8.4, 3.4, H-3a), 2.84 
(1 H, ddd, J = 11.3, 5.7, 5.7, H-5a), 2.72-2.63 (1 H, m, H-3b), 2.56 (1 H, dddd, J = 19.7, 
5.6, 2.8, 2.6, H-15a), 2.50 (1 H, ddd, J = 11.3, 5.6, 5.3, H-5b), 2.38 (1 H, dd, J = 9.5, 3.2, 
H-11), 2.44-2.11 (4 H, m, H-1a, 6, 16), 2.07 (1 H, dddd, J = 19.7, 5.2, 2.3, 1.5, H-15b), 
2.00-1.86 (1 H, m, H-2a), 1.82-1.67 (2 H, m, H-1b, 2b), 1.07 (3 H, d, J = 7.1, H-17); δC 
(100 MHz, CDCl3) 201.4 (CO, C-12), 147.9 (CH, C-14), 139.1 (C, C-8), 128.3 (CH, C-
13), 124.5 (CH, C-7), 74.7 (CH, C-10), 59.8 (CH, C-9), 56.6 (CH, C-11), 53.0 (CH2, C-
3), 46.3 (CH2, C-5), 30.1 (CH, C-16), 30.0 (CH2, C-15), 29.6 (CH2, C-1), 25.5 (CH2, C-
6), 22.3 (CH2, C-2), 19.9 (CH3, C-17); m/z (ESI) 262 [MH]
+
; [HRMS (ESI): calcd. for 
C16H24NO2, 262.1802. Found: [MH]
+

























methylcyclohex-2-en-1-one 294: (18 mg, 10%) as an off-white solid; mp. 105-108 ºC; 
Rf 0.35 (DCM/MeOH/NH3, 40:9:1); [α]
24
D –65.4 (c 0.55, CHCl3); υmax/cm
-1
 (thin film) 
3340 (br), 2956, 2915, 1668, 730; δH (400 MHz, CDCl3) 6.82-6.77 (1 H, m, H-14), 5.95 
(1 H, ddd, J = 10.1, 2.4, 1.6, H-13), 5.74-5.71 (1 H, m, H-7), 4.26 (1 H, d, J = 7.9, H-
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10), 3.12-3.05 (1 H, m, H-9), 2.88 (1 H, ddd, J = 10.6, 8.5, 3.5, H-3a), 2.76 (1 H, ddd, J 
= 11.3, 5.7, 5.7 H-5a), 2.63-2.48 (2 H, m, H-3b, 15a), 2.47 (1 H, ddd, J = 11.3, 5.6, 5.6, 
H-5b), 2.31 (1 H, dd, J = 7.9, 4.3, H-11), 2.28-2.19 (3 H, m, H-6, 16), 2.09-1.98 (2 H, m, 
H-1a, 15b), 1.93-1.80 (1 H, m, H-2a), 1.78-1.66 (1 H, m, H-2b), 1.53-1.42 (1 H, m, H-1b), 
1.02 (3 H, d, J = 7.0, H-17); δC (100 MHz, CDCl3) 201.0 (CO, C-12), 147.6 (CH, C-14), 
139.6 (C, C-8), 128.5 (CH, C-13), 122.1 (CH, C-7), 73.4 (CH, C-10), 60.1 (CH, C-9), 
57.5 (CH, C-11), 52.7 (CH2, C-3), 46.3 (CH2, C-5), 30.8 (CH, C-16), 30.4 (CH2, C-15), 
28.2 (CH2, C-1), 25.4 (CH2, C-6), 22.0 (CH2, C-2), 19.9 (CH3, C-17); m/z (ESI) 262 
[MH]
+
; [HRMS (ESI): calcd. for C16H24NO2, 262.1802. Found: [MH]
+
, 262.1803 (0.5 
ppm error)]. 
























2-en-1-one 17:  To a stirred solution of DMSO (21 µL, 0.30 mmol, 2.0 equiv.) in DCM 
(4 mL) at −78 ºC was added dropwise trifluoroacetic anhydride (32 µL, 0.23 mmol, 1.5 
equiv.).  The colourless solution was held at −78 ºC for 30 min., before adding alcohol 
287 (40 mg, 0.15 mmol, 1.0 equiv.) as a pre-cooled solution in DCM (2 mL) via 
cannula.  The reaction was held at −78 ºC for 1 h, then Et3N (105 µL, 0.75 mmol, 5.0 
equiv.) was added dropwise.  The yellow solution was held at −78 ºC for a further 15 
min., then warmed to rt and held for 1 h.  The reaction was quenched with sat. aq. 
NaHCO3 (20 mL), then the aqueous phase was extracted with DCM (4 × 10 mL).  The 
combined organic extracts were washed with brine (10 mL), dried (Na2SO4), then 
concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 190:9:1) to give the title compound 17 (32 
mg, 80%) as a colourless oil. To a solution of the product 17 (14 mg, 0.05 mmol, 1.0 
equiv.) in DCM (1 mL) at 0 ºC was added dropwise TFA (5 µL, 0.07 mmol, 1.4 equiv). 
The colourless solution was held at 0 ºC for 15 min., then warmed to rt and held for 1 h.  
The pale yellow solution was concentrated in vacuo to afford the title compound 
17·TFA (19 mg, Quant.) as a pale yellow oil; Rf 0.69 (DCM/MeOH/NH3, 40:9:1); [α]
22
D 
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+73.7 (c 0.10, MeOH), (Lit.
25
 +65.7 (c 0.09, MeOH)); υmax/cm
-1
 (thin film) 2959, 1676, 
1656, 1390, 1190; δH (400 MHz, DMSO-d6) 10.37 (1 H, br s, NH
+
), 7.35 (1 H, dd, J = 
3.8, 3.8, H-7), 7.16 (1 H, ddd, J = 9.9, 5.5, 2.2, H-14), 5.97 (1 H, dd, J = 9.9, 2.1, H-13), 
4.40 (1 H, dd, J = 8.7, 8.7, H-9), 4.33 (1 H, d, J = 11.5, H-11), 3.62-3.50 (1 H, m, H-3a), 
3.41-3.27 (2 H, m, H-3b, 5a), 3.18-3.05 (1 H, m, H-5b), 2.66-2.59 (2 H, m, H-6), 2.53-
2.37 (3 H, m, H-1a, 15a, 16), 2.27-2.15 (1 H, m, H-15b), 2.08-1.98 (2 H, m, H-2), 1.71-
1.58 (1 H, m, 1b) 0.86 (3 H, d, J = 6.2, H-17); δC (100 MHz, DMSO-d6) 198.3 (CO, C-
10), 196.7 (CO, C-12), 151.6 (CH, C-14), 140.1 (CH, C-7), 137.2 (C, C-8), 128.3 (CH, 
C-13), 59.2 (CH, C-11), 57.9 (CH, C-9), 52.9 (CH2, C-3), 43.1 (CH2, C-5), 33.0 (CH, 
C-16), 32.6 (CH2, C-15), 28.1 (CH2, C-1), 22.9 (CH2, C-6), 20.2 (CH2, C-2), 19.1 (CH3, 
C-17); m/z (ESI) 260 [MH]
+
; [HRMS (ESI): calcd. for C16H22NO2, 260.1645. Found: 
[MH]
+
, 260.1644 (0.4 ppm error)]. 
Lab Book Ref. = JDC/14/54 







5-one 15:  To a stirred solution of diketone 17 (14 mg, 0.054 mmol, 1.0 equiv.) in 1 M 
aq. HCl (1 mL) at 0 ºC was added dropwise 35% aq. NH3 (1 mL, ca. 18 mmol).  The 
yellow solution was held at 0 ºC for 30 min., then warmed to rt and held for 2 h.  The 
yellow solution was diluted with brine (10 mL), then extracted with DCM (4 × 5 mL).  
The combined organic extracts were washed with brine (5 mL), dried (Na2SO4), then 
concentrated in vacuo to afford a yellow film which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 90:9:1) to give the title compound 15 (10 mg, 
72%) as a yellow film; Rf 0.33 (DCM/MeOH/NH3, 90:9:1); [α]
20
D = −177.5 (c 0.08, 
DCM), (Lit.
55
 −159.0 (c 0.08, DCM)); υmax/cm
-1
 (neat) 2954, 2872, 1730, 1578, 1341, 
1102; δH (400 MHz, CDCl3) 6.41 (1 H, ddd, J = 4.2, 4.2, 1.5, H-7), 4.63 (1 H, dddd, J = 
3.6, 3.3, 1.8, 1.8, H-14), 3.70-3.63 (1 H, m, H-9), 3.55 (1 H, d, J = 3.1, H-11), 2.92 (1 H, 
ddd, J = 10.2, 7.7, 4.7, H-3a), 2.87 (1 H, ddd, J = 11.0, 3.2, 3.2, H-5a), 2.77 (1 H, ddd, J 
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= 10.2, 8.2, 7.5, H-3b), 2.64 (1 H, ddd, J = 11.0, 7.0, 5.1, H-5b), 2.47-2.36 (1 H, m, H-6a), 
2.36-2.24 (2 H, m, H-1a, 6b), 2.16 (1 H, ddd, J = 18.8, 3.3, 2.7, H-13a), 2.06 (1 H, dd, J 
= 18.8, 1.8, H-13b), 2.00-1.92 (1 H, m, H-15a), 1.91-1.72 (3 H, m, H-2, 16), 1.35 (1 H, 
dddd, J = 12.7, 10.3, 9.3, 7.6, H-1b), 1.27 (1 H, ddd, J = 12.6, 4.5, 1.8, H-15b), 1.06 (3 H, 
d, J = 7.0, H-17); δC (100 MHz, CDCl3) 208.9 (CO, C-12), 171.1 (CN, C-10), 138.6 (C, 
C-8), 130.2 (CH, C-7), 58.9 (CH, C-9), 56.5 (CH, C-11), 55.6 (CH, C-14), 52.6 (CH2, 
C-3), 45.2 (CH2, C-5), 40.0 (CH2, C-13), 32.2 (CH2, C-15), 30.0 (CH2, C-1), 29.2 (CH, 
C-16), 24.9 (CH2, C-6), 22.4 (CH2, C-2), 21.2 (CH3, C-17); m/z (ESI) 259 [MH]
+
; 
[HRMS (ESI): calcd. for C16H23N2O, 259.1805. Found: [MH]
+
, 259.1810 (2.1 ppm 
error)]. 
Lab Book Ref. = JDC/14/56 






1-[(8aS)-1,2,3,5,6,8a-Hexahydroindolizin-8-yl]butan-1-one 57:  To a stirred solution 
of thioester 400 (54 mg, 0.21 mmol, 1.0 equiv.) in THF (1 mL) at 0 ºC was added 
Fe(acac)3 (3 mg, 0.008 mmol, 0.04 equiv.).  The orange solution was held at 0 ºC for 5 
min., then propyl magnesium bromide (2.0 M in Et2O, 145 µL, 0.29 mmol, 1.4 equiv.) 
was added dropwise.  The resulting black solution was held at 0 ºC for 30 min., then 
quenched with sat. aq. NH4Cl (1 mL).  The aqueous phase was extracted with DCM (3 
× 5 mL), then the combined organic extracts were washed with brine (5 mL), dried 
(Na2SO4), then concentrated in vacuo to afford an orange oil which was purified by 
column chromatography (SiO2, DCM/MeOH, 98:2-9:1) to give the title compound 57 
(16 mg, 39%) as a colourless oil; Rf 0.16 (DCM/MeOH, 9:1); υmax/cm
-1
 (neat) = 2961, 
2875, 1666, 1461, 1395, 1201; δH (400 MHz, CDCl3) 6.92 (1 H, ddd, J = 4.3, 4.2, 1.4, 
H-7), 3.77 (1 H, dd, J = 8.6, 8.3, H-9), 3.09 (1 H, ddd, J = 11.1, 8.3, 8.3, H-3a), 3.01-
2.94 (1 H, m, H-3b), 2.89-2.84 (2 H, m, H-5), 2.68-2.53 (1 H, m, H-6a), 2.63 (1 H, dt, J 
= 16.4, 7.3, H-11a), 2.58 (1 H, dt, J = 16.4, 7.3, H-11b), 2.52-2.42 (2 H, m, H-1a, 6b), 
1.96-1.87 (2 H, m, H-2), 1.62 (2 H, qt, J = 7.4, 7.3, H-12), 1.47 (1 H, dddd, J = 13.1, 9.8, 
9.7, 8.3, H-1b), 0.91 (3 H, t, J = 7.4, H-13); δC (100 MHz, CDCl3) 199.8 (CO, C-10), 
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139.9 (C, C-8), 136.3 (CH, C-7), 58.6 (CH, C-9), 52.9 (CH2, C-3), 44.8 (CH2, C-5), 
39.1 (CH2, C-11), 29.4 (CH2, C-1), 24.6 (CH2, C-6), 21.9 (CH2, C-2), 17.9 (CH2, C-12), 
13.7 (CH3, C-13); m/z (ESI) 194 [MH]
+
; [HRMS (ESI): calcd. for C12H20NO, 194.1539. 
Found: [MH]
+
, 194.1541 (0.9 ppm error)]. 
Lab Book Ref. = JDC/12/1 






(2E)-1-[(8aS)-1,2,3,5,6,8a-Hexahydroindolizin-8-yl]-3-phenylprop-2-en-1-one 421:  
To a stirred solution thioester 400 (20 mg, 0.08 mmol, 1.0 equiv.), styrenyl boronic acid 
(21 mg, 0.14 mmol, 1.7 equiv.), copper(I) thiophene carboxylate (27 mg, 0.14 mmol, 
1.7 equiv.) and Pd2(dba)3 (2 mg, 0.002 mmol, 0.025 equiv.) in THF (1 mL, degassed) 
under argon (flask purged via 5 × vacuum/Ar cycles) at rt was added P(OEt)3 (3 µL, 
0.02 mmol, 0.2 equiv.).  The dark brown solution was held at rt for 4 h, then quenched 
with sat. aq. NaHCO3 (2 mL).  The aqueous phase was extracted with DCM (3 × 5 mL), 
then the combined organic extracts were washed with brine (5 mL), dried (Na2SO4), 
then concentrated in vacuo to afford a brown oil which was purified by column 
chromatography (SiO2, DCM/MeOH/NH3, 95:5:0-190:9:1) to give the title compound 
421 (11 mg, 56%) as a yellow film; Rf 0.11 (DCM/MeOH, 9:1); υmax/cm
-1
 (thin film) 
2923, 1654, 1597, 1202; δH (400 MHz, CDCl3) 7.65 (1 H, d, J = 15.7, H-12), 7.61-7.54 
(2 H, m, ArH), 7.41-7.37 (3 H, m, ArH), 7.23 (1 H, d, J = 15.7, H-11), 7.06 (1 H, ddd, J 
= 4.2, 4.2, 1.5, H-7), 4.02 (1 H, dd, J = 9.2, 8.6, H-9), 3.23 (1 H, ddd, J = 10.7, 8.3, 8.3, 
H-3a), 3.05 (1 H, ddd, J = 10.7, 6.7, 6.7, H-3b), 3.01-2.96 (2 H, m, H-5), 2.79-2.68 (1 H, 
m, H-6a), 2.63-2.52 (2 H, m, H-1a, 6b), 2.04-1.95 (2 H, m, H-2), 1.58 (1 H, ddd, J = 13.1, 
9.4, 9.2, H-1b); δC (100 MHz, CDCl3) 188.9 (CO, C-10), 143.9 (CH, C-12), 140.2 (C, C-
8), 136.2 (CH, C-7), 134.7 (C, ArC), 130.5 (CH, ArCH), 128.9 (2 × CH, ArCH), 128.3 
(2 × CH, ArCH), 120.6 (CH, C-11), 58.9 (CH, C-9), 53.0 (CH2, C-3), 45.0 (CH2, C-5), 
29.3 (CH2, C-1), 24.3 (CH2, C-6), 21.8 (CH2, C-2); m/z (ESI) 254 [MH]
+
; [HRMS (ESI): 
calcd. for C17H20NO, 254.1539. Found: [MH]
+
, 254.1536 (1.5 ppm error)]. 
  282 




(2E)-1-[(8aS)-1,2,3,5,6,8a-Hexahydroindolizin-8-yl]but-2-en-1-one 422:  To a stirred 
solution thioester 400 (200 mg, 0.77 mmol, 1.0 equiv.), cis-propenyl boronic acid (113 
mg, 1.31 mmol, 1.7 equiv.), copper(I) thiophene carboxylate (250 mg, 1.31 mmol, 1.7 
equiv.) and Pd2(dba)3 (18 mg, 0.02 mmol, 0.025 equiv.) in THF (10 mL, degassed) 
under argon (flask purged via 5 × vacuum/Ar cycles) at rt was added P(OEt)3 (26 µL, 
0.15 mmol, 0.2 equiv.).  The dark brown solution was held at rt for 4 h, then quenched 
with sat. aq. NaHCO3 (5 mL).  The aqueous phase was extracted with DCM (3 × 10 
mL), then the combined organic extracts were washed with brine (10 mL), dried 
(Na2SO4), then concentrated in vacuo to afford a brown oil which was purified by 
column chromatography (SiO2, DCM/MeOH, 9:1-4:1) to give the title compound 422 
(102 mg, 69%) as an orange oil containing minor aromatic impurities; Rf 0.16 
(DCM/MeOH, 4:1); υmax/cm
-1
 (neat) 2958, 1662, 1616, 1443, 1293, 1205; δH (400 MHz, 
CDCl3) 6.87-6.83 (1 H, m, H-7), 6.85 (1 H, dq, J = 15.1, 6.9, H-12), 6.57 (1 H, dq, J = 
15.1, 1.4, H-11), 3.71 (1 H, dd, J = 7.8, 7.5, H-9), 2.92 (2 H, dd, J = 7.2, 7.2, H-3), 2.91-
2.82 (1 H, m, H-5a), 2.75 (1 H, ddd, J = 11.2, 5.5, 5.5, H-5b), 2.49-2.41 (2 H, m, H-6), 
2.40-2.31 (1 H, m, 1a), 1.91-1.79 (2 H, m, H-2), 1.87 (3 H, dd, J = 6.9, 1.4, H-13), 1.41 
(1 H, dddd, J = 13.0, 9.8, 9.7, 7.8, H-1b); δC (100 MHz, CDCl3) 189.8 (C, C-10), 143.2 
(CH, C-12), 140.9 (C, C-8), 136.5 (CH, C-7), 126.4 (CH, C-11), 58.5 (CH, C-9), 52.4 
(CH2, C-3), 44.7 (CH2, C-5), 29.1 (CH2, C-1), 24.6 (CH2, C-6), 22.0 (CH2, C-2), 18.3 
(CH3, C-13); m/z (ESI) 192 [MH]
+
; [HRMS (ESI): calcd. for C12H18NO, 192.1383. 
Found: [MH]
+
, 192.1382 (0.4 ppm error)]. 









419:  To a stirred solution of enone 422 (102 mg, 0.53 mmol, 1.0 equiv.) in 1 M. aq. 
HCl (2.5 mL) at 0 ºC was added 35 % aq. NH3 (5 mL).  The solution was held at 0 ºC 
for 30 min., then diluted with H2O (10 mL).  The aqueous phase was extracted with 
DCM (3 × 10 mL), then the combined organics were washed with brine (10 mL), dried 
(Na2SO4), then concentrated in vacuo to afford a yellow oil which was purified by 
column chromatography (SiO2, DCM/MeOH/NH3, 190:9:1-90:9:1) to give the title 
compound 419 (28 mg, 25%) as a yellow oil containing minor diastereomeric impurities; 
Rf 0.16 (DCM/MeOH/NH3, 90:9:1); υmax/cm
-1
 (neat) 2960, 2928, 2799, 1705, 1330, 
1168; δH (400 MHz, CDCl3) 3.80 (1 H, dqd, J = 6.9, 6.8, 1.8, H-12), 3.13 (1 H, ddd, J = 
11.4, 4.1, 2.5, H-5a), 3.02 (1 H, ddd, J = 8.8, 8.6, 2.3, H-3a), 2.87 (1 H, ddd, J = 10.7, 
10.7, 4.2, H-7), 2.71 (1 H, dd, J = 12.8, 6.9, H-11a), 2.31 (1 H, ddd, J = 12.8, 6.0, 3.6, 
H-1a), 2.20 (1 H, dd, J = 12.8, 1.8, H-11b), 2.12 (3 H, m, H-3b, 5b, 8), 2.04 (1 H, ddd, J = 
9.7, 9.5, 6.0, H-9), 1.91-1.71 (4 H, m, H-2, 6), 1.37-1.26 (1 H, m, 1b), 1.16 (3 H, t, J = 
6.9, H-13); δC (100 MHz, CDCl3) 208.9 (CO, C-10), 62.0 (CH, C-8), 61.8 (CH, C-9), 
56.1 (CH, C-7), 53.1 (CH2, C-3), 51.3 (CH, C-12), 50.4 (CH2, C-5), 49.1 (CH2, C-11), 
33.1 (CH2, C-6), 29.0 (CH2, C-1), 21.7 (CH2, C-2), 19.8 (CH3, C-13); m/z (ESI) 209 
[MH]
+
; [HRMS (ESI): calcd. for C12H21N2O, 209.1648. Found: [MH]
+
, 209.1645 (1.8 
ppm error)]. 
Lab Book Ref. = JDC/14/49 





Appendix I.  Comparison of 
1



























(d6-DMSO, 400 MHz) 
Tamura (ppm) 
(d6-DMSO, 300 MHz) 
Carroll (ppm) 
(d6-DMSO, 600 MHz) 
    
1 1.64 m / 2.45 m 1.64 m 1.62 dddd / 2.40 dddd 
2 2.03 m / 2.03 m 2.01 m / 2.01 m 2.00 t / 2.00 t 
3 3.35 m / 3.55 m 3.34 m / 3.55 m 3.28 m / 3.48 ddd 
4 10.37 bs 10.15 bs 10.25 bs 
5 3.35 m / 3.11 m 3.34 m / 3.11 m 3.28 m / 3.09 ddd 
6 2.61 m 2.62 m 2.60 m 
7 7.35 dd 7.34 dd 7.30 bdd 
8 / / / 
9 4.40 dd 4.39 bs 4.32 dd 
10 / / / 
11 4.33 d 4.32 d 4.29 d 
12 / / / 
13 5.97 dd 5.96 dd 5.94 d 
14 7.16 ddd 7.15 m 7.13 ddd 
15 2.21 m / 2.45 m 2.20 m / 2.44 m 2.20 dd / 2.45 m 
16 2.45 m 2.44 m 2.45 m / 2.40 ddq 





(d6-DMSO, 100 MHz) 
Tamura (ppm) 
(d6-DMSO, 75 MHz) 
Carroll (ppm) 
(d6-DMSO, 100 MHz) 
    
1 28.1 28.1 28.2 
2 20.2 20.3 20.3 
3 52.9 53.0 52.9 
4 / / / 
5 43.1 43.1 43.2 
6 22.9 23.0 23.0 
7 140.1 140.2 140.1 
8 137.2 137.3 137.7 
9 57.9 58.0 58.0 
10 198.3 198.4 198.3 
11 59.2 59.3 59.3 
12 196.7 196.8 196.6 
13 128.3 128.4 128.4 
14 151.6 151.8 151.6 
15 32.6 32.7 32.6 
16 33.0 33.0 33.0 
17 19.1 19.2 19.1 
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(CDCl3, 400 MHz) 
Tamura (ppm) 
(CDCl3, 600 MHz) 
Carroll (ppm) 
(CDCl3, 600 MHz) 
    
1 1.35 dddd / 2.30 m 1.34 m / 2.30 m 1.35 dddd / 2.30 m 
2 1.80 m 1.80 m 1.76 m / 1.80 m 
3 2.77 ddd / 2.92 ddd 2.8 m / 2.91 ddd 2.78 ddd / 2.92 ddd 
4 / / / 
5 2.64 ddd / 2.87 ddd 2.65 ddd / 2.86 ddd 2.64 ddd / 2.87 ddd 
6 2.30 m / 2.41 m 2.30 m / 2.40 m 2.30 m / 2.40 m 
7 6.41 ddd 6.40 ddd 6.40 s 
8 / / / 
9 3.66 m 3.69 m 3.67 dd 
10 / / / 
11 3.55 d 3.53 d 3.54 d 
12 / / / 
13 2.06 dd / 2.16 ddd 2.04 dd / 2.14 ddd 2.05 d / 2.16 bd 
14 4.63 ddt 4.61 m 4.62 s 
15 1.27 ddd / 1.96 m 1.25 ddd / 1.95 m 1.26 dd / 1.95 bdd 
16 1.80 m 1.80 m 1.78 m 





(CDCl3, 100 MHz) 
Tamura (ppm) 
(CDCl3, 150 MHz) 
Carroll (ppm) 
(CDCl3, 150 MHz) 
    
1 30.0 30.0 29.0 
2 22.4 22.3 21.5 
3 52.6 52.6 51.5 
4 / / / 
5 45.2 45.2 44.1 
6 24.9 24.8 24.0 
7 130.2 130.2 129.4 
8 138.6 138.4 138.0 
9 58.9 58.9 58.1 
10 171.1 171.0 170.3 
11 56.5 56.4 57.0 
12 208.9 208.9 207.8 
13 40.0 40.0 39.2 
14 55.6 55.6 54.9 
15 32.2 32.2 31.4 
16 29.2 29.2 28.9 











































































































Identification code  2010src0766 
Empirical formula  C9H13NO2 
Formula weight  167.20 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.60970(10) Å α= 95.1970(10)°. 
 b = 10.5480(3) Å β= 91.371(2)°. 
 c = 12.7041(3) Å γ= 104.645(2)°. 
Volume 852.41(3) Å3 
Z 4 
Density (calculated) 1.303 Mg/m3 
Absorption coefficient 0.092 mm-1 
F(000) 360 
Crystal size 0.23 x 0.11 x 0.07 mm3 
Theta range for data collection 3.19 to 27.67°. 
Index ranges -8<=h<=8, -13<=k<=13, -16<=l<=16 
Reflections collected 14864 
Independent reflections 3919 [R(int) = 0.0378] 
Completeness to theta = 27.67° 98.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.994 and 0.910 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3919 / 0 / 229 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0451, wR2 = 0.1006 
R indices (all data) R1 = 0.0526, wR2 = 0.1060 








Identification code  rjt1007a 
Empirical formula  C9 H13 N O2 
Formula weight  167.20 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 6.9758(10) Å α= 90°. 
 b = 9.1944(13) Å β= 90.960(3)°. 
 c = 13.0978(19) Å γ= 90°. 
Volume 840.0(2) Å3 
Z 4 
Density (calculated) 1.322 Mg/m3 
Absorption coefficient 0.093 mm-1 
F(000) 360 
Crystal size 0.39 x 0.14 x 0.11 mm3 
Theta range for data collection 2.71 to 28.39°. 
Index ranges -8<=h<=9, -12<=k<=12, -17<=l<=17 
Reflections collected 8378 
Independent reflections 2108 [R(int) = 0.0285] 
Completeness to theta = 28.39° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.990 and 0.792 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2108 / 0 / 111 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0414, wR2 = 0.1087 
R indices (all data) R1 = 0.0462, wR2 = 0.1129 











Identification code  rjt0906 
Empirical formula  C15H16N4O8 
Formula weight  380.32 
Temperature  120(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 6.50220(10) Å α= 90°. 
 b = 10.7807(2) Å β= 90°. 
 c = 23.3302(3) Å γ= 90°. 
Volume 1635.41(4) Å3 
Z 4 
Density (calculated) 1.545 Mg/m3 
Absorption coefficient 1.096 mm-1 
F(000) 792 
Crystal size 0.30 x 0.12 x 0.07 mm3 
Theta range for data collection 3.79 to 70.87°. 
Index ranges -7<=h<=7, -12<=k<=12, -27<=l<=27 
Reflections collected 14408 
Independent reflections 3020 [R(int) = 0.0646] 
Completeness to theta = 70.87° 96.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.930 and 0.622 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3020 / 0 / 250 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0380, wR2 = 0.0943 
R indices (all data) R1 = 0.0455, wR2 = 0.0987 
Absolute structure parameter 0.1(2) 









Identification code  rjt1010  
Empirical formula  C28H28N8O15  
Formula weight  716.58  
Temperature / K  110.0  
Crystal system  Monoclinic  
Space group  P21/n  
a / Å, b / Å, c / Å  7.0516(6), 17.5740(12), 24.3588(16)  
α/°, β/°, γ/°  90.00, 95.553(7), 90.00  
Volume / Å3  3004.5(4)  
Z  4  
ρcalc / mg mm
-3  1.584  
µ / mm-1  0.131  
F(000)  1488  
Crystal size / mm3  0.2389 × 0.0855 × 0.0853  
Theta range for data collection  2.86 to 25.05°  
Index ranges  -8 ≤ h ≤ 8, -20 ≤ k ≤ 20, -29 ≤ l ≤ 28  
Reflections collected  29380  
Independent reflections  5329[R(int) = 0.0725]  
Data/restraints/parameters  5329/6/485  
Goodness-of-fit on F2  0.960  
Final R indexes [I>2σ (I)] R1 = 0.0474, wR2 = 0.1025  
Final R indexes [all data]  R1 = 0.0833, wR2 = 0.1110  
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Abstract: An efficient one-pot amination/lactamisation sequence
for the preparation of 2-azabicyclo[2.2.2]octanones from 6-car-
boalkoxycyclohex-2-enones and aqueous ammonia is described.
Scope and limitation studies are reported for this tandem procedure
and a range of bicyclic compounds have been prepared, two of
which were characterised by X-ray crystallography.
Key words: amination, lactamisation, azabicyclo[2.2.2]octanones,
bicyclic compounds, 6-carboalkoxycyclohex-2-enones
Functionalised 2-azabicyclo[2.2.2]octan-3-ones occur in
a number of natural products such as 3-oxocoronaridine
(1)1 and brevianamide A (2; Scheme 1).2 The best-
described procedures for the preparation simple 2-azabi-
cyclo[2.2.2]octan-3-ones involve the use of either Diels–
Alder cycloaddition routes3 or the thermal cyclisation of
aminocyclohexane carboxylic acids.4 We recently de-
scribed an efficient method for preparing isoquinuclidino-
nes from 6-acylcyclohex-2-enones using a tandem
amination/imination sequence.5 Herein we describe the
application of a similar tandem procedure to prepare func-
tionalised 2-azabicyclo[2.2.2]octane-3,5-diones 5 from 6-
carboalkoxycyclohex-2-enones 3 as shown in Scheme 1.
Thus, we envisaged that conjugate addition of ammonia
into enones 3 would generate intermediate amino esters 4
which we expected to undergo intramolecular lactamisa-
tion to give the desired lactams 5, possibly in a one-pot
process.
Scheme 1
In order to establish the viability of this approach, we ini-
tially decided to examine the cyclisation of the known6
methyl-substituted cyclohexenone 3a (Scheme 2 and
Table 1).
Scheme 2
The first attempt was carried out using ammonia in iso-
propanol (IPA) but only a trace amount of 8b-methyl-2-
azabicyclo[2.2.2]octane-3,5-dione (5a)7 was observed,
even after extended reaction times. On changing to 35%
aqueous ammonia, success was achieved under a range of
conditions (entries 2–5). When THF or dichloromethane
were employed as co-solvents (entry 2), quantitative con-
versions were observed with a reaction time of 24 hours
but the use of acetonitrile or methanol as co-solvent gave
full conversion in just a few hours (entries 3 and 4). The
optimum procedure, however, used 35% aqueous ammo-
nia without a co-solvent and under these conditions the
conversion was complete after one hour at room tempera-
ture (entry 5). All of the aqueous ammonia examples re-
sulted in the formation of a single diastereomeric product
which was confirmed as the desired methylated 2-azabi-
cyclo[2.2.2]octane-3,5-dione 5a by 1H NMR/13C NMR







































Table 1 Conversion of Enone 3a into 8b-Methyl-2-azabicyclo-
[2.2.2]octane-3,5-dione (5a)a
Entry NH3 source Co-solvent Time (h) Conv.b
1 2.0 M in IPA – 24 <5%
2 35% aq THFc 24 100%
3 35% aq MeCN 6 100%
4 35% aq MeOH 2 100%
5 35% aq – 1 100%
a
 All reactions were performed on a 0.1 mmol scale; entries 2–5 were 
carried out using 35% aq NH3 (0.25 mL) and solvent (0.5 mL).
b
 Conversion estimated by 1H NMR spectroscopy.
c











































Appendix XI – Synlett, 2010, 2805-2807
294
2806 J. D. Cuthbertson et al. LETTER
Synlett 2010, No. 18, 2805–2807 © Thieme Stuttgart · New York
d = 4.0 and 3.1 ppm; 13C NMR signals at d = 205.1 ppm
(bridging ketone) and d = 171.8 ppm (amide)]. This dia-
stereomer was confirmed as the 8b-methyl isomer by
NMR analysis and by X-ray crystallography of a crystal-
line derivative (see later), and the isomeric 8a-methyl iso-
mer 6 was not observed; we assume that the 1,4-addition
of ammonia occurs preferentially anti to the methyl sub-
stituent and that this is followed by in situ lactamisation.
Having confirmed the viability of the one-pot amination/
lactamisation sequence, the scope of the transformation
was investigated using a range of substrates (Table 2).
First the required b-ketoesters 3 were prepared; substrate
3b was prepared using a literature8 procedure and the re-
maining substrates were obtained from cyclohexenones 7
by treatment with LDA in THF–DMPU followed by trap-
ping with ethyl cyanoformate.
As can be seen, the tandem amination/lactamisation se-
quence was applicable to a range of substituted b-keto es-
ters. The reactions generally proceeded rapidly to give the
expected 2-azabicyclo[2.2.2]octane-3,5-diones 5 in good
to excellent yields. The initial example giving the 8b-me-
thyl product 5a proceeded in 93% isolated yield (entry 1)
and the corresponding process with a phenyl substituent
(3b → 5b) also proceeded smoothly and stereoselectively
(entry 2). However, cyclisation was not observed when 3-
methyl-6-carboethoxycyclohexenone (3c) was employed
as starting material (entry 3), presumably substitution at
the b-position of the enone disfavours the initial 1,4-addi-
tion of ammonia. Moving on to disubstituted enones (en-
tries 4–6), 2-azabicyclo[2.2.2]octane-3,5-diones 5d–5f
were obtained bearing 7,7-, 6,8- and 4,8- substitution pat-
terns in good to excellent yields. The successful cyclisa-
tion of the carvone-derived cyclohexenone (3e → 5e;
entry 5) indicated that the tandem amination/lactamisa-
tion sequence is compatible with substitution at the a-
position of the cyclohexenone. Similarly, the successful
formation of azabicyclo[2.2.2]octane 5f (entry 6; struc-
ture confirmed by X-ray crystallography, Figure 1) illus-
trates that ammonia addition/cyclisation can occur on
same face as methyl substituent (cyclisation is not possi-
ble from the anti-addition product due to the presence of
the a-methyl substituent preventing ester epimerisation).
In both of the latter examples (entries 5 and 6) longer re-
action times were required for cyclisation to go to comple-
tion. Finally, in this part of the study, we investigated
cyclisation of the parent unsubstituted cyclohexenone 3g
(entry 7); in this case the unpurified reaction mixture was
slightly more complex but the required 2-azabicyclo-
[2.2.2]octane-3,5-dione 5g was isolated by column chro-
matography in 60% yield.
Finally, we briefly explored the use of substituted amines
in this process in order to directly prepare N-substituted 2-
azabicyclo[2.2.2]octane-3,5-diones 8 (Scheme 3). First,
the readily available enone 3a was treated with excess
aqueous methylamine. This procedure generated the ex-
Figure 1 X-ray structure of compound 5f depicted using ORTEP-3
(CCDC 789903)
Table 2 Scope of Amination/Cyclisation Sequencea























 All reactions were performed on a 0.25 mmol scale using 35% aq 




 Diastereomeric ratio ca. 4:1
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pected bicyclic product but, somewhat surprisingly in
view of the ammonia reactions, led to the formation of the
unstable imine 9 (characterised by NMR spectroscopy
only). However, imine 9 could be readily hydrolysed with
10% aqueous HCl to afford the desired 2-azabicyclo-
[2.2.2]octane 8a in 53% overall yield.
Subsequently, it was found that the unwanted imine for-
mation could be precluded by the use of a stoichiometric
amount of methylamine giving adduct 8a directly in 62%
yield (Scheme 3). Similar reactions using allylamine and
propylamine gave the corresponding N-alkyl-2-azabicyclo-
[2.2.2]octane-3,5-diones 8b and 8c in fair yields. This
process is susceptible to steric effects, however, and no
cyclisation was observed when cyclohexenone 3a was
treated with tert-butylamine, anisidine or benzylamine.
The structure of N-methyl 8b-methyl-2-azabicyclo-
[2.2.2]octane-3,5-dione (8a) was confirmed by X-ray
crystallography (Figure 2).
Figure 2 X-ray structure of compound 8a depicted using ORTEP-3
(CCDC 789904)
In summary, an efficient tandem amination/lactamisation
sequence has been developed for the preparation of 2-
azabicyclo[2.2.2]octane-3,5-diones from 6-carboalkoxy-
cyclohex-2-enones and aqueous ammonia. The scope and
limitations of this methodology have been investigated
and it has been extended to the direct preparation of some
N-substituted 2-azabicyclo[2.2.2]octane-3,5-diones. Ap-
plications of the amination/lactamisation sequence in the
synthesis of polycyclic alkaloids are currently under in-
vestigation.
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8a; R = Me, 62%
8b; R = allyl, 43%
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The facile synthesis of a range of novel isoquinuclidinones from 6-acyl-cyclohex-2-enones is descr
employing aqueous ammonia in a one-pot procedure involving initial conjugate addition of ammonia
lowed by cyclisation via intramolecular imine formation. The scope and limitations of the methodo
are described as is an efﬁcient synthesis of the Elaeocarpus alkaloid ()-mearsine.








































andThe development of new and improved routes to nitroge
taining heterocycles represents an important and continuin
lenge in organic chemistry,1 due to the prevalence o
systems in natural products and pharmaceuticals/agroche
Recently,1b we have become interested in naturally occurri
quinuclidine alkaloids such as compounds 1–3 isolated from
niphyllum,2 Securinega3 and Tabernaemontana4 species, respe
(Fig. 1). In turn, we were attracted to the rare isoquinucli
alkaloids mearsine 45 and grandisine B 56 which contain th
sual 2-azabicyclo[2.2.2]oct-2-en-5-one nucleus.
Functionalised 2-azabicyclo[2.2.2]octanes have previousl
prepared via Diels–Alder cyclisations,7 thermal cyclisation
amino-cyclohexane carboxaldehyde derivatives,8 double con
addition of aqueous ammonia into bifunctional Michael acce
and recently via cyclisation of silyl enol ethers onto im
ions.10 However, to our knowledge, there are no established
ods for the direct preparation of 2-azabicyclo[2.2.2]oct-2
ones (i.e., containing both the ketone and imine functiona
Retrosynthetic analysis as shown in Scheme 1, based on th
synthetic proposal for mearsine put forward by Bick and co
ers,5 suggested that the target compounds 6 might be ac
from 6-acyl-cyclohex-2-enones 8 by initial conjugate addiand
ield
evier Ltd. All rights reserved.























ammonia to give the intermediate amine 7 which might then
expected to give the bicyclic system by intramolecular im
formation.
In this Letter, we describe the successful implementation of
tandem amination/imination route to isoquinuclidinones 6
one-pot process, and its application in natural product synth
Similar chemistry was utilised by Tamura and co-workers as
of their recent total synthesis of grandisine B 5.11
Initial studies concentrated on the cyclisation of diketone
which bears the 5-methyl substituent found inmearsine 4 and g
disine B 5. This was prepared (Scheme 2) by treatment of 5-met
cyclohexenone 912 with LDA in THF at78 C and subsequent t
pingwith cyclohexane carboxaldehyde, followedby oxidationo
resulting b-hydroxy ketone 1013 using Dess–Martin periodin
The novel 1,3-diketone 8a exists as a mixture of diasteroisom
tautomers, with the trans-diastereoisomer predominating.
With the desired 1,3-diketone 8a in hand, we were in a posi
to investigate the proposed cyclisation sequence (Scheme 3). U
treatment of diketone 8a with 35% aqueous ammonia in metha
rapid consumption of starting material was observed, with the
mation of a single product. Isolation and analysis by 1H/13C N
spectroscopy revealed the product to be the desired isoquinuc
none 6a [characteristic bridgehead proton signals at 4.5
3.2 ppm; 13C NMR signals at 209.0 ppm (bridging ketone)















































































Figure 1. Isoquinuclidine and isoquinuclidinone alkaloids.
J. D. Cuthbertson et al. / Tetrahedron Letters 52 (2011) 2024–2027 2025
Appendix XII – Tetrahedron Lett., 2011, 52, 2024-2027as a single diastereoisomer (8b-Me) and the isomeric compoun
(8a-Me) was not observed. We assume that initial, reversible
addition of ammonia occurs followed by imine formation; pres
ably, some addition of ammonia syn-to the methyl group ta
place but cyclisation to give 11 is unfavourable for steric reas
Having conﬁrmed the viability of the proposed sequence,
scope of the reaction was investigated next utilising a rang
substituted diketone substrates 8 (Table 1). The starting 1,3-d
tones 8 were prepared from the corresponding cyclohexeno
using the procedure outlined in Scheme 2.
As can be seen, this tandem process was compatible wi
range of aliphatic, aromatic and alkenyl substituents on the ket
(entries i–iv). However, on increasing the steric bulk of the sub
uents on the cyclohexenone ring, longer reaction times were
quired although the expected isoquinuclidinones 6e–g w
obtained in fair to excellent yield (entries v–vii). In the cas
the 5-phenyl-cyclohexenone 8f, a number of by-products w
formed in addition to isoquinuclidinone 6f (entry vi), and w










MeOH, 0 ºC to rt, 2 h
Scheme 3. Synthesis of isoquinuclid
298f
f
isoquinuclidinone 6g was formed but a three-day reaction tim
was required (entry vii). In all cases, the reactions proceeded stere
oselectively to give the 8b-substituted products exclusively.
Attempts were also made to prepare the ‘unsubstituted’ isoqu
inuclidinones 6h and 6i (Scheme 4). However, treatment of precur
sors 8h and 8i using the optimised reaction conditions did no
produce the expected isoquinuclidinones 6h and 6i but instea
gave clean conversion to the monocyclic methyl esters 12a an
12b. It seems likely that isoquinuclidinones 6h and 6iwere forme
but then underwent methoxide-induced ring-opening as illus
trated in Scheme 4 to give compounds 13.15 We assume that th
additional substitution around the isoquinuclidinone ring in com
pounds 6a–g slows down this ring-opening process. The structura
resemblance between esters 12 and the Elaeocarpus alkaloid gran
disine G 13, recently isolated by Carroll and co-workers,16 shoul
also be noted; it was proposed that grandisine G 13 results from
the corresponding methanol-induced ring-opening of grandisin
B 5.16
In order to demonstrate the utility of this tandem amination
imination sequence, we utilised the procedure in a short total syn
thesis of ()-mearsine 4 (Scheme 5). Mearsine was isolated in 198
by Bick and co-workers from the Australian rainforest species Per
pentadenia mearsii,5 and subsequently the (+)-enantiomer of mear
sine was synthesised from (+)-pulegone by Crouse and Pinder.1
The ﬁrst requirement was to prepare the requisite cyclohexenon
8j and this was achieved prepared from 2,4-pentanedione and cro
tonaldehyde via an enantioselective, organocatalytic Michael addOO
DMP
DCM, 0 ºC to  rt
98% 8a










inone 6a via amination/imination sequence.
Table 1
Scope of amination/cyclisation sequencea










































































a All reactions were performed on 0.25 mmol scale using MeOH (1 mL), 35% aq NH3 (0.5 mL) at 0 C to rt.
b Isolated yields.
c Representative experimental procedure.14
d An inseparable mixture of 6f (conﬁrmed by 1H NMR/HRMS) and by-products obtained; yield estimated using NMR spectroscopy.












12a, R = Ph (72%)








R MeOH, 0 ºC to rt
8h, R = Ph
8i, R = n-C5H11
-OMe
X
6h, R = Ph
6i, R = n-C5H11
Scheme 4. Methoxide promoted ring-opening of isoquinuclidinone 6.
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Scheme 5. Synthesis of ()-mearsine 4.
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pentanedione to crotonaldehyde mediated by Jorgensen’s cata
14 (1 mol %)19 gave aldehyde 15 in 91% unpuriﬁed yield. Imm
ate treatment of the aldehyde 15 with pTSA (10 mol %) furnis
the desired cyclohexenone 8j, which was isolated as a com
mixture of diastereoisomers/tautomers. Treatment of diketon
with 35% aqueous ammonia in methanol initiated the requ
tandem amination/imination sequence to produce ()-mear
4 in 82% yield;20 the melting point (mp 38–40 C; lit.5 43–44
and spectral data for the isolated product corresponded closel
those reported,5,17 although there was a discrepancy in the opt
rotation data {lit. [a]D 34.5 (c 0.495, CH2Cl2);5 synthetic 4,
252.6 (c 0.51, CH2Cl2)}. For this reason, chiral HPLC analysis (P
nomenex Lux Cellulose-2 column, 95:5 iso-hexane/EtOH, ﬂow
1.0 mL/min) was performed which conﬁrmed that the enan
meric ratio was 90.5:9.5, and conclusive evidence for the struc
and relative stereochemistry of synthetic 4 was provided by sin
crystal X-ray analysis of the picrate salt (mp 208–210 C dec;
mp 212–213 C).
In summary, a tandem amination/imination route has b
developed to convert 6-acyl-cyclohex-2-enones 8 into isoquin
lidinones 6 in a one-pot process.
The scope and limitations of the methodology have been in
tigated, and the utility of the sequence has been demonstra
with an efﬁcient synthesis of the alkaloid ()-mearsine (the
synthesis of the ()-enantiomer). Applications of this new tand
methodology in the preparation of more complex natural prod
targets are currently underway.
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ABSTRACT
An efficient new alkyne-acetal cyclization procedure has been developed to prepare enantiopure indolizidine building blocks from L-proline and
then applied to prepare the Elaeocarpus-derived alkaloids grandisine B and grandisine D in an efficient manner. However, evidence is presented
which indicates that grandisine B does not occur naturally but is formed by reaction of grandisine D with ammonia during the extraction/
purification process.
The Elaeocarpaceae plant family has been the source of
numerous, structurally diverse alkaloids over the years.1
Carroll and co-workers recently reported the isolation of
theElaeocarpus-derived indolizine alkaloids grandisines A
1 and B 2 (Figure 1) from the Australian rainforest tree
Elaeocarpus grandis as part of a high throughput drug
discovery program.2a Subsequently, further studies re-
vealed the presence of five additional members of this
family, grandisines CG (37).2b These indolizidine alka-
loids have attracted considerable attention as they display
human δ-opioid receptor affinity.2 First, Danishefsky and
Maloney reported a total synthesis of (þ)-grandisine A 1,3
and then Tamura’s group published a total synthesis of
(þ)-grandisine D 4 (as its TFA salt).4 Most recently, the
latter group reported the conversion of grandisine B 2 into
grandisine D 4 by the double addition of ammonia5
(following the biosynthetic proposal by Carroll2).
Our interest also focused on grandisine B 2, particularly
in view of its structural novelty; it contains an unprece-
dented combination of both indolizidine and isoquinucli-
dinone units linked by a Csp2Csp2 bond. Although many
indolizidine alkaloids have been isolated,6 isoquinuclidi-
none alkaloids are very rare indeed. In fact, mearsine 8,7,8
isolated from another member of the Elaeocarpaceae
family, Peripentadenia mearsii, appears to be the only
other published example. We recently reported a facile
route to a range of isoquinuclidinones from 6-acyl-cyclo-
hex-2-enones, employing aqueous ammonia in a one-pot
tandem amination/imination procedure, and applied this
†University of York.
‡AstraZeneca.
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methodologyaspart of an efficient synthesis of ()-mearsine
8.9Herein, we report an efficient new route to grandisineD 4
and its conversion into grandisine B 2 (with confirmation by
X-ray crystallography); we also discuss the likely nonbiolo-
gical origin of grandisine B 2.
Our retrosynthetic approach is illustrated in Figure 2.
Disconnection of the isoquinuclidinone moiety of grand-
isine B 2 by an imination/amination sequence via amine 9
leads back to grandisineD 4. The use of an aldol/oxidation
sequence involving enolate 10 derived from (S)-5-methyl-
cyclohexenone10 then leads to the requirement for indoli-
zidine 11.
Given the recent interest in the cyclization reactions of
alkynyl aldehydes/acetals,11 we envisaged preparing 11
utimately from alkyne 12 which we felt would be readily
accessible from L-proline.
The preparation of the key indolizidine building block is
shown inScheme1.Thus, alkyne13was readily accessedona
multigram scale fromcommercially availableN-Boc-prolinol
in ca. 70% overall yield (3 steps) using known procedures.12
Boc deprotection followed by N-alkylation with iodo-acetal
14 proceeded readily to afford acetal 15 in 79%yield over the
two steps. Thioalkynes are known to undergo hydration in
acidic media to afford the corresponding thioester,13 and
therefore, deprotonation of alkyne 15 with n-butyllithium
and trapping with ethyl disulfide afforded the cyclization
precursor12 in85%yield.Pleasingly,onheatinga solutionof
thioalkyne 12 in formic acid,14 clean cyclizationwasobserved
giving thioester 16 as the sole product and as a single
enantiomer {[R]D87 (c 0.97, CHCl3)}. This is an extremely
efficient route (7 steps fromN-Boc-prolinol, ca. 50%overall,
unoptimised yield) which appears to be simple, robust, and
scaleable. In order to prepare the desired allylic alcohol 17,
thioester 16 was converted into the corresponding methyl
ester and then reduced using DibalH15 (direct reduction of
the thioester proved problematic).
Figure 1. Structure of grandisines and mearsine.
Figure 2. Retrosynthetic analysis of grandisine B 2.
Scheme 1. Synthesis of Indolizidine Alcohol 17
(9) Cuthbertson, J. D.; Godfrey, A. A.; Taylor, R. J. K. Tetrahedron
Lett. 2011, 52, 2024. See also: Cuthbertson, J. D.; Godfrey, A. A.;
Taylor, R. J. K. Synlett 2010, 2805.
(10) (a) (S)-5-Methylcyclohexenone is available via a number of
procedures; see: Carpenter, R. D.; Fettinger, J. C.; Lam, K. S.; Kurth,
M. J.Angew. Chem., Int. Ed. 2008, 47, 6407 and ref 10b for lead references.
(b)Carlone,A.;Marigo,M.;North,C.; Landa,A.; Jorgensen,K.A.Chem.
Commun. 2006, 4928.
(11) (a) Gonzalez-Rodriguez, C.; Escalante, L.; Varela, J. A.; Castedo,
L.; Saa, C. Org. Lett. 2009, 11, 1531. (b) Xu, T.; Yang, Q.; Yu, Z.; Li,
D.; Dong, J.; Li, Y. Chem.;Eur. J. 2010, 16, 9264 and references
therein.
(12) Paul, A.; Bitterman, H.; Gmeiner, P. Tetrahedron 2006, 62, 8919
and references therein.
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26, 4521.
(14) Menashe, N.; Shvo, Y. J. Org. Chem. 1993, 58, 7434.
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We were now in a position to explore the final steps of
the grandisine synthesis (Scheme 2). Swern oxidation of
alcohol 17 gave aldehyde 11 which was reacted with the
lithium enolate derived from (S)-5-methyl-cyclohexenone
10 (90:10 er; obtained from tert-butyl acetoacetate and
crotonaldehyde by an organocatalytic procedure).10b This
aldol reaction produced allylic alcohol 19 along with the
diastereoisomer 18 derived from (R)-5-methyl-cyclohexe-
none, which was readily removed by chromatography.
Alcohol 19 was obtained as a single diastereomer, tenta-
tively assigned as the trans-isomer about the ring. Oxida-
tion using Swern conditions gave grandisine D 4 in
80% yield {[R]D þ73.7 (c 0.1, MeOH); published values:
[R]D
2þ34.6 (c0.09,MeOH); [R]D4,5þ65.7 (c0.09,MeOH)}.
Compound 4 was assigned as the trans-isomer, as evi-
denced by the large coupling constant (11.5 Hz) although
minor traces of the enol tautomer/cis-isomer were also
observed in the 1H NMR spectrum.
With grandisine D 4 in hand, we were in a position to
investigate the one-pot tandem amination/imination
sequence to generate grandisine B 2 (Scheme 3). This
reaction had also been utilized by Tamura’s group in
their studies.5 Upon treatment of diketone 4 with 35%
aq ammonia, the target compound 2 was obtained
stereoselectively in 72% yield; key spectroscopic data
were consistent with those published (see Supporting
Information). The isolation paper2 and the publication
by Tamura et al.5 were inconsistent concerning the
optical rotation data {[R]Dþ11 (c 0.1,CH2Cl2)2; [R]D159
(c 0.08, CH2Cl2)
5}. Our sample had [R]D 177.5
(c 0.08, CH2Cl2), which agreed well with Tamura’s
value. A further indication of the purity was that
compound 2, as its dipicrate salt, was readily crystal-
lized and, for the first time, an X-ray crystal structure
was obtained which fully confirmed the published
structure (Scheme 3).
On close reading of the original publications describing
the isolation of grandisine B, our attention was drawn to
the extraction conditions: “The aqueous layer (400 mL)
was basified with 27% NH4OH (2  200 mL) and
partitioned with CH2Cl2.”
2 These conditions were ex-
tremely close to the ones we had employed for the
conversion of grandisine D 4 into grandisine B 2; we
therefore conjectured about the origin of grandisine B
2. One distinct possibility appeared to be that grand-
isine D 4 is a true natural product but that on extraction
using ammonia it is converted into grandisine B 2. If
true, then grandisine B 2 is not a natural product and is
actually an artefact of the extraction procedure.16 To
gain greater understanding, we contacted Professor
Carroll who replied stating “Yes, we have certainly
speculated about whether some of these compounds
might be artefacts of the extraction and purification
process. Grandisines B, F, and G in particular are not
observed by (þ) ESI MS in crude methanol extracts of
the leaves suggesting that these compounds at least are
artefacts formed on treatment with ammonia.” It
would therefore appear that grandisine B 2 is not
naturally occurring but is formed by reaction of grand-
isine D 4 with ammonia during the extraction/purifica-
tion process.
In summary, an efficient new alkyne cyclization proce-
dure has been developed to prepare enantiopure indolizi-
dine building blocks from L-proline. Using this
methodology, the natural product grandisine D 4 has been
prepared in an efficient manner (9 steps, 14% overall yield
from the known alkynyl-pyrrolidine 13; 13 steps, 10%
overall yield from prolinol); this route compares well with
the procedure recently published by Tamura et al. (15
steps, 12% overall yield from (S)-malic acid).4
In addition, a tandem imination/amination sequence
has been employed for the assembly of the isoquinuclidi-
none moiety in the conversion of grandisine D 4 into
grandisine B 2 (and the first X-ray of grandisine B as its
dipicrate salt has been obtained). Perhaps most
Scheme 3. Synthesis of Grandisine B 2a
aX-ray structure of compound 2 3 (picric acid)2 depicted using
ORTPE-3 (CCDC 815228); picrate anions omitted for clarity.
Scheme 2. Synthesis of Grandisine D 4
(16) For other examples of ammonia-induced artefact formation
during the isolation of natural products, see: (a) Wenkert, E.; Fuchs,
A.; McChesney, J. D J. Org. Chem. 1965, 30, 2931 (rosmaricine). (b)
Suliman, M.; Martin, M. -T.; Pais, M.; Hadi, H. A.; Awang, K.
Phytochem. 1998, 49, 2192 (desmosine).
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significantly, evidence is presented which indicates that
grandisine B 2 does not occur naturally but is formed by
reaction of grandisine D 4 with ammonia during the
extraction/purification process.
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Abstract – The utility of formic acid for the cyclisation of alkyne !-acetals is 
described; the scope and limitations of this process are outlined and a range of 
acylated heterocyclic building blocks (2,5-dihydrofurans, 2,5-dihydro-1H-pyrroles, 
tetrahydropyridines, 2H-chromenes, 1,2-dihydroquinolines and benzoxepin- 
5(2H)-ones are reported.  
Dedicated to Professor Al Padwa to acknowledge his outstanding contributions to 
heterocyclic chemistry – and his friendship in the Lake District, in Istanbul, and in 
many other exotic locations! 
 
INTRODUCTION  
Partially reduced heterocycles bearing acyl substituents are valuable synthetic building blocks and are 
also found in biologically active natural products including cycloepoxydon (1), anatoxin A (2) and 
myceliothermophin E (3)  (Figure 1).1-3 
 






As part of a natural product synthesis programme,4 we required ready access to a range of acylated 
dihydrofurans, dihydropyrroles, and higher homologues 5 of this type. Given our interest in tandem 
reactions,4,5 we became attracted to approaches based on the cyclisation of !-formyl alkynes which can be 
mediated by both Lewis and Brønsted acids.6,7  Given that aliphatic aldehydes can be difficult to purify 
and prone to decomposition on storage, we explored the direct use of the corresponding alkyne !-acetals 





RESULTS AND DISCUSSION 
Initial studies were carried out using the known alkynyl acetal 4a,7e which was readily prepared from 
alcohol 6 and commercially available acetal 7 using a modification of the published procedure (HMPA 
was omitted).7e  When the acetal is prepared using this method, its direct use in the subsequent 
cyclisation reaction, removing the need to hydrolyse to the aldehyde, is obviously beneficial.  A range of 
Lewis and Brønsted acids have been employed for alkyne cyclisations,6,7 but our attention was taken by a 
report from Menashe and Shvo on the use of formic acid as an economical, metal-free method for the 
conversion of alkynes into carbonyl compounds.9  We therefore explored the use of these formic acid 
conditions for the conversion of acetal 4a into dihydrofuran 5a (Scheme 2).  We were delighted to 
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 observe that, on heating acetal 4a in neat formic acid at 100 ºC, rapid conversion into dihydrofuran 5a 
took place and, after purification, compound 5a was isolated in 98% yield.  The reaction was also found 
to proceed at lower temperatures, with a resulting increase in reaction time (e.g. rt, 24 h, 98%).  The 
practicality of this procedure should be emphasised – on completion of the reaction, the formic acid can 






Based on related studies, a number of mechanistic proposals could be considered, including: (i) initial 
addition of formic acid to the alkyne giving an intermediate 7 followed by an aldol-type condensation;7d  
(ii) proceeding by the intermediacy of an oxete 8;7a,7f,7g,10 (iii) a Prins-type cyclisation initiated by 
formation of oxonium ion 9.7e,g,h  We have not carried out a detailed mechanistic study on this process 
but when the reaction was carried at r.t. and stopped after ~30 min, potential intermediates tentatively 
assigned as enol formates 10 {e.g. for 10a, HRMS (ESI): calcd. for C12H12NaO4, 243.0628. Found: 
[MNa]+, 243.0627 (0.1 ppm error); 1H NMR, 8.14 ppm, OCHO} were isolated in addition to the expected 
product 5a; this observation is in accord with the operation of a Prins-type process. 
 
Having established conditions for the efficient cyclisation of acetal 4a, we were in a position to 
investigate the scope of the transformation.  Thus, a range of substrates 4b-4g were prepared via 
alkylation of the corresponding propargylic alcohols or N-tosyl amines and subjected to the formic acid 
conditions (Table 1).   
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 Table 1. Scope of formic acid-mediated cyclisation sequencea 
 






















aAll reactions were performed on a 0.25 mmol scale using formic acid (1 mL) at 100 ºC for 30 min.  
bIsolated yields after purification by column chromatography. 
cNovel products. 
dA reaction time of 2 h was employed. 
 
As can be seen from Table 1, all of the substrates 4a-4g were found to cyclise in moderate to excellent 
yield.  In terms of dihydrofuran preparation, both aromatic and aliphatic alkyne substituents were 
tolerated (entries i-iv).  The reaction was also found to be applicable to secondary and tertiary 
propargylic alcohols, which gave the methyl substituted dihydrofuran 5c and the spirocyclic example 5d, 
respectively.  This methodology was equally applicable to the production of nitrogen heterocycles 
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 (entries v-vi); thus, N-Ts amine 4e gave 2,5-dihydro-1H-pyrrole 5e, and the higher homologue 4f gave 
tetrahydropyridine 5f.  Finally (entry vii), an example is shown to illustrate that heteroatom-substituted 
alkynes are also compatible with this methodology.4c  Alkyne 4g, easily available from L-proline, was 
treated with formic acid under the standard conditions giving almost quantitative cyclisation to the 
bicyclic thioester 5g {["]D !87 (c 0.97, CHCl3)}.   Such thioesters appear to be valuable synthetic 
building blocks and, indeed, thioester 5g has recently been employed by our group to prepare 
(!)-grandisine B and (+)-grandisine D via a novel synthetic route.4c  In the final part of this study, we 
examined the cyclisation reactions of phenol- and aniline-derived substrates 11, 12 and 15. On subjection 
to the standard reaction conditions, the aromatic precursors 11 and 12 were converted into the novel 
chromene and 1,2-dihydroquinoline derivatives 13 and 14, respectively, in reasonable yield.  In all of the 
previous examples, cyclisation was observed at the proximal alkyne carbon atom but endo-cyclisation 
was seen when unsubstituted alkyne 15 was subjected to the reaction conditions. In this instance the 
known benzoxepinone derivative 1611 was isolated in 31% yield along with the formyl analogue 17 (39%; 





In summary, a simple formic acid procedure has been developed for the conversion of alkyne !-acetals 
directly into acyl heterocyclic building blocks.  Preliminary studies into the scope and limitations of the 
methodology have been investigated and the sequence has been utilised to prepare 2,5-dihydrofurans, 
3,6-dihydro-2H-pyrans, 2,5-dihydro-1H-pyrroles, tetrahydropyridines, 2H-chromenes, 
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 1,2-dihydroquinolines and benzoxepin-5(2H)-ones.  We are currently exploring the use of several of 
these compounds in natural product synthesis.  
EXPERIMENTAL 
NMR spectra were recorded on a Jeol ECX-400 instrument at 400 MHz (1H) and 100 MHz (13C); 
chemical shifts (") are quoted in parts per million (ppm) calibrated to residual non-deuterated solvent (1H 
NMR: CDCl3 at 7.26 ppm; 13C NMR: CDCl3 at 77.0 ppm).  Coupling constants (J) are quoted in Hertz 
and are to the nearest 0.1 Hz. Infrared spectra were recorded on a ThermoNicolet IR100 spectrometer 
with NaCl plates.  Low resolution electrospray ionisation (ESI) mass spectra were recorded on a Kratos 
MS 25 spectrometer.  High resolution mass spectra were recorded on a Bruker MicrOTOF spectrometer.  
Melting points were recorded on Gallenkamp apparatus and are uncorrected.  Thin layer 
chromatography was performed on aluminium plates coated with Merck Silica gel 60 F254 and flash 
column chromatography was carried out using Fluka flash silica gel 60 and the specified eluent.  PE 
refers to the fraction of petroleum ether that boils in the range 40-60 °C.   Cyclisation substrates 4a,7e 
4e,7e 4f,7f 4g4c and 2-(pent-1-ynyl)aniline12 were prepared using previously reported methods and other 
starting materials were prepared using related procedures.  All other chemicals used in this study were 
commercially available and used as received. 
 
Typical Alkyne-Acetal Cyclisation Procedure:  
(2,5-Dihydrofuran-3-yl)(phenyl)methanone 5a: A stirred solution of alkyne 4a (62 mg, 0.25 mmol) in 
formic acid (1 mL) was heated at 100 ºC (oil-bath pre-heated) for 30 min.  The solution was cooled to rt 
and then concentrated in vacuo to afford the crude product which was purified by column 
chromatography (SiO2, PE/EtOAc, 9:1) to give compound 5a (43 mg, 98%) as a crystalline solid; mp. 
67-69 ºC; Rf 0.23 (PE/EtOAc, 4:1) (other data fully consistent to published values7a). 
 
All other products were prepared using the above procedure.  Products 5e,7a 5f,7f 5g4c and 1611 gave data 
fully consistent to published values.  Data for novel products follow: 
 
1-(2,5-Dihydrofuran-3-yl)propan-1-one 5b (22 mg, 70%); pale yellow oil; Rf 0.21 (PE/EtOAc, 4:1); IR 
(neat) 2855, 1738, 1124, 1074 cm!1; 1H NMR (400 MHz, CDCl3) " 1.13 (t, J = 7.3 Hz, 3H), 2.72 (q, J = 
7.3 Hz, 2H), 4.80-4.88 (m, 4H), 6.71-6.74 (m, 1H); 13C NMR (100 MHz, CDCl3) " 7.9 (CH3), 32.7 (CH2), 
74.4 (CH2), 76.3 (CH2), 136.3 (CH), 141.0 (C), 197.0 (C); m/z (ESI) 127 [MH]+; [HRMS (ESI): calcd. for 
C7H11O2, 127.0754. Found: [MH]+, 127.0757 (2.7 ppm error)]. 
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 (2-Methyl-2,5-dihydrofuran-3-yl)(phenyl)methanone 5c: purified by column chromatography (SiO2, 
PE/EtOAc, 9:1) as a pale yellow oil (38 mg, 80%); Rf 0.33 (PE/EtOAc, 4:1); IR (neat) 2973, 2848, 1644, 
1359, 1276, 1240, 1084 cm!1; 1H NMR (400 MHz, CDCl3) " 1.45 (d, J = 6.3 Hz, 3H), 4.77 (ddd, J = 16.1, 
4.9, 1.9 Hz, 1H), 4.93 (ddd, J = 16.1, 5.6, 1.9 Hz, 1H), 5.30-5.38 (m, 1H), 6.54-6.56 (m, 1H), 7.44-7.49 
(m, 2H), 7.54-7.60 (m, 1H), 7.77-7.81 (m, 2H); 13C NMR (100 MHz, CDCl3) " 20.5 (CH3), 74.5 (CH2), 
82.2 (CH), 128.4 (2 # CH), 128.8 (2 # CH), 132.6 (CH), 138.2 (C), 139.5 (CH), 143.5 (C), 191.4 (C); m/z 
(ESI) 189 [MH]+; [HRMS (ESI): calcd. for C12H13O2, 189.0910. Found: [MH]+, 189.0912 (1.2 ppm 
error)]. 
 
1-Oxaspiro[4.5]dec-3-en-4-yl(phenyl)methanone 5d: purified by column chromatography (SiO2, 
PE/EtOAc, 19:1 to 9:1) as a yellow oil (39 mg, 64%); Rf 0.49 (PE/EtOAc, 4:1); IR (neat) 2929, 1646, 
1317, 1240, 1089 cm!1; 1H NMR (400 MHz, CDCl3) " 1.23-1.36 (m, 1H), 1.61-1.76 (m, 7H), 2.00-2.11 
(m, 2H), 4.75 (d, J = 1.9 Hz, 2H), 6.45 (t, J = 1.9 Hz, 1H), 7.42-7.47 (m, 2H), 7.53-7.58 (m, 1H), 
7.73-7.77 (m, 2H); 13C NMR (100 MHz, CDCl3) " 22.3 (2 # CH2), 25.0 (CH2), 34.1 (2 # CH2), 71.9 (CH2), 
90.4 (C), 128.3 (2 # CH), 128.9 (2 # CH2), 132.4 (CH), 139.1 (C), 139.9 (CH), 145.5 (C), 192.4 (C); m/z 
(ESI) 265 [MNa]+; [HRMS (ESI): calcd. for C16H18NaO2, 265.1199. Found: [MNa]+, 265.1192 (2.5 ppm 
error)]. 
 
1-(2H-Chromen-4-yl)butan-1-one 13: purified by column chromatography (SiO2, PE/EtOAc, 9:1) as a 
yellow oil (29 mg, 57%); Rf 0.48 (PE/EtOAc, 4:1); IR (neat) 2964, 1682, 1485, 1456, 1226 cm!1; 1H 
NMR (400 MHz, CDCl3) " 0.98 (t, J = 7.4 Hz, 3H), 1.72 (qt, J = 7.4, 7.3 Hz, 2H), 2.75 (t, J = 7.3 Hz, 2H), 
4.82 (d, J = 4.1 Hz, 2H), 6.56 (t, J = 4.1 Hz, 1H), 6.87 (dd, J = 8.0, 1.3 Hz, 1H), 6.95 (ddd, J = 7.8, 7.6, 
1.3 Hz, 1H), 7.18 (ddd, J = 8.0, 7.6, 1.6 Hz, 1H), 7.75 (dd, J = 7.8, 1.6 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) " 13.8 (CH3), 17.9 (CH2), 41.6 (CH2), 64.3 (CH2), 116.3 (CH), 119.7 (C), 121.6 (CH), 126.6 (CH), 
128.9 (CH), 129.8 (CH), 135.1 (C), 154.3 (C), 200.7 (C); m/z (ESI) 225 [MNa]+; [HRMS (ESI): calcd. for 
C13H14NaO2, 225.0886. Found: [MNa]+, 225.0890 (1.8 ppm error)]. 
 
1-{1-[(4-Methylphenyl)sulfonyl]-1,2-dihydroquinolin-4-yl}butan-1-one 14: purified by column 
chromatography (SiO2, PE/EtOAc, 9:1) as a yellow oil (54 mg, 60%); Rf 0.33 (PE/EtOAc, 4:1); IR (neat) 
2964, 1683, 1354, 1165, 1089 cm!1; 1H NMR (400 MHz, CDCl3) " 0.85 (t, J = 7.4 Hz, 3H), 1.47 (qt, J = 
7.4, 7.3 Hz, 2H), 2.24 (t, J = 7.3 Hz, 2H), 2.30 (s, 3H), 4.47 (d, J = 4.6 Hz, 2H), 6.24 (t, J = 4.6 Hz, 1H), 
7.08 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.3 Hz, 2H), 7.25-7.30 (m, 1H), 7.37 (ddd, J = 7.8, 7.7, 1.6 Hz, 1H), 
7.61 (d, J = 7.8, 1.4, 1H), 7.73 (dd, J = 8.1, 1.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) " 13.7 (CH3), 17.5 
(CH2), 21.4 (CH3), 41.2 (CH2), 44.8 (CH2), 126.7 (CH), 126.8 (C), 126.9 (CH), 127.2 (2 # CH), 127.7 
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 (CH), 128.9 (CH), 129.3 (2 # CH), 130.7 (CH), 135.6 (C), 136.1 (C), 136.5 (C), 143.7 (C), 199.7 (C); m/z 
(ESI) 356 [MH]+; [HRMS (ESI): calcd. for C20H22NO3S, 356.1315. Found: [MH]+, 356.1313 (0.6 ppm 
error)]. 
 
5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepin-3-yl formate 17: purified by column chromatography (SiO2, 
PE/Et2O, 20:1 to 10:1) as a colourless crystalline solid (15 mg 39%); mp 60-62 °C; Rf 0.19 (PE/Et2O, 
4:1); IR (thin film) 3429, 1718, 1653, 1475, 1302, 1165, 1108, 1012 cm!1; 1H NMR (400 MHz, CDCl3) " 
3.21 (dd, J = 12.3, 7.5 Hz, 1H), 3.28 (dd, J = 12.3, 6.0 Hz, 1H), 4.28-4.37 (m, 2H), 5.52-5.58 (m, 1H), 
7.11-7.16 (m, 2H), 7.44-7.48 (m, 1H), 7.84 (dd, J = 7.9, 1.8, 1H), 8.06 (s, 1H); 13C NMR (100 MHz, 
CDCl3) " 46.2 (CH2), 76.1 (CH), 76.7 (CH2), 120.7 (CH), 123.4 (CH), 127.8 (C), 129.8 (CH), 134.4 (CH), 
159.9 (CH), 162.8 (C), 194.7 (C); ); m/z (ESI) 229 [MNa]+; [HRMS (ESI): calcd. for C11H10NaO4, 
229.0471. Found: [MNa]+, 229.0470 (1.8 ppm error)]. 
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Boc2O tert-Butyl dicarbonate 
br Broad 
CAN Ceric(IV) ammonium nitrate 
Cbz Carbobenzyloxy 
COSY Correlation spectroscopy 
Cu(OTf)2 Copper(II) trifluoromethanesulfonate 





DEAD Diethyl azodicarboxylate 




  315 
DMP Dess-Martin periodinane 
DMPU 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO Dimethyl sulfoxide 
equiv. Equivalent 
ESI Electrospray ionisation 
Et Ethyl 
Ether Diethyl ether 
EtOAc Ethyl acetate 
g Gram(s) 
h Hour(s) 
HEK Human embryonic kidney 
HMBC Heteronuclear multiple bond correlation 
HMDS Hexamethyldisilazane 
HRMS High resolution mass spectrometry 





J Coupling constant in Hz 
KOt-Bu Potassium tert-Butoxide 
LDA Lithium diisopropylamine 
LHMDS Lithium hexamethyldisilazane 
m Multiplet 
M Molar 
  316 
m/z Mass to charge ratio 






mp. Melting point 
Ms Methanesulfonyl 
MS Mass spectrometry 
Nap Naphthyl 
NBS N-Bromosuccinimide 




NMR Nuclear magnetic resonance 
nOe Nuclear Overhauser effect 
n-Pr n-Propyl 
p para 





  317 
ppm Parts per million 
PPTS Pyridinium p-toluenesulfonate 
Pr Propyl 




R Alkyl group (undefined) 
Rf Retention factor 
RSM Recovered starting material 
rt Room temperature 
s Singlet 
SAR Structure-activity relationship 
s-BuLi sec-Butyllithium 
SDS Sodium dodecyl sulfate 
SM Starting material 
t Triplet 
TBAF Tetrabutylammonium fluoride 
TBDMS tert-Butyldimethylsilyl 




Tf2O Trifluormethanesulfonic anhydride 
TFA Trifluoroacetic acid 
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TFAA Trifluoroacetic anhydride 
TfOH Trifluoromethanesulfonic acid 
THF Tetrahydrofuran 
THP Tetrahydropyran 
TIPSCl Triisopropylsilyl chloride 
TLC Thin layer chromatography 
TMEDA Tetramethylethylenediamine 
TMS Trimethylsilyl 
TMSCl Trimethylsilyl chloride 
TMSOTf Trimethylsilyl trifluoromethanesulfonate 
Ts p-Toluenesulfonyl 
TsCN p-Toluenesulfonyl cyanide 
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